CUMULATIVE SUPPLEMENT 10
October 2025



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

45th EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

2025

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

45th EDITION

Cumulative Supplement 10
October 2025

CONTENTS

PAGE

Contents

1.0 INTRODUCTION v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT vi
1.2 CUMULATIVE SUPPLEMENT CONTENT vi
1.3 APPLICANT NAME CHANGES vii
1.4 LEVOTHYROXINE SODIUM ix
1.5 AVAILABILITY OF THE EDITION x
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST xi
1.7 CUMULATIVE SUPPLEMENT LEGEND xii

DRUG PRODUCT LISTS

Prescription Drug Product List 1-1
OTC Drug Product List 2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List 3-1
Orphan Products Designations and Approvals List 4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution 5-1

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

A. Patent and Exclusivity Lists A-1
B. Patent and Exclusivity Terms B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

45th EDITION

CUMULATIVE SUPPLEMENT 10
October 2025

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
ALLIED PHARMA INC (ALLIED)	ANDA REPOSITORY LLC (ANDA REPOSITORY)
ANDA REPOSITORY LLC (ANDA REPOSITORY)	TP ANDA HOLDINGS LLC (TP ANDA HOLDINGS)
AVIV PHARMA INC (AVIV PHARMA)	PHARMOBEDIENT CONSULTING LLC (PHARMOBEDIENT)
BEXIMCO PHARMACEUTICALS USA INC (BEXIMCO PHARMS USA)	REGCON HOLDINGS LLC (REGCON HOLDINGS)
BEXIMCO PHARMACEUTICALS USA INC (BEXIMCO USA)	REGCON HOLDINGS LLC (REGCON HOLDINGS)
CARNEGIE PHARMACEUTICALS LLC (CARNEGIE)	PHARMOBEDIENT CONSULTING LLC (PHARMOBEDIENT)
DR REDDYS LABORATORIES INC (DR REDDYS LABS INC)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)

DR REDDYS LABORATORIES LTD
(DR REDDYS)

DR REDDYS LABORATORIES LTD
(DR REDDYS LABS LTD)

DR REDDYS LABORATORIES SA
(DR REDDYS LABS SA)

ENDO OPERATIONS LTD
(ENDO OPERATIONS)

ESJAY PHARMA LLC
(ESJAY PHARMA)

GRAVITI PHARMACEUTICALS INC
(GRAVITI PHARMS)

GRAVITI PHARMACEUTICALS PRIVATE LTD (GRAVITI PHARMS)

ICU MEDICAL INC
(ICU MEDICAL INC)

INDOCO REMEDIES LTD
(INDOCO)

INDOCO REMEDIES LTD
(INDOCO REMEDIES)

MYLAN INSTITUTIONAL LLC
(MYLAN INSTITUTIONAL)

MYLAN LABORATORIES LTD
(MYLAN LABS LTD)

MYLAN PHARMACEUTICALS INC
(MYLAN)

MYLAN PHARMACEUTICALS INC
(MYLAN PHARMS INC)

MYLAN TECHNOLOGIES INC
(MYLAN TECHNOLOGIES)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

RUBICON RESEARCH PRIVATE LTD
(RUBICON)

SENORES PHARMACEUTICALS INC
(SENORES PHARMS)

STERISCIENCE SPECIALITIES PTE LTD (STERISCIENCE SPECLTS)

SENORES PHARMACEUTICALS INC
(SENORES PHARMS)

SENORES PHARMACEUTICALS INC
(SENORES PHARMS)

SENORES PHARMACEUTICALS INC
(SENORES PHARMS)

PH HEALTH LTD
(PH HEALTH)

NOVITIUM PHARMA LLC
(NOVITUM PHARMA)

RISING PHARMA HOLDINGS INC
(RISING)

RISING PHARMA HOLDINGS INC
(RISING)

OTSUKA ICU MEDICAL LLC
(OTSUKA ICU MEDCL)

REGCON HOLDINGS LLC
(REGCON HOLDINGS)

REGCON HOLDINGS LLC
(REGCON HOLDINGS)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

NORVIUM BIOSCIENCE LLC
(NORVIUM BIOSCIENCE)

PHARMOBEDIENT CONSULTING LLC
(PHARMOBEDIENT)

RUBICON RESEARCH LTD
(RUBICON RESEARCH)

ANDA REPOSITORY LLC
(ANDA REPOSITORY)

ONESOURCE SPECIALTY PTE LTE
(ONESOURCE SPECIALTY)

STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)	STRIDES PHARMA INTERNATIONAL AG (STRIDES PHARMA INTL)
STRIDES SOFTGELS PTE LTD (STRIDES SOFTGELS)	ONESOURCE SPECIALTY PTE LTD (ONESOURCE SPECIALTY)
TARO PHARMACEUTICALS INC (TARO)	SUN PHARMA CANADA INC (SUN PHARMA CANADA)
TRUPHARMA LLC (TRUPHARMA)	TP ANDA HOLDINGS LLC (TP ANDA HOLDINGS)
WOCKHARDT LTD (WOCKHARDT)	WOCKHARDT BIO AG (WOCKHARDT BIO AG)
XTTRIUM LABORATORIES INC (XTTRIUM)	PHARMOBEDIENT CONSULTING LLC (PHARMOBEDIENT)
XTTRIUM LABORATORIES INC (XTTRIUM LABS INC)	PHARMOBEDIENT CONSULTING LLC (PHARMOBEDIENT)

1.4 LEVOTHYROXINE SODIUM[1]

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[2]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence

[1] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.
[2] Please consult the Active Section of the Orange Book for information on other strengths.

codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM[3]	MYLAN	0.3MG	A076187	–	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

[3] Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
https://www.fda.gov/about-fda/reports-manuals-forms/forms.

The current listing of the Orphan Product Designations and Approvals is available at https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2024	MAR 2025	JUN 2025	SEP 2025	DEC 2025
DRUG PRODUCTS	23856	23679	23798	24012	
LISTED SINGLE SOURCE	2772 (11.8%)	2740 (11.6%)	2744 (11.5%)	2776 (11.6%)	

MULTISOURCE	20814 (88.2%)	20939 (88.4%)	21054 (88.5%)	21236 (88.4%)
THERAPEUTICALLY EQUIVALENT	20741 (87.9%)	20826 (88%)	20952 (88%)	21137 (88%)
NOT THERAPEUTICALLY EQUIVALENT	73 (0.3%)	113 (0.5%)	102 (0.4%)	99 (0.4%)
EXCEPTIONS[4]	47 (0.2%)	47 (0.2%)	47 (0.2%)	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	43	13	7	20
NUMBER OF APPLICANTS	1197	1209	1226	1200

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN[5]	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration

[4] Amino acid containing products of varying composition (see Introduction, page xx of the List).
[5] The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB			HETERO LABS LTD V	EQ 600MG BASE;300MG	A205412	001	Apr 16, 2025	Apr NEWA
	@		MACLEODS PHARMS LTD	EQ 600MG BASE;300MG	A212663	001	Dec 19, 2024	Jun DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB			REGCON HOLDINGS	500MG	A215086	001	Mar 23, 2023	Sep CAHN
	@		TEVA PHARMS USA	250MG	A208432	001	Oct 31, 2018	Mar DISC
	@			500MG	A210726	001	Jan 26, 2023	Mar DISC

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB			BIONPHARMA	333MG	A219904	001	Sep 18, 2025	Sep NEWA
AB			GLENMARK PHARMS LTD	333MG	A202229	001	Jul 16, 2013	Mar CMFD

ACECLIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VIZZ

	+!		LENZ THERAP	EQ 1.44% BASE	N218585	001	Jul 31, 2025	Jul NEWA

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP1			ASPIRO	1GM/100ML (10MG/ML)	A216617	001	Jul 27, 2022	Mar CTEC
AP	+!		B BRAUN MEDICAL	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021	Mar CFTG
AP2	+!			1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021	Mar CFTG
	!		BAXTER HLTHCARE CORP	650MG/65ML (10MG/ML)	A214331	002	May 21, 2025	May NEWA
AP1				1GM/100ML (10MG/ML)	A214331	001	Sep 17, 2021	Mar CTEC
AP1			EUGIA PHARMA	1GM/100ML (10MG/ML)	A210969	001	Oct 21, 2020	Mar CTEC
AP			GLAND	500MG/50ML (10MG/ML)	A219215	001	Apr 02, 2025	Mar NFTG
AP2				1GM/100ML (10MG/ML)	A219215	002	Apr 02, 2025	Mar NFTG
AP1			HIKMA	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Mar CTEC
AP1			INFORLIFE	1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Mar CTEC
AP1			MYLAN	1GM/100ML (10MG/ML)	A213255	001	Aug 07, 2020	Mar CTEC
AP1	!		SANDOZ	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar CTEC
AP1			WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Mar CTEC

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

ALLZITAL

AA	!		PHARMOBEDIENT	325MG;25MG	A203484	001	Dec 04, 2015	Sep CAHN

BUTALBITAL AND ACETAMINOPHEN

AA			ANDA REPOSITORY	300MG;50MG	A207386	001	Nov 15, 2016	Sep CAHN
AA			PHARMOBEDIENT	325MG;50MG	A203484	002	Dec 04, 2015	Sep CAHN

BUTAPAP

AA	!		ANDA REPOSITORY	325MG;50MG	A089987	001	Oct 26, 1992	Sep CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

SOLUTION;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A>	!		GENUS	325MG/15ML;50MG/15ML;40MG/15ML	A040387	001	Jan 31, 2003	Oct CAHN
>D>	!		MIKART	325MG/15ML;50MG/15ML;40MG/15ML	A040387	001	Jan 31, 2003	Oct CAHN

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA			ANDA REPOSITORY	325MG;50MG;40MG	A089175	001	Jan 21, 1987	Sep CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

	@		AVIV PHARMA	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

	@	PHARMOBEDIENT	325MG;30MG;16MG	A204209	001	Sep 30, 2016	Sep	CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	@	CHARTWELL	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992	Feb	DISC
	!	GENUS LIFESCIENCES	120MG/5ML;12MG/5ML	A087508	001		Feb	CTEC
	@	XTTRIUM LABS INC	120MG/5ML;12MG/5ML	A087006	001		Feb	CAHN

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	@	ANI PHARMS	300MG;15MG	A088629	002	Mar 06, 1985	May	CAHN
	@		300MG;30MG	A088629	003	Mar 06, 1985	May	CAHN
	@ +		300MG;60MG	A088629	001	Mar 06, 1985	May	CAHN
AA		HIBROW HLTHCARE	300MG;15MG	A211610	001	Jun 27, 2019	Sep	CAHN
AA			300MG;30MG	A211610	002	Jun 27, 2019	Sep	CAHN
AA			300MG;60MG	A211610	003	Jun 27, 2019	Sep	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	CHARTWELL	325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Feb	DISC
AA	!	WES PHARMA INC	325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Feb	CHRS

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	CHARTWELL	300MG;5MG	A040658	001	Jan 19, 2006	Feb	DISC
	@		300MG;7.5MG	A040658	002	Mar 24, 2006	Feb	DISC
	@		300MG;10MG	A040658	003	Jun 23, 2004	Feb	DISC
	@		325MG;7.5MG	A040432	001	Jan 22, 2003	Feb	DISC
AA		HIBROW HLTHCARE	300MG;5MG	A207509	001	Oct 29, 2018	Sep	CAHN
AA			300MG;7.5MG	A207509	002	Oct 29, 2018	Sep	CAHN
AA			300MG;10MG	A207509	003	Oct 29, 2018	Sep	CAHN
	@	RHODES PHARMS	300MG;5MG	A207808	001	Mar 30, 2018	Jan	DISC
	@		300MG;7.5MG	A207808	002	Mar 30, 2018	Jan	DISC
	@		300MG;10MG	A207808	003	Mar 30, 2018	Jan	DISC
AA	!	SPECGX LLC	300MG;5MG	A206718	001	Mar 31, 2017	Feb	CHRS
AA	!		300MG;7.5MG	A206718	002	Mar 31, 2017	Feb	CHRS
AA	!		300MG;10MG	A206718	003	Mar 31, 2017	Feb	CHRS

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

	!	ABHAI LLC	325MG/5ML;5MG/5ML	A211499	001	Dec 31, 2018	Sep	CTEC
	@	SANKALP LIFECARE	325MG/5ML;5MG/5ML	A201448	001	Aug 26, 2021	Sep	DISC
AA			325MG/5ML;5MG/5ML	A201448	001	Aug 26, 2021	Apr	CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

	@	CHARTWELL	325MG;5MG	A207834	001	Aug 15, 2019	Feb	DISC
	@		325MG;7.5MG	A207834	002	Aug 15, 2019	Feb	DISC
	@		325MG;10MG	A207834	003	Aug 15, 2019	Feb	DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

	@	MPP PHARMA	325MG;37.5MG	A078778	001	Apr 07, 2014	Jun	CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB		MPP PHARMA	500MG	A204691	001	Mar 29, 2016	May	CAHN

TABLET;ORAL

ACETAZOLAMIDE

AB		AUROBINDO PHARMA LTD	125MG	A212089	001	May 30, 2025	May	NEWA
AB			250MG	A212089	002	May 30, 2025	May	NEWA

DIAMOX

	@ +	TEVA BRANDED PHARM	125MG	N008943	001		Feb	CAHN
	@ +		250MG	N008943	002		Feb	CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP		GLAND	EQ 500MG BASE/VIAL	A219775	001	Jun 17, 2025	Jun NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

	@	TARO	2%	A088638	001	Sep 06, 1984	Aug DISC

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN		CONBA USA	10%	A214177	001	Mar 14, 2025	Mar NEWA
AN			20%	A214177	002	Mar 14, 2025	Mar NEWA
AN		SOMERSET THERAPS LLC	10%	A219194	001	Feb 12, 2025	Jan NEWA
AN			20%	A219194	002	Feb 12, 2025	Jan NEWA

ACETYLCYSTEINE LYSINE

FOR SOLUTION;ORAL

LEGUBETI

	@ +	GALEPHAR	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jul DISC
	+!		EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jun CMFD
	@ +		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jul DISC
	+!		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jun CMFD

ACITRETIN

CAPSULE;ORAL

ACITRETIN

	@	MYLAN	17.5MG	A203707	001	Sep 10, 2015	Apr CAHN
	@		22.5MG	A203707	002	Sep 10, 2015	Apr CAHN

ACOLTREMON

SOLUTION/DROPS;OPHTHALMIC

TRYPTYR

	+!	ALCON LABS INC	0.003%	N217370	001	May 28, 2025	May NEWA

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB		REGCON HOLDINGS	200MG	A075090	001	Jan 26, 1999	Sep CAHN

CREAM;TOPICAL

ACYCLOVIR

	@	CIPLA	5%	A212981	001	May 02, 2025	May DISC
AB			5%	A212981	001	May 02, 2025	Apr NEWA
BX		ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023	Mar CTEC

OINTMENT;TOPICAL

ACYCLOVIR

	@	APOTEX	5%	A210774	001	Sep 06, 2019	Jan DISC
	@	CHARTWELL MOLECULAR	5%	A206437	001	Jul 31, 2017	Feb CAHN
	@	CIPLA	5%	A211794	001	Jan 18, 2019	May DISC
BX			5%	A211794	001	Jan 18, 2019	Mar CTEC

TABLET;BUCCAL

SITAVIG

	@ +	LIGAND PHARMS	50MG	N203791	001	Apr 12, 2013	Jul DISC
	+!		50MG	N203791	001	Apr 12, 2013	Jun CAHN

TABLET;ORAL

ACYCLOVIR

AB		AUROBINDO PHARMA USA	400MG	A075211	001	Sep 28, 1998	Aug CMFD
AB			800MG	A075211	002	Sep 28, 1998	Aug CMFD

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

AP		FRESENIUS KABI USA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	May CMFD
	@		EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Feb DISC

ALBUTEROL SULFATE

AEROSOL, METERED;INHALATION

ALBUTEROL SULFATE

AB2	PADAGIS US	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar	CMFD

POWDER, METERED;INHALATION

PROAIR DIGIHALER

@ +	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Feb	CAHN

PROAIR RESPICLICK

+!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Feb	CAHN

SOLUTION;INHALATION

ALBUTEROL SULFATE

AN	RITEDOSE CORP	EQ 0.5% BASE	A218386	001	Mar 12, 2025	Feb	NEWA

SYRUP;ORAL

ALBUTEROL SULFATE

@	COSETTE	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Jan	DISC

TABLET;ORAL

ALBUTEROL SULFATE

AB	ACERTIS PHARMS	EQ 2MG BASE	A211397	001	Oct 26, 2018	May	CAHN
AB		EQ 4MG BASE	A211397	002	Oct 26, 2018	May	CAHN

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

ALCLOMETASONE DIPROPIONATE

@	GLENMARK PHARMS LTD	0.05%	A079061	001	Jun 23, 2009	Jul	DISC

OINTMENT;TOPICAL

ALCLOMETASONE DIPROPIONATE

@	GLENMARK PHARMS LTD	0.05%	A079227	001	Jul 30, 2009	Jul	DISC

ALCOHOL

SOLUTION;INTRA-ARTERIAL

ABLYSINOL

AP +!	BPI LABS	99% (5ML)	N207987	002	Jun 21, 2018	Jun	CFTG

DEHYDRATED ALCOHOL

AP	ACCORD HLTHCARE	99% (5ML)	A217845	001	Jun 23, 2025	Jun	NFTG
AP	BRECKENRIDGE	99% (5ML)	A219444	001	Jun 23, 2025	Jun	NFTG
AP	INGENUS PHARMS LLC	99% (5ML)	A219569	001	Jul 09, 2025	Jun	NEWA
AP	XGEN PHARMS	99% (5ML)	A219400	001	Jun 23, 2025	Jun	NFTG

SOLUTION;INTRAVENOUS

DEHYDRATED ALCOHOL

>A> +!	ROYAL PHARMS	98% (5ML)	N214988	001	Oct 23, 2025	Oct	NEWA

ALENDRONATE SODIUM

TABLET;ORAL

ALENDRONATE SODIUM

@	APOTEX	EQ 5MG BASE	A077982	001	Aug 04, 2008	Mar	DISC
@		EQ 10MG BASE	A077982	002	Aug 04, 2008	Mar	DISC
@		EQ 35MG BASE	A077982	003	Aug 04, 2008	Mar	DISC
@		EQ 70MG BASE	A077982	004	Aug 04, 2008	Mar	DISC

ALFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

ALFENTA

+!	RISING	EQ 0.5MG BASE/ML	N019353	001	Dec 29, 1986	Aug	CTEC

ALFENTANIL

@	HOSPIRA	EQ 0.5MG BASE/ML	A075221	001	Oct 28, 1999	Aug	DISC

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB	AUROBINDO PHARMA LTD	100MG	A215091	001	Apr 14, 2025	Apr	NEWA
AB		300MG	A215091	002	Apr 14, 2025	Apr	NEWA
AB	INDOCO	200MG	A204467	003	May 22, 2025	May	NEWA
@	NORTHSTAR HLTHCARE	100MG	A078253	001	Sep 11, 2007	Aug	DISC
@		300MG	A078253	002	Sep 11, 2007	Aug	DISC
AB	ZYDUS PHARMS	200MG	A210117	003	Jun 13, 2025	Jun	NEWA

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

AB		HIBROW HLTHCARE	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Aug CMFD
AB			EQ 1MG BASE	A211621	002	Sep 16, 2019	Aug CMFD

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

	@	APOTEX INC	0.25MG	A077741	001	Jan 19, 2007	Mar DISC
	@		0.5MG	A077741	002	Jan 19, 2007	Mar DISC
	@		1MG	A077741	003	Jan 19, 2007	Mar DISC
	@		2MG	A077741	004	Jan 19, 2007	Mar DISC
	@	SUN PHARM	0.25MG	A090082	001	Jun 17, 2010	Jul DISC
	@		0.5MG	A090082	002	Jun 17, 2010	Jul DISC
	@		1MG	A090082	003	Jun 17, 2010	Jul DISC
	@		2MG	A090082	004	Jun 17, 2010	Jul DISC

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

	@	APOTEX INC	0.5MG	A078449	001	Nov 12, 2008	Mar DISC
	@		1MG	A078449	004	Dec 23, 2015	Mar DISC
	@		2MG	A078449	002	Nov 12, 2008	Mar DISC
	@		3MG	A078449	003	Nov 12, 2008	Mar DISC

ALPROSTADIL

SUPPOSITORY;URETHRAL

MUSE

	@ +	VIATRIS	0.125MG	N020700	001	Nov 19, 1996	Feb CAHN
	@ +		0.25MG	N020700	002	Nov 19, 1996	Feb CAHN
	@ +		0.5MG	N020700	003	Nov 19, 1996	Feb CAHN
	@ +		1MG	N020700	004	Nov 19, 1996	Feb CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

AMANTADINE HYDROCHLORIDE

	@	ZYDUS	EQ 68.5MG BASE	A214897	001	Aug 26, 2024	May DISC

GOCOVRI

	+	SUPERNUS PHARMS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	May CTEC

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

	@	ADAPTIS	50MG/5ML	A075819	001	Sep 11, 2002	Sep CAHN
	@	AEONIUM PHARMA PVT	50MG/5ML	A075819	001	Sep 11, 2002	Sep CAHN
	@	BAJAJ	50MG/5ML	A075819	001	Sep 11, 2002	Mar CAHN
AA		SHREE HARI INTL	50MG/5ML	A214178	001	Aug 20, 2021	Aug CAHN

AMCINONIDE

LOTION;TOPICAL

AMCINONIDE

	!	SOLUBIOMIX	0.1%	A076329	001	Nov 06, 2002	Feb CAHN

OINTMENT;TOPICAL

AMCINONIDE

	!	GENUS	0.1%	A076096	001	Nov 19, 2002	Aug CTEC
	@	TARO PHARM INDS	0.1%	A076367	001	Mar 19, 2003	Aug DISC

AMINOCAPROIC ACID

INJECTABLE;INJECTION

AMINOCAPROIC ACID

AP		GEN ILAC	250MG/ML	A215374	001	Aug 28, 2025	Aug NEWA

SOLUTION;ORAL

AMINOCAPROIC ACID

AA		AJENAT PHARMS	0.25GM/ML	A213825	001	Apr 08, 2021	Jan CAHN
AA		APOZEAL PHARMS	0.25GM/ML	A213216	001	May 19, 2025	May NEWA
AA		REGCON HOLDINGS	0.25GM/ML	A215510	001	Mar 23, 2022	Sep CAHN
AA		SCIEGEN PHARMS INC	0.25GM/ML	A213216	001	May 19, 2025	Sep CAHN
	@	TARO	0.25GM/ML	A214458	001	Mar 24, 2023	Aug DISC
AA	!	TP ANDA HOLDINGS	0.25GM/ML	A212494	001	Aug 11, 2020	Aug CAHN

TABLET;ORAL

AMINOCAPROIC ACID

AB		SOMERSET THERAPS LLC	500MG	A213944	001	Sep 14, 2022	Sep CAHN
AB			1GM	A213944	002	Sep 14, 2022	Sep CAHN

AMINOPHYLLINE

INJECTABLE;INJECTION

AMINOPHYLLINE

	+!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983	Jun	CRLD

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE;ORAL

PASER

	!	ADAPTIS	4GM/PACKET	A074346	001	Jun 30, 1994	Sep	CAHN

AMIODARONE HYDROCHLORIDE

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

	@	TARO	300MG	A076362	002	Dec 02, 2003	Aug	DISC
	@		400MG	A076362	001	Nov 29, 2002	Aug	DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	@	BRECKENRIDGE	10MG	A216243	001	Jun 06, 2022	Aug	DISC
	@		25MG	A216243	002	Jun 06, 2022	Aug	DISC
	@		50MG	A216243	003	Jun 06, 2022	Aug	DISC
	@		75MG	A216243	004	Jun 06, 2022	Aug	DISC
	@		100MG	A216243	005	Jun 06, 2022	Aug	DISC
	@		150MG	A216243	006	Jun 06, 2022	Aug	DISC
BX		RUBICON	10MG	A215376	001	May 01, 2023	Mar	CTEC
BX			25MG	A215376	002	May 01, 2023	Mar	CTEC
BX			50MG	A215376	003	May 01, 2023	Mar	CTEC
BX			75MG	A215376	004	May 01, 2023	Mar	CTEC
BX			100MG	A215376	005	May 01, 2023	Mar	CTEC
BX			150MG	A215376	006	May 01, 2023	Mar	CTEC
AB		UNIQUE PHARM	10MG	A218389	001	Jun 23, 2025	Jun	NEWA
AB			25MG	A218389	002	Jun 23, 2025	Jun	NEWA
AB			50MG	A218389	003	Jun 23, 2025	Jun	NEWA
AB			75MG	A218389	004	Jun 23, 2025	Jun	NEWA
AB			100MG	A218389	005	Jun 23, 2025	Jun	NEWA
AB			150MG	A218389	006	Jun 23, 2025	Jun	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	@	MICRO LABS	EQ 12.5MG BASE;5MG	A211925	001	Feb 02, 2022	Apr	DISC
	@		EQ 25MG BASE;10MG	A211925	002	Feb 02, 2022	Apr	DISC
		MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Apr	CTEC
	!		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Apr	CTEC
	@	TP ANDA HOLDINGS	EQ 12.5MG BASE;5MG	A070765	001	Dec 10, 1986	Sep	CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	@	CHARTWELL RX	50MG;4MG	A071863	001	Dec 21, 1987	Jun	CAHN

AMLODIPINE BESYLATE

FOR SOLUTION;ORAL

SDAMLO

	@ +	BRILLIAN PHARMA	EQ 2.5MG BASE/BOT	N219531	001	Jul 24, 2025	Aug	DISC
	+!		EQ 2.5MG BASE/BOT	N219531	001	Jul 24, 2025	Jul	NEWA
	@ +		EQ 5MG BASE/BOT	N219531	002	Jul 24, 2025	Aug	DISC
	+!		EQ 5MG BASE/BOT	N219531	002	Jul 24, 2025	Jul	NEWA
	@ +		EQ 10MG BASE/BOT	N219531	003	Jul 24, 2025	Aug	DISC
	+!		EQ 10MG BASE/BOT	N219531	003	Jul 24, 2025	Jul	NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		ALEMBIC	EQ 2.5MG BASE;EQ 10MG BASE	A217279	001	May 22, 2025	May	NEWA
AB			EQ 2.5MG BASE;EQ 20MG BASE	A217279	002	May 22, 2025	May	NEWA
AB			EQ 2.5MG BASE;EQ 40MG BASE	A217279	003	May 22, 2025	May	NEWA
AB			EQ 5MG BASE;EQ 10MG BASE	A217279	004	May 22, 2025	May	NEWA
AB			EQ 5MG BASE;EQ 20MG BASE	A217279	005	May 22, 2025	May	NEWA
AB			EQ 5MG BASE;EQ 40MG BASE	A217279	006	May 22, 2025	May	NEWA

TABLET;ORAL
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		EQ 5MG BASE;EQ 80MG BASE	A217279	007	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 10MG BASE	A217279	008	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 20MG BASE	A217279	009	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 40MG BASE	A217279	010	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 80MG BASE	A217279	011	May 22, 2025	May	NEWA
AB	APDM PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb	CAHN
AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb	CAHN
AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb	CAHN
AB	NEOCUBES PHARMA	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Sep	CAHN
AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Sep	CAHN
AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Sep	CAHN
AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Sep	CAHN
AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Sep	CAHN
AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Sep	CAHN
AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Sep	CAHN
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Sep	CAHN
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Sep	CAHN
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Sep	CAHN
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Sep	CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	CHARTWELL RX	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	Apr	CAHN
@		EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	Apr	CAHN
@		EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	Apr	CAHN
@		EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	Apr	CAHN
@		EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	Apr	CAHN
@		EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	Apr	CAHN
@	RISING	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010	Aug	CAHN
@		EQ 5MG BASE;10MG	A077375	002	May 21, 2010	Aug	CAHN
@		EQ 5MG BASE;20MG	A077375	003	May 21, 2010	Aug	CAHN
@		EQ 10MG BASE;20MG	A077375	004	May 21, 2010	Aug	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	HETERO LABS LTD V	EQ 5MG BASE;12.5MG;20MG	A209242	001	Oct 06, 2025	Sep	NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A209242	002	Oct 06, 2025	Sep	NEWA
AB		EQ 5MG BASE;25MG;40MG	A209242	003	Oct 06, 2025	Sep	NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A209242	004	Oct 06, 2025	Sep	NEWA
AB		EQ 10MG BASE;25MG;40MG	A209242	005	Oct 06, 2025	Sep	NEWA
AB	MACLEODS PHARMS LTD	EQ 5MG BASE;12.5MG;20MG	A207088	001	Jul 18, 2025	Jul	NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A207088	002	Jul 18, 2025	Jul	NEWA
AB		EQ 5MG BASE;25MG;40MG	A207088	003	Jul 18, 2025	Jul	NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A207088	004	Jul 18, 2025	Jul	NEWA
AB		EQ 10MG BASE;25MG;40MG	A207088	005	Jul 18, 2025	Jul	NEWA
AB	PIRAMAL	EQ 5MG BASE;12.5MG;20MG	A210718	001	May 14, 2025	May	NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A210718	002	May 14, 2025	May	NEWA
AB		EQ 5MG BASE;25MG;40MG	A210718	003	May 14, 2025	May	NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A210718	004	May 14, 2025	May	NEWA
AB		EQ 10MG BASE;25MG;40MG	A210718	005	May 14, 2025	May	NEWA
@	TORRENT	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	Jun	DISC
@		EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	Jun	DISC
@		EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	Jun	DISC

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET;ORAL
WIDAPLIK

@ +	AZURITY	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Sep	CAHN
@ +		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Sep	CAHN
@ +		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Sep	CAHN
+	GEORGE MEDICINES	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun	NEWA

TABLET;ORAL
WIDAPLIK

@ +		EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun DISC
+		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun NEWA
@ +		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun DISC
+!		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun NEWA
@ +		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL
AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	HETERO LABS LTD V	EQ 5MG BASE;20MG	A209591	001	Feb 14, 2025	Feb NEWA
AB		EQ 5MG BASE;40MG	A209591	002	Feb 14, 2025	Feb NEWA
AB		EQ 10MG BASE;20MG	A209591	003	Feb 14, 2025	Feb NEWA
AB		EQ 10MG BASE;40MG	A209591	004	Feb 14, 2025	Feb NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS
AMMONIA N 13

AP	SOFIE	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Mar CAHN

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
ADZENYS XR-ODT

AB	+ NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jul CTEC
AB	+	EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jul CTEC
AB	+	EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jul CTEC
AB	+	EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jul CTEC
AB	+	EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jul CTEC
AB	+!	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jul CTEC

AMPHETAMINE

AB	ACTAVIS LABS FL INC	EQ 3.1MG BASE	A209253	001	Jun 22, 2023	Jul CMFD
AB		EQ 6.3MG BASE	A209253	002	Jun 22, 2023	Jul CMFD
AB		EQ 9.4MG BASE	A209253	003	Jun 22, 2023	Jul CMFD
AB		EQ 12.5MG BASE	A209253	004	Jun 22, 2023	Jul CMFD
AB		EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Jul CMFD
AB		EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Jul CMFD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jan CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jan CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jan CMFD
AB		5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jan CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jan CMFD
AB	PHARMOBEDIENT	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Sep CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Sep CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Sep CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Sep CAHN
AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Sep CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Sep CAHN

AMPHETAMINE SULFATE

TABLET;ORAL
AMPHETAMINE SULFATE

@	RHODES PHARMS	5MG	A213852	001	Sep 07, 2021	Jan DISC
@		10MG	A213852	002	Sep 07, 2021	Jan DISC

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX;INJECTION
ABELCET

@ +	LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995	Aug DISC

INJECTABLE, LIPOSOMAL;INJECTION
AMPHOTERICIN B

AB	AVET LIFESCIENCES	50MG/VIAL	A215354	001	Jun 02, 2025	May NEWA
AB	MYLAN LABS LTD	50MG/VIAL	A212967	001	Jun 30, 2025	Jun NEWA

AMPICILLIN SODIUM

>D>			POWDER;INTRAVENOUS						
>D>			AMPICILLIN SODIUM						
>D>	AP	!	SANDOZ	EQ 1GM BASE/VIAL	A062738	001	Feb 19, 1987	Oct DISC
>A>		@		EQ 1GM BASE/VIAL	A062738	001	Feb 19, 1987	Oct DISC
>D>	AP	!		EQ 2GM BASE/VIAL	A062738	002	Feb 19, 1987	Oct DISC
>A>		@		EQ 2GM BASE/VIAL	A062738	002	Feb 19, 1987	Oct DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

			INJECTABLE;INJECTION						
			AMPICILLIN AND SULBACTAM						
		@	HIKMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Mar DISC
		@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Mar DISC
>D>	AP		SANDOZ	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065310	001	Jul 25, 2006	Oct DISC
>A>		@		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065310	001	Jul 25, 2006	Oct DISC
>D>	AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065310	002	Jul 25, 2006	Oct DISC
>A>		@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065310	002	Jul 25, 2006	Oct DISC

ANAGRELIDE HYDROCHLORIDE

			CAPSULE;ORAL						
			ANAGRELIDE HYDROCHLORIDE						
		@	BARR LABS	EQ 0.5MG BASE	A076530	001	Apr 18, 2005	Mar CAHN
		@		EQ 1MG BASE	A076530	002	Apr 18, 2005	Mar CAHN
	AB		CIPLA	EQ 0.5MG BASE	A076468	001	Apr 18, 2005	Aug CAHN
	AB	!		EQ 1MG BASE	A076468	002	Apr 18, 2005	Aug CAHN
	AB		NOVITIUM PHARMA	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Sep CMFD
	AB			EQ 1MG BASE	A076811	002	Apr 18, 2005	Sep CMFD

ANASTROZOLE

			TABLET;ORAL						
			ANASTROZOLE						
		@	PHARMOBEDIENT	1MG	A091051	001	Jun 28, 2010	Sep CAHN

ANGIOTENSIN II ACETATE

			SOLUTION;INTRAVENOUS						
			ANGIOTENSIN II ACETATE						
	AP		GLAND	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	A216966	001	Jun 03, 2025	May NFTG
			GIAPREZA						
	AP	+!	LA JOLLA PHARMA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	May CFTG

APALUTAMIDE

			TABLET;ORAL						
			APALUTAMIDE						
	AB		ZYDUS	60MG	A217113	001	Mar 17, 2025	Mar NFTG
			ERLEADA						
	AB	+	JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Mar CFTG

APIXABAN

			FOR SUSPENSION;ORAL						
			ELIQUIS SPRINKLE						
		+!	BRISTOL	0.15MG	N220073	001	Apr 17, 2025	Apr NEWA
			TABLET;ORAL						
			APIXABAN						
		@	HETERO LABS LTD V	2.5MG	A210066	001	Nov 21, 2023	Apr DISC
		@		5MG	A210066	002	Nov 21, 2023	Apr DISC
		@	IMPAX	2.5MG	A209810	001	Feb 14, 2025	Jul DISC
	AB			2.5MG	A209810	001	Feb 14, 2025	Feb NEWA
		@		5MG	A209810	002	Feb 14, 2025	Jul DISC
	AB			5MG	A209810	002	Feb 14, 2025	Feb NEWA
		@	MACLEODS PHARMS LTD	2.5MG	A210067	001	Feb 27, 2025	Jun DISC
	AB			2.5MG	A210067	001	Feb 27, 2025	Feb NEWA
		@		5MG	A210067	002	Feb 27, 2025	Jun DISC
	AB			5MG	A210067	002	Feb 27, 2025	Feb NEWA
		@	TORRENT	2.5MG	A210156	001	Dec 17, 2024	Jun DISC
		@		5MG	A210156	002	Dec 17, 2024	Jun DISC

TABLET, FOR SUSPENSION;ORAL
ELIQUIS
+! BRISTOL MYERS SQUIBB 0.5MG N202155 003 Apr 17, 2025 Apr NEWA

APOMORPHINE HYDROCHLORIDE
SOLUTION;SUBCUTANEOUS
ONAPGO
+! MDD US 98MG/20ML (4.9MG/ML) N214056 001 Feb 03, 2025 Feb NEWA

APREMILAST
TABLET;ORAL
APREMILAST
@ GLENMARK PHARMS LTD 10MG A211674 001 Oct 16, 2023 Jun DISC
@ 20MG A211674 002 Oct 16, 2023 Jun DISC
@ 30MG A211674 003 Oct 16, 2023 Jun DISC
@ MACLEODS PHARMS LTD 10MG A211788 001 Nov 25, 2024 Jun DISC
@ 20MG A211788 002 Nov 25, 2024 Jun DISC
@ 30MG A211788 003 Nov 25, 2024 Jun DISC
@ TORRENT 10MG A211834 001 Jun 20, 2025 Jul DISC
AB 10MG A211834 001 Jun 20, 2025 Jun NEWA
@ 20MG A211834 002 Jun 20, 2025 Jul DISC
AB 20MG A211834 002 Jun 20, 2025 Jun NEWA
@ 30MG A211834 003 Jun 20, 2025 Jul DISC
AB 30MG A211834 003 Jun 20, 2025 Jun NEWA
TABLET, EXTENDED RELEASE;ORAL
OTEZLA XR
+! AMGEN INC 75MG N210745 001 Aug 29, 2025 Aug NEWA

APREPITANT
CAPSULE;ORAL
EMEND
@ + MSD 40MG N021549 003 Jun 30, 2006 Aug CAHN
AB + 80MG N021549 001 Mar 26, 2003 Aug CAHN
AB +! 125MG N021549 002 Mar 26, 2003 Aug CAHN

ARFORMOTEROL TARTRATE
SOLUTION;INHALATION
ARFORMOTEROL TARTRATE
AN AUCTA EQ 0.015MG BASE/2ML A218380 001 Feb 03, 2025 Jan NEWA
>D> AN MANKIND PHARMA EQ 0.015MG BASE/2ML A216128 001 Nov 15, 2022 Oct CHRS
>A> AN ! EQ 0.015MG BASE/2ML A216128 001 Nov 15, 2022 Oct CHRS
AN MICRO LABS EQ 0.015MG BASE/2ML A218555 001 Mar 07, 2025 Feb NEWA
AN NEOCUBES PHARMA EQ 0.015MG BASE/2ML A216303 001 May 17, 2024 Sep CAHN
AN SABA ILAC SANAYI EQ 0.015MG BASE/2ML A218429 001 Apr 25, 2025 Apr NEWA
AN SLATE RUN PHARMA EQ 0.015MG BASE/2ML A213762 001 Jun 22, 2021 Sep CAHN
BROVANA
>D> AN +! LUPIN EQ 0.015MG BASE/2ML N021912 001 Oct 06, 2006 Oct DISC
>A> @ + EQ 0.015MG BASE/2ML N021912 001 Oct 06, 2006 Oct DISC

ARGATROBAN
INJECTABLE;INJECTION
ARGATROBAN
@ FRESENIUS KABI USA 250MG/2.5ML (100MG/ML) N201811 001 Mar 23, 2015 Jul DISC
INJECTABLE;INTRAVENOUS
ARGATROBAN IN SODIUM CHLORIDE
AP +! PLANO PHARMS 125MG/125ML (1MG/ML) N022485 001 May 09, 2011 Mar CAHN

ARIPIPRAZOLE
FILM;ORAL
MEZOFY
@ + CMG PHARM CO LTD 5MG N211448 001 Apr 15, 2025 Aug DISC
+ 5MG N211448 001 Apr 15, 2025 Apr NEWA
@ + 10MG N211448 002 Apr 15, 2025 Aug DISC
+! 10MG N211448 002 Apr 15, 2025 Apr NEWA
@ + 15MG N211448 003 Apr 15, 2025 Aug DISC
+ 15MG N211448 003 Apr 15, 2025 Apr NEWA
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY MAINTENA KIT
+ OTSUKA PHARM CO LTD 300MG/VIAL N202971 001 Feb 28, 2013 Jan CTEC
+! 400MG/VIAL N202971 002 Feb 28, 2013 Jan CTEC
+! 400MG N202971 004 Sep 29, 2014 Jul CHRS

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARIPIPRAZOLE

		@	MYLAN	300MG/VIAL	A216608	001	Dec 03, 2024	Jan DISC
		@		400MG/VIAL	A216608	002	Dec 03, 2024	Jan DISC

SOLUTION;ORAL
ARIPIPRAZOLE

>A>	AA		QUAGEN	1MG/ML	A215582	001	Oct 22, 2025	Oct NEWA
	AA		VISTAPHARM LLC	1MG/ML	A212870	001	Dec 26, 2019	Jan CAHN

TABLET;ORAL
ARIPIPRAZOLE

		@	RISING	2MG	A206240	001	Sep 19, 2018	Aug CAHN
		@		5MG	A206240	002	Sep 19, 2018	Aug CAHN
		@		10MG	A206240	003	Sep 19, 2018	Aug CAHN
		@		15MG	A206240	004	Sep 19, 2018	Aug CAHN
		@		20MG	A206240	005	Sep 19, 2018	Aug CAHN
		@		30MG	A206240	006	Sep 19, 2018	Aug CAHN

ARMODAFINIL

TABLET;ORAL
NUVIGIL

	AB	+	NUVO PHARMS	50MG	N021875	001	Jun 15, 2007	Jan CAHN
		@ +		100MG	N021875	002	Mar 26, 2009	Jan CAHN
	AB	+		150MG	N021875	003	Jun 15, 2007	Jan CAHN
	AB	+		200MG	N021875	005	Mar 26, 2009	Jan CAHN
	AB	+!		250MG	N021875	004	Jun 15, 2007	Jan CAHN

ARSENIC TRIOXIDE

INJECTABLE;INJECTION
ARSENIC TRIOXIDE

	AP		MSN	1MG/ML	A217413	001	Apr 20, 2023	Sep CAHN
	AP			2MG/ML	A217413	002	Apr 20, 2023	Sep CAHN
	AP		NOVAST LABS	1MG/ML	A209315	001	Nov 15, 2018	Aug CAHN
		@		2MG/ML	A209315	002	Jan 14, 2021	Aug CAHN

ARTICAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CYKLX

		+!	AM GENOMICS	EQ 8% BASE	N218643	001	Aug 15, 2025	Aug NEWA

ASCORBIC ACID

SOLUTION;INTRAVENOUS
ASCOR

	AP	+!	MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001	Oct 02, 2017	Aug CFTG

ASCORBIC ACID

	AP		FRESENIUS KABI USA	25,000MG/50ML (500MG/ML)	A217131	001	Aug 07, 2025	Aug NFTG

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID

		@	TARO	4.7GM;100GM;1.015GM;5.9GM;2.69 1GM;7.5GM	A207498	001	Jun 28, 2024	Aug DISC

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

	AA		MPP PHARMA	325MG;50MG;40MG	A078149	001	Jun 13, 2007	May CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL
CARISOPRODOL AND ASPIRIN

		@	CHARTWELL	325MG;200MG	A040116	001	Apr 25, 1996	Sep CAHN

ATENOLOL

TABLET;ORAL
ATENOLOL

	AB		AIPING PHARM INC	25MG	A072304	002	Jul 31, 1992	Jul CAHN
	AB			50MG	A072304	003	Jul 18, 1988	Jul CAHN
	AB			100MG	A072304	001	Jul 15, 1988	Jul CAHN
		@	NOVITIUM PHARMA	100MG	A073543	001	Dec 19, 1991	Aug CAHN
	AB		PHARMOBEDIENT	25MG	A073026	002	May 01, 1992	Sep CAHN
	AB			50MG	A073026	003	Sep 17, 1991	Sep CAHN

TABLET;ORAL
ATENOLOL

AB			100MG	A073026	001	Sep 17, 1991	Sep CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL
ATENOLOL AND CHLORTHALIDONE

AB		AIPING PHARM INC	50MG;25MG	A072302	002	May 31, 1990	Jul CAHN
AB			100MG;25MG	A072302	001	May 31, 1990	Jul CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL
ATOMOXETINE HYDROCHLORIDE

AB	!	HETERO LABS LTD V	EQ 60MG BASE	A202682	005	Mar 11, 2021	Aug CHRS
		STRATTERA					
	@ +	LILLY	EQ 10MG BASE	N021411	002	Nov 26, 2002	Aug DISC
	@ +		EQ 18MG BASE	N021411	003	Nov 26, 2002	Aug DISC
	@ +		EQ 25MG BASE	N021411	004	Nov 26, 2002	Aug DISC
	@ +		EQ 40MG BASE	N021411	005	Nov 26, 2002	Aug DISC
	@ +		EQ 60MG BASE	N021411	006	Nov 26, 2002	Aug DISC
	@ +		EQ 80MG BASE	N021411	007	Feb 14, 2005	Aug DISC
	@ +		EQ 100MG BASE	N021411	008	Feb 14, 2005	Aug DISC

ATORVASTATIN CALCIUM

TABLET;ORAL
ATORVASTATIN CALCIUM

AB		APOTEX	EQ 10MG BASE	A214969	001	Sep 02, 2021	Jun CAHN
AB			EQ 20MG BASE	A214969	002	Sep 02, 2021	Jun CAHN
AB			EQ 40MG BASE	A214969	003	Sep 02, 2021	Jun CAHN
AB			EQ 80MG BASE	A214969	004	Sep 02, 2021	Jun CAHN
	@	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Mar DISC
	@		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr DISC
	@		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr DISC
	@		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr DISC
>A> AB		TEVA PHARMS INC	EQ 10MG BASE	A220276	001	Nov 13, 2025	Oct NEWA
>A> AB			EQ 20MG BASE	A220276	002	Nov 13, 2025	Oct NEWA
>A> AB			EQ 40MG BASE	A220276	003	Nov 13, 2025	Oct NEWA
>A> AB			EQ 80MG BASE	A220276	004	Nov 13, 2025	Oct NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL
LYPQOZET

		NORVIUM BIOSCIENCE	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Aug CAHN
			EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Aug CAHN
			EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Aug CAHN
	!		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Aug CAHN

ATOVAQUONE

SUSPENSION;ORAL
ATOVAQUONE

	@	APOTEX	750MG/5ML	A209750	001	Oct 11, 2017	Mar DISC
AB		PAI HOLDINGS	750MG/5ML	A214272	001	Oct 25, 2021	Jun CAHN

ATRACURIUM BESYLATE

INJECTABLE;INJECTION
ATRACURIUM BESYLATE

	@	EUGIA PHARMA	10MG/ML	A206011	001	Apr 08, 2015	Jul DISC
		ATRACURIUM BESYLATE PRESERVATIVE FREE					
	@	EUGIA PHARMA	10MG/ML	A206010	001	Apr 08, 2015	Jul DISC

ATRASENTAN HYDROCHLORIDE

TABLET;ORAL
VANRAFIA

	+!	NOVARTIS	EQ 0.75MG BASE	N219208	001	Apr 02, 2025	Apr NEWA

ATROPINE SULFATE

SOLUTION;INTRAVENOUS
ATROPINE SULFATE

>D> AP	+!	ACCORD HLTHCARE	0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020	Oct DISC
>A>	@ +		0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020	Oct DISC
AP	+		1MG/ML (1MG/ML)	N214652	002	Sep 29, 2020	Sep CHRS
>D> AP		AM REGENT	0.4MG/ML (0.4MG/ML)	A216120	001	May 26, 2022	Oct CHRS

SOLUTION;INTRAVENOUS
ATROPINE SULFATE

>A>	AP	!		0.4MG/ML (0.4MG/ML)	A216120	001	May 26, 2022	Oct CHRS
	AP	!		1MG/ML (1MG/ML)	A216120	002	May 26, 2022	Sep CHRS
>A>	AP		HIKMA	0.4MG/ML (0.4MG/ML)	A217345	001	Oct 24, 2025	Oct NEWA
>A>	AP			1MG/ML (1MG/ML)	A217345	002	Oct 24, 2025	Oct NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

		+!	HIKMA	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Jul CRLD

TABLET;ORAL
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	AA		ANI PHARMS	0.025MG;2.5MG	A086727	001		Sep CMFD

AVANAFIL

TABLET;ORAL
STENDRA

	AB	+	VIVUS LLC	50MG	N202276	001	Apr 27, 2012	Jul CAHN
	AB	+		100MG	N202276	002	Apr 27, 2012	Jul CAHN
	AB	+!		200MG	N202276	003	Apr 27, 2012	Jul CAHN

AVATROMBOPAG MALEATE

GRANULE;ORAL
DOPTELET SPRINKLE

		+!	AKARX INC	EQ 10MG BASE	N219696	001	Jul 24, 2025	Jul NEWA

AVIBACTAM SODIUM; AZTREONAM

POWDER;INTRAVENOUS
EMBLAVEO

		+!	ABBVIE	EQ 0.5GM BASE/VIAL;1.5GM/VIAL	N217906	001	Feb 07, 2025	Feb NEWA

AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE

CAPSULE, TABLET;ORAL
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)

		+!	VERASTEM INC	EQ 0.8MG BASE;EQ 200MG BASE	N219616	001	May 08, 2025	May NEWA

AXITINIB

TABLET;ORAL
>A> AXITINIB

>A>	AB		APOTEX	1MG	A211650	001	Oct 30, 2025	Oct NFTG
>A>	AB			5MG	A211650	002	Oct 30, 2025	Oct NFTG

INLYTA

>D>		+	PF PRISM CV	1MG	N202324	001	Jan 27, 2012	Oct CFTG
>A>	AB	+		1MG	N202324	001	Jan 27, 2012	Oct CFTG
>D>		+!		5MG	N202324	002	Jan 27, 2012	Oct CFTG
>A>	AB	+!		5MG	N202324	002	Jan 27, 2012	Oct CFTG

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

	AP		RELIANCE LIFE	100MG/VIAL	A217453	001	May 20, 2025	May NEWA

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OPTIVAR

		@ +	RISING	0.05%	N021127	001	May 22, 2000	Sep CAHN

SPRAY, METERED;NASAL
ASTELIN

		@ +	RISING	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Sep CAHN

ASTEPRO

		@ +	NORVIUM BIOSCIENCE	0.137MG/SPRAY	N022203	001	Oct 15, 2008	Jan CAHN
		@		0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Jan CAHN
		@ +	VIATRIS	0.137MG/SPRAY	N022203	001	Oct 15, 2008	Apr CAHN
		@		0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Apr CAHN

AZELASTINE HYDROCHLORIDE

		@	BIONPHARMA	0.137MG/SPRAY	A090176	001	Jul 28, 2015	Jan DISC
		@	PADAGIS US	0.137MG/SPRAY	A202609	001	Mar 17, 2017	Aug DISC
	AB			0.137MG/SPRAY	A202609	001	Mar 17, 2017	Jun CAHN

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB		TEVA PHARMS USA INC	0.137MG/SPRAY;0.05MG/SPRAY	A	208436	001	Apr 08, 2025	Mar NEWA

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE

AB		ALKEM LABS LTD	EQ 40MG MEDOXOMIL;12.5MG	A	217490	001	Jan 21, 2025	Jan NFTG
AB			EQ 40MG MEDOXOMIL;25MG	A	217490	002	Jan 21, 2025	Jan NFTG

EDARBYCLOR

AB	+	AZURITY	EQ 40MG MEDOXOMIL;12.5MG	N	202331	001	Dec 20, 2011	Jan CFTG
AB	+!		EQ 40MG MEDOXOMIL;25MG	N	202331	002	Dec 20, 2011	Jan CFTG

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

	@	AMNEAL	EQ 100MG BASE/5ML	A	205666	001	Jul 19, 2018	Sep DISC
	@		EQ 200MG BASE/5ML	A	205666	002	Jul 19, 2018	Sep DISC
AB		CHARTWELL RX	EQ 100MG BASE/5ML	A	065488	001	May 15, 2015	Feb CMFD
AB			EQ 200MG BASE/5ML	A	065488	002	May 15, 2015	Feb CMFD
AB		ZHEJIANG POLY PHARM	EQ 100MG BASE/5ML	A	217036	001	Jul 27, 2023	Mar CAHN
AB			EQ 200MG BASE/5ML	A	217036	002	Jul 27, 2023	Mar CAHN

ZITHROMAX

	@ +	PFIZER	EQ 1GM BASE/PACKET	N	050693	001	Sep 28, 1994	Apr DISC

INJECTABLE;INJECTION

AZITHROMYCIN

	@	HOSPIRA	EQ 500MG BASE/VIAL	A	065511	001	Jun 26, 2009	Apr DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

LUMI-SPORYN

AT	+	CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N	050417	001		Feb CPOT

BACLOFEN

GRANULES;ORAL

LYVISPAH

	@ +	AMNEAL	5MG/PACKET	N	215422	001	Nov 22, 2021	Jun DISC
	@ +		10MG/PACKET	N	215422	002	Nov 22, 2021	Jun DISC
	@ +		20MG/PACKET	N	215422	003	Nov 22, 2021	Jun DISC

SOLUTION;ORAL

BACLOFEN

		RUBICON RESEARCH	5MG/5ML	A	214445	001	Dec 06, 2024	May CAHN
AA			10MG/5ML	A	214445	002	Jun 03, 2025	May NFTG

OZOBAX DS

AA	+!	METACEL PHARMS LLC	10MG/5ML	N	208193	002	Oct 12, 2023	May CFTG

TABLET;ORAL

BACLOFEN

AB		APPCO	5MG	A	090334	003	Jan 31, 2025	Jan NEWA
AB	!	RUBICON RESEARCH	5MG	A	209102	001	Nov 28, 2017	Jul CAHN
AB			10MG	A	209102	002	Nov 28, 2017	Jul CAHN
AB			15MG	A	209102	004	Feb 05, 2024	Jul CAHN
AB			20MG	A	209102	003	Nov 28, 2017	Jul CAHN
AB		YILING	10MG	A	074584	001	Aug 19, 1996	Jun CAHN
AB			20MG	A	074584	002	Aug 19, 1996	Jun CAHN

BALOXAVIR MARBOXIL

FOR SUSPENSION;ORAL

XOFLUZA

	+	GENENTECH INC	30MG/PACKET	N	214410	002	May 30, 2025	Jun NEWA
	+!		40MG/PACKET	N	214410	003	May 30, 2025	Jun NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB		CARNEGIE	750MG	A	219422	001	Apr 03, 2025	Mar NEWA
>D>	@	NOVITIUM PHARMA	750MG	A	077807	001	Dec 28, 2007	Oct CMFD
>A> AB			750MG	A	077807	001	Dec 28, 2007	Oct CMFD

TABLET;ORAL
BALSALAZIDE DISODIUM

	@	AARXION ANDA HLDING	1.1GM	A206336	001	Sep 08, 2015	Aug CAHN

BARICITINIB

TABLET;ORAL
OLUMIANT

AB	+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019	Aug CTEC
AB	+		2MG	N207924	001	May 31, 2018	Aug CTEC
AB	+!		4MG	N207924	003	May 10, 2022	Aug CFTG
AB		MSN	1MG	A217585	001	Aug 08, 2025	Aug NEWA
AB			2MG	A217585	002	Aug 08, 2025	Aug NEWA
AB			4MG	A217585	003	Aug 08, 2025	Aug NFTG

BARIUM SULFATE

FOR SUSPENSION;ORAL
E-Z-CAT DRY

	@ +	BRACCO	40%	N208036	003	Jan 03, 2017	Aug CPOT

E-Z-HD

	+!	BRACCO	98%	N208036	001	Jan 11, 2016	Aug CPOT

E-Z-PAQUE

	+!	BRACCO	96%	N208036	002	Apr 07, 2017	Aug CPOT

VARIBAR THIN LIQUID

	+!	BRACCO	81%	N208036	004	Apr 30, 2019	Aug CPOT

SUSPENSION;ORAL
ENTERO VU 24%

	+!	BRACCO	24%	N208143	008	May 29, 2020	Aug CPOT

LIQUID E-Z-PAQUE

	+!	BRACCO	60%	N208143	003	Mar 01, 2017	Aug CPOT

READI-CAT 2

	+!	BRACCO	2%	N208143	001	Jan 15, 2016	Aug CPOT

READI-CAT 2 SMOOTHIE

	+!	BRACCO	2%	N208143	002	Jan 15, 2016	Aug CPOT

TAGITOL V

	+!	BRACCO	40%	N208143	005	Aug 04, 2017	Aug CPOT

VARIBAR HONEY

	+!	BRACCO	40%	N208143	007	Mar 26, 2018	Aug CPOT

VARIBAR NECTAR

	+!	BRACCO	40%	N208143	004	Jul 07, 2017	Aug CPOT

VARIBAR THIN HONEY

	+!	BRACCO	40%	N208143	006	Jan 23, 2018	Aug CPOT

TABLET;ORAL
E-Z-DISK

	+!	BRACCO	700MG	N219840	001	Aug 01, 2025	Aug NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION
QVAR 40

	@ +	TEVA BRANDED PHARM	0.04MG/INH	N020911	002	Sep 15, 2000	Mar CAHN

QVAR 80

	@ +	TEVA BRANDED PHARM	0.08MG/INH	N020911	001	Sep 15, 2000	Mar CAHN

AEROSOL, METERED;NASAL
QNASL

	+	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014	Feb CAHN
	+!		0.08MG/ACTUATION	N202813	001	Mar 23, 2012	Feb CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER;INTRAVENOUS
BENDAMUSTINE HYDROCHLORIDE

	@	APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023	May DISC
	@		100MG/VIAL	A204230	002	Jun 05, 2023	May DISC

SOLUTION;INTRAVENOUS
BENDAMUSTINE HYDROCHLORIDE

	@ +	DR REDDYS	100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Jul DISC
	+!		100MG/4ML (25MG/ML)	N219014	001	Jul 03, 2025	Jul NEWA

BENZOYL PEROXIDE

CREAM;TOPICAL

EPSOLAY

	+!	MAYNE PHARMA	5%	N214510	001	Apr 22, 2022	May	CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>D>	@	ENCUBE	5%;EQ 1% BASE	A204087	001	Jun 27, 2017	Oct	CMFD
>A> AB			5%;EQ 1% BASE	A204087	001	Jun 27, 2017	Oct	CMFD

BENZOYL PEROXIDE; TRETINOIN

CREAM;TOPICAL

TWYNEO

	+!	MAYNE PHARMA	3%;0.1%	N214902	001	Jul 26, 2021	May	CAHN

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA		QUAGEN	0.5MG	A212694	001	Feb 11, 2025	Jan	NEWA
AA			1MG	A212694	002	Feb 11, 2025	Jan	NEWA
AA			2MG	A212694	003	Feb 11, 2025	Jan	NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

	@	CHARTWELL MOLECULAR	EQ 0.05% BASE	A076603	001	Jan 23, 2004	Feb	CAHN
	@	GLENMARK PHARMS INC	EQ 0.05% BASE	A078930	001	Sep 23, 2008	Jul	DISC
AB	!	TARO	EQ 0.05% BASE	A076543	001	Dec 09, 2003	Jul	CHRS

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

	@	TARO	EQ 0.05% BASE	A074271	001	Sep 15, 1994	Jul	DISC

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

	@	TARO	EQ 0.05% BASE	A076753	001	Oct 12, 2004	Aug	DISC

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

	@	PADAGIS ISRAEL	0.064%;0.005%	A212367	001	Sep 11, 2020	Jan	DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

	@	GLENMARK SPECLT	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015	Aug	DISC

BETAMETHASONE VALERATE

LOTION;TOPICAL

BETAMETHASONE VALERATE

>D> AB		KANCHAN HLTHCARE	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Oct	CAHN
AB			EQ 0.1% BASE	A070052	001	Jul 31, 1985	Aug	CAHN
>A> AB		SENORES PHARMS	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Oct	CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT		CHARTWELL RX	EQ 0.5% BASE	A078694	001	Nov 16, 2009	Aug	CAHN
	@	PHARMOBEDIENT	EQ 0.5% BASE	A075386	001	Jun 30, 2000	Sep	CAHN
	@	RENOVA PHARMS	EQ 0.5% BASE	A075386	001	Jun 30, 2000	Jun	CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA		HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Jul	CMFD
AA			10MG	A091256	002	May 04, 2010	Jul	CMFD
AA			25MG	A091256	003	May 04, 2010	Jul	CMFD
AA			50MG	A091256	004	May 04, 2010	Jul	CMFD

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

	@	CIPLA	75MG	A210352	001	Dec 10, 2024	Jan DISC

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

	@	APOTEX	50MG	A200274	001	May 21, 2015	Mar DISC

BIMATOPROST

GEL;OPHTHALMIC

ZOLYMBUS

	+!	THEA PHARMA	0.01%	N217307	001	Sep 09, 2025	Sep NEWA

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AB		AMNEAL	0.01%	A217289	001	Sep 22, 2025	Sep NEWA
AB		MANKIND PHARMA	0.01%	A218196	001	Mar 17, 2025	Mar NFTG

LUMIGAN

AB	+!	ABBVIE	0.01%	N022184	001	Aug 31, 2010	Mar CFTG

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

		RUBICON	2.5MG	A075643	003	Mar 07, 2025	Mar NEWA
AB		TP ANDA HOLDINGS	5MG	A075474	001	Oct 25, 2002	Aug CAHN
AB			10MG	A075474	002	Oct 25, 2002	Aug CAHN
AB		UNIQUE PHARM	5MG	A219044	001	Apr 16, 2025	Apr NEWA
AB			10MG	A219044	002	Apr 16, 2025	Apr NEWA

ZEBETA

	@ +	TEVA BRANDED PHARM	5MG	N019982	002	Jul 31, 1992	Apr CAHN
	@ +		10MG	N019982	001	Jul 31, 1992	Apr CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ZIAC

AB	+	TEVA BRANDED PHARM	2.5MG;6.25MG	N020186	003	Mar 26, 1993	Apr CAHN
AB	+		5MG;6.25MG	N020186	001	Mar 26, 1993	Apr CAHN
AB	+!		10MG;6.25MG	N020186	002	Mar 26, 1993	Apr CAHN

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

>D> AP		EUGIA PHARMA	250MG/VIAL	A205962	001	Jul 27, 2018	Oct DISC
>A>	@		250MG/VIAL	A205962	001	Jul 27, 2018	Oct DISC

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

	@	BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022	May DISC
AP		MEDICAMEN BIOTECH	3.5MG/VIAL	A218688	001	Jun 02, 2025	May NEWA
AP		VILIN BIO MED	3.5MG/VIAL	A218688	001	Jun 02, 2025	Aug CAHN

BOSENTAN

TABLET, FOR SUSPENSION;ORAL

BOSENTAN

AB		NATCO PHARMA LTD	32MG	A213154	001	Feb 05, 2025	Jan NFTG

TRACLEER

AB	+!	ACTELION	32MG	N209279	001	Sep 05, 2017	Jan CFTG

BOSUTINIB MONOHYDRATE

TABLET;ORAL

BOSULIF

AB	+!	PF PRISM CV	EQ 100MG BASE	N203341	001	Sep 04, 2012	May CFTG
AB	+		EQ 500MG BASE	N203341	002	Sep 04, 2012	May CFTG

BOSUTINIB MONOHYDRATE

AB		ALEMBIC	EQ 100MG BASE	A209543	001	May 23, 2025	May NFTG
AB			EQ 500MG BASE	A209543	002	May 23, 2025	May NFTG

BRENSOCATIB

TABLET;ORAL

BRINSUPRI

	+	INSMED INC	10MG	N217673	001	Aug 12, 2025	Aug NEWA
	+!		25MG	N217673	002	Aug 12, 2025	Aug NEWA

BREXANOLONE

SOLUTION;INTRAVENOUS

ZULRESSO

	@ +	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jan DISC

BREXPIPRAZOLE

TABLET;ORAL

BREXPIPRAZOLE

AB		ALEMBIC	0.25MG	A213683	001	Jan 13, 2025	Jan NEWA
AB			0.5MG	A213683	002	Jan 13, 2025	Jan NEWA
AB			1MG	A213683	003	Jan 13, 2025	Jan NEWA
AB			2MG	A213683	004	Jan 13, 2025	Jan NEWA
AB			3MG	A213683	005	Jan 13, 2025	Jan NEWA
AB			4MG	A213683	006	Jan 13, 2025	Jan NEWA
	@	APOTEX	0.25MG	A213731	001	Feb 24, 2025	Mar DISC
AB			0.25MG	A213731	001	Feb 24, 2025	Feb NEWA
	@		0.5MG	A213731	002	Feb 24, 2025	Mar DISC
AB			0.5MG	A213731	002	Feb 24, 2025	Feb NEWA
	@		1MG	A213731	003	Feb 24, 2025	Mar DISC
AB			1MG	A213731	003	Feb 24, 2025	Feb NEWA
	@		2MG	A213731	004	Feb 24, 2025	Mar DISC
AB			2MG	A213731	004	Feb 24, 2025	Feb NEWA
	@		3MG	A213731	005	Feb 24, 2025	Mar DISC
AB			3MG	A213731	005	Feb 24, 2025	Feb NEWA
	@	CHARTWELL RX	0.25MG	A213758	001	Oct 25, 2023	Sep CAHN
	@		0.5MG	A213758	002	Oct 25, 2023	Sep CAHN
	@		1MG	A213758	003	Oct 25, 2023	Sep CAHN
	@		2MG	A213758	004	Oct 25, 2023	Sep CAHN
	@		3MG	A213758	005	Oct 25, 2023	Sep CAHN
	@		4MG	A213758	006	Oct 25, 2023	Sep CAHN

REXULTI

AB	+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Jan CTEC
AB	+		0.5MG	N205422	002	Jul 10, 2015	Jan CTEC
AB	+		1MG	N205422	003	Jul 10, 2015	Jan CTEC
AB	+!		2MG	N205422	004	Jul 10, 2015	Jan CTEC
AB	+		3MG	N205422	005	Jul 10, 2015	Jan CTEC
AB	+		4MG	N205422	006	Jul 10, 2015	Jan CTEC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AB		UPSHER SMITH LABS	0.1%	A217599	001	Jul 30, 2025	Jul NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

	@	AMNEAL	0.2%;EQ 0.5% BASE	A217288	001	Dec 30, 2024	Jan DISC
AB		CAPLIN	0.2%;EQ 0.5% BASE	A219093	001	Feb 25, 2025	Feb NEWA
AB		REGCON HOLDINGS	0.2%;EQ 0.5% BASE	A201949	001	Oct 04, 2022	Sep CAHN

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

BRINZOLAMIDE

	@	PADAGIS US	1%	A211914	001	Jul 28, 2023	Jul DISC

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA	+	XTTRIUM LABS INC	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Feb CAHN

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		BIONPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	May CMFD
AA		HIBROW HLTHCARE	2MG/5ML;10MG/5ML;30MG/5ML	A211170	001	Jun 16, 2020	Sep CAHN
	@	TARO	2MG/5ML;10MG/5ML;30MG/5ML	A205112	001	Feb 27, 2017	Aug DISC

BUDESONIDE

SUSPENSION;INHALATION

BUDESONIDE

AN		EUGIA PHARMA	0.5MG/2ML	A216667	001	Nov 29, 2023	Aug CMFD
	@	SANDOZ	0.25MG/2ML	A201966	003	Sep 27, 2013	Feb DISC
	@		0.5MG/2ML	A201966	002	Sep 27, 2013	Feb DISC
	@		1MG/2ML	A201966	001	Sep 27, 2013	Feb DISC

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP		ASPIRO	0.25MG/ML	A218746	001	Feb 27, 2025	Feb NEWA

SPRAY;NASAL

ENBUMYST

	+!	CORSTASIS THERAP	0.5MG/SPRAY	N219500	001	Sep 12, 2025	Sep NEWA

TABLET;ORAL

BUMETANIDE

AB		JUBILANT GENERICS	0.5MG	A212470	001	Aug 05, 2025	Jul NEWA
AB			1MG	A212470	002	Aug 05, 2025	Jul NEWA
AB			2MG	A212470	003	Aug 05, 2025	Jul NEWA
AB		MANKIND PHARMA	0.5MG	A219291	001	Apr 03, 2025	Mar NEWA
AB			1MG	A219291	002	Apr 03, 2025	Mar NEWA
AB			2MG	A219291	003	Apr 03, 2025	Mar NEWA

BUPIVACAINE

INJECTABLE, LIPOSOMAL;INJECTION

BUPIVACAINE LIPOSOME

	@	HENGRUI PHARMA	133MG/10ML (13.3MG/ML)	A214348	001	Jul 01, 2024	Aug DISC
	@		266MG/20ML (13.3MG/ML)	A214348	002	Jul 01, 2024	Aug DISC

EXPAREL

	+!	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Aug CTEC
	+!		266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Aug CTEC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

AB		STRIDES PHARMA INTL	5MCG/HR	A207490	001	May 17, 2022	Sep CAHN
	@		7.5MCG/HR	A207490	005	Mar 21, 2023	Sep CAHN
AB			10MCG/HR	A207490	002	May 17, 2022	Sep CAHN
AB			15MCG/HR	A207490	003	May 17, 2022	Sep CAHN
AB			20MCG/HR	A207490	004	May 17, 2022	Sep CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP		SOMERSET THERAPS LLC	EQ 0.3MG BASE/ML	A219302	001	Jan 30, 2025	Jan NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

	@	PHARMOBEDIENT	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun CAHN
	@		EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		DIFGEN PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A212756	003	Feb 13, 2025	Feb NEWA
AB			EQ 4MG BASE;EQ 1MG BASE	A212756	004	Feb 13, 2025	Feb NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3		ANNORA PHARMA	150MG	A217898	001	Oct 01, 2025	Sep NEWA
AB3			300MG	A217898	002	Oct 01, 2025	Sep NEWA
AB1		AUROBINDO PHARMA USA	100MG	A090325	001	Apr 08, 2010	Aug CMFD
AB1			150MG	A090325	002	Apr 08, 2010	Aug CMFD
AB1			200MG	A090325	003	Apr 08, 2010	Aug CMFD
AB1		IPCA LABS LTD	100MG	A207874	001	May 02, 2025	Apr NEWA
AB1			150MG	A207874	002	May 02, 2025	Apr NEWA
AB1			200MG	A207874	003	May 02, 2025	Apr NEWA
	@	SUN PHARM	150MG	A200216	001	Nov 30, 2020	Feb DISC
	@		300MG	A203650	001	Dec 31, 2020	Feb DISC
	@	TWI PHARMS	150MG	A210081	001	Nov 03, 2017	Aug DISC

		TABLET, EXTENDED RELEASE;ORAL						
		BUPROPION HYDROCHLORIDE						
		@	300MG	A210081	002	Nov 03, 2017	Aug DISC
		FORFIVO XL						
>D>		@ + TWI PHARMS	450MG	N022497	001	Nov 10, 2011	Oct CMFD
>A>		+!	450MG	N022497	001	Nov 10, 2011	Oct CMFD
		@ +	450MG	N022497	001	Nov 10, 2011	Jun DISC
	BUSPIRONE HYDROCHLORIDE							
		CAPSULE;ORAL						
		BUCAPSOL						
>A>		EPIC PHARMA LLC	7.5MG	A218628	001	Mar 13, 2025	Oct CAHN
>A>			10MG	A218628	002	Mar 13, 2025	Oct CAHN
>A>			15MG	A218628	003	Mar 13, 2025	Oct CAHN
>A>		PANGEA	7.5MG	A218628	001	Mar 13, 2025	Oct CTNA
>A>			10MG	A218628	002	Mar 13, 2025	Oct CTNA
>A>			15MG	A218628	003	Mar 13, 2025	Oct CTNA
		BUSPIRONE HYDROCHLORIDE						
		EPIC PHARMA LLC	7.5MG	A218628	001	Mar 13, 2025	Feb NEWA
			10MG	A218628	002	Mar 13, 2025	Feb NEWA
			15MG	A218628	003	Mar 13, 2025	Feb NEWA
>D>		PANGEA	7.5MG	A218628	001	Mar 13, 2025	Oct CTNA
			7.5MG	A218628	001	Mar 13, 2025	Jul CAHN
>D>			10MG	A218628	002	Mar 13, 2025	Oct CTNA
			10MG	A218628	002	Mar 13, 2025	Jul CAHN
>D>			15MG	A218628	003	Mar 13, 2025	Oct CTNA
			15MG	A218628	003	Mar 13, 2025	Jul CAHN
		TABLET;ORAL						
		BUSPIRONE HYDROCHLORIDE						
	AB	ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Apr CHRS
	AB	AIPING PHARM INC	7.5MG	A202087	005	Jul 03, 2025	Jun NEWA
	BX	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Mar CTEC
	BX		7.5MG	A208972	002	Apr 16, 2019	Mar CTEC
	BX		10MG	A208972	003	Apr 16, 2019	Mar CTEC
	BX		15MG	A208972	004	Apr 16, 2019	Mar CTEC
	BX		30MG	A208972	005	Apr 16, 2019	Mar CTEC
	BX	INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Mar CTEC
	BX		7.5MG	A209696	002	May 03, 2018	Mar CTEC
	BX		10MG	A209696	003	May 03, 2018	Mar CTEC
	BX		15MG	A209696	004	May 03, 2018	Mar CTEC
	BX		30MG	A209696	005	May 03, 2018	Mar CTEC
	AB	RISING	7.5MG	A075413	004	Oct 06, 2025	Sep NEWA
	AB		30MG	A075413	005	Oct 06, 2025	Sep NEWA
	AB	! UNICHEM	15MG	A210907	003	Nov 14, 2019	Apr CHRS
	BUSULFAN							
		INJECTABLE;INJECTION						
		BUSULFAN						
		@ APOTEX	6MG/ML	A210448	001	May 07, 2019	Jan DISC
	BUTABARBITAL SODIUM							
		TABLET;ORAL						
		BUTISOL SODIUM						
		@ PHARMOBEDIENT	15MG	N000793	002		Sep CAHN
		@ +	30MG	N000793	004		Sep CAHN
		@	50MG	N000793	003		Sep CAHN
		@	100MG	N000793	005		Sep CAHN
	BUTORPHANOL TARTRATE							
		SPRAY, METERED;NASAL						
		BUTORPHANOL TARTRATE						
	AB	! HIKMA	1MG/SPRAY	A075824	001	Mar 12, 2002	May CHRS
		@ RISING	1MG/SPRAY	A075759	001	Aug 08, 2001	May DISC
		STADOL						
		@ + BRISTOL MYERS SQUIBB	1MG/SPRAY	N019890	001	Dec 12, 1991	May CRLD
	CABERGOLINE							
		TABLET;ORAL						
		CABERGOLINE						
	AB	AMNEAL	0.5MG	A218618	001	Jun 26, 2024	Sep CAHN

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFFEINE CITRATE

@	EUGIA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A	205013	001	Sep 22, 2015	Jul	DISC

SOLUTION;ORAL

CAFFEINE CITRATE

@	SUN PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A	090357	001	Sep 30, 2009	Feb	DISC

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

!	ANDA REPOSITORY	100MG;1MG	A	040590	001	Sep 16, 2005	Sep	CAHN

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

AP	AMNEAL	200 IU/ML	A	216294	001	Sep 26, 2025	Sep	NEWA
AP	SAGENT	200 IU/ML	A	219196	001	Jul 09, 2025	Jun	NEWA

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB	ONESOURCE SPECIALTY	0.25MCG	A	091356	001	Dec 12, 2014	Jun	CAHN
AB !		0.5MCG	A	091356	002	Dec 12, 2014	Jun	CAHN

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB	MPP PHARMA	667MG	A	203179	001	Oct 26, 2015	May	CAHN

PHOSLO

@	FRESENIUS MEDCL CARE	333.5MG	N	021160	001	Apr 02, 2001	Sep	CAHN
@		667MG	N	021160	002	Apr 02, 2001	Sep	CAHN

PHOSLO GELCAPS

@ +	FRESENIUS MEDCL CARE	667MG	N	021160	003	Apr 02, 2001	Sep	CAHN

SOLUTION;ORAL

PHOSLYRA

@ +	FRESENIUS MEDCL CARE	667MG/5ML	N	022581	001	Apr 18, 2011	Sep	CAHN

TABLET;ORAL

PHOSLO

@ +	FRESENIUS MEDCL CARE	667MG	N	019976	001	Dec 10, 1990	Sep	CAHN

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

AP	SQUARE PHARMS PLC	100MG/ML	A	217463	001	Sep 29, 2025	Sep	NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

@ +	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N	021703	010	Oct 10, 2008	Feb	CAHN

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N	021703	012	Oct 10, 2008	Feb	CAHN

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N	021703	011	Oct 10, 2008	Feb	CAHN

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

@ +	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N	021703	013	Oct 10, 2008	Feb	CAHN

INJECTABLE;INJECTION

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Feb CAHN

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Feb CAHN

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Feb CAHN

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Feb CAHN

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Feb CAHN

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Feb CAHN

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Feb CAHN

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Feb CAHN

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+!	VANTIVE US HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Feb CAHN

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

@ +	VANTIVE US HLTHCARE	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Feb CAHN

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Feb CAHN

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

+!	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	001	Nov 30, 1984	Feb CTEC

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

+!	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	002	Nov 30, 1984	Feb CTEC

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

+!	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	003	Nov 30, 1984	Feb CTEC

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	001		Feb CAHN

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;	N017512	003		Feb CAHN

SOLUTION;INTRAPERITONEAL

		DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
			392MG/100ML						
		DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2 MG/100ML;567MG/100ML;392MG/100 ML	N	017512	002			Feb CAHN
		DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	020183	001	Dec 04, 1992		Feb CAHN
		DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	020183	002	Dec 04, 1992		Feb CAHN
		DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
	@ +	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	020183	003	Dec 04, 1992		Feb CAHN
		DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N	020183	004	Dec 04, 1992		Feb CAHN
		DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	012	Jan 10, 1989		Feb CAHN
		DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	013	Jul 11, 1990		Feb CAHN
		DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER							
	+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	014	Jul 11, 1990		Feb CTEC
AT	+		18.3MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	014	Jul 11, 1990		Feb CAHN
		DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N	017512	015	Jul 11, 1990		Feb CAHN
		DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2M G/100ML;567MG/100ML;392MG/100M L	N	017512	007	Jul 09, 1984		Feb CAHN
		DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2M G/100ML;567MG/100ML;392MG/100M L	N	017512	008	Jul 09, 1984		Feb CAHN
		DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2M G/100ML;567MG/100ML;392MG/100M L	N	017512	010	Nov 18, 1985		Feb CAHN
		DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2 MG/100ML;567MG/100ML;392MG/100 ML	N	017512	009	Jul 09, 1984		Feb CAHN
		DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	004			Feb CAHN
AT	+		25.7MG/100ML;1.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	020163	001	Dec 04, 1992		Feb CAHN
		DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	005			Feb CAHN
AT	+		25.7MG/100ML;2.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	020163	002	Dec 04, 1992		Feb CAHN
		DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
	@ +	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08M G/100ML;538MG/100ML;448MG/100M L	N	017512	011	Nov 18, 1985		Feb CAHN

SOLUTION;INTRAPERITONEAL
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N017512	006			Feb CAHN
AT	+		25.7MG/100ML;4.25GM/100ML;5.08 MG/100ML;538MG/100ML;448MG/100 ML	N020163	003	Dec 04, 1992		Feb CAHN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+!	VANTIVE US HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314 GM/1000ML;2.21GM/1000ML;6.95GM /1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015		Feb CAHN

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+!	VANTIVE US HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015		Feb CAHN

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS
CALCIUM GLUCONATE IN SODIUM CHLORIDE

	!	AMNEAL	1GM/50ML (20MG/ML)	A217174	001	Sep 05, 2023		Aug CTEC
AP	!		1GM/50ML (20MG/ML)	A217174	001	Sep 05, 2023		Aug CHRS
	!		2GM/100ML (20MG/ML)	A217174	002	Sep 05, 2023		Aug CTEC
AP	!		2GM/100ML (20MG/ML)	A217174	002	Sep 05, 2023		Aug CHRS
	@ +	FRESENIUS KABI USA	1GM/50ML (20MG/ML)	N208418	004	Jun 17, 2021		Aug DISC
	@ +		2GM/100ML (20MG/ML)	N208418	005	Jun 17, 2021		Aug DISC

CANDESARTAN CILEXETIL

TABLET;ORAL
CANDESARTAN CILEXETIL

AB		ZYDUS LIFESCIENCES	4MG	A091390	001	Aug 23, 2017		Jan CMFD
AB			8MG	A091390	002	Aug 23, 2017		Jan CMFD
AB			16MG	A091390	003	Aug 23, 2017		Jan CMFD
AB			32MG	A091390	004	Aug 23, 2017		Jan CMFD

CANGRELOR

POWDER;INTRAVENOUS
CANGRELOR

AP		GLAND	50MG/VIAL	A213551	001	Aug 11, 2025		Aug NFTG

KENGREAL

AP	+!	CHIESI	50MG/VIAL	N204958	001	Jun 22, 2015		Aug CFTG

CAPECITABINE

TABLET;ORAL
CAPECITABINE

BX		TEYRO LABS	150MG	A217237	001	Oct 23, 2023		Mar CTEC
BX			500MG	A217237	002	Oct 23, 2023		Mar CTEC

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION
CAPREOMYCIN SULFATE

	@	PHARMOBEDIENT	EQ 1GM BASE/VIAL	A202634	001	Nov 27, 2017		Sep CAHN

CAPTOPRIL

TABLET;ORAL
CAPOTEN

	@ +	AARXION ANDA HLDING	12.5MG	N018343	005	Jan 17, 1985		Sep CAHN
	@ +		25MG	N018343	002			Sep CAHN
	@ +		37.5MG	N018343	006	Sep 17, 1986		Sep CAHN
	@ +		50MG	N018343	001			Sep CAHN
	@ +		75MG	N018343	007	Jun 13, 1995		Sep CAHN
	@ +		100MG	N018343	003			Sep CAHN
	@ +		150MG	N018343	004	Jun 13, 1995		Sep CAHN

CAPTOPRIL

AB		AIPING PHARM INC	12.5MG	A214442	001	Jan 27, 2023		Jul CAHN
AB			25MG	A214442	002	Jan 27, 2023		Jul CAHN
AB			50MG	A214442	003	Jan 27, 2023		Jul CAHN
AB			100MG	A214442	004	Jan 27, 2023		Jul CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		ANI PHARMS	100MG	A076697	001	May 20, 2011	May CAHN
AB			200MG	A076697	002	May 20, 2011	May CAHN
AB			300MG	A076697	003	May 20, 2011	May CAHN
	@	TARO	100MG	A201106	001	Jun 21, 2013	Aug DISC
	@		200MG	A201106	002	Jun 21, 2013	Aug DISC
	@		300MG	A201106	003	Jun 21, 2013	Aug DISC

TABLET;ORAL

CARBAMAZEPINE

AB		ALEMBIC	200MG	A216623	001	Apr 16, 2025	Apr NEWA

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		ALEMBIC	100MG	A219939	001	Jul 25, 2025	Jul NEWA
AB			200MG	A219939	002	Jul 25, 2025	Jul NEWA
AB			400MG	A219939	003	Jul 25, 2025	Jul NEWA
AB		ALKEM LABS LTD	100MG	A217277	001	Jan 14, 2025	Jan NEWA
AB			200MG	A217277	002	Jan 14, 2025	Jan NEWA
AB			400MG	A217277	003	Jan 14, 2025	Jan NEWA
	@	OSMOTICA PHARM US	100MG	A215664	001	Oct 22, 2024	Apr DISC
	@		200MG	A215664	002	Oct 22, 2024	Apr DISC
	@		400MG	A215664	003	Oct 22, 2024	Apr DISC
AB		SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Jun CAHN
AB			200MG	A216235	002	Mar 02, 2023	Jun CAHN
AB			400MG	A216235	003	Mar 02, 2023	Jun CAHN
AB		TORRENT	100MG	A212524	001	Jan 13, 2025	Jan NEWA
AB			200MG	A212524	002	Jan 13, 2025	Jan NEWA
AB			400MG	A212524	003	Jan 13, 2025	Jan NEWA
AB		YICHANG HUMANWELL	100MG	A219072	001	Jan 16, 2025	Jan NEWA
AB			200MG	A219072	002	Jan 16, 2025	Jan NEWA
AB			400MG	A219072	003	Jan 16, 2025	Jan NEWA

CARBIDOPA

TABLET;ORAL

CARBIDOPA

	@	ALVOGEN	25MG	A204291	001	Jan 08, 2016	Aug DISC

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		MACLEODS PHARMS LTD	12.5MG;200MG;50MG	A214495	001	Apr 15, 2025	Apr NEWA
AB			18.75MG;200MG;75MG	A214495	002	Apr 15, 2025	Apr NEWA
AB			25MG;200MG;100MG	A214495	003	Apr 15, 2025	Apr NEWA
AB			31.25MG;200MG;125MG	A214495	004	Apr 15, 2025	Apr NEWA
AB			37.5MG;200MG;150MG	A214495	005	Apr 15, 2025	Apr NEWA
AB			50MG;200MG;200MG	A214495	006	Apr 15, 2025	Apr NEWA
	@	SUN PHARM	25MG;200MG;100MG	A079085	001	May 10, 2012	Jul DISC
	@		37.5MG;200MG;150MG	A079085	002	May 10, 2012	Jul DISC

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

	@	APOTEX INC	10MG;100MG	A077120	001	Jun 02, 2008	Mar DISC
	@		25MG;100MG	A077120	002	Jun 02, 2008	Mar DISC
	@		25MG;250MG	A077120	003	Jun 02, 2008	Mar DISC
AB		ASCENT PHARMS INC	10MG;100MG	A218939	001	Jan 14, 2025	Jan NEWA
AB			25MG;100MG	A218939	002	Jan 14, 2025	Jan NEWA
AB			25MG;250MG	A218939	003	Jan 14, 2025	Jan NEWA
	@	NORVIUM BIOSCIENCE	10MG;100MG	A090324	001	Sep 28, 2009	Jul DISC
	@		25MG;250MG	A090324	003	Sep 28, 2009	Jun DISC

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

	@	APOTEX	25MG;100MG	A076212	001	Jun 16, 2004	Mar DISC
	@		50MG;200MG	A076212	002	Jun 16, 2004	Mar DISC

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

>D>	@	RISING	10MG;100MG	A078893	001	Sep 18, 2008	Oct CMFD
>A> AB			10MG;100MG	A078893	001	Sep 18, 2008	Oct CMFD
>D>	@		25MG;100MG	A078893	002	Sep 18, 2008	Oct CMFD
>A> AB			25MG;100MG	A078893	002	Sep 18, 2008	Oct CMFD

TABLET, ORALLY DISINTEGRATING;ORAL
CARBIDOPA AND LEVODOPA

>D>		@		25MG;250MG	A078893	003	Sep 18, 2008	Oct CMFD
>A>	AB			25MG;250MG	A078893	003	Sep 18, 2008	Oct CMFD
>D>			SUN PHARM	10MG;100MG	A078690	001	Jul 31, 2009	Oct CTEC
>A>	AB			10MG;100MG	A078690	001	Jul 31, 2009	Oct CTEC
>D>				25MG;100MG	A078690	002	Jul 31, 2009	Oct CTEC
>A>	AB			25MG;100MG	A078690	002	Jul 31, 2009	Oct CTEC
>D>		!		25MG;250MG	A078690	003	Jul 31, 2009	Oct CTEC
>A>	AB	!		25MG;250MG	A078690	003	Jul 31, 2009	Oct CTEC

CARBINOXAMINE MALEATE

TABLET;ORAL
CARBINOXAMINE MALEATE

>D>		@	ANDA REPOSITORY	4MG	A090435	001	Apr 15, 2010	Oct CAHN
>A>		@	SENORES PHARMS	4MG	A090435	001	Apr 15, 2010	Oct CAHN
		@		4MG	A090435	001	Apr 15, 2010	Jan CAHN

CARBOPLATIN

INJECTABLE;INTRAVENOUS
CARBOPLATIN

>D>	AP		FRESENIUS KABI USA	450MG/45ML (10MG/ML)	A077247	003	Oct 21, 2004	Oct DISC
>A>		@		450MG/45ML (10MG/ML)	A077247	003	Oct 21, 2004	Oct DISC

SOLUTION;INTRAVENOUS
KYXATA

		@ +	AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N219921	001	Aug 08, 2025	Sep DISC
		+!		20MG/2ML (10MG/ML)	N219921	001	Aug 08, 2025	Aug NEWA
		+!		80MG/8ML (10MG/ML)	N219921	002	Aug 08, 2025	Aug NEWA
		+!		500MG/50ML (10MG/ML)	N219921	003	Aug 08, 2025	Aug NEWA

CARFILZOMIB

POWDER;INTRAVENOUS
KYPROLIS

		+!	ONYX PHARMS AMGEN	10MG/VIAL	N202714	003	Jun 07, 2018	Jun CHRS
		+!		30MG/VIAL	N202714	002	Jun 03, 2016	Jun CHRS

CARISOPRODOL

TABLET;ORAL
CARISOPRODOL

	AA		FOSUN WANBANG	350MG	A081025	001	Apr 13, 1989	Jan CAHN
	AB		HERITAGE	250MG	A205126	001	Jul 08, 2015	Jun CAHN
	AA			350MG	A205126	002	Jul 08, 2015	Jun CAHN
	AB		INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun CAHN
	AA			350MG	A205126	002	Jul 08, 2015	Jun CAHN
	AB		MPP PHARMA	250MG	A207237	001	May 11, 2017	May CAHN
	AA			350MG	A207237	002	Sep 21, 2020	May CAHN
	AA		POINTVIEW HLDINGS	350MG	A211789	001	Oct 20, 2021	Apr CAHN

CARMUSTINE

INJECTABLE;INJECTION
CARMUSTINE

		@	HENGRUI PHARMA	100MG/VIAL	A211202	001	Mar 12, 2021	Sep DISC
		@	NOVAST LABS	100MG/VIAL	A211011	001	Jun 21, 2022	Aug CAHN

CARVEDILOL

TABLET;ORAL
CARVEDILOL

	AB		GRAVITI PHARMS	3.125MG	A076649	001	Sep 05, 2007	Feb CAHN
	AB			6.25MG	A076649	002	Sep 05, 2007	Feb CAHN
	AB			12.5MG	A076649	003	Sep 05, 2007	Feb CAHN
	AB			25MG	A076649	004	Sep 05, 2007	Feb CAHN
		@	NORVIUM BIOSCIENCE	3.125MG	A077316	001	Sep 05, 2007	Feb CAHN
		@		6.25MG	A077316	002	Sep 05, 2007	Mar DISC
	AB			6.25MG	A077316	002	Sep 05, 2007	Feb CAHN
		@		12.5MG	A077316	003	Sep 05, 2007	Apr DISC
	AB			12.5MG	A077316	003	Sep 05, 2007	Feb CAHN
		@		25MG	A077316	004	Sep 05, 2007	Apr DISC
	AB			25MG	A077316	004	Sep 05, 2007	Feb CAHN
		@	TARO	3.125MG	A077780	001	Sep 05, 2007	Aug DISC
		@		6.25MG	A077780	002	Sep 05, 2007	Aug DISC
		@		12.5MG	A077780	003	Sep 05, 2007	Aug DISC
		@		25MG	A077780	004	Sep 05, 2007	Aug DISC

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

COREG CR

AB	+	WAYLIS THERAP	10MG	N022012	001	Oct 20, 2006	Jun	CMFD
AB	+		20MG	N022012	002	Oct 20, 2006	Jun	CMFD
AB	+		40MG	N022012	003	Oct 20, 2006	Jun	CMFD
AB	+		80MG	N022012	004	Oct 20, 2006	Jun	CMFD

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CASPOFUNGIN ACETATE

AP		HANGZHOU ZHONGMEI	50MG/VIAL	A216506	001	Jul 18, 2025	Jul	NEWA
AP			70MG/VIAL	A216506	002	Jul 18, 2025	Jul	NEWA

CEDAZURIDINE; DECITABINE

TABLET;ORAL

INQOVI

	+!	TAIHO ONCOLOGY	100MG;35MG	N212576	001	Jul 07, 2020	Feb	CAHN

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

		QILU ANTIBIOTICS	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A203661	001	Dec 28, 2015	Jan	CAHN
			EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022	Jan	CAHN
AP	!		EQ 10GM BASE/VIAL	A209217	001	Oct 17, 2018	Jan	CAHN
>D> AP		SANDOZ	EQ 1GM BASE/VIAL	A065345	001	May 09, 2007	Oct	DISC
>A>	@		EQ 1GM BASE/VIAL	A065345	001	May 09, 2007	Oct	DISC

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

	!	QILU ANTIBIOTICS	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan	CAHN
AP	!		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan	CAHN
AP	!		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan	CAHN

CEFIXIME

FOR SUSPENSION;ORAL

CEFIXIME

AB		AJENAT PHARMS	100MG/5ML	A206938	001	Feb 06, 2017	Jul	CAHN
AB			200MG/5ML	A206938	002	Feb 06, 2017	Jul	CAHN
AB			500MG/5ML	A206939	001	Feb 06, 2017	Jul	CAHN

TABLET;ORAL

CEFIXIME

	@	FDC LTD	400MG	A206358	001	Dec 17, 2024	Jul	DISC

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

VANTIN

	@ +	PFIZER	EQ 50MG BASE/5ML	N050675	001	Aug 07, 1992	Mar	CAHN
	@ +		EQ 100MG BASE/5ML	N050675	002	Aug 07, 1992	Mar	CAHN

TABLET;ORAL

VANTIN

	@ +	PFIZER	EQ 100MG BASE	N050674	001	Aug 07, 1992	Mar	CAHN
	@ +		EQ 200MG BASE	N050674	002	Aug 07, 1992	Mar	CAHN

CEFPROZIL

FOR SUSPENSION;ORAL

CEFPROZIL

	@	APOTEX INC	125MG/5ML	A065351	001	Feb 29, 2012	Mar	DISC
	@		250MG/5ML	A065351	002	Feb 29, 2012	Mar	DISC

TABLET;ORAL

CEFPROZIL

	@	APOTEX INC	250MG	A065327	001	Mar 26, 2008	Mar	DISC
	@		500MG	A065327	002	Mar 26, 2008	Mar	DISC

CEFTIBUTEN DIHYDRATE

CAPSULE;ORAL

CEDAX

@	BURKE THERAP	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jul	CAHN

FOR SUSPENSION;ORAL

CEDAX

@ +	BURKE THERAP	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jul	CAHN
@ +		EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jul	CAHN

CEFTOBIPROLE MEDOCARIL SODIUM

POWDER;INTRAVENOUS

ZEVTERA

+!	ISTX	667MG/VIAL	N218275	001	Apr 03, 2024	Apr	CMFD
@ +		667MG/VIAL	N218275	001	Apr 03, 2024	Mar	CAHN

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AP	QILU ANTIBIOTICS	EQ 10GM BASE/VIAL	A209218	001	Oct 17, 2018	Jan	CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP	QILU ANTIBIOTICS	EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jan	CAHN

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

@	APOTEX	EQ 250MG BASE	A065069	001	Oct 02, 2002	Mar	DISC
@		EQ 500MG BASE	A065069	002	Oct 02, 2002	Mar	DISC

CELECOXIB

CAPSULE;ORAL

CELECOXIB

@	PANGEA	200MG	A212925	001	Dec 09, 2020	Feb	CAHN
@		400MG	A212925	002	Dec 09, 2020	Feb	CAHN
@	STRIDES PHARMA	100MG	A213127	001	Apr 29, 2025	Jul	DISC
AB		100MG	A213127	001	Apr 29, 2025	Apr	NEWA
@		200MG	A213127	002	Apr 29, 2025	Jul	DISC
AB		200MG	A213127	002	Apr 29, 2025	Apr	NEWA
@		400MG	A213127	003	Apr 29, 2025	Jul	DISC
AB		400MG	A213127	003	Apr 29, 2025	Apr	NEWA
AB	ZYDUS PHARMS	50MG	A205938	001	Jul 14, 2025	Jul	NEWA
AB		100MG	A205938	002	Jul 14, 2025	Jul	NEWA
AB		200MG	A205938	003	Jul 14, 2025	Jul	NEWA
AB		400MG	A205938	004	Jul 14, 2025	Jul	NEWA

SUSPENSION;ORAL

VYSCOXA

+!	CARWIN PHARM ASSOC	10MG/ML	N211759	001	Jul 29, 2025	Aug	CAHN
+!	CODADOSE INC	10MG/ML	N211759	001	Jul 29, 2025	Jul	NEWA

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

AB	AJENAT PHARMS	EQ 250MG BASE	A062713	001	Jul 15, 1988	Jul	CAHN
AB		EQ 500MG BASE	A062713	002	Jul 15, 1988	Jul	CAHN

TABLET;ORAL

CEPHALEXIN

	TEVA	EQ 250MG BASE	A063024	002	Jan 12, 1989	Aug	CMS1

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CETIRIZINE HYDROCHLORIDE

AA	BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	May	CMFD

ZYRTEC

@ +	J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb	CRLD

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS

CETRORELIX ACETATE

AP			XIROMED	EQ 0.25MG BASE/VIAL	A218061	001	Jun 03, 2025	May NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB			RUBICON	30MG	A216682	001	Apr 06, 2023	Jun CTEC
BX				30MG	A216682	001	Apr 06, 2023	Mar CTEC

CHENODIOL

TABLET;ORAL

CTEXLI

		+!	MIRUM	250MG	N219488	001	Feb 21, 2025	Feb NEWA

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

AP			SUN PHARM	EQ 500MG BASE/VIAL	A091546	001	Jul 26, 2011	Jun CMFD

CHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

CHLOROTHIAZIDE-RESERPINE

		@	PHARMOBEDIENT	500MG;0.125MG	A087745	001	May 06, 1982	Sep CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

		@	APOZEAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017	Apr CAHN
		@	SCIEGEN PHARMS INC	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017	Sep CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

>D>		!	GENUS	30MG/ML	A214542	001	Jun 02, 2021	Oct CTEC
>A>	AB	!		30MG/ML	A214542	001	Jun 02, 2021	Oct CTEC
>D>		!		100MG/ML	A214542	002	Jun 02, 2021	Oct CTEC
>A>	AB	!		100MG/ML	A214542	002	Jun 02, 2021	Oct CTEC
>A>	AB		RUBICON	30MG/ML	A216678	001	Oct 10, 2025	Oct NEWA
>A>	AB			100MG/ML	A216678	002	Oct 10, 2025	Oct NEWA

SONAZINE

		@	ALLIED	30MG/ML	A080983	004		Jul CAHN
		@		100MG/ML	A080983	005		Jul CAHN
		@	SAPTALIS PHARMS	30MG/ML	A080983	004		Sep CAHN
		@		100MG/ML	A080983	005		Sep CAHN

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB			AUROBINDO PHARMA LTD	10MG	A216788	001	Apr 25, 2025	Apr NEWA
AB				25MG	A216788	002	Apr 25, 2025	Apr NEWA
AB				50MG	A216788	003	Apr 25, 2025	Apr NEWA
AB				100MG	A216788	004	Apr 25, 2025	Apr NEWA
AB				200MG	A216788	005	Apr 25, 2025	Apr NEWA
AB			CHARTWELL RX	10MG	A212630	001	Nov 29, 2021	Sep CAHN
AB				25MG	A212630	002	Nov 29, 2021	Sep CAHN
AB				50MG	A212630	003	Nov 29, 2021	Sep CAHN
AB				100MG	A212630	004	Nov 29, 2021	Sep CAHN
AB				200MG	A212630	005	Nov 29, 2021	Sep CAHN
		@	SUN PHARM	10MG	A214256	001	Oct 26, 2020	Jul DISC
		@		25MG	A214256	002	Oct 26, 2020	Jul DISC
		@		50MG	A214256	003	Oct 26, 2020	Jul DISC
		@		100MG	A214256	004	Oct 26, 2020	Jul DISC
		@		200MG	A214256	005	Oct 26, 2020	Jul DISC
AB			ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Feb CAHN
AB				25MG	A212630	002	Nov 29, 2021	Feb CAHN
AB				50MG	A212630	003	Nov 29, 2021	Feb CAHN
AB				100MG	A212630	004	Nov 29, 2021	Feb CAHN
AB				200MG	A212630	005	Nov 29, 2021	Feb CAHN

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

	@		PHARMOBEDIENT	100MG	A088549	002	Jun 01, 1984	Sep CAHN
	@			250MG	A088549	001	Jun 01, 1984	Sep CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

	@		AIPING PHARM INC	25MG	A087380	001		Jan CAHN
	@			25MG	A087381	002		Aug CMS1
	@			50MG	A087381	001		Jan CAHN

HEMICLOR

	+!		PRM PHARMA	12.5MG	N218647	001	Mar 17, 2025	Mar NEWA

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AA			AJENAT PHARMS	250MG	A215540	001	Jan 24, 2023	Jan CAHN
AA	!		ANDA REPOSITORY	250MG	A207483	001	Jun 24, 2016	Sep CAHN
AB	!			375MG	A040861	001	Jun 01, 2010	Sep CAHN
AB	!			750MG	A040861	002	Jun 01, 2010	Sep CAHN
AB			APPCO	375MG	A212047	001	Jan 27, 2023	Mar CAHN
AB				750MG	A212047	002	Jan 27, 2023	Mar CAHN
	@		CHARTWELL RX	250MG	A087981	001	Sep 20, 1983	Apr CAHN
>D> AB			RISING	500MG	A213126	002	Apr 05, 2022	Oct CTEC
>A> AA				500MG	A213126	002	Apr 05, 2022	Oct CTEC

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

	@		AIPING PHARM INC	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Jul CAHN
	@			EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Jul CAHN

CHOLESTYRAMINE LIGHT

	@		MACLEODS PHARMS LTD	EQ 4GM RESIN/SCOOPFUL	A209109	001	Oct 31, 2024	Jun DISC
	@			EQ 4GM RESIN/PACKET	A209109	002	Oct 31, 2024	Jun DISC
AB			PHARMOBEDIENT CNSLTG	EQ 4GM RESIN/PACKET	A209599	001	Nov 12, 2020	Apr CAHN
AB				EQ 4GM RESIN/SCOOPFUL	A209599	002	Nov 12, 2020	Apr CAHN

PREVALITE

AB			AIPING PHARM INC	EQ 4GM RESIN/PACKET	A073263	001	Feb 22, 1996	Jul CAHN
AB				EQ 4GM RESIN/SCOOPFUL	A073263	002	Oct 30, 1997	Jul CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB	!		AUROBINDO PHARMA LTD	EQ 135MG FENOFIBRIC ACID	A212598	002	Jul 25, 2019	Apr CHRS

TRILIPIX

	@ +		ABBVIE	EQ 45MG FENOFIBRIC ACID	N022224	001	Dec 15, 2008	Jul DISC
	@ +			EQ 135MG FENOFIBRIC ACID	N022224	002	Dec 15, 2008	Apr DISC

CICLOPIROX

SHAMPOO;TOPICAL

CICLOPIROX

>D>	@		ENCUBE	1%	A209975	001	Apr 05, 2018	Oct CMFD
>A> AT				1%	A209975	001	Apr 05, 2018	Oct CMFD
AT	!		PADAGIS US	1%	A078594	001	Feb 16, 2010	Mar CHRS

LOPROX

	@ +		BAUSCH	1%	N021159	001	Feb 28, 2003	Mar DISC

SOLUTION;TOPICAL

CICLOPIROX

	@		TARO PHARM INDS	8%	A078144	001	Sep 18, 2007	Aug DISC

SUSPENSION;TOPICAL

CICLOPIROX

	@		TARO	0.77%	A077092	001	Aug 10, 2005	Aug DISC

CIDOFOVIR

SOLUTION;INTRAVENOUS

CIDOFOVIR

	AP		AVET LIFESCIENCES	EQ 75MG BASE/ML	A202501	001	Jul 26, 2012	May CDFR
	AP			EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A202501	001	Jul 26, 2012	May CPOT
	AP	!	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May CDFR
	AP	!		EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A201276	001	Jun 27, 2012	May CPOT

VISTIDE

	@	+	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May CDFR
	@	+		EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	N020638	001	Jun 26, 1996	May CPOT

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

	@		SANKALP LIFECARE	50MG	A077708	001	Sep 28, 2009	Apr CAHN
	@			100MG	A077708	002	Sep 28, 2009	Apr CAHN

CIMETIDINE

TABLET;ORAL

CIMETIDINE

	@		HIKMA	200MG	A074890	001	Dec 18, 1998	Jun CAHN
	@			300MG	A074890	002	Dec 18, 1998	Jun CAHN
	@			400MG	A074890	003	Dec 18, 1998	Jun CAHN
	@			800MG	A074890	004	Dec 18, 1998	Jun CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

	AB		PIRAMAL	EQ 30MG BASE	A210207	001	Aug 01, 2018	Jan CAHN
	AB			EQ 60MG BASE	A210207	002	Aug 01, 2018	Jan CAHN
	AB			EQ 90MG BASE	A210207	003	Aug 01, 2018	Jan CAHN
	@		RISING	EQ 30MG BASE	A203422	001	Oct 16, 2018	Aug CAHN
	@			EQ 60MG BASE	A203422	002	Oct 16, 2018	Aug CAHN
	@			EQ 90MG BASE	A203422	003	Oct 16, 2018	Aug CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN

>D>	AP	!	BAXTER HLTHCARE CORP	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Oct DISC
>A>		@		200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Oct DISC
>D>	AP	!		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Oct DISC
>A>		@		400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Oct DISC
>D>	AP		HIKMA FARMACEUTICA	200MG/20ML (10MG/ML)	A076717	001	Dec 22, 2009	Oct CHRS
>A>	AP	!		200MG/20ML (10MG/ML)	A076717	001	Dec 22, 2009	Oct CHRS
>A>		!		200MG/20ML (10MG/ML)	A076717	001	Dec 22, 2009	Oct CTEC
>D>	AP			400MG/40ML (10MG/ML)	A076717	002	Dec 22, 2009	Oct CHRS
>A>	AP	!		400MG/40ML (10MG/ML)	A076717	002	Dec 22, 2009	Oct CHRS
>A>		!		400MG/40ML (10MG/ML)	A076717	002	Dec 22, 2009	Oct CTEC

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

	@		PHARMOBEDIENT	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Sep CAHN

SOLUTION/DROPS;OTIC

CETRAXAL

	AB	+!	LAB SALVAT	EQ 0.2% BASE	N021918	001	May 01, 2009	Aug CAHN

CIPROFLOXACIN HYDROCHLORIDE

	AB		NEW HEIGHTSRX	EQ 0.2% BASE	A217887	001	Nov 05, 2024	Jul CAHN

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

>D>		+!	SANDOZ	EQ 0.2% BASE;1%	N020805	001	Feb 10, 1998	Oct CFTG
>A>	AB	+!		EQ 0.2% BASE;1%	N020805	001	Feb 10, 1998	Oct CFTG

>A> CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE

>A>	AB		COSETTE PHARMS NC	EQ 0.2% BASE;1%	A218273	001	Nov 10, 2025	Oct NFTG

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPROFLOXACIN AND DEXAMETHASONE

AB		AMNEAL	0.3%;0.1%	A216501	001	Mar 22, 2024	Apr CTNA

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

	@	EUGIA PHARMA	EQ 2MG BASE/ML	A209144	001	May 08, 2020	Jul DISC
AP		GLAND	EQ 2MG BASE/ML	A215516	001	May 24, 2022	Mar CAHN
AP			EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar CAHN
AP			EQ 10MG BASE/ML	A215516	002	May 24, 2022	Mar CAHN
	@	HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Feb DISC
AP		HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb CMS1

CISATRACURIUM BESYLATE PRESERVATIVE FREE

	@	EUGIA PHARMA	EQ 2MG BASE/ML	A209665	001	Oct 27, 2020	Jul DISC
	@	HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Feb DISC
	@		EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Feb DISC

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

	@	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Mar DISC
	@		EQ 20MG BASE	A077046	002	Nov 24, 2004	Mar DISC
	@		EQ 40MG BASE	A077046	003	Nov 24, 2004	Mar DISC
	@	GLENMARK PHARMS LTD	EQ 10MG BASE	A077654	001	Feb 27, 2009	Aug DISC
	@		EQ 20MG BASE	A077654	002	Feb 27, 2009	Aug DISC
	@		EQ 40MG BASE	A077654	003	Feb 27, 2009	Aug DISC

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

	@	JUBILANT CADISTA	250MG	A206714	001	Apr 25, 2019	Apr CAHN
	@		500MG	A206714	002	Apr 25, 2019	Apr CAHN
AB		NOVITIUM PHARMA	250MG	A202710	001	Jun 10, 2013	Aug CAHN
AB			500MG	A202710	002	Jun 10, 2013	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB		MPP PHARMA	500MG	A203243	001	Feb 29, 2016	May CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

	@	ALMAJECT	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Feb DISC
	@		EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Feb DISC
	@	FRESENIUS KABI USA	EQ 150MG BASE/ML	A065346	001	Mar 29, 2007	Jun DISC
	@		EQ 150MG BASE/ML	A065347	001	May 09, 2007	Jun DISC

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		CARNEGIE	EQ 1% BASE	A219612	001	Jun 13, 2025	Jun NEWA

CLOBAZAM

FILM;ORAL

SYMPAZAN

	+	ASSERTIO SPECLTY	5MG	N210833	001	Nov 01, 2018	Aug CAHN
	+		10MG	N210833	002	Nov 01, 2018	Aug CAHN
	+!		20MG	N210833	003	Nov 01, 2018	Aug CAHN

SUSPENSION;ORAL

CLOBAZAM

	@	VISTAPHARM LLC	2.5MG/ML	A210746	001	Jul 10, 2019	Jan CAHN

TABLET;ORAL

CLOBAZAM

	@	CHARTWELL RX	10MG	A211959	001	Dec 09, 2020	Sep CAHN
	@		20MG	A211959	002	Dec 09, 2020	Sep CAHN
	@	ESJAY PHARMA	5MG	A209308	003	Oct 19, 2021	Feb CAHN
	@		10MG	A209308	001	Oct 22, 2018	Jul DISC
AB			10MG	A209308	001	Oct 22, 2018	Feb CAHN
	@		20MG	A209308	002	Oct 22, 2018	Feb CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

	@	NOVAST LABS	0.05%		A206805	001	Jul 31, 2017	Sep CAHN
	@	TARO	0.05%		A208563	001	Mar 14, 2024	Aug DISC

CREAM;TOPICAL

CLOBETASOL PROPIONATE

	@	GLENMARK SPECLT	0.05%		A209095	001	May 10, 2018	Jul DISC

LOTION;TOPICAL

CLOBETASOL PROPIONATE

	@	BEACH PRODS	0.05%		A208667	001	Nov 29, 2016	May CAHN

IMPEKLO

	@ +	NORVIUM BIOSCIENCE	0.05%		N213691	001	May 19, 2020	Jan CAHN

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

	@	GLENMARK SPECLT	0.05%		A208933	001	Mar 20, 2017	Jul DISC

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

	@	GLENMARK PHARMS LTD	0.05%		A210190	001	Apr 18, 2018	Jul DISC
	@	TARO	0.05%		A075363	001	Dec 29, 2000	Aug DISC

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

	@	GLENMARK SPECLT	0.05%		A209004	001	Mar 26, 2018	Jul DISC
	@	MACLEODS PHARMS LTD	0.05%		A214345	001	Dec 02, 2024	Jun DISC

SUSPENSION/DROPS;OPHTHALMIC

BYQLOVI

	+!	FORMOSA	0.05%		N218158	001	Mar 04, 2024	May CTNA
	+!		0.05%		N218158	001	Mar 04, 2024	Feb CAHN
	+!	HARROW EYE	0.05%		N218158	001	Mar 04, 2024	Sep CAHN

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP	!	MEITHEAL	20MG/20ML (1MG/ML)		A213461	001	Oct 23, 2020	Jul CHRS

CLOLAR

	@ +	GENZYME	20MG/20ML (1MG/ML)		N021673	001	Dec 28, 2004	Jul DISC

CLOMIPHENE CITRATE

TABLET;ORAL

CLOMIPHENE CITRATE

AB		ACCORD HLTHCARE	50MG		A219406	001	Oct 03, 2025	Sep NEWA
>A> AB		NOVITIUM PHARMA	50MG		A219781	001	Oct 17, 2025	Oct NEWA

MILOPHENE

AB		GRANATA BIO CORP	50MG		A072196	001	Dec 20, 1988	Aug CMFD
	@		50MG		A072196	001	Dec 20, 1988	Aug CAHN

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB		IXORA LIFESCIENCE	25MG		A211364	001	Feb 07, 2020	Sep CAHN
AB			50MG		A211364	002	Feb 07, 2020	Sep CAHN
AB			75MG		A211364	003	Feb 07, 2020	Sep CAHN
AB		LEADING	25MG		A211364	001	Feb 07, 2020	Jun CAHN
AB			50MG		A211364	002	Feb 07, 2020	Jun CAHN
AB			75MG		A211364	003	Feb 07, 2020	Jun CAHN

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

	@	SUN PHARM INDS INC	0.125MG		A078654	001	Aug 27, 2014	Jan DISC
	@		0.25MG		A078654	002	Aug 27, 2014	Jan DISC
	@		0.5MG		A078654	003	Aug 27, 2014	Jan DISC
	@		1MG		A078654	004	Aug 27, 2014	Jan DISC
	@		2MG		A078654	005	Aug 27, 2014	Jan DISC

CLONIDINE

SYSTEM;TRANSDERMAL

CLONIDINE

>D>	AB		INGENUS PHARMS LLC	0.1MG/24HR	A	076157	001	Aug 18, 2009	Oct DISC
>A>		@		0.1MG/24HR	A	076157	001	Aug 18, 2009	Oct DISC
	AB			0.1MG/24HR	A	076157	001	Aug 18, 2009	Sep CAHN
>D>	AB			0.2MG/24HR	A	076157	002	Aug 18, 2009	Oct DISC
>A>		@		0.2MG/24HR	A	076157	002	Aug 18, 2009	Oct DISC
	AB			0.2MG/24HR	A	076157	002	Aug 18, 2009	Sep CAHN
>D>	AB			0.3MG/24HR	A	076157	003	Aug 18, 2009	Oct DISC
>A>		@		0.3MG/24HR	A	076157	003	Aug 18, 2009	Oct DISC
	AB			0.3MG/24HR	A	076157	003	Aug 18, 2009	Sep CAHN

CLONIDINE HYDROCHLORIDE

SOLUTION;ORAL

JAVADIN

>A>			AZURITY	0.02MG/ML	N	220256	001	Oct 23, 2025	Oct NEWA

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

	@		RUBICON RESEARCH	0.1MG	A	210680	001	Apr 30, 2018	Apr CAHN
	AB1		SOMERSET THERAPS LLC	0.1MG	A	211433	001	Oct 12, 2018	Mar CMFD

CLOTRIMAZOLE

SOLUTION;TOPICAL

CLOTRIMAZOLE

	AT		TP ANDA HOLDINGS	1%	A	212281	001	Jul 25, 2019	Aug CAHN

SOLUTION/DROPS;OTIC

CLOTIC

>A>		+!	CARWIN PHARM ASSOC	1%	N	217628	001	Sep 26, 2025	Oct CAHN
>D>		+!	LAB SALVAT	1%	N	217628	001	Sep 26, 2025	Oct CAHN
		+!		1%	N	217628	001	Sep 26, 2025	Sep NEWA

CLOZAPINE

TABLET;ORAL

CLOZAPINE

	@		SUN PHARM INDS INC	25MG	A	075713	001	Nov 15, 2002	Apr DISC
	@			50MG	A	075713	003	Aug 19, 2005	Apr DISC
	@			100MG	A	075713	002	Nov 15, 2002	Apr DISC
	@			200MG	A	075713	004	Nov 07, 2017	Apr DISC

TABLET, ORALLY DISINTEGRATING;ORAL

FAZACLO ODT

>D>		@	JAZZ	50MG	N	021590	003	Jun 03, 2005	Oct CRLD
>A>		@ +		50MG	N	021590	003	Jun 03, 2005	Oct CRLD

COBICISTAT

TABLET;ORAL

TYBOST

>D>		+	GILEAD SCIENCES INC	90MG	N	203094	002	Jun 20, 2025	Oct DISC
>A>		@ +		90MG	N	203094	002	Jun 20, 2025	Oct DISC
		+		90MG	N	203094	002	Jun 20, 2025	Jul NEWA

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

		+	JANSSEN PRODS	150MG;EQ 675MG BASE	N	205395	002	Mar 21, 2025	Mar NEWA
		+!		150MG;EQ 800MG BASE	N	205395	001	Jan 29, 2015	Mar CPOT
		+!		150MG;800MG	N	205395	001	Jan 29, 2015	Mar CAIN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

>D>	AA	!	CHARTWELL	10MG/5ML;5MG/5ML;6.25MG/5ML	A	040660	001	Dec 07, 2006	Oct CAHN
	AA	!		10MG/5ML;5MG/5ML;6.25MG/5ML	A	040660	001	Dec 07, 2006	Sep CAHN
>A>	AA	!	GENUS LIFESCIENCES	10MG/5ML;5MG/5ML;6.25MG/5ML	A	040660	001	Dec 07, 2006	Oct CAHN

PROMETH VC W/ CODEINE

	@		CHARTWELL RX	10MG/5ML;5MG/5ML;6.25MG/5ML	A	088764	001	Oct 31, 1984	Apr CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		CHARTWELL RX	10MG/5ML;6.25MG/5ML	A	090180	001	Mar 17, 2010	Apr CAHN
AA	!	COSETTE	10MG/5ML;6.25MG/5ML	A	200386	001	Jun 29, 2012	May CAHN
AA		XTTRIUM LABS INC	10MG/5ML;6.25MG/5ML	A	088875	001	Dec 17, 1984	Feb CAHN

PROMETHAZINE WITH CODEINE

	@	PHARM ASSOC	10MG/5ML;6.25MG/5ML	A	040650	001	Jan 31, 2006	Jan DISC

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

	@	HIKMA	30MG/5ML	N	202245	001	Jun 30, 2011	Jun CAHN

TABLET;ORAL

CODEINE SULFATE

AB	+	HIKMA	15MG	N	022402	001	Jul 16, 2009	Jun CAHN
AB	+		30MG	N	022402	002	Jul 16, 2009	Jun CAHN
AB	+!		60MG	N	022402	003	Jul 16, 2009	Jun CAHN

COLESEVELAM HYDROCHLORIDE

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

	@	MACLEODS PHARMS LTD	625MG	A	204893	001	Apr 18, 2025	Jul DISC
AB			625MG	A	204893	001	Apr 18, 2025	Apr NEWA

COLESTIPOL HYDROCHLORIDE

TABLET;ORAL

COLESTIPOL HYDROCHLORIDE

AB		CARNEGIE	1GM	A	220012	001	Sep 15, 2025	Sep NEWA

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

	@	ADRASTEA PHARMA	EQ 150MG BASE/VIAL	A	064216	001	Feb 26, 1999	Jul DISC
	@	NEXUS	EQ 150MG BASE/VIAL	A	065177	001	Mar 19, 2004	Apr DISC
	@	PHARMOBEDIENT	EQ 150MG BASE/VIAL	A	064216	001	Feb 26, 1999	Sep CAHN

COPPER

SYSTEM;INTRAUTERINE

MIUDELLA

	+!	SEBELA WOMENS HLTH	N/A	N	218201	001	Feb 24, 2025	Feb NEWA

COPPER CU-64 DOTATATE

SOLUTION;INTRAVENOUS

DETECTNET

	+!	CURIUM	4mL (1mCi/ML)	N	213227	001	Sep 03, 2020	Jan CAHN

CROMOLYN SODIUM

CONCENTRATE;ORAL

GASTROCROM

AA	+!	VIATRIS SPECIALTY	100MG/5ML	N	020479	001	Feb 29, 1996	Feb CAHN

SOLUTION;INHALATION

CROMOLYN SODIUM

AN		FERA PHARMS LLC	10MG/ML	A	075437	001	Apr 21, 2000	Apr CAHN
	@	HIKMA	10MG/ML	A	075333	001	Apr 30, 2002	Jun CAHN

CUPRIC SULFATE

INJECTABLE;INJECTION

CUPRIC SULFATE

	!	AM REGENT	EQ 0.4MG COPPER/ML	A	216324	001	Dec 16, 2022	Jan CTEC
	@	APOTEX CORP	EQ 0.4MG COPPER/ML	A	218745	001	Aug 19, 2024	Jan DISC

CYANOCOBALAMIN

INJECTABLE;INJECTION

CYANOCOBALAMIN

>D>	@	EUGIA PHARMA	1MG/ML	A	213874	001	Dec 08, 2020	Oct CMFD
>A> AP			1MG/ML	A	213874	001	Dec 08, 2020	Oct CMFD
AP		MEITHEAL	1MG/ML	A	214316	001	Nov 15, 2024	Apr CAHN

DODEX

	@	ACCORD HLTHCARE	1MG/ML	A	083022	001		Jan DISC

SPRAY, METERED;NASAL
CALOMIST

	@	PH HEALTH	25MCG/SPRAY	N022102	001	Jul 27, 2007	Jul	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE
TABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

>D>	AB	SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Oct	DISC
>A>	@		5MG	A078722	001	May 12, 2008	Oct	DISC
>D>	AB		7.5MG	A078722	002	May 12, 2008	Oct	DISC
>A>	@		7.5MG	A078722	002	May 12, 2008	Oct	DISC
>D>	AB		10MG	A078722	003	May 12, 2008	Oct	DISC
>A>	@		10MG	A078722	003	May 12, 2008	Oct	DISC

TABLET;SUBLINGUAL
TONMYA

	+!	TONIX	2.8MG	N219428	001	Aug 15, 2025	Aug	NEWA

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
CYCLOMYDRIL

	+!	ALCON LABS INC	0.2%;1%	A084300	001		May	CRLD

CYCLOPHOSPHAMIDE
CAPSULE;ORAL
CYCLOPHOSPHAMIDE

AB		EIRGEN	25MG	A218282	001	Dec 03, 2024	Aug	CAHN
AB			50MG	A218282	002	Dec 03, 2024	Aug	CAHN
AB		SENORES PHARMS	25MG	A209872	001	May 07, 2018	Sep	CAHN
AB			50MG	A209872	002	May 07, 2018	Sep	CAHN
AB		TRI-SOURCE PHARMA	25MG	A218282	001	Dec 03, 2024	Apr	CAHN
AB			50MG	A218282	002	Dec 03, 2024	Apr	CAHN

SOLUTION;INTRAVENOUS
FRINDOVYX

	+!	AVYXA HOLDINGS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Sep	CTNA
	+!		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Sep	CTNA
	+!		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Sep	CTNA

CYCLOSPORINE
CAPSULE;ORAL
CYCLOSPORINE

AB1		QILU	25MG	A219049	001	Sep 15, 2025	Sep	NEWA
AB1			100MG	A219049	002	Sep 15, 2025	Sep	NEWA

EMULSION;OPHTHALMIC
CYCLOSPORINE

	@	APOTEX	0.05%	A207606	001	Jan 12, 2023	Apr	DISC
BX			0.05%	A207606	001	Jan 12, 2023	Mar	CTEC

SOLUTION;ORAL
CYCLOSPORINE

	@	ABBVIE	100MG/ML	A065025	001	Mar 03, 2000	Feb	DISC

CYPROHEPTADINE HYDROCHLORIDE
SYRUP;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA		INVATECH	2MG/5ML	A209108	001	Oct 16, 2018	Sep	CAHN

CYTARABINE; DAUNORUBICIN
POWDER;INTRAVENOUS
VYXEOS

	+!	JAZZ PHARMS THERAP	100MG;44MG	N209401	001	Aug 03, 2017	Jul	CAHN

DABIGATRAN ETEXILATE MESYLATE
CAPSULE;ORAL
DABIGATRAN ETEXILATE MESYLATE

AB		AUROBINDO PHARMA	EQ 75MG BASE	A208039	001	May 14, 2025	May	NEWA
AB			EQ 110MG BASE	A208039	002	May 14, 2025	May	NEWA
AB			EQ 150MG BASE	A208039	003	May 14, 2025	May	NEWA
	@	BRECKENRIDGE	EQ 75MG BASE	A207922	001	Dec 19, 2024	Jun	DISC
	@		EQ 110MG BASE	A207922	003	Dec 19, 2024	Jun	DISC
	@		EQ 150MG BASE	A207922	002	Dec 19, 2024	Jun	DISC
AB		DR REDDYS	EQ 75MG BASE	A208048	001	Jan 28, 2025	Jan	NEWA
AB			EQ 110MG BASE	A208048	002	Jan 28, 2025	Jan	NEWA
AB			EQ 150MG BASE	A208048	003	Jan 28, 2025	Jan	NEWA

CAPSULE;ORAL
DABIGATRAN ETEXILATE MESYLATE

	AB		MYLAN	EQ 75MG BASE	A208067	001	Feb 03, 2025	Jan NEWA
	AB			EQ 150MG BASE	A208067	002	Feb 03, 2025	Jan NEWA

DACARBAZINE

INJECTABLE;INJECTION
DACARBAZINE

		@	HOSPIRA	200MG/VIAL	A075940	001	Oct 18, 2001	Mar DISC

DALBAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS
DALBAVANCIN HYDROCHLORIDE

>A>	AP		FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A217591	001	Nov 10, 2025	Oct NEWA
>A>	AP		TEVA PHARMS INC	EQ 500MG BASE/VIAL	A219465	001	Oct 23, 2025	Oct NFTG

DALVANCE

>D>		+!	ABBVIE	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Oct CFTG
>A>	AP	+!		EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Oct CFTG

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL
AMPYRA

	AB	+!	MERZ	10MG	N022250	001	Jan 22, 2010	Feb CAHN

DALFAMPRIDINE

		@	SUN PHARM	10MG	A208292	001	May 21, 2019	Aug DISC

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL
QTERN

		@ +	ASTRAZENECA AB	5MG;EQ 5MG BASE	N209091	002	May 02, 2019	Jun DISC
		@ +		10MG;EQ 5MG BASE	N209091	001	Feb 27, 2017	Jun DISC

DAPSONE

GEL;TOPICAL
ACZONE

>D>	AB	+!	ABBVIE	5%	N021794	001	Jul 07, 2005	Oct CAHN
>A>	AB	+!	ALMIRALL	5%	N021794	001	Jul 07, 2005	Oct CAHN

DAPSONE

	AB		AUROBINDO PHARMA LTD	5%	A218457	001	Apr 04, 2025	Mar NEWA

TABLET;ORAL
DAPSONE

	AB		SOLIS PHARMS	25MG	A203887	001	May 06, 2016	Apr CAHN
	AB			100MG	A203887	002	May 06, 2016	Apr CAHN

DAPTOMYCIN

POWDER;INTRAVENOUS
DAPTOMYCIN

		@	FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jan DISC
		@	HANGZHOU ZHONGMEI	500MG/VIAL	A215215	001	Nov 26, 2021	Jun DISC
		@ +	MAIA PHARMS INC	350MG/VIAL	N217630	001	Nov 21, 2024	May DISC
		+!		500MG/VIAL	N217630	002	Nov 21, 2024	Jun CHRS
		+		500MG/VIAL	N217630	002	Nov 21, 2024	Jun CMFD
		@ +		500MG/VIAL	N217630	002	Nov 21, 2024	May DISC

DARUNAVIR

TABLET;ORAL
DARUNAVIR

	AB		ANNORA PHARMA	600MG	A216168	001	Jan 21, 2025	Jan NEWA
	AB			800MG	A216168	002	Jan 21, 2025	Jan NEWA
	AB		HETERO LABS LTD III	400MG	A202083	001	Sep 14, 2023	Jul CTEC
	AB		MYLAN	75MG	A202136	001	Jul 22, 2025	Jul NFTG
	AB			150MG	A202136	002	Jul 22, 2025	Jul NFTG
				300MG	A202136	003	Jul 22, 2025	Jul NFTG
	AB			400MG	A202136	004	Jul 22, 2025	Jul NEWA
	AB			600MG	A202136	005	Jul 22, 2025	Jul NEWA
		@	TEVA PHARMS USA	600MG	A202118	001	Nov 21, 2017	Jul DISC

PREZISTA

	AB	+	JANSSEN PRODS	75MG	N021976	004	Dec 18, 2008	Jul CFTG
	AB	+		150MG	N021976	005	Dec 18, 2008	Jul CFTG

DASATINIB

TABLET;ORAL

DASATINIB

>A>	AB		ALEMBIC	20MG	A216261	001	Nov 06, 2025	Oct NEWA
>A>	AB			50MG	A216261	002	Nov 06, 2025	Oct NEWA
>A>	AB			70MG	A216261	003	Nov 06, 2025	Oct NEWA
>A>	AB			80MG	A216261	004	Nov 06, 2025	Oct NEWA
>A>	AB			100MG	A216261	005	Nov 06, 2025	Oct NEWA
>A>	AB			140MG	A216261	006	Nov 06, 2025	Oct NEWA
	AB		BIOCON PHARMA	20MG	A217217	001	Mar 03, 2025	Feb NEWA
	AB			50MG	A217217	002	Mar 03, 2025	Feb NEWA
	AB			70MG	A217217	003	Mar 03, 2025	Feb NEWA
	AB			80MG	A217217	004	Mar 03, 2025	Feb NEWA
	AB			100MG	A217217	005	Mar 03, 2025	Feb NEWA
	AB			140MG	A217217	006	Mar 03, 2025	Feb NEWA
	AB		DR REDDYS	20MG	A213383	001	Mar 03, 2025	Feb NEWA
	AB			50MG	A213383	002	Mar 03, 2025	Feb NEWA
	AB			70MG	A213383	003	Mar 03, 2025	Feb NEWA
	AB			80MG	A213383	004	Mar 03, 2025	Feb NEWA
	AB			100MG	A213383	005	Mar 03, 2025	Feb NEWA
	AB			140MG	A213383	006	Mar 03, 2025	Feb NEWA
	AB		EUGIA PHARMA	20MG	A216547	001	Apr 22, 2025	Apr NEWA
	AB			50MG	A216547	002	Apr 22, 2025	Apr NEWA
	AB			70MG	A216547	003	Apr 22, 2025	Apr NEWA
	AB			80MG	A216547	004	Apr 22, 2025	Apr NEWA
	AB			100MG	A216547	005	Apr 22, 2025	Apr NEWA
	AB			140MG	A216547	006	Apr 22, 2025	Apr NEWA
	AB		LUPIN	20MG	A214350	001	Aug 25, 2025	Aug NEWA
	AB			50MG	A214350	002	Aug 25, 2025	Aug NEWA
	AB			70MG	A214350	003	Aug 25, 2025	Aug NEWA
	AB			80MG	A214350	004	Aug 25, 2025	Aug NEWA
	AB			100MG	A214350	005	Aug 25, 2025	Aug NEWA
	AB			140MG	A214350	006	Aug 25, 2025	Aug NEWA
	AB		TEVA PHARMS USA	20MG	A211094	001	Aug 27, 2025	Aug NEWA
	AB			50MG	A211094	002	Aug 27, 2025	Aug NEWA
	AB			70MG	A211094	003	Aug 27, 2025	Aug NEWA
	AB			80MG	A211094	004	Aug 27, 2025	Aug NEWA
	AB			100MG	A211094	005	Aug 27, 2025	Aug NEWA
	AB			140MG	A211094	006	Aug 27, 2025	Aug NEWA
	AB		ZYDUS PHARMS	20MG	A218719	001	Mar 03, 2025	Feb NEWA
	AB			50MG	A218719	002	Mar 03, 2025	Feb NEWA
	AB			70MG	A218719	003	Mar 03, 2025	Feb NEWA
	AB			80MG	A218719	004	Mar 03, 2025	Feb NEWA
	AB			100MG	A218719	005	Mar 03, 2025	Feb NEWA
	AB			140MG	A218719	006	Mar 03, 2025	Feb NEWA

PHYRAGO

		+	HANDA THERAP	20MG	N216099	001	Dec 05, 2023	Jan CAHN
		+		50MG	N216099	002	Dec 05, 2023	Jan CAHN
		+		70MG	N216099	003	Dec 05, 2023	Jan CAHN
		+		80MG	N216099	004	Dec 05, 2023	Jan CAHN
		+!		100MG	N216099	005	Dec 05, 2023	Jan CAHN
		+		140MG	N216099	006	Dec 05, 2023	Jan CAHN

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

	AP		ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Apr CHRS
	AP	!	DR REDDYS	50MG/VIAL	A203131	001	Jul 11, 2013	Apr CHRS
>D>	AP		EUGIA PHARMA	50MG/VIAL	A214569	001	Sep 20, 2021	Oct DISC
>A>		@		50MG/VIAL	A214569	001	Sep 20, 2021	Oct DISC

POWDER;INTRAVENOUS

DECITABINE

		@ +	SUN PHARM	50MG/VIAL	N205582	001	Jan 28, 2014	Aug DISC

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

	AB		AUROBINDO PHARMA	90MG	A215137	001	Sep 08, 2025	Aug NEWA
	AB			180MG	A215137	002	Sep 08, 2025	Aug NEWA
	AB			360MG	A215137	003	Sep 08, 2025	Aug NEWA
	AB		EPIC PHARMA LLC	90MG	A214559	001	Mar 09, 2021	Sep CAHN
	AB			180MG	A214559	002	Mar 09, 2021	Sep CAHN

GRANULE;ORAL
DEFERASIROX

AB			360MG	A214559	003	Mar 09, 2021	Sep CAHN

TABLET;ORAL
DEFERASIROX

AB		JUBILANT GENERICS	90MG	A211660	001	Apr 11, 2025	Apr NEWA
AB			180MG	A211660	002	Apr 11, 2025	Apr NEWA
AB			360MG	A211660	003	Apr 11, 2025	Apr NEWA
	@	SUN PHARM	90MG	A211641	001	Jan 02, 2020	Apr DISC
	@		180MG	A211641	003	Jun 15, 2020	Apr DISC
	@		360MG	A211641	002	Jan 02, 2020	Apr DISC

TABLET, FOR SUSPENSION;ORAL
DEFERASIROX

	@	PHARMOBEDIENT	125MG	A206585	001	May 17, 2024	Sep CAHN
	@		250MG	A206585	002	May 17, 2024	Sep CAHN
	@		500MG	A206585	003	May 17, 2024	Sep CAHN
	@	TORRENT	125MG	A209426	001	Nov 05, 2024	Jun DISC
	@		250MG	A209426	002	Nov 05, 2024	Jun DISC
	@		500MG	A209426	003	Nov 05, 2024	Jun DISC

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION
DESFERAL

AP	+!	MITEM PHARMA	500MG/VIAL	N016267	001		Aug CAHN
	@ +		2GM/VIAL	N016267	002	May 25, 2000	Aug CAHN

DEFLAZACORT

SUSPENSION;ORAL
DEFLAZACORT

AB		UPSHER SMITH LABS	22.75MG/ML	A216992	001	Aug 11, 2025	Aug NEWA
AB		ZYDUS LIFESCIENCES	22.75MG/ML	A220042	001	Oct 03, 2025	Sep NEWA

PYQUVI

AB		AUCTA	22.75MG/ML	A219417	001	Jun 30, 2025	Jun NEWA

TABLET;ORAL
DEFLAZACORT

AB		SUN PHARM	6MG	A217741	001	Mar 18, 2025	Mar NEWA
AB			18MG	A217741	002	Mar 18, 2025	Mar NEWA
AB			30MG	A217741	003	Mar 18, 2025	Mar NEWA
AB			36MG	A217741	004	Mar 18, 2025	Mar NEWA

JAYTHARI

AB		ZYDUS LIFESCIENCES	6MG	A219254	001	Apr 08, 2025	Mar NEWA
AB			18MG	A219254	002	Apr 08, 2025	Mar NEWA
AB			30MG	A219254	003	Apr 08, 2025	Mar NEWA
AB			36MG	A219254	004	Apr 08, 2025	Mar NEWA

DELGOCITINIB

CREAM;TOPICAL
ANZUPGO

	+!	LEO PHARMA AS	2%	N219155	001	Jul 23, 2025	Jul NEWA

DESLORATADINE

SOLUTION;ORAL
DESLORATADINE

	!	TARO	0.5MG/ML	A202936	001	May 26, 2016	Sep CMFD

TABLET;ORAL
DESLORATADINE

AB		AJENAT PHARMS	5MG	A078355	001	Apr 19, 2012	Jan CAHN

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION
DDAVP

AP	+!	NORDIC PHARMA	0.004MG/ML	N018938	001	Mar 30, 1984	Aug CAHN
	@		0.015MG/ML	N018938	002	Apr 25, 1995	Aug CAHN

TABLET;ORAL
DESMOPRESSIN ACETATE

	@	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May DISC
	@		0.2MG	A201831	002	May 28, 2015	May DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-21

AVERI

		AVION PHARMS	0.15MG;0.03MG	A218933	001	May 02, 2025	Apr NEWA

TABLET;ORAL-28

AVERI

AB		AVION PHARMS	0.15MG;0.03MG	A218933	002	May 02, 2025	Apr NEWA

DESONIDE

CREAM;TOPICAL

DESONIDE

AB	!	CADILA	0.05%	A210198	001	Nov 20, 2019	Jul CHRS
	@	GLENMARK SPECLT	0.05%	A209729	001	Jul 24, 2017	Jul DISC
	@ +	PADAGIS US	0.05%	N017010	001		Jul DISC

GEL;TOPICAL

DESONIDE

	!	SENORES PHARMS	0.05%	A202470	001	May 11, 2020	Sep CAHN

LOTION;TOPICAL

DESONIDE

AB	!	ALEMBIC	0.05%	A213632	001	Aug 24, 2020	Sep CHRS
	@	GLENMARK SPECLT	0.05%	A209494	001	Sep 26, 2017	Jul DISC

DESOWEN

	@	GALDERMA LABS LP	0.05%	A072354	001	Jan 24, 1992	Sep DISC

OINTMENT;TOPICAL

DESONIDE

	@	GLENMARK PHARMS LTD	0.05%	A209996	001	Sep 15, 2017	Jul DISC

DESOWEN

	@	GALDERMA LABS LP	0.05%	A071425	001	Jun 15, 1988	May DISC

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

	@	GLENMARK PHARMS LTD	0.25%	A202838	001	Sep 20, 2013	Jul DISC
AB	!	ZYDUS LIFESCIENCES	0.25%	A205206	001	Sep 19, 2017	Jul CHRS

SPRAY;TOPICAL

TOPICORT

AT	+!	SUN PHARMA CANADA	0.25%	N204141	001	Apr 11, 2013	Aug CAHN

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB		HIKMA	EQ 25MG BASE	A204083	002	Feb 16, 2016	Aug CMS1
AB			EQ 50MG BASE	A204083	003	Feb 16, 2016	Aug CMS1
AB		MACLEODS PHARMS LTD	EQ 50MG BASE	A211427	001	Jan 15, 2025	Jan NEWA
AB			EQ 100MG BASE	A211427	002	Jan 15, 2025	Jan NEWA
AB		MEDICAP LABS	EQ 50MG BASE	A204805	001	May 07, 2019	Feb CAHN
AB			EQ 100MG BASE	A204805	002	May 07, 2019	Feb CAHN

DEUTETRABENAZINE

TABLET;ORAL

AUSTEDO

	+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Feb CAHN
	+		6MG	N208082	001	Apr 03, 2017	Jan CTEC
	+		9MG	N208082	002	Apr 03, 2017	Feb CAHN
	+		9MG	N208082	002	Apr 03, 2017	Jan CTEC
	+!		12MG	N208082	003	Apr 03, 2017	Feb CAHN
	+!		12MG	N208082	003	Apr 03, 2017	Jan CTEC

DEUTETRABENAZINE

	@	AUROBINDO PHARMA LTD	6MG	A215971	001	Dec 26, 2024	Jan DISC
	@		9MG	A215971	002	Dec 26, 2024	Jan DISC
	@		12MG	A215971	003	Dec 26, 2024	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

AUSTEDO XR

	+	TEVA	24MG	N216354	003	Feb 17, 2023	Jul CHRS
	+!		48MG	N216354	007	May 29, 2024	Jul CHRS

DEXAMETHASONE

TABLET;ORAL

DEXAMETHASONE

AB	+	HIKMA	0.5MG	A084612	002			Apr CMS1
AB	+		0.75MG	A084612	003			Apr CMS1
AB	+!		1MG	A084612	004	Sep 15, 1983		Apr CMS1
AB	+		1.5MG	A084612	005			Apr CMS1
AB	+!		2MG	A084612	006			Apr CMS1
AB	+!		6MG	A084612	007	Sep 15, 1983		Apr CMS1
AB		PHARMOBEDIENT	1.5MG	A201270	001	Jul 17, 2017		Sep CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

	@	EUGIA PHARMA	EQ 4MG PHOSPHATE/ML	A206781	001	Dec 01, 2015		Jul DISC

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

POLMON

	!	CARWIN PHARM ASSOC	2MG/5ML	A202520	001	Jul 16, 2018		Mar CAHN
	!	CARWIN PHARMS	2MG/5ML	A202520	001	Jul 16, 2018		Feb CAHN
	!	PHARMOBEDIENT	2MG/5ML	A202520	001	Jul 16, 2018		Aug CAHN

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXLANSOPRAZOLE

>A> AB		ALEMBIC	30MG	A219115	001	Nov 12, 2025		Oct NEWA
>A> AB			60MG	A219115	002	Nov 12, 2025		Oct NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		HIKMA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	A206407	003	May 30, 2025		May NFTG
AP			EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020		May CAHN
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020		May CAHN

PRECEDEX

AP	+!	HOSPIRA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020		May CFTG

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		MEDICAP LABS	5MG	A078992	001	Nov 23, 2021		Feb CAHN
AB			10MG	A078992	002	Nov 23, 2021		Feb CAHN
AB			15MG	A078992	003	Nov 18, 2013		Feb CAHN
AB			30MG	A078992	004	Nov 18, 2013		Feb CAHN
AB			20MG	A078992	005	Nov 23, 2021		Feb CAHN
AB			40MG	A078992	006	Nov 23, 2021		Feb CAHN
	@	SUN PHARM INDS INC	5MG	A206734	001	Nov 05, 2021		Jul DISC
	@		10MG	A206734	002	Nov 05, 2021		Jul DISC
	@		15MG	A206734	003	Nov 05, 2021		Jul DISC
	@		20MG	A206734	004	Nov 05, 2021		Jul DISC
	@		25MG	A206734	005	Nov 05, 2021		Jul DISC
	@		30MG	A206734	006	Nov 05, 2021		Jul DISC
	@		35MG	A206734	007	Nov 05, 2021		Jul DISC
	@		40MG	A206734	008	Nov 05, 2021		Jul DISC

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

	@	RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017		Jan DISC
	@		5MG	A208756	002	Nov 20, 2017		Jan DISC
	@		10MG	A208756	003	Nov 20, 2017		Jan DISC

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP		MSN	EQ 250MG BASE/VIAL	A216748	001	Mar 26, 2025		Mar NEWA
AP			EQ 500MG BASE/VIAL	A216748	002	Mar 26, 2025		Mar NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE DM

AA	!	PAI HOLDINGS	15MG/5ML;6.25MG/5ML	A040649	001	Feb 14, 2006	Apr	CAHN

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		COSETTE	15MG/5ML;6.25MG/5ML	A091687	001	Jun 28, 2012	May	CAHN

PROMETHAZINE W/ DEXTROMETHORPHAN

AA		XTTRIUM LABS INC	15MG/5ML;6.25MG/5ML	A088864	001	Jan 04, 1985	Feb	CAHN

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

>D> AP	!	BELOTECA	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Oct	CAHN
>D> AP			50MG/10ML (5MG/ML)	A211998	001	Dec 26, 2019	Oct	CAHN
AP		GALENICUM HLTH	50MG/10ML (5MG/ML)	A216422	001	May 19, 2025	May	NEWA
>A> AP	!	REGCON HOLDINGS	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Oct	CAHN
>A> AP			50MG/10ML (5MG/ML)	A211998	001	Dec 26, 2019	Oct	CAHN

DIAZOXIDE CHOLINE

TABLET, EXTENDED RELEASE;ORAL

VYKAT XR

+		SOLENO THERAP	25MG	N216665	001	Mar 26, 2025	Mar	NEWA
+			75MG	N216665	002	Mar 26, 2025	Mar	NEWA
+!			150MG	N216665	003	Mar 26, 2025	Mar	NEWA

DICLOFENAC POTASSIUM

CAPSULE;ORAL

DICLOFENAC POTASSIUM

AB		ONESOURCE SPECIALTY	25MG	A210078	001	Dec 03, 2019	Jun	CAHN

ZIPSOR

AB	+!	ASIO HOLDINGS	25MG	N022202	001	Jun 16, 2009	Aug	CAHN

FOR SOLUTION;ORAL

CAMBIA

AB	+!	ASIO HOLDINGS	50MG	N022165	001	Jun 17, 2009	Aug	CAHN

DICLOFENAC POTASSIUM

AB		TORRENT	50MG	A215891	001	Jan 22, 2025	Jan	NEWA
AB		UMEDICA	50MG	A217010	001	Aug 29, 2025	Aug	NEWA

TABLET;ORAL

DICLOFENAC POTASSIUM

AB		RK PHARMA	50MG	A075463	001	Jul 26, 1999	Mar	CHRS
AB	!	RUBICON	50MG	A075229	001	Nov 20, 1998	Mar	CHRS
AB		UMEDICA	25MG	A215750	002	Jun 30, 2025	Jun	NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

BX		ALEMBIC	3%	A212351	001	Jul 27, 2022	Mar	CTEC

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AB		ENCUBE	2%	A217646	001	Apr 09, 2025	Mar	NEWA

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

AB		AUROBINDO PHARMA USA	50MG	A075281	002	Feb 12, 2002	Apr	CMFD
AB			75MG	A075281	003	Feb 12, 2002	Apr	CMFD
>A> AB		UMEDICA	25MG	A219945	001	Nov 05, 2025	Oct	NEWA
>A> AB			50MG	A219945	002	Nov 05, 2025	Oct	NEWA
>A> AB			75MG	A219945	003	Nov 05, 2025	Oct	NEWA

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB		NOVAST LABS	100MG	A216275	001	Sep 23, 2022	Apr	CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

AB		RISING	10MG	A219242	001	Jun 23, 2025	Jun	NEWA

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

@		NEXUS	10MG/ML	A206468	001	Feb 01, 2019	Apr	DISC

TABLET;ORAL
DICYCLOMINE HYDROCHLORIDE

AB		PRINSTON INC	20MG	A218310	001	Jun 06, 2025	May NEWA
AB		RUBICON RESEARCH	20MG	A216736	001	Dec 14, 2022	Mar CAHN
	!		40MG	A216736	002	Mar 25, 2025	Mar NEWA

DIETHYLPROPION HYDROCHLORIDE
TABLET;ORAL
TENUATE

	@ +	MPP PHARMA	25MG	N011722	002		Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
TENUATE DOSPAN

	@ +	ANI PHARMS	75MG	N012546	001		Apr CAHN

DIFELIKEFALIN ACETATE
SOLUTION;INTRAVENOUS
KORSUVA

	+!	VIFOR INTL	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021	Apr CAHN

DIFLUPREDNATE
EMULSION;OPHTHALMIC
DIFLUPREDNATE

AB		MYLAN LABS LTD	0.05%	A212566	001	Mar 20, 2025	Mar NEWA
AB		UPSHER SMITH LABS	0.05%	A218191	001	Feb 11, 2025	Jan NEWA

DIGOXIN
ELIXIR;ORAL
DIGOXIN

AA	+!	HIKMA	0.05MG/ML	N021648	001	Aug 26, 2004	Jun CAHN

DIHYDROERGOTAMINE MESYLATE
INJECTABLE;INJECTION
DIHYDROERGOTAMINE MESYLATE

	@	BAXTER HLTHCARE CORP	1MG/ML	A216747	001	Jan 07, 2025	Jun DISC
	@	CIPLA	1MG/ML	A212334	001	Sep 20, 2024	Jan DISC
AP		MILLA PHARMS	1MG/ML	A212046	001	Jan 07, 2020	Sep CAHN

POWDER;NASAL
ATZUMI

	+!	SATSUMA PHARMS	EQ 5.2MG BASE	N217901	001	Apr 30, 2025	Apr NEWA

SOLUTION;SUBCUTANEOUS
BREKIYA (AUTOINJECTOR)

	+!	AMNEAL	1MG/ML	N215400	001	May 14, 2025	May NEWA

SPRAY, METERED;NASAL
DIHYDROERGOTAMINE MESYLATE

AB		AGGREGA	0.5MG/SPRAY	A215228	001	Feb 26, 2025	Feb NEWA
AB		SOMERSET THERAPS LLC	0.5MG/SPRAY	A215228	001	Feb 26, 2025	Sep CAHN

DILTIAZEM HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB1		AMTA	60MG	A219073	001	Mar 24, 2025	Mar NEWA
AB1			90MG	A219073	002	Mar 24, 2025	Mar NEWA
AB1			120MG	A219073	003	Mar 24, 2025	Mar NEWA
AB1		NOVAST LABS	60MG	A218032	001	Jul 02, 2025	Jun NEWA
AB1			90MG	A218032	002	Jul 02, 2025	Jun NEWA
AB1			120MG	A218032	003	Jul 02, 2025	Jun NEWA
	@	SUN PHARM	120MG	A203023	001	Jun 08, 2017	Apr DISC
	@		180MG	A203023	002	Jun 08, 2017	Mar DISC
	@		240MG	A203023	003	Jun 08, 2017	Mar DISC
	@		300MG	A203023	004	Jun 08, 2017	Feb DISC
AB1		UTOPIC PHARMS	60MG	A219073	001	Mar 24, 2025	Apr CAHN
AB1			90MG	A219073	002	Mar 24, 2025	Apr CAHN
AB1			120MG	A219073	003	Mar 24, 2025	Apr CAHN

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE

	@	EUGIA PHARMA	5MG/ML	A216552	001	Mar 29, 2023	Aug DISC

SOLUTION;INTRAVENOUS
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

	+!	HQ SPCLT PHARMA	100MG/100ML (1MG/ML)	N218038	001	Feb 21, 2025	Feb NEWA
	+!		250MG/250ML (1MG/ML)	N218038	002	Feb 21, 2025	Feb NEWA

TABLET;ORAL
DILTIAZEM HYDROCHLORIDE

AB		ZYDUS LIFESCIENCES	30MG		A219253	001	Aug 08, 2025	Aug NEWA
AB			60MG		A219253	002	Aug 08, 2025	Aug NEWA
AB			90MG		A219253	003	Aug 08, 2025	Aug NEWA
AB			120MG		A219253	004	Aug 08, 2025	Aug NEWA

DIMETHYL FUMARATE
CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

	@	CIPLA	120MG		A210305	001	Sep 24, 2020	Feb DISC
	@		240MG		A210305	002	Sep 24, 2020	Feb DISC
	@	TORRENT	120MG		A210390	001	Jan 06, 2025	Jun DISC
	@		240MG		A210390	002	Jan 06, 2025	Jun DISC

DIPHENHYDRAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP		AVET LIFESCIENCES	50MG/ML		A205336	001	Jun 24, 2025	Jun NEWA
AP		MICRO LABS	50MG/ML		A219845	001	Aug 22, 2025	Aug NEWA
AP	!	NORVIUM BIOSCIENCE	50MG/ML		A040498	001	Jul 12, 2005	Feb CAHN

DIPYRIDAMOLE
TABLET;ORAL
DIPYRIDAMOLE

AB		BARR LABS	75MG		A087717	001	Oct 03, 1990	Mar CAHN

DIROXIMEL FUMARATE
CAPSULE, DELAYED RELEASE;ORAL
>A> DIROXIMEL FUMARATE

>A> AB		ZYDUS	231MG		A218596	001	Nov 12, 2025	Oct NFTG

VUMERITY

>D>	+!	BIOGEN INC	231MG		N211855	001	Oct 29, 2019	Oct CFTG
>A> AB	+!		231MG		N211855	001	Oct 29, 2019	Oct CFTG

DIVALPROEX SODIUM
CAPSULE, DELAYED REL PELLETS;ORAL
DIVALPROEX SODIUM

AB		MANKIND PHARMA	EQ 125MG VALPROIC ACID		A217358	001	Aug 12, 2025	Aug NEWA

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

	@	APOTEX	EQ 125MG VALPROIC ACID		A077615	003	Jul 29, 2008	Mar DISC
	@		EQ 250MG VALPROIC ACID		A077615	002	Jul 29, 2008	Mar DISC
	@		EQ 500MG VALPROIC ACID		A077615	001	Jul 29, 2008	Mar DISC

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

AB		SCIEGEN PHARMS INC	EQ 250MG VALPROIC ACID		A078705	002	Feb 10, 2009	Jul CAHN
AB			EQ 500MG VALPROIC ACID		A078705	001	Aug 04, 2009	Jul CAHN
	@	YICHANG HUMANWELL	EQ 250MG VALPROIC ACID		A214462	001	Mar 15, 2021	Jul CAHN
	@		EQ 500MG VALPROIC ACID		A214462	002	Mar 15, 2021	Jul CAHN

DOCETAXEL
INJECTABLE;INJECTION
DOCETAXEL

AP	!	AMNEAL	20MG/ML (20MG/ML)		A209640	001	Jan 19, 2018	Apr CHRS
AP	!		80MG/4ML (20MG/ML)		A209640	002	Jan 19, 2018	Apr CHRS
AP	!		160MG/8ML (20MG/ML)		A209640	003	Jan 19, 2018	Apr CHRS
	@	EUGIA PHARMA	20MG/2ML (10MG/ML)		A214575	001	Jun 25, 2021	Aug DISC
	@		80MG/8ML (10MG/ML)		A214575	002	Jun 25, 2021	Aug DISC
	@		160MG/16ML (10MG/ML)		A214575	003	Jun 25, 2021	Aug DISC
AP		GUANGDONG SUNHO	20MG/ML (20MG/ML)		A213768	001	May 13, 2025	May NEWA
AP			80MG/4ML (20MG/ML)		A213768	002	May 13, 2025	May NEWA
	@	NOVAST LABS	20MG/2ML (10MG/ML)		A207563	001	Aug 31, 2017	Sep CAHN
AP			80MG/8ML (10MG/ML)		A207563	002	Aug 31, 2017	Sep CAHN
AP			160MG/16ML (10MG/ML)		A207563	003	Aug 31, 2017	Sep CAHN

TAXOTERE

	@ +	SANOFI AVENTIS US	20MG/ML (20MG/ML)		N020449	003	Aug 03, 2010	Apr DISC
	@ +		80MG/4ML (20MG/ML)		N020449	004	Aug 02, 2010	Apr DISC
AP	+		160MG/8ML (20MG/ML)		N020449	005	Apr 13, 2012	Apr CHRS

		SOLUTION;INTRAVENOUS						
		BEIZRAY						
		+! ZHUHAI	80MG/4ML (20MG/ML)	N218711	001	Oct 23, 2024	Sep	CMFD
		@ +	80MG/4ML (20MG/ML)	N218711	001	Oct 23, 2024	Apr	DISC
>D>		DONEPEZIL HYDROCHLORIDE						
>D>		SYSTEM;TRANSDERMAL						
>D>		ADLARITY						
>D>		+ CORIUM	5MG/DAY	N212304	001	Mar 11, 2022	Oct	DISC
>A>		@ +	5MG/DAY	N212304	001	Mar 11, 2022	Oct	DISC
>D>		+!	10MG/DAY	N212304	002	Mar 11, 2022	Oct	DISC
>A>		@ +	10MG/DAY	N212304	002	Mar 11, 2022	Oct	DISC
		TABLET;ORAL						
		DONEPEZIL HYDROCHLORIDE						
>A>		@ AIPING PHARM INC	5MG	A090290	001	May 31, 2011	Oct	CAHN
>A>		@	10MG	A090290	002	May 31, 2011	Oct	CAHN
		@ INDICUS PHARMA	5MG	A201634	001	Jun 13, 2012	Apr	DISC
		@	10MG	A201634	002	Jun 13, 2012	Apr	DISC
>D>		@ SANDOZ	5MG	A090290	001	May 31, 2011	Oct	CAHN
>D>		@	10MG	A090290	002	May 31, 2011	Oct	CAHN
		TABLET, ORALLY DISINTEGRATING;ORAL						
		DONEPEZIL HYDROCHLORIDE						
>A>		@ AIPING PHARM INC	5MG	A091198	001	May 10, 2011	Oct	CAHN
>A>		@	10MG	A091198	002	May 10, 2011	Oct	CAHN
>D>		@ SANDOZ	5MG	A091198	001	May 10, 2011	Oct	CAHN
>D>		@	10MG	A091198	002	May 10, 2011	Oct	CAHN
		DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE						
		CAPSULE, EXTENDED RELEASE;ORAL						
		MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE						
	AB	AMNEAL	10MG;7MG	A208328	003	Feb 27, 2025	Feb	NFTG
	AB		10MG;21MG	A208328	004	Feb 27, 2025	Feb	NEWA
	AB	MACLEODS PHARMS LTD	10MG;14MG	A208672	001	Jul 15, 2025	Jul	NEWA
	AB		10MG;28MG	A208672	002	Jul 15, 2025	Jul	NEWA
	AB	XIAMEN LP PHARM CO	10MG;14MG	A216901	001	Jul 15, 2025	Jul	NEWA
	AB		10MG;28MG	A216901	002	Jul 15, 2025	Jul	NEWA
		NAMZARIC						
	AB	+ ABBVIE	10MG;7MG	N206439	003	Jul 18, 2016	Feb	CFTG
		DONIDALORSEN SODIUM						
		SOLUTION;SUBCUTANEOUS						
		DAWNZERA (AUTOINJECTOR)						
		+! IONIS PHARMS INC	EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML)	N219407	001	Aug 21, 2025	Aug	NEWA
		DORDAVIPRONE HYDROCHLORIDE						
		CAPSULE;ORAL						
		MODEYSO						
		+! CHIMERIX	EQ 125MG BASE	N219876	001	Aug 06, 2025	Aug	NEWA
		DORZOLAMIDE HYDROCHLORIDE						
		SOLUTION/DROPS;OPHTHALMIC						
		DORZOLAMIDE HYDROCHLORIDE						
	AT	SOMERSET THERAPS LLC	EQ 2% BASE	A215004	001	Feb 11, 2025	Jan	NEWA
		DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE						
		SOLUTION/DROPS;OPHTHALMIC						
		DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE						
	AT2	IDENTIRX	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	Feb	NEWA
	AT2	NEW HEIGHTSRX	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	Jul	CAHN
		DOXAZOSIN MESYLATE						
		TABLET;ORAL						
		DOXAZOSIN MESYLATE						
	AB	APPCO	EQ 1MG BASE	A209013	001	Apr 17, 2018	Mar	CAHN
	AB		EQ 2MG BASE	A209013	002	Apr 17, 2018	Mar	CAHN
	AB		EQ 4MG BASE	A209013	003	Apr 17, 2018	Mar	CAHN
	AB		EQ 8MG BASE	A209013	004	Apr 17, 2018	Mar	CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

	@	ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Jan	DISC
AB		IXORA LIFESCIENCE	EQ 10MG BASE	A211619	001	Mar 09, 2021	Sep	CAHN
AB			EQ 25MG BASE	A211619	002	Mar 09, 2021	Sep	CAHN
AB			EQ 50MG BASE	A211619	003	Mar 09, 2021	Sep	CAHN
AB			EQ 75MG BASE	A211619	004	Mar 09, 2021	Sep	CAHN
AB			EQ 100MG BASE	A211619	005	Mar 09, 2021	Sep	CAHN
AB		PTS CONSULTING	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar	CAHN
AB			EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar	CAHN
AB			EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar	CAHN
AB			EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar	CAHN
AB			EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar	CAHN
	@	TARO	EQ 10MG BASE	A213063	001	Jul 01, 2020	Aug	DISC
	@		EQ 25MG BASE	A213063	002	Jul 01, 2020	Aug	DISC
	@		EQ 50MG BASE	A213063	003	Jul 01, 2020	Aug	DISC
	@		EQ 75MG BASE	A213063	004	Jul 01, 2020	Aug	DISC
	@		EQ 100MG BASE	A213063	005	Jul 01, 2020	Aug	DISC
BX		ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar	CTEC
BX			EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar	CTEC
BX			EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar	CTEC
BX			EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar	CTEC
BX			EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar	CTEC
BX			EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar	CTEC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB		AJANTA PHARMA LTD	EQ 3MG BASE	A218564	001	Jul 01, 2024	Aug	CMFD
AB			EQ 6MG BASE	A218564	002	Jul 01, 2024	Aug	CMFD
AB		AUROBINDO PHARMA LTD	EQ 3MG BASE	A216041	001	Jul 25, 2024	Jun	CMFD
AB			EQ 6MG BASE	A216041	002	Jul 25, 2024	Jun	CMFD
BX		MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar	CTEC
BX			EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar	CTEC
AB		TARO	EQ 3MG BASE	A219058	001	Aug 06, 2025	Jul	NEWA
AB			EQ 6MG BASE	A219058	002	Aug 06, 2025	Jul	NEWA

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

AB	!	AVET	2.5MCG	A205360	003	Sep 15, 2020	Aug	CHRS

HECTOROL

	@ +	SANOFI	0.5MCG	N020862	002	Apr 23, 2004	Aug	DISC
	@ +		1MCG	N020862	003	Jul 13, 2009	Aug	DISC
	@ +		2.5MCG	N020862	001	Jun 09, 1999	Aug	DISC

INJECTABLE;INJECTION

DOXERCALCIFEROL

>D> AP	+	HOSPIRA	4MCG/2ML (2MCG/ML)	N208614	001	Jul 24, 2018	Oct	DISC
>A>	@ +		4MCG/2ML (2MCG/ML)	N208614	001	Jul 24, 2018	Oct	DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB		ALEMBIC	20MG/10ML (2MG/ML)	A219199	001	Jun 27, 2025	Jun	NEWA
AB			50MG/25ML (2MG/ML)	A219199	002	Jun 27, 2025	Jun	NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB		CHANGZHOU PHARM	40MG	A219978	001	Oct 01, 2025	Sep	NEWA
AB		MACLEODS PHARMS LTD	40MG	A210381	001	Mar 27, 2025	Mar	NEWA
AB		PRINSTON INC	40MG	A217098	001	Jan 27, 2025	Jan	NEWA

TABLET;ORAL

DOXYCYCLINE

>A>	@	APPCO	EQ 50MG BASE	A065377	001	Nov 07, 2006	Oct	CAHN
>A>	@		EQ 75MG BASE	A065377	002	Nov 07, 2006	Oct	CAHN
>A>	@		EQ 100MG BASE	A065377	003	Nov 07, 2006	Oct	CAHN
>A>	@		EQ 150MG BASE	A065427	001	Jun 07, 2007	Oct	CAHN
>A>	@	CHARTWELL RX	EQ 50MG BASE	A065377	001	Nov 07, 2006	Oct	CAHN
>A>	@		EQ 75MG BASE	A065377	002	Nov 07, 2006	Oct	CAHN
>A>	@		EQ 100MG BASE	A065377	003	Nov 07, 2006	Oct	CAHN
>A>	@		EQ 150MG BASE	A065427	001	Jun 07, 2007	Oct	CAHN
>D>	@	SOMERSET THERAPS LLC	EQ 50MG BASE	A065377	001	Nov 07, 2006	Oct	CAHN

TABLET;ORAL
DOXYCYCLINE

>D>		@		EQ 75MG BASE	A065377	002	Nov 07, 2006	Oct CAHN
>D>		@		EQ 100MG BASE	A065377	003	Nov 07, 2006	Oct CAHN
>D>		@		EQ 150MG BASE	A065427	001	Jun 07, 2007	Oct CAHN

DOXYCYCLINE HYCLATE

CAPSULE;ORAL
DOXYCYCLINE HYCLATE

		@	BIONPHARMA	EQ 50MG BASE	A209393	001	Dec 10, 2020	Apr CAHN
		@		EQ 100MG BASE	A209393	002	Dec 10, 2020	Apr CAHN
	AB	!	HIKMA INTL PHARMS	EQ 100MG BASE	A062396	001	May 07, 1984	Feb CHRS
	AB		STRIDES PHARMA	EQ 50MG BASE	A062337	001	Mar 29, 1982	Jul CMFD
	AB			EQ 100MG BASE	A062337	002	Mar 29, 1982	Jul CMFD

VIBRAMYCIN

		@ +	PFIZER	EQ 100MG BASE	N050007	002		Feb DISC

INJECTABLE;INJECTION
DOXYCYCLINE HYCLATE

		@	AMNEAL	EQ 100MG BASE/VIAL	A217487	001	Dec 04, 2024	Jan DISC
	AP		ASPIRO	EQ 100MG BASE/VIAL	A218888	001	Aug 05, 2025	Jul NEWA
	AP		DR REDDYS	EQ 100MG BASE/VIAL	A218753	001	Jul 01, 2025	Jun NEWA
	AP		PRECISION DOSE INC	EQ 100MG BASE/VIAL	A217078	001	Feb 21, 2025	Feb NEWA
>A>	AP		STERISCIENCE	EQ 100MG BASE/VIAL	A217972	001	Nov 06, 2025	Oct NEWA

TABLET;ORAL
DOXYCYCLINE HYCLATE

		@	AVIV PHARMA	EQ 100MG BASE	A209560	001	Apr 15, 2024	May CAHN
		@	MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jun DISC
	AB		PHARMOBEDIENT	EQ 20MG BASE	A065287	001	Feb 28, 2006	Sep CAHN
		@		EQ 100MG BASE	A213475	001	Mar 10, 2021	Sep CAHN

DROSPIRENONE; ESTRADIOL

TABLET;ORAL
ANGELIQ

>D>		+!	BAYER HLTHCARE	0.5MG;1MG	N021355	002	Sep 28, 2005	Oct CFTG
>A>	AB	+!		0.5MG;1MG	N021355	002	Sep 28, 2005	Oct CFTG

>A> DROSPIRENONE AND ESTRADIOL

>A>	AB		NOVAST LABS	0.5MG;1MG	A218031	001	Oct 28, 2025	Oct NFTG

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL
DROSPIRENONE AND ETHINYL ESTRADIOL

	AB		PHARMOBEDIENT	3MG;0.02MG	A203291	001	Jul 18, 2017	Sep CAHN

DROXIDOPA

CAPSULE;ORAL
DROXIDOPA

	AB		JUBILANT CADISTA	100MG	A214391	001	Feb 18, 2021	Apr CAHN
	AB			200MG	A214391	002	Feb 18, 2021	Apr CAHN
	AB			300MG	A214391	003	Feb 18, 2021	Apr CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
CYMBALTA

		@ +	LILLY	EQ 20MG BASE	N021427	001	Aug 03, 2004	Aug DISC
		@ +		EQ 30MG BASE	N021427	002	Aug 03, 2004	Aug DISC
		@ +		EQ 60MG BASE	N021427	004	Aug 03, 2004	Aug DISC

DULOXETINE HYDROCHLORIDE

		@	ADAPTIS	EQ 20MG BASE	A090723	001	Dec 11, 2013	Aug CAHN
		@		EQ 30MG BASE	A090723	002	Dec 11, 2013	Aug CAHN
		@		EQ 60MG BASE	A090723	003	Dec 11, 2013	Aug CAHN
	AB	!	AJANTA PHARMA LTD	EQ 60MG BASE	A208706	003	Jan 06, 2017	Aug CHRS
		@	GRAVITI PHARMS	EQ 20MG BASE	A090723	001	Dec 11, 2013	Sep CAHN
		@		EQ 30MG BASE	A090723	002	Dec 11, 2013	Sep CAHN
		@		EQ 60MG BASE	A090723	003	Dec 11, 2013	Sep CAHN
		@	TORRENT	EQ 20MG BASE	A090774	001	Dec 11, 2013	Jul DISC
		@		EQ 30MG BASE	A090774	002	Dec 11, 2013	Jul DISC
		@		EQ 60MG BASE	A090774	003	Dec 11, 2013	Jul DISC

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

	@	AVIV PHARMA	0.5MG	A204705	001	Nov 20, 2015	May	CAHN
AB		GRAVITI PHARMS	0.5MG	A204376	001	Apr 07, 2017	Sep	CAHN
	@	PH HEALTH	0.5MG	A202421	001	Nov 20, 2015	Jul	CAHN

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	!	ZYDUS PHARMS	0.5MG;0.4MG	A207769	001	May 24, 2018	Sep	CHRS

JALYN

AB	+	WAYLIS THERAP	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Sep	CHRS

EDARAVONE

SOLUTION;INTRAVENOUS

EDARAVONE

>D> AP		GLAND	30MG/100ML (0.3MG/ML)	A216199	001	May 06, 2024	Oct	CHRS
>A> AP	!		30MG/100ML (0.3MG/ML)	A216199	001	May 06, 2024	Oct	CHRS
>D> AP		LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Oct	DISC
>A>	@		30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Oct	DISC
	@		30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr	DISC
AP		PHARMOBEDIENT	30MG/100ML (0.3MG/ML)	A217565	001	Oct 31, 2024	Sep	CAHN
>D> AP			60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Oct	CHRS
>A> AP	!		60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Oct	CHRS
AP			60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Sep	CAHN

RADICAVA

>D> AP	+!	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Oct	DISC
>A>	@ +		30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Oct	DISC
>D> AP	+!		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Oct	CHRS
>A> AP	+		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Oct	CHRS

SUSPENSION;ORAL

RADICAVA ORS

	+!	KK BCJ-94	105MG/5ML	N215446	001	May 12, 2022	Jul	CAHN

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

AB		NORVIUM BIOSCIENCE	600MG	A204869	001	Mar 12, 2018	May	CAHN

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

	@	CHARTWELL RX	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Apr	CAHN

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL

VANIQA

	@ +	ABBVIE	13.9%	N021145	001	Jul 27, 2000	Feb	CAHN

ELAMIPRETIDE HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS

FORZINITY

	+!	STEALTH BIOTHERAPS	EQ 280MG BASE/3.5ML (EQ 80MG BASE/ML)	N215244	001	Sep 19, 2025	Sep	NEWA

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AB		ANNORA PHARMA	EQ 20MG BASE	A219143	001	Jul 07, 2025	Jun	NEWA
AB			EQ 40MG BASE	A219143	002	Jul 07, 2025	Jun	NEWA

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

	@	APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jan	DISC

>A>	ELINZANETANT							
>A>	CAPSULE;ORAL							
>A>	LYNKUET							
>A>	+!	BAYER HLTHCARE	60MG	N219469	001	Oct 24, 2025	Oct NEWA	
	ELTROMBOPAG OLAMINE							
	TABLET;ORAL							
	ELTROMBOPAG OLAMINE							
AB		HETERO LABS LTD V	EQ 12.5MG ACID	A206788	001	Jan 17, 2025	Jan NFTG	
AB			EQ 25MG ACID	A206788	002	Jan 17, 2025	Jan NFTG	
AB			EQ 50MG ACID	A206788	003	Jan 17, 2025	Jan NFTG	
AB			EQ 75MG ACID	A206788	004	Jan 17, 2025	Jan NFTG	
	PROMACTA							
AB	+	NOVARTIS	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Jan CFTG	
AB	+		EQ 25MG ACID	N022291	001	Nov 20, 2008	Jan CFTG	
AB	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Jan CFTG	
AB	+!		EQ 75MG ACID	N022291	003	Sep 08, 2009	Jan CFTG	
	ELUXADOLINE							
	TABLET;ORAL							
	ELUXADOLINE							
	@	ZYDUS PHARMS	75MG	A213522	001	Mar 14, 2025	Aug DISC	
AB			75MG	A213522	001	Mar 14, 2025	Mar NFTG	
	@		100MG	A213522	002	Mar 14, 2025	Aug DISC	
AB			100MG	A213522	002	Mar 14, 2025	Mar NFTG	
	VIBERZI							
	+	ABBVIE	75MG	N206940	001	May 27, 2015	Aug CTEC	
AB	+		75MG	N206940	001	May 27, 2015	Mar CFTG	
	+!		100MG	N206940	002	May 27, 2015	Aug CTEC	
AB	+!		100MG	N206940	002	May 27, 2015	Mar CFTG	
	EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE							
	TABLET;ORAL							
	COMPLERA							
AB	+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	May CFTG	
	EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE							
AB		MYLAN	200MG;EQ 25MG BASE;300MG	A208452	001	May 20, 2025	May NFTG	
	EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE							
	TABLET;ORAL							
	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE							
AB		HETERO LABS LTD III	100MG;150MG	A201806	002	Mar 03, 2025	Feb NEWA	
AB			133MG;200MG	A201806	003	Mar 03, 2025	Feb NEWA	
AB			167MG;250MG	A201806	004	Mar 03, 2025	Feb NEWA	
	ENALAPRIL MALEATE							
	TABLET;ORAL							
	ENALAPRIL MALEATE							
AB		SENORES PHARMS	2.5MG	A075483	001	Aug 22, 2000	Jun CAHN	
AB			5MG	A075483	002	Aug 22, 2000	Jun CAHN	
AB			10MG	A075483	003	Aug 22, 2000	Jun CAHN	
AB			20MG	A075483	004	Aug 22, 2000	Jun CAHN	
	ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE							
	TABLET;ORAL							
	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE							
	@	MPP PHARMA	5MG;12.5MG	A076486	001	Oct 27, 2004	Jun CAHN	
	@		10MG;25MG	A076486	002	Oct 27, 2004	Jun CAHN	
	ENALAPRILAT							
	INJECTABLE;INJECTION							
	ENALAPRILAT							
	@	HOSPIRA	1.25MG/ML	A075458	001	Aug 22, 2000	Aug DISC	
	ENFUVIRTIDE							
	INJECTABLE;SUBCUTANEOUS							
	FUZEON							
	@ +	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003	Mar DISC	

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB		EMERGE BIOSCIENCE	300MG/3ML (100MG/ML)	A214856	001	Jun 14, 2022	Sep CAHN

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP		EMERGE BIOSCIENCE	30MG/0.3ML (100MG/ML)	A206834	001	Nov 29, 2019	Sep CAHN
AP			40MG/0.4ML (100MG/ML)	A206834	002	Nov 29, 2019	Sep CAHN
AP			60MG/0.6ML (100MG/ML)	A206834	003	Nov 29, 2019	Sep CAHN
AP			80MG/0.8ML (100MG/ML)	A206834	004	Nov 29, 2019	Sep CAHN
AP			100MG/ML (100MG/ML)	A206834	005	Nov 29, 2019	Sep CAHN
AP			120MG/0.8ML (150MG/ML)	A206834	006	Nov 29, 2019	Sep CAHN
AP			150MG/ML (150MG/ML)	A206834	007	Nov 29, 2019	Sep CAHN

ENTECAVIR

TABLET;ORAL

ENTECAVIR

	@	BRECKENRIDGE	0.5MG	A208721	001	Mar 15, 2018	May DISC
	@		1MG	A208721	002	Mar 15, 2018	May DISC

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

	@	ZYDUS PHARMS	40MG	A209667	001	Sep 26, 2024	Feb DISC

XTANDI

	+!	ASTELLAS	40MG	N203415	001	Aug 31, 2012	Feb CTEC

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

REZIPRES

	@ +	DR REDDYS LABS SA	47MG/10ML (4.7MG/ML)	N213536	004	Dec 07, 2023	May DISC

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

AKOVAZ

AP3	+!	EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Mar CTEC

EMERPHED

AP1	+!	NEXUS	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Mar CTEC
AP	+!		50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Jan CFTG

EPHEDRINE SULFATE

AP2	+!	ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Mar CTEC
AP	+!		25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Feb CFTG
AP2	+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Mar CTEC
AP	+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Feb CFTG
AP2		FRESENIUS KABI USA	25MG/5ML (5MG/ML)	A218271	001	Mar 11, 2025	Mar CTEC
AP			25MG/5ML (5MG/ML)	A218271	001	Mar 11, 2025	Feb NFTG
AP2			50MG/10ML (5MG/ML)	A218271	002	Mar 11, 2025	Mar CTEC
AP			50MG/10ML (5MG/ML)	A218271	002	Mar 11, 2025	Feb NFTG
AP1		GLAND	50MG/10ML (5MG/ML)	A218211	001	Jan 16, 2025	Mar CTEC
AP			50MG/10ML (5MG/ML)	A218211	001	Jan 16, 2025	Jan NFTG
AP3		HIKMA	25MG/5ML (5MG/ML)	A217721	001	Oct 11, 2024	Mar CTEC
AP2	+!	PH HEALTH	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Aug CAHN
AP2	+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Aug CAHN

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

	@	PHARMOBEDIENT	0.05%	A090870	001	Mar 14, 2011	Sep CAHN
	@	RENOVA PHARMS	0.05%	A090870	001	Mar 14, 2011	Feb CAHN

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR

EPI E Z PEN JR

	@	VIATRIS	0.15MG/DELIVERY	N019430	004	Aug 03, 1995	May CAHN

EPIPEN E Z PEN

	@	VIATRIS	0.3MG/DELIVERY	N019430	003	Aug 03, 1995	May CAHN

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

EPIPEN

AB	+!	VIATRIS	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	May CAHN

			INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS						
			EPIPEN JR.						
	AB	+!	VIATRIS	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	May	CAHN
			TWINJECT						
		@	IMPAX	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	May	CTNA
		@		EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	May	CTNA
			SOLUTION;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS						
			EPINEPHRINE						
	AP		GLAND PHARMA LTD	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Jan	NFTG
			SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS						
			EPINEPHRINE						
>A>	AP		AMNEAL	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	A217485	001	Oct 14, 2025	Oct	NEWA
	AP	+!	BPI LABS	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Jan	CFTG
	AP	+!		30MG/30ML (1MG/ML)	N205029	004	Feb 14, 2024	Sep	CFTG
		+!	FRESENIUS KABI USA	30MG/30ML (1MG/ML)	N215425	001	Mar 13, 2025	Mar	NEWA
	AP		GLAND	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Mar	CDFR
	AP			30MG/30ML (1MG/ML)	A219239	002	Oct 02, 2025	Sep	NFTG
			SOLUTION;INTRAVENOUS						
			ADRENALIN						
		+!	PH HEALTH	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023	Jul	CAHN
		+!		4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023	Jul	CAHN
		+!		5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023	Jul	CAHN
		+!		8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	Jul	CAHN
		+!		10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	Jul	CAHN
			SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS						
			EPINEPHRINE						
	AP		GLAND	1MG/ML (1MG/ML)	A218144	001	Jun 03, 2025	May	NEWA
			SPRAY;NASAL						
			NEFFY						
		+!	ARS PHARMS OPERATION	1MG/SPRAY	N214697	002	Mar 05, 2025	Apr	CHRS
		+		1MG/SPRAY	N214697	002	Mar 05, 2025	Mar	NEWA
			EPINEPHRINE BITARTRATE						
			SOLUTION;INTRAVENOUS						
			EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
		+!	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N218475	001	Feb 28, 2025	Feb	NEWA
			EPIRUBICIN HYDROCHLORIDE						
			INJECTABLE;INJECTION						
			EPIRUBICIN HYDROCHLORIDE						
>D>	AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Oct	DISC
>A>		@		50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Oct	DISC
>D>	AP			200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Oct	DISC
>A>		@		200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Oct	DISC
		@	PHARMOBEDIENT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Aug	CAHN
		@		200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Aug	CAHN
			EPLERENONE						
			TABLET;ORAL						
			EPLERENONE						
		@	AARXION ANDA HLDING	25MG	A203896	001	Feb 02, 2017	Sep	CAHN
		@		50MG	A203896	002	Feb 02, 2017	Sep	CAHN
		@	THINKRX	25MG	A203896	001	Feb 02, 2017	Mar	CAHN
		@		50MG	A203896	002	Feb 02, 2017	Mar	CAHN
			EPTIFIBATIDE						
			INJECTABLE;INJECTION						
			EPTIFIBATIDE						
	AP		MEITHEAL	2MG/ML	A213599	001	May 09, 2024	Apr	CAHN
	AP			75MG/100ML	A213599	002	May 09, 2024	Apr	CAHN
			ERGOCALCIFEROL						
			CAPSULE;ORAL						
			ERGOCALCIFEROL						
	AA	!	ONESOURCE SPECIALTY	50,000 IU	A090455	001	Aug 03, 2010	Jun	CAHN

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS

ERIBULIN MESYLATE

AP		CHIA TAI TIANQING	1MG/2ML (0.5MG/ML)	A218743	001	Mar 04, 2025	Feb NEWA
AP		DR REDDYS	1MG/2ML (0.5MG/ML)	A217473	001	Jul 03, 2025	Jun NEWA
AP		GLENMARK PHARMS INC	1MG/2ML (0.5MG/ML)	A218142	001	Aug 05, 2025	Sep CAHN
AP		JIANGXI KVVIT PHARM	1MG/2ML (0.5MG/ML)	A218281	001	Jun 28, 2024	Apr CAHN
AP		SANDOZ	1MG/2ML (0.5MG/ML)	A214310	001	Jun 09, 2025	May NEWA
AP		XILING LAB	1MG/2ML (0.5MG/ML)	A218142	001	Aug 05, 2025	Jul NEWA

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

	@	APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019	Jan DISC
	@		EQ 100MG BASE	A208396	002	Nov 05, 2019	Jan DISC
	@		EQ 150MG BASE	A208396	003	Nov 05, 2019	Jan DISC
	@	NATCO PHARMA LTD	EQ 100MG BASE	A208488	002	Nov 05, 2019	Aug DISC
	@	SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019	Jan DISC
	@		EQ 100MG BASE	A210300	002	Nov 05, 2019	Feb DISC
	@		EQ 150MG BASE	A210300	003	Nov 05, 2019	Jan DISC

ERTUGLIFLOZIN

TABLET;ORAL

ERTUGLIFLOZIN

	@	HETERO LABS LTD V	5MG	A217071	001	Sep 17, 2024	Apr DISC
	@		15MG	A217071	002	Sep 17, 2024	Apr DISC
	@	HIKMA	5MG	A216842	001	Jan 21, 2025	Feb DISC
AB			5MG	A216842	001	Jan 21, 2025	Jan NEWA
	@		15MG	A216842	002	Jan 21, 2025	Feb DISC
AB			15MG	A216842	002	Jan 21, 2025	Jan NEWA

STEGLATRO

	+	MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Apr CTEC
	+!		15MG	N209803	002	Dec 19, 2017	Apr CTEC

ERYTHROMYCIN

GEL;TOPICAL

ERYGEL

>D> AT	+!	MYLAN	2%	N050617	001	Oct 21, 1987	Oct DISC
>A>	@ +		2%	N050617	001	Oct 21, 1987	Oct DISC

ERYTHROMYCIN

>D> AT		PADAGIS US	2%	A063211	001	Jan 29, 1993	Oct CHRS
>A> AT	!		2%	A063211	001	Jan 29, 1993	Oct CHRS

TABLET;ORAL

ERYTHROMYCIN

AB		ABON PHARMS LLC	250MG	A219691	001	Sep 23, 2025	Sep NEWA
AB			500MG	A219691	002	Sep 23, 2025	Sep NEWA
AB		PHARMOBEDIENT	250MG	A061621	001		Sep CAHN
AB			500MG	A061621	002		Sep CAHN

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE

	@	AZURITY	EQ 250MG BASE	A060359	001		Apr DISC

ESCITALOPRAM OXALATE

CAPSULE;ORAL

ESCITALOPRAM

	+!	ALMATICA	EQ 15MG BASE	N219130	001	Aug 29, 2025	Aug NEWA

ESCITALOPRAM OXALATE

	@	RISING	EQ 5MG BASE	A077660	001	Jul 31, 2007	Aug CAHN
	@		EQ 10MG BASE	A077660	002	Jul 31, 2007	Aug CAHN
	@		EQ 20MG BASE	A077660	003	Jul 31, 2007	Aug CAHN

SOLUTION;ORAL

ESCITALOPRAM OXALATE

	@	TARO	EQ 5MG BASE/5ML	A079121	001	May 03, 2012	Aug DISC

TABLET;ORAL

ESCITALOPRAM OXALATE

AB		ASCENT PHARMS INC	EQ 5MG BASE	A215177	001	Jul 15, 2025	Jul NEWA
AB			EQ 10MG BASE	A215177	002	Jul 15, 2025	Jul NEWA
AB			EQ 20MG BASE	A215177	003	Jul 15, 2025	Jul NEWA

ESLICARBAZEPINE ACETATE

TABLET;ORAL

ESLICARBAZEPINE ACETATE

AB		APOTEX	200MG	A211236	001	Dec 07, 2023	Apr CMFD
AB			400MG	A211236	002	Dec 07, 2023	Apr CMFD
AB			600MG	A211236	003	Dec 07, 2023	Apr CMFD
AB			800MG	A211236	004	Dec 07, 2023	Apr CMFD
AB		JUBILANT GENERICS	200MG	A211219	001	Aug 04, 2025	Jul NEWA
AB			400MG	A211219	002	Aug 04, 2025	Jul NEWA
AB			600MG	A211219	003	Aug 04, 2025	Jul NEWA
AB			800MG	A211219	004	Aug 04, 2025	Jul NEWA
AB		LUPIN LTD	200MG	A211246	001	Mar 27, 2024	Mar CMFD
AB			400MG	A211246	002	Mar 27, 2024	Mar CMFD
AB			600MG	A211246	003	Mar 27, 2024	Mar CMFD
AB			800MG	A211246	004	Mar 27, 2024	Mar CMFD
>A> AB		SPH ZHONGXI PHARM	200MG	A211247	001	Nov 03, 2025	Oct NEWA
>A> AB			400MG	A211247	002	Nov 03, 2025	Oct NEWA
>A> AB			600MG	A211247	003	Nov 03, 2025	Oct NEWA
>A> AB			800MG	A211247	004	Nov 03, 2025	Oct NEWA
AB		TORRENT	200MG	A211227	001	Feb 27, 2024	May CMFD
AB			400MG	A211227	002	Feb 27, 2024	May CMFD
AB			600MG	A211227	003	Feb 27, 2024	May CMFD
AB			800MG	A211227	004	Feb 27, 2024	May CMFD

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

	@	CIPLA	EQ 20MG BASE	A078003	001	Jan 26, 2015	Aug CAHN
	@		EQ 40MG BASE	A078003	002	Jan 26, 2015	Aug CAHN
AB		GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Apr CAHN
AB			EQ 40MG BASE	A213859	002	Nov 18, 2020	Apr CAHN
	@	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Feb DISC
	@		EQ 40MG BASE	A078003	002	Jan 26, 2015	Feb DISC
	@	MACLEODS PHARMS LTD	EQ 20MG BASE	A208511	001	Oct 23, 2024	Jun DISC
	@		EQ 40MG BASE	A208511	002	Oct 23, 2024	Jun DISC
AB		SUN PHARM	EQ 20MG BASE	A209735	001	Apr 30, 2018	Jul CMFD
AB			EQ 40MG BASE	A209735	002	Apr 30, 2018	Jul CMFD

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		AUROBINDO PHARMA LTD	EQ 5MG BASE/PACKET	A218948	001	Apr 15, 2025	Apr NEWA
AB			EQ 10MG BASE/PACKET	A219213	001	Apr 15, 2025	Apr NEWA
AB			EQ 20MG BASE/PACKET	A218948	002	Apr 15, 2025	Apr NEWA
AB			EQ 40MG BASE/PACKET	A218948	003	Apr 15, 2025	Apr NEWA
AB		TORRENT	EQ 2.5MG BASE/PACKET	A212651	001	Mar 05, 2025	Feb NEWA
AB			EQ 5MG BASE/PACKET	A212651	002	Mar 05, 2025	Feb NEWA
AB			EQ 10MG BASE/PACKET	A212652	001	Mar 05, 2025	Feb NEWA
AB			EQ 20MG BASE/PACKET	A212651	003	Mar 05, 2025	Feb NEWA
AB			EQ 40MG BASE/PACKET	A212651	004	Mar 05, 2025	Feb NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

	@	NORVIUM BIOSCIENCE	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Feb CAHN
	@		EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Feb CAHN

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP		EPIC PHARMA LLC	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jul CAHN
	@	EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul DISC
	@	PHARMOBEDIENT	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Jul CAHN
	@		EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Jul CAHN
AP		YANGTZE	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jan NEWA

ESTRADIOL

CREAM;VAGINAL

ESTRADIOL

AB		ENCUBE	0.01%	A209767	001	Mar 05, 2018	Jan CAHN

GEL;TRANSDERMAL

ESTRADIOL

AB		ENCUBE	0.1% (0.25GM/PACKET)	A218507	001	Mar 05, 2025	Feb NEWA
AB			0.1% (0.5GM/PACKET)	A218507	002	Mar 05, 2025	Feb NEWA

GEL;TRANSDERMAL
ESTRADIOL

AB		0.1% (0.75GM/PACKET)	A218507	003	Mar 05, 2025	Feb	NEWA
AB		0.1% (1.25GM/PACKET)	A218507	005	Mar 05, 2025	Feb	NEWA
AB		0.1% (1GM/PACKET)	A218507	004	Mar 05, 2025	Feb	NEWA

GEL, METERED;TRANSDERMAL
ELESTRIN

	+! VIATRIS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Feb	CAHN

TABLET;ORAL
ESTRADIOL

@	RUBICON RESEARCH	0.5MG	A040114	003	Mar 14, 1996	Apr	CAHN
@		1MG	A040114	001	Mar 14, 1996	Apr	CAHN
@		2MG	A040114	002	Mar 14, 1996	Apr	CAHN

ESTRADIOL VALERATE
INJECTABLE;INJECTION
DELESTROGEN

AO	+! PH HEALTH	10MG/ML	N009402	002		Aug	CAHN
AO	+!	20MG/ML	N009402	004		Aug	CAHN
@ +		40MG/ML	N009402	003		Aug	CAHN

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
TABLET;ORAL
MYFEMBREE

	+! SUMITOMO PHARMA AM	1MG;0.5MG;40MG	N214846	001	May 26, 2021	Aug	CAHN

ESTROGENS, CONJUGATED
TABLET;ORAL
CONJUGATED ESTROGENS

>A> AB	NOVAST LABS	0.3MG	A214025	001	Oct 15, 2025	Oct	NFTG
>A> AB		0.45MG	A214025	002	Oct 15, 2025	Oct	NFTG
>A> AB		0.625MG	A214025	003	Oct 15, 2025	Oct	NFTG
>A> AB		0.9MG	A214023	001	Oct 15, 2025	Oct	NFTG
>A> AB		1.25MG	A214023	002	Oct 15, 2025	Oct	NFTG

PREMARIN

>D> +	WYETH PHARMS	0.3MG	N004782	003		Oct	CFTG
>A> AB +		0.3MG	N004782	003		Oct	CFTG
>D> +		0.45MG	N004782	006	Jul 16, 2003	Oct	CFTG
>A> AB +		0.45MG	N004782	006	Jul 16, 2003	Oct	CFTG
>D> +!		0.625MG	N004782	004		Oct	CFTG
>A> AB +!		0.625MG	N004782	004		Oct	CFTG
>D> +!		0.9MG	N004782	005	Jan 26, 1984	Oct	CFTG
>A> AB +!		0.9MG	N004782	005	Jan 26, 1984	Oct	CFTG
>D> +!		1.25MG	N004782	001		Oct	CFTG
>A> AB +!		1.25MG	N004782	001		Oct	CFTG

ESZOPICLONE
TABLET;ORAL
ESZOPICLONE

@	AVIV PHARMA	1MG	A203087	001	May 08, 2019	May	CAHN
@		2MG	A203087	002	May 08, 2019	May	CAHN
@		3MG	A203087	003	May 08, 2019	May	CAHN

ETHACRYNATE SODIUM
INJECTABLE;INJECTION
ETHACRYNATE SODIUM

>D> AP	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A204634	001	Aug 23, 2016	Oct	DISC
>A> @		EQ 50MG BASE/VIAL	A204634	001	Aug 23, 2016	Oct	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL
TABLET;ORAL
LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	NAARI PTE	0.03MG;0.15MG	A203871	001	Nov 13, 2015	Sep	CAHN
AB		0.03MG,0.01MG;0.15MG,N/A	A203872	001	Dec 22, 2015	Sep	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE
TABLET;ORAL-28
GENCEPT 10/11-28

@	BARR LABS	0.035MG,0.035MG;0.5MG,1MG	A072697	001	Feb 28, 1992	Mar	CAHN

NORTREL 0.5/35-28

AB	BARR LABS	0.035MG;0.5MG	A072695	001	Feb 28, 1992	Mar	CAHN

		TABLET;ORAL-28							
		NORTREL 1/35-28							
	AB	!	BARR LABS	0.035MG;1MG	A072696	001	Feb 28, 1992	Mar	CAHN
		TABLET, CHEWABLE;ORAL							
		KAITLIB FE							
	AB	!	LUPIN LTD	0.025MG;0.8MG	A203448	001	Dec 17, 2015	Apr	CHRS
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
		@ +	TEVA BRANDED PHARM	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Apr	DISC
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE							
		TABLET;ORAL							
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	AB		BARR LABS	0.02MG;1MG	A090938	001	Dec 01, 2014	Mar	CAHN
		TABLET;ORAL-21							
		JUNEL 1/20							
	AB		BARR LABS	0.02MG;1MG	A076380	001	May 30, 2003	Mar	CAHN
		TABLET;ORAL-28							
		BLISOVI FE 1.5/30							
	AB		LUPIN LTD	0.03MG;1.5MG	A201585	001	Nov 18, 2015	Apr	CTEC
		ETHINYL ESTRADIOL; NORGESTIMATE							
		TABLET;ORAL-28							
		NORGESTIMATE AND ETHINYL ESTRADIOL							
		@	NAARI PTE	0.035MG,0.035MG,0.035MG;0.18MG ,0.215MG,0.25MG	A203870	001	Nov 12, 2015	Sep	CAHN
		@		0.035MG;0.25MG	A203865	001	Oct 27, 2015	Sep	CAHN
	AB			0.025MG,0.025MG,0.025MG;0.18MG ,0.215MG,0.25MG	A203873	001	May 12, 2016	Sep	CAHN
>D>		ETHIONAMIDE							
>D>		TABLET;ORAL							
>D>		TRECATOR							
>D>		+!	WYETH PHARMS	250MG	N013026	002		Oct	DISC
>A>		@ +		250MG	N013026	002		Oct	DISC
		ETHOSUXIMIDE							
		SYRUP;ORAL							
		ETHOSUXIMIDE							
	AA		CHARTWELL RX	250MG/5ML	A040506	001	Dec 22, 2003	Aug	CAHN
		ETODOLAC							
		TABLET;ORAL							
		ETODOLAC							
		@	SENORES PHARMS	400MG	A074839	001	Jul 11, 1997	Jul	CAHN
		ETOPOSIDE							
		CAPSULE;ORAL							
		VEPESID							
		@ +	ONESOURCE SPECIALTY	50MG	N019557	001	Dec 30, 1986	Jun	CAHN
		@ +		100MG	N019557	002	Dec 30, 1986	Jun	CAHN
		ETRAVIRINE							
		TABLET;ORAL							
		ETRAVIRINE							
	AB		BIONPHARMA	100MG	A219152	001	Oct 02, 2025	Sep	NEWA
	AB			200MG	A219152	002	Oct 02, 2025	Sep	NEWA
		EVEROLIMUS							
		TABLET;ORAL							
		EVEROLIMUS							
	AB		BIOCON PHARMA	0.25MG	A216140	001	Apr 09, 2025	Mar	NEWA
	AB			0.5MG	A216140	002	Apr 09, 2025	Mar	NEWA
	AB			0.75MG	A216140	003	Apr 09, 2025	Mar	NEWA
	AB			1MG	A216140	004	Apr 09, 2025	Mar	NEWA
	AB		BRECKENRIDGE	1MG	A205432	004	Sep 03, 2025	Aug	NEWA
		@	MYLAN	2.5MG	A212936	001	Jun 08, 2020	Mar	DISC
		@		5MG	A212936	002	Jun 08, 2020	Mar	DISC
		@		7.5MG	A212936	003	Jun 08, 2020	Mar	DISC
		@		10MG	A212936	004	Jun 08, 2020	Mar	DISC
>A>	AB		NOVUGEN	2.5MG	A219955	001	Oct 30, 2025	Oct	NEWA
>A>	AB			5MG	A219955	002	Oct 30, 2025	Oct	NEWA
>A>	AB			7.5MG	A219955	003	Oct 30, 2025	Oct	NEWA

		TABLET;ORAL						
		EVEROLIMUS						
>A>	AB		10MG		A219955	004	Oct 30, 2025	Oct NEWA
		TABLET, FOR SUSPENSION;ORAL						
		EVEROLIMUS						
	AB	AMNEAL	2MG		A218863	001	Jan 10, 2025	Jan NEWA
	AB		3MG		A218863	002	Jan 10, 2025	Jan NEWA
	AB		5MG		A218863	003	Jan 10, 2025	Jan NEWA
	AB	NATCO	2MG		A217640	001	Jan 28, 2025	Jan NEWA
	AB		3MG		A217640	002	Jan 28, 2025	Jan NEWA
	AB		5MG		A217640	003	Jan 28, 2025	Jan NEWA
		EXEMESTANE						
		TABLET;ORAL						
		EXEMESTANE						
		@ HIKMA	25MG		A077431	001	Apr 01, 2011	Sep DISC
		EXENATIDE SYNTHETIC						
		INJECTABLE;SUBCUTANEOUS						
		BYETTA						
		@ + ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)		N021773	001	Apr 28, 2005	Apr DISC
		@ +	600MCG/2.4ML (250MCG/ML)		N021773	002	Apr 28, 2005	Apr DISC
		EXENATIDE SYNTHETIC						
		! AMNEAL	300MCG/1.2ML (250MCG/ML)		A206697	001	Nov 19, 2024	Apr CTEC
	AP	!	300MCG/1.2ML (250MCG/ML)		A206697	001	Nov 19, 2024	Apr CHRS
		!	600MCG/2.4ML (250MCG/ML)		A206697	002	Nov 19, 2024	Apr CTEC
	AP	!	600MCG/2.4ML (250MCG/ML)		A206697	002	Nov 19, 2024	Apr CHRS
		SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS						
		BYDUREON BCISE						
		@ + ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)		N209210	001	Oct 20, 2017	Mar DISC
		EZETIMIBE						
		TABLET;ORAL						
		EZETIMIBE						
		@ MACLEODS PHARMS LTD	10MG		A211159	001	Apr 29, 2024	Jun DISC
		EZETIMIBE; SIMVASTATIN						
		TABLET;ORAL						
		EZETIMIBE AND SIMVASTATIN						
		@ AMNEAL PHARMS CO	10MG;10MG		A208831	001	Nov 21, 2017	Jul DISC
		@	10MG;20MG		A208831	002	Nov 21, 2017	Jul DISC
		@	10MG;40MG		A208831	003	Nov 21, 2017	Jul DISC
		@	10MG;80MG		A208831	004	Nov 21, 2017	Jul DISC
		@ SCIEGEN PHARMS INC	10MG;10MG		A211663	001	Dec 10, 2024	Jun DISC
		@	10MG;20MG		A211663	002	Dec 10, 2024	Jun DISC
		@	10MG;40MG		A211663	003	Dec 10, 2024	Jun DISC
		@	10MG;80MG		A211663	004	Dec 10, 2024	Jun DISC
		@ TORRENT	10MG;10MG		A209461	001	Jan 27, 2025	Jun DISC
	AB		10MG;10MG		A209461	001	Jan 27, 2025	Jan NEWA
		@	10MG;20MG		A209461	002	Jan 27, 2025	Jun DISC
	AB		10MG;20MG		A209461	002	Jan 27, 2025	Jan NEWA
		@	10MG;40MG		A209461	003	Jan 27, 2025	Jun DISC
	AB		10MG;40MG		A209461	003	Jan 27, 2025	Jan NEWA
		@	10MG;80MG		A209461	004	Jan 27, 2025	Jun DISC
	AB		10MG;80MG		A209461	004	Jan 27, 2025	Jan NEWA
		FAMOTIDINE						
		FOR SUSPENSION;ORAL						
		FAMOTIDINE						
	AB	APPCO	40MG/5ML		A217655	001	Jun 16, 2023	Mar CAHN
	AB	AUROBINDO PHARMA LTD	40MG/5ML		A219091	001	Jul 09, 2025	Jun NEWA
		@ BIONPHARMA	40MG/5ML		A219153	001	Jun 23, 2025	Jul DISC
	AB		40MG/5ML		A219153	001	Jun 23, 2025	Jun NEWA
	AB	LANNETT CO INC	40MG/5ML		A217982	001	Jun 02, 2025	May NEWA
	AB	MSN	40MG/5ML		A219863	001	Jul 24, 2025	Jul NEWA
	AB	NOVITIUM PHARMA	40MG/5ML		A201995	001	May 30, 2014	Jun CAHN
		SOLUTION;INTRAVENOUS						
		FAMOTIDINE						
		+! SAGENT	20MG/5ML (4MG/ML)		N219935	001	Jul 16, 2025	Jul NEWA
		+!	40MG/10ML (4MG/ML)		N219935	002	Jul 16, 2025	Jul NEWA
		+!	200MG/50ML (4MG/ML)		N219935	003	Jul 16, 2025	Jul NEWA

TABLET;ORAL
FAMOTIDINE

@	APOTEX	20MG	A075611	001	Jul 23, 2001	Mar DISC
@		40MG	A075611	002	Jul 23, 2001	Mar DISC
AB	BEXIMCO PHARMS USA	20MG	A218631	001	Mar 25, 2025	Mar NEWA
AB		40MG	A218631	002	Mar 25, 2025	Mar NEWA
AB	RISING	20MG	A075704	001	Apr 16, 2001	Aug CMFD
AB		40MG	A075704	002	Apr 16, 2001	Aug CMFD

FAMOTIDINE; IBUPROFEN

TABLET;ORAL
IBUPROFEN AND FAMOTIDINE

AB	AUROBINDO PHARMA LTD	26.6MG;800MG	A219538	001	Jun 30, 2025	Jun NEWA
AB	ENDO OPERATIONS	26.6MG;800MG	A203658	001	Mar 22, 2024	Feb CTNA
@	TORRENT	26.6MG;800MG	A215925	001	Mar 18, 2024	Feb CTNA
AB	ZYDUS PHARMS	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb NEWA

FEBUXOSTAT

TABLET;ORAL
FEBUXOSTAT

AB	MSN	40MG	A210461	001	Dec 30, 2019	Jan CTEC
AB		80MG	A210461	002	Dec 30, 2019	Jan CTEC

FELBAMATE

TABLET;ORAL
FELBAMATE

@	ALVOGEN	400MG	A204595	001	Jan 11, 2016	May DISC
@		600MG	A204595	002	Jan 11, 2016	May DISC

FENOFIBRATE

CAPSULE;ORAL
FENOFIBRATE (MICRONIZED)

AB	CHARTWELL RX	43MG	A090859	001	Mar 01, 2012	Apr CAHN
AB		130MG	A090859	002	Mar 01, 2012	Apr CAHN

TABLET;ORAL
FENOFIBRATE

@	BAUSCH	48MG	A090715	001	Apr 05, 2012	Aug DISC
AB		48MG	A090715	001	Apr 05, 2012	Aug CAHN
@		145MG	A090715	002	Apr 05, 2012	Aug DISC
AB		145MG	A090715	002	Apr 05, 2012	Aug CAHN
AB	BOSTAL	48MG	A208476	001	Feb 10, 2021	Aug CAHN
AB		54MG	A207803	001	Dec 19, 2017	Aug CAHN
AB		145MG	A208476	002	Feb 10, 2021	Aug CAHN
AB		160MG	A207803	002	Dec 19, 2017	Aug CAHN
AB	CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Mar CTEC
AB		120MG	A217732	002	Sep 07, 2023	Mar CTEC
@	MYLAN	54MG	A076520	001	Oct 25, 2007	Feb DISC
@		160MG	A076520	003	Oct 25, 2007	Feb DISC
@	SUN PHARM	48MG	A200884	001	Sep 07, 2017	Jan DISC
@		145MG	A200884	002	Sep 07, 2017	Apr DISC

FENOFIBRIC ACID

TABLET;ORAL
FIBRICOR

@ +	ATHENA	105MG	N022418	002	Aug 14, 2009	Sep DISC
+!		105MG	N022418	002	Aug 14, 2009	Jun CMFD

FERUMOXYTOL

SOLUTION;INTRAVENOUS
FERABRIGHT

>A> +!	COVIS	EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Oct NEWA
>A> +!		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N219868	002	Oct 16, 2025	Oct NEWA

FIDAXOMICIN

TABLET;ORAL
DIFICID

AB +!	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Jul CTEC

FIDAXOMICIN

AB	ACTAVIS LABS FL	200MG	A208443	001	Jan 16, 2024	Jul CMFD

FINASTERIDE; TADALAFIL

CAPSULE;ORAL

FINASTERIDE AND TADALAFIL

			NOVITIUM PHARMA	5MG;5MG	A218499	001	Mar 19, 2025	Mar NEWA

FINERENONE

TABLET;ORAL

KERENDIA

		+	BAYER HLTHCARE	40MG	N215341	003	Jul 11, 2025	Jul NEWA

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

>D>	AB		MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Oct DISC
>A>		@		EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Oct DISC

FITUSIRAN SODIUM

SOLUTION;SUBCUTANEOUS

QFITLIA

		+!	GENZYME CORP	EQ 20MG BASE/0.2ML (EQ 20MG BASE/0.2ML)	N219019	001	Mar 28, 2025	Mar NEWA
		+!		EQ 50MG BASE/0.5ML (EQ 50MG BASE/0.5ML)	N219019	002	Mar 28, 2025	Mar NEWA

FLUCONAZOLE

TABLET;ORAL

FLUCONAZOLE

		@	TARO	50MG	A076507	001	Jul 29, 2004	Aug DISC
		@		100MG	A076507	002	Jul 29, 2004	Aug DISC
		@		150MG	A076507	003	Jul 29, 2004	Aug DISC
		@		200MG	A076507	004	Jul 29, 2004	Aug DISC

FLUCYTOSINE

CAPSULE;ORAL

FLUCYTOSINE

	AB		LAURUS	250MG	A218005	001	Jul 23, 2025	Jul NEWA
	AB			500MG	A218005	002	Jul 23, 2025	Jul NEWA

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

	AP		BAMF	20-400mCi/ML	A216125	001	Mar 11, 2025	Feb NEWA
>D>	AP		MEM SLOAN-KETTERING	20-300mCi/ML	A208679	001	Dec 08, 2016	Oct DISC
>A>		@		20-300mCi/ML	A208679	001	Dec 08, 2016	Oct DISC
	AP		SOFIE	20-300mCi/ML	A204463	001	Oct 21, 2014	Mar CAHN
		@	WISCONSIN	20-500mCi/ML	A203709	001	Oct 23, 2013	Aug DISC

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

		@	TARO	0.025%	A087104	001	Apr 27, 1982	Aug DISC

OIL;TOPICAL

FLUCINOLONE ACETONIDE

		@	GLENMARK PHARMS LTD	0.01%	A210556	001	Oct 25, 2018	Jul DISC

FLUOCINONIDE ACETONIDE

		@	GLENMARK PHARMS LTD	0.01%	A210539	001	Oct 26, 2018	Aug DISC

OIL/DROPS;OTIC

FLUOCINONIDE ACETONIDE

		@	GLENMARK PHARMS LTD	0.01%	A211815	001	Dec 14, 2018	Aug DISC

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

		@	TARO	0.025%	A040041	001	Sep 15, 1994	Aug DISC

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

	AB1		ENCUBE	0.05%	A211410	001	Oct 16, 2018	Feb CMFD
		@	GLENMARK PHARMS LTD	0.1%	A091282	001	Jul 14, 2014	Aug DISC
		@ +	SUN PHARMA CANADA	0.05%	N019117	001	Jun 26, 1984	Aug CAHN

	GEL;TOPICAL							
	FLUOCINONIDE							
AB		PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Feb	CMFD
	SOLUTION;TOPICAL							
	FLUOCINONIDE							
AT		QUAGEN	0.05%	A216389	001	Feb 26, 2025	Feb	NEWA
	@	SAPTALIS PHARMS	0.05%	A207554	001	Mar 18, 2019	Feb	CAHN
	@	SCIEGEN PHARMS INC	0.05%	A207554	001	Mar 18, 2019	Sep	CAHN
	FLUORESCEIN SODIUM							
	INJECTABLE;INTRAVENOUS							
	AK-FLUOR 25%							
	@ +	LONG GROVE PHARMS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008	May	DISC
	FLUORESCEIN SODIUM							
AP		NEXUS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A215709	001	Sep 25, 2023	Mar	CAHN
	!		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	May	CTEC
AP			EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Mar	CAHN
	FLUORODOPA F-18							
	SOLUTION;INTRAVENOUS							
	FLUORODOPA F18							
	+!	FEINSTEIN	1-40mCi/ML	N200655	001	Oct 10, 2019	Feb	CPOT
	FLUOROURACIL							
	CREAM;TOPICAL							
	FLUOROURACIL							
AB		ENCUBE	5%	A216942	001	Feb 12, 2025	Jan	NEWA
	INJECTABLE;INJECTION							
	FLUOROURACIL							
AP		ACCORD HLTHCARE	500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007	Jul	CHRS
AP			1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007	Jul	CHRS
	@		2.5GM/50ML (50MG/ML)	A040798	002	Apr 26, 2007	May	DISC
AP			5GM/100ML (50MG/ML)	A040798	001	Apr 26, 2007	Jul	CHRS
AP	!	ALEMBIC	2.5GM/50ML (50MG/ML)	A217295	001	Mar 03, 2023	May	CHRS
AP	!	FRESENIUS KABI USA	500MG/10ML (50MG/ML)	A040279	002	Sep 30, 1998	Jul	CHRS
AP	!		1GM/20ML (50MG/ML)	A040279	001	Sep 30, 1998	Jul	CHRS
AP	!		5GM/100ML (50MG/ML)	A040278	002	Sep 30, 1998	Jul	CHRS
AP		KINDOS	5GM/100ML (50MG/ML)	A215699	001	Feb 06, 2025	Jan	NEWA
	FLUOXETINE HYDROCHLORIDE							
	CAPSULE;ORAL							
	FLUOXETINE HYDROCHLORIDE							
	@	CHARTWELL RX	EQ 10MG BASE	A078143	001	Jan 16, 2008	Jul	CAHN
	@		EQ 20MG BASE	A078143	002	Jan 16, 2008	Jul	CAHN
	@		EQ 40MG BASE	A078143	003	Jan 16, 2008	Jul	CAHN
	SOLUTION;ORAL							
	FLUOXETINE HYDROCHLORIDE							
AA		SCIEGEN PHARMS INC	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002	Jun	CMFD
AA		SOLIS PHARMS	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	Apr	CAHN
	TABLET;ORAL							
	FLUOXETINE HYDROCHLORIDE							
	@	APPCO	EQ 10MG BASE	A211696	001	Jan 30, 2019	Feb	CAHN
	@		EQ 20MG BASE	A211696	002	Jan 30, 2019	Feb	CAHN
AB			EQ 60MG BASE	A211477	001	Nov 21, 2018	Jun	CAHN
AB	!	AUROBINDO PHARMA LTD	EQ 20MG BASE	A213286	002	Apr 08, 2020	Jun	CHRS
AB	!		EQ 60MG BASE	A213265	001	Jun 10, 2020	Apr	CHRS
	@	CHARTWELL RX	EQ 10MG BASE	A211444	001	Sep 13, 2022	Mar	CAHN
	@		EQ 20MG BASE	A211444	002	Sep 13, 2022	Mar	CAHN
AB		DR REDDYS	EQ 20MG BASE	A076006	002	Apr 23, 2018	Jun	CHRS
	@ +	TWI PHARMS	EQ 60MG BASE	N202133	001	Oct 06, 2011	Apr	DISC
	FLUOXETINE HYDROCHLORIDE; OLANZAPINE							
	CAPSULE;ORAL							
	OLANZAPINE AND FLUOXETINE HYDROCHLORIDE							
AB	!	TEVA PHARMS	EQ 50MG BASE;EQ 6MG BASE	A077528	003	Jun 19, 2012	Jun	CHRS
	SYMBYAX							
	@ +	LILLY	EQ 25MG BASE;EQ 3MG BASE	N021520	001	Apr 09, 2007	Feb	DISC
	@ +		EQ 25MG BASE;EQ 6MG BASE	N021520	002	Dec 24, 2003	Feb	DISC
	@ +		EQ 25MG BASE;EQ 12MG BASE	N021520	004	Dec 24, 2003	Feb	DISC

		CAPSULE;ORAL						
		SYMBYAX						
		@ +	EQ 50MG BASE;EQ 6MG BASE	N021520	003	Dec 24, 2003	Feb	DISC
		@ +	EQ 50MG BASE;EQ 12MG BASE	N021520	005	Dec 24, 2003	Feb	DISC
	FLUPHENAZINE HYDROCHLORIDE							
		TABLET;ORAL						
		FLUPHENAZINE HYDROCHLORIDE						
AB		CHARTWELL RX	1MG	A215141	001	Oct 20, 2021	Sep	CAHN
AB			2.5MG	A215141	002	Oct 20, 2021	Sep	CAHN
AB			5MG	A215141	003	Oct 20, 2021	Sep	CAHN
AB			10MG	A215141	004	Oct 20, 2021	Sep	CAHN
	@	TWI PHARMS	1MG	A215848	004	Dec 14, 2022	Jul	DISC
	@		2.5MG	A215848	001	Apr 01, 2022	Jul	DISC
	@		5MG	A215848	002	Apr 01, 2022	Jul	DISC
	@		10MG	A215848	003	Apr 01, 2022	Jul	DISC
AB		ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Feb	CAHN
AB			2.5MG	A215141	002	Oct 20, 2021	Feb	CAHN
AB			5MG	A215141	003	Oct 20, 2021	Feb	CAHN
AB			10MG	A215141	004	Oct 20, 2021	Feb	CAHN
	FLURANDRENOLIDE							
		CREAM;TOPICAL						
		CORDRAN SP						
	@ +	INA PHARMS	0.025%	N012806	003		May	CAHN
	@ +		0.05%	N012806	002		May	CAHN
		LOTION;TOPICAL						
		CORDRAN						
	@ +	INA PHARMS	0.05%	N013790	001		May	CAHN
		OINTMENT;TOPICAL						
		CORDRAN						
	@ +	INA PHARMS	0.025%	N012806	004		May	CAHN
	@ +		0.05%	N012806	001		May	CAHN
	FLURAZEPAM HYDROCHLORIDE							
		CAPSULE;ORAL						
		FLURAZEPAM HYDROCHLORIDE						
	@	NOVITIUM PHARMA	15MG	A070444	001	Mar 20, 1986	Aug	CAHN
	FLURBIPROFEN							
		TABLET;ORAL						
		FLURBIPROFEN						
	!	NEW HEIGHTSRX	100MG	A074431	001	May 31, 1995	Jul	CAHN
	FLUTICASONE PROPIONATE							
		CREAM;TOPICAL						
		FLUTICASONE PROPIONATE						
>D>	@	ENCUBE	0.05%	A076633	001	May 14, 2004	Oct	CMFD
>A> AB			0.05%	A076633	001	May 14, 2004	Oct	CMFD
		LOTION;TOPICAL						
		FLUTICASONE PROPIONATE						
	@	GLENMARK PHARMS LTD	0.05%	A090759	001	May 02, 2011	Aug	DISC
	!	PADAGIS ISRAEL	0.05%	A091553	001	Jul 30, 2013	Aug	CTEC
AB	!		0.05%	A091553	001	Jul 30, 2013	Aug	CHRS
		OINTMENT;TOPICAL						
		FLUTICASONE PROPIONATE						
	@	CHARTWELL RX	0.005%	A076300	001	May 14, 2004	Mar	CAHN
		SPRAY, METERED;NASAL						
		FLUTICASONE PROPIONATE						
AB		RUBICON RESEARCH	0.05MG/SPRAY	A218321	001	Jun 05, 2025	May	NEWA
	FLUVOXAMINE MALEATE							
		CAPSULE, EXTENDED RELEASE;ORAL						
		FLUVOXAMINE MALEATE						
AB		ANNORA PHARMA	100MG	A217024	001	Jul 30, 2025	Jul	NEWA
AB			150MG	A217024	002	Jul 30, 2025	Jul	NEWA
		TABLET;ORAL						
		FLUVOXAMINE MALEATE						
AB		AIPING PHARM INC	25MG	A075888	001	Nov 29, 2000	Jul	CAHN
AB			50MG	A075888	002	Nov 29, 2000	Jul	CAHN
AB	!		100MG	A075888	003	Nov 29, 2000	Jul	CAHN

TABLET;ORAL
FLUVOXAMINE MALEATE

	@		QUAGEN	25MG	A075889	001	Nov 29, 2000	Sep CAHN
	@			50MG	A075889	002	Nov 29, 2000	Sep CAHN
	@			100MG	A075889	003	Nov 29, 2000	Sep CAHN

FOLIC ACID

TABLET;ORAL
FOLIC ACID

	AA		AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Mar CAHN
>D>	AA		ATHEM	1MG	A211064	001	Mar 08, 2019	Oct CAHN
>A>	AA		RISING	1MG	A211064	001	Mar 08, 2019	Oct CAHN

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS
FONDAPARINUX SODIUM

>D>	AP		BRIGHTGENE	2.5MG/0.5ML	A218312	001	Dec 18, 2024	Oct DISC
>A>		@		2.5MG/0.5ML	A218312	001	Dec 18, 2024	Oct DISC
		@	HANGZHOU ZHONGMEI	2.5MG/0.5ML	A216493	001	Aug 19, 2024	Jul DISC
		@		5MG/0.4ML	A216493	002	Aug 19, 2024	Jul DISC
		@		7.5MG/0.6ML	A216493	003	Aug 19, 2024	Jul DISC
		@		10MG/0.8ML	A216493	004	Aug 19, 2024	Jul DISC

FORMOTEROL FUMARATE

SOLUTION;INHALATION
FORMOTEROL FUMARATE

	AN		DEVA HOLDING AS	0.02MG/2ML	A218308	001	Feb 11, 2025	Jan NEWA
	AN		DR REDDYS	0.02MG/2ML	A215907	001	Jan 30, 2025	Jan NEWA

PERFOROMIST

	AN	+!	VIATRIS SPECIALTY	0.02MG/2ML	N022007	001	May 11, 2007	Feb CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS
FOSAPREPITANT DIMEGLUMINE

	@		PIRAMAL CRITICAL	EQ 150MG BASE/VIAL	A214683	001	May 16, 2023	Apr DISC
	@		PRAXGEN	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Jan CAHN

FOSCARNET SODIUM

SOLUTION;INTRAVENOUS
FOSCARNET SODIUM

	AP		AMNEAL	2.4GM/100ML	A216602	001	Mar 01, 2024	Sep CDFR
	AP			6GM/250ML (24MG/ML)	A216602	001	Mar 01, 2024	Sep CPOT
	AP		AVET LIFESCIENCES	2.4GM/100ML	A213807	001	Jun 05, 2023	Sep CDFR
	AP			6GM/250ML (24MG/ML)	A213807	001	Jun 05, 2023	Sep CPOT
	AP		FRESENIUS KABI USA	2.4GM/100ML	A212483	001	Jan 29, 2021	Sep CDFR
	AP			6GM/250ML (24MG/ML)	A212483	001	Jan 29, 2021	Sep CPOT
	AP		GLAND	2.4GM/100ML	A213001	001	Apr 21, 2021	Sep CDFR
	AP			6GM/250ML (24MG/ML)	A213001	001	Apr 21, 2021	Sep CPOT
		@	HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005	Sep CDFR
		@		6GM/250ML (24MG/ML)	A077174	001	May 31, 2005	Sep CPOT
		@		12GM/500ML (24MG/ML)	A077174	002	May 31, 2005	Sep DISC
				12GM/500ML (24MG/ML)	A077174	002	May 31, 2005	Sep NEWA
	AP		SCIECURE	2.4GM/100ML	A213987	001	Nov 29, 2023	Sep CDFR
	AP			6GM/250ML (24MG/ML)	A213987	001	Nov 29, 2023	Sep CPOT

FOSCAVIR

	AP	+!	CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Sep CDFR
	AP	+!		6GM/250ML (24MG/ML)	N020068	001	Sep 27, 1991	Sep CPOT
		@ +		12GM/500ML (24MG/ML)	N020068	002	Sep 27, 1991	Sep DISC
		+		12GM/500ML (24MG/ML)	N020068	002	Sep 27, 1991	Sep NEWA

FOSFOMYCIN DISODIUM

>A> POWDER;INTRAVENOUS
>A> CONTEPO

>A>		+!	MEITHEAL	EQ 6GM BASE/VIAL	N212271	001	Oct 22, 2025	Oct NEWA

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL
FOSFOMYCIN TROMETHAMINE

	AA		PRECISION DOSE INC	EQ 3GM BASE/PACKET	A217187	001	Jun 03, 2025	May NEWA

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

	@	APOTEX	10MG	A076906	001	May 17, 2005	Mar DISC
	@		20MG	A076906	002	May 17, 2005	Mar DISC
	@		40MG	A076906	003	May 17, 2005	Mar DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>D>	@	AVET LIFESCIENCES	10MG;12.5MG	A079025	001	Sep 17, 2010	Oct CAHN
>D>	@		20MG;12.5MG	A079025	002	Sep 17, 2010	Oct CAHN
>A>	@	CHARTWELL RX	10MG;12.5MG	A079025	001	Sep 17, 2010	Oct CAHN
>A>	@		20MG;12.5MG	A079025	002	Sep 17, 2010	Oct CAHN

FOSPHENYTOIN SODIUM

SOLUTION;INTRAVENOUS

SESQUIENT

	@ +	LUPIN	EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020	Sep DISC
	+!		EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020	Aug CMFD
	@ +		EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020	Sep DISC
	+!		EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020	Aug CMFD

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

AB		LEADING	EQ 2.5MG BASE	A216998	001	Apr 16, 2025	Apr NEWA
AB		RENATA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	Aug CAHN

FULVESTRANT

SOLUTION;INTRAMUSCULAR

FULVESTRANT

	@	EUGIA PHARMA	250MG/5ML (50MG/ML)	A208811	001	Jul 23, 2019	Aug DISC

FUROSEMIDE

SOLUTION;ORAL

LASIX

>D>	@	SANOFI AVENTIS US	10MG/ML	N017688	001		Oct CRLD
>A>	@ +		10MG/ML	N017688	001		Oct CRLD

SOLUTION;SUBCUTANEOUS

LASIX ONYU

>A>	+!	SQ INNOVATION	80MG/2.67ML (30MG/ML)	N217294	001	Oct 07, 2025	Oct NEWA

TABLET;ORAL

FUROSEMIDE

AB		AUROBINDO PHARMA LTD	20MG	A218831	001	Jul 17, 2025	Jul NEWA
AB			40MG	A218831	002	Jul 17, 2025	Jul NEWA
AB			80MG	A218831	003	Jul 17, 2025	Jul NEWA
>D>	@	ESJAY PHARMA	20MG	N018415	001	Jul 27, 1982	Oct CMFD
>A> AB			20MG	N018415	001	Jul 27, 1982	Oct CMFD
>D>	@		40MG	N018415	002	Jul 27, 1982	Oct CMFD
>A> AB			40MG	N018415	002	Jul 27, 1982	Oct CMFD
>D>	@		80MG	N018415	003	Nov 26, 1984	Oct CMFD
>A> AB			80MG	N018415	003	Nov 26, 1984	Oct CMFD
AB		HIKMA	20MG	N018823	001	Nov 10, 1983	Jun CAHN
AB			40MG	N018823	002	Nov 10, 1983	Jun CAHN
	@	NORVIUM BIOSCIENCE	80MG	A070082	001	Oct 29, 1986	Feb CAHN

FUTIBATINIB

TABLET;ORAL

LYTGOBI

	+	TAIHO ONCOLOGY	16MG	N214801	002	Jul 28, 2025	Aug NEWA

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB		ANDA REPOSITORY	100MG	A219319	001	Aug 07, 2025	Sep CAHN
AB			300MG	A219319	002	Aug 07, 2025	Sep CAHN
AB			400MG	A219319	003	Aug 07, 2025	Sep CAHN

CAPSULE;ORAL
GABAPENTIN

AB		SENORES PHARMS	100MG	A219319	001	Aug 07, 2025	Sep	CAHN
AB			300MG	A219319	002	Aug 07, 2025	Sep	CAHN
AB			400MG	A219319	003	Aug 07, 2025	Sep	CAHN
AB		STALLION LABS	100MG	A219319	001	Aug 07, 2025	Aug	NEWA
AB			300MG	A219319	002	Aug 07, 2025	Aug	NEWA
AB			400MG	A219319	003	Aug 07, 2025	Aug	NEWA
	@	TARO	100MG	A077261	001	Aug 02, 2013	Aug	DISC
	@		300MG	A077261	002	Aug 02, 2013	Aug	DISC
	@		400MG	A077261	003	Aug 02, 2013	Aug	DISC

SOLUTION;ORAL
GABAPENTIN

AA		AJENAT PHARMS	250MG/5ML	A091286	001	Mar 14, 2016	Jan	CAHN
AA		PAI HOLDINGS PHARM	250MG/5ML	A211330	001	Dec 03, 2019	Apr	CMFD
	@	TARO	250MG/5ML	A076672	001	Jul 03, 2013	Aug	DISC

TABLET;ORAL
GABAPENTIN

	@	ACTAVIS ELIZABETH	600MG	A075694	001	Oct 21, 2004	Jul	DISC
	@		800MG	A075694	002	Oct 21, 2004	Jul	DISC
	@	ALLIED	600MG	A076877	001	Jul 06, 2006	Jul	CAHN
	@		800MG	A076877	002	Jul 06, 2006	Jul	CAHN
	@	APOTEX	100MG	A077894	001	Oct 10, 2006	Mar	DISC
	@		300MG	A077894	002	Oct 10, 2006	Mar	DISC
	@		400MG	A077894	003	Oct 10, 2006	Mar	DISC
		IVAX SUB TEVA PHARMS	300MG	A076017	002	Apr 28, 2004	Mar	CTEC
AB2		SCIEGEN PHARMS INC	300MG	A218491	001	Sep 19, 2025	Sep	NEWA
AB2			600MG	A218491	002	Sep 19, 2025	Sep	NEWA
	@	SENORES PHARMS	600MG	A076877	001	Jul 06, 2006	Sep	CAHN
	@		800MG	A076877	002	Jul 06, 2006	Sep	CAHN
AB		ZYDUS PHARMS	450MG	A203934	003	Aug 25, 2025	Aug	NFTG
AB			750MG	A203934	004	Aug 25, 2025	Aug	NFTG
AB			900MG	A203934	005	Aug 25, 2025	Aug	NFTG

GRALISE

AB	+	ALMATICA	450MG	N022544	003	Apr 18, 2023	Aug	CFTG
AB	+		750MG	N022544	004	Apr 18, 2023	Aug	CFTG
AB	+!		900MG	N022544	005	Apr 18, 2023	Aug	CFTG

GADOBUTROL

SOLUTION;INTRAVENOUS
GADOBUTROL

AP		HAINAN POLY PHARM	1.20944GM/2ML (604.72MG/ML)	A217480	003	Apr 16, 2025	Apr	NEWA
AP			6.0472GM/10ML (604.72MG/ML)	A217480	004	Apr 16, 2025	Apr	NEWA
AP			18.1416GM/30ML (604.72MG/ML)	A217480	005	Apr 16, 2025	Apr	NEWA
AP			39.3068GM/65ML (604.72MG/ML)	A217480	006	Apr 16, 2025	Apr	NEWA

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS
GADOTERATE MEGLUMINE

>D> AP		HENGRUI PHARMA	1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022	Oct	DISC
>A>	@		1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022	Oct	DISC
>D> AP			3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022	Oct	DISC
>A>	@		3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022	Oct	DISC
>D> AP			5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022	Oct	DISC
>A>	@		5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022	Oct	DISC
>D> AP			7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022	Oct	DISC
>A>	@		7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022	Oct	DISC
>D> AP			37.69GM/100ML (376.9MG/ML)	A215304	005	Apr 15, 2022	Oct	DISC
>A>	@		37.69GM/100ML (376.9MG/ML)	A215304	005	Apr 15, 2022	Oct	DISC

GADOTERIDOL

INJECTABLE;INJECTION
GADOTERIDOL

AP		HAINAN POLY	279.3MG/ML	A218749	001	Feb 11, 2025	Jan	NFTG

PROHANCE

AP	+!	BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992	Jan	CFTG

GALLIUM GA-68 EDOTREOTIDE

SOLUTION;INTRAVENOUS

GALLIUM GA 68 EDOTREOTIDE

>A>	AP		METHODIST	0.5-4mCi/ML	A218845	001	Oct 10, 2025	Oct NFTG
>D>		+!	UIHC PET IMAGING	0.5-4mCi/ML	N210828	001	Aug 21, 2019	Oct CFTG
>A>	AP	+!		0.5-4mCi/ML	N210828	001	Aug 21, 2019	Oct CFTG

GALLIUM GA-68 GOZETOTIDE

POWDER;INTRAVENOUS

GOZELLIX

		+!	TELIX INNOVATIONS	N/A	N219592	001	Mar 20, 2025	Mar NEWA

GANCICLOVIR

SOLUTION;INTRAVENOUS

GANZYK-RTU

		@ +	EXELA PHARMA	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Apr DISC

GANIRELIX ACETATE

INJECTABLE;INJECTION

GANIRELIX ACETATE

	AP		QILU	250MCG/0.5ML	A218855	001	Apr 23, 2025	Apr NEWA
	AP		TRIS PHARMA INC	250MCG/0.5ML	A219454	001	Jun 27, 2025	Jun NEWA

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

	AT		CAPLIN	0.5%	A213542	001	Nov 03, 2021	Sep CMFD
		@		0.5%	A213542	001	Nov 03, 2021	May CAHN

GEFITINIB

TABLET;ORAL

GEFITINIB

	AB		CIPLA	250MG	A211826	001	May 16, 2025	May NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

		@	HIKMA INTL PHARMS	EQ 200MG BASE/VIAL	A206617	001	Jun 25, 2021	May DISC
		@		EQ 1GM BASE/VIAL	A206617	002	Jun 25, 2021	May DISC

SOLUTION;INTRAVENOUS

AVGEMSI

		@ +	AVYXA HOLDINGS	EQ 200MG BASE/5.26ML (EQ 38MG BASE/ML)	N219920	001	Jun 27, 2025	Aug DISC
		+!		EQ 200MG BASE/5.26ML (EQ 38MG BASE/ML)	N219920	001	Jun 27, 2025	Jun NEWA
		+!		EQ 1GM BASE/26.3ML (EQ 38MG BASE/ML)	N219920	002	Jun 27, 2025	Jun NEWA
		+!		EQ 2GM BASE/52.6ML (EQ 38MG BASE/ML)	N219920	003	Jun 27, 2025	Jun NEWA

SYSTEM;INTRAVESICAL

INLEXZO

		+!	JANSSEN BIOTECH	EQ 225MG BASE	N219683	001	Sep 09, 2025	Sep NEWA

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

		@	APOTEX	600MG	A075034	001	Jul 20, 1998	Mar DISC

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

			BAXTER HLTHCARE	EQ 1.2MG BASE/ML	A062373	007	Sep 07, 1982	Aug CTEC
				EQ 1.6MG BASE/ML	A062373	008	Sep 07, 1982	Aug CTEC
				EQ 80MG BASE/100ML	A062373	002	Sep 07, 1982	Aug CTEC
				EQ 100MG BASE/100ML	A062373	005	Sep 07, 1982	Aug CTEC
		@	HOSPIRA	EQ 1.2MG BASE/ML	A062414	001	Aug 15, 1983	Aug DISC
		@		EQ 1.6MG BASE/ML	A062414	003	Aug 15, 1983	Aug DISC
		@		EQ 80MG BASE/100ML	A062414	008	Aug 15, 1983	Aug DISC
		@		EQ 100MG BASE/100ML	A062414	010	Aug 15, 1983	Aug DISC

OINTMENT;TOPICAL
GENTAMICIN SULFATE

@	TARO	EQ 0.1% BASE	A062477	001	Dec 23, 1983		Jul DISC

SOLUTION/DROPS;OPHTHALMIC
GENTAK

@	PHARMOBEDIENT	EQ 0.3% BASE	A064163	001	Oct 12, 2001		Sep CAHN

GEPIRONE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
EXXUA

+!	FABRE KRAMER	EQ 18.2MG BASE	N021164	001	Sep 22, 2023		Sep CMFD
+		EQ 36.3MG BASE	N021164	002	Sep 22, 2023		Sep CMFD
+		EQ 54.5MG BASE	N021164	003	Sep 22, 2023		Sep CMFD
+!		EQ 72.6MG BASE	N021164	004	Sep 22, 2023		Sep CMFD

GEPOTIDACIN MESYLATE
TABLET;ORAL
BLUJEPA

+!	GLAXOSMITHKLINE	EQ 750MG BASE	N218230	001	Mar 25, 2025		Mar NEWA

GLATIRAMER ACETATE
INJECTABLE;SUBCUTANEOUS
GLATIRAMER ACETATE

AP	CHEMI SPA	20MG/ML	A208468	001	May 07, 2025		Apr NEWA
AP		40MG/ML	A208468	002	May 07, 2025		Apr NEWA

GLIMEPIRIDE
TABLET;ORAL
AMARYL

@ +	SANOFI AVENTIS US	1MG	N020496	001	Nov 30, 1995		Feb DISC
@ +		2MG	N020496	002	Nov 30, 1995		Feb DISC
@ +		4MG	N020496	003	Nov 30, 1995		Feb DISC

GLIMEPIRIDE

@	ANDA REPOSITORY	1MG	A076802	001	Oct 06, 2005		Sep CAHN
@		2MG	A076802	002	Oct 06, 2005		Sep CAHN
@		4MG	A076802	003	Oct 06, 2005		Sep CAHN
AB !	DR REDDYS LABS LTD	1MG	A077091	001	Oct 06, 2005		Feb CHRS
@	QUAGEN	1MG	A077624	001	Nov 28, 2005		Sep CAHN
@		2MG	A077624	002	Nov 28, 2005		Sep CAHN
@		4MG	A077624	003	Nov 28, 2005		Sep CAHN

GLIPIZIDE
TABLET;ORAL
GLIPIZIDE

@	AIPING PHARM INC	5MG	A074305	001	Apr 07, 1995		Jan CAHN
@		10MG	A074305	002	Apr 07, 1995		Jan CAHN
AB	OXFORD PHARMS	5MG	A074378	001	Nov 28, 1994		Apr CMFD
AB		10MG	A074378	002	Nov 28, 1994		Apr CMFD

TABLET, EXTENDED RELEASE;ORAL
GLUCOTROL XL

@ +	PFIZER	2.5MG	N020329	003	Aug 10, 1999		Apr DISC
AB +		5MG	N020329	001	Apr 26, 1994		Apr CMFD
AB +		10MG	N020329	002	Apr 26, 1994		Apr CHRS

GLIPIZIDE; METFORMIN HYDROCHLORIDE
TABLET;ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE

@	NOVITIUM PHARMA	2.5MG;250MG	A078083	001	Apr 12, 2007		Sep CAHN
@		2.5MG;500MG	A078083	002	Apr 12, 2007		Sep CAHN
@		5MG;500MG	A078083	003	Apr 12, 2007		Sep CAHN

GLUCAGON
INJECTABLE;INJECTION
GLUCAGON

AP	CIPLA	1MG/VIAL	A218813	001	Sep 15, 2025		Sep NEWA
AP	LUPIN LTD	1MG/VIAL	A214457	001	Jul 22, 2025		Jul NEWA

SOLUTION;INTRAVENOUS
GVOKE VIALDX

+!	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025		Mar NEWA

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

GLYCEROL PHENYLBUTYRATE

>D>		@	PH HEALTH	1.1GM/ML	A	205742	001	Dec 02, 2021	Oct CMFD
>A>	AA			1.1GM/ML	A	205742	001	Dec 02, 2021	Oct CMFD

RAVICTI

>D>		+!	HORIZON THERAP US	1.1GM/ML	N	203284	001	Feb 01, 2013	Oct CTEC
>A>	AA	+!		1.1GM/ML	N	203284	001	Feb 01, 2013	Oct CTEC

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

		@	XIROMED	0.2MG/ML	A	212227	001	Mar 04, 2021	Jan DISC

ROBINUL

>D>		@ +	HIKMA	0.2MG/ML	N	017558	001		Oct CMFD
>A>	AP	+		0.2MG/ML	N	017558	001		Oct CMFD

POWDER;INHALATION

SEEBRI NEOHALER

		@ +	NOVARTIS	15.6MCG/INH	N	207923	001	Oct 29, 2015	May CTNA

SOLUTION;ORAL

GLYCOPYRROLATE

>A>	AA		AJENAT PHARMS	1MG/5ML	A	219267	001	Oct 27, 2025	Oct NEWA
	AA		MSN	1MG/5ML	A	216084	001	Apr 08, 2025	Mar NEWA
	AA		SCIEGEN PHARMS INC	1MG/5ML	A	216297	001	Oct 07, 2024	Sep CAHN

TABLET;ORAL

GLYCOPYRROLATE

	AA		CHARTWELL RX	1MG	A	040847	001	Mar 21, 2008	Feb CAHN
	AA			2MG	A	040847	002	Mar 21, 2008	Feb CAHN
	AA		REGCON HOLDINGS	1MG	A	091182	001	Feb 03, 2014	Sep CAHN
	AA			2MG	A	091182	002	Feb 03, 2014	Sep CAHN

GLYCOPYRROLATE; INDACATEROL MALEATE

POWDER;INHALATION

UTIBRON NEOHALER

		@ +	NOVARTIS	15.6MCG/INH;27.5MCG/INH	N	207930	001	Oct 29, 2015	May CTNA

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

	AT		SAPTALIS PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A	065187	001	Oct 28, 2005	Feb CAHN
	AT		SCIEGEN PHARMS INC	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A	065187	001	Oct 28, 2005	Sep CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION;ORAL

GRANISETRON HYDROCHLORIDE

			INTRA SANA LABS	EQ 2MG BASE/10ML	A	219282	001	Mar 17, 2025	Mar NEWA

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

		@	APOTEX INC	EQ 1MG BASE	A	078843	001	Feb 27, 2008	Mar DISC
		@	TARO	EQ 1MG BASE	A	090817	001	May 28, 2010	Aug DISC

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

	AB		AIPING PHARM INC	EQ 1MG BASE	A	216399	001	Jun 08, 2022	Jul CAHN
	AB			EQ 2MG BASE	A	216399	002	Jun 08, 2022	Jul CAHN
	BX		RUBICON	EQ 1MG BASE	A	216762	001	Oct 17, 2023	Mar CTEC
	BX			EQ 2MG BASE	A	216762	002	Oct 17, 2023	Mar CTEC

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

	AB		FOSUN WANBANG	EQ 1MG BASE	A	217638	001	Jun 12, 2024	Mar CMFD
		@		EQ 1MG BASE	A	217638	001	Jun 12, 2024	Jan CAHN
	AB			EQ 2MG BASE	A	217638	002	Jun 12, 2024	Mar CMFD
		@		EQ 2MG BASE	A	217638	002	Jun 12, 2024	Jan CAHN
	AB			EQ 3MG BASE	A	217638	003	Jun 12, 2024	Mar CMFD
		@		EQ 3MG BASE	A	217638	003	Jun 12, 2024	Jan CAHN
	AB			EQ 4MG BASE	A	217638	004	Jun 12, 2024	Mar CMFD
		@		EQ 4MG BASE	A	217638	004	Jun 12, 2024	Jan CAHN
	AB		RUBICON	EQ 1MG BASE	A	219689	001	Apr 15, 2025	Apr NEWA

TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

AB			EQ 2MG BASE	A219689	002	Apr 15, 2025	Apr NEWA
AB			EQ 3MG BASE	A219689	003	Apr 15, 2025	Apr NEWA
AB			EQ 4MG BASE	A219689	004	Apr 15, 2025	Apr NEWA

HALCINONIDE

CREAM;TOPICAL
HALOG

	@ +	WESTWOOD SQUIBB	0.025%	N017818	001		Aug CRLD

OINTMENT;TOPICAL
HALOG

	@ +	BRISTOL MYERS SQUIBB	0.025%	N018125	001		Aug CRLD

SOLUTION;TOPICAL
HALCINONIDE

	!	ENCUBE	0.1%	A217671	001	May 29, 2024	Mar CMFD
	@		0.1%	A217671	001	May 29, 2024	Jan DISC

HALOBETASOL PROPIONATE

CREAM;TOPICAL
HALOBETASOL PROPIONATE

	@	TARO	0.05%	A077227	001	Aug 04, 2005	Aug DISC

LOTION;TOPICAL
ULTRAVATE

	+!	LACER PHARMA	0.05%	N208183	001	Nov 06, 2015	Apr CMFD
	@ +		0.05%	N208183	001	Nov 06, 2015	Jan CAHN

OINTMENT;TOPICAL
HALOBETASOL PROPIONATE

	@	TARO	0.05%	A076994	001	Dec 16, 2004	Aug DISC

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION;TOPICAL
DUOBRII

AB	+!	BAUSCH	0.01%;0.045%	N209354	001	Apr 25, 2019	Apr CFTG

HALOBETASOL PROPIONATE AND TAZAROTENE

>A> AB		SUN PHARMA CANADA	0.01%;0.045%	A217190	001	May 02, 2025	Oct CAHN
>D> AB		TARO	0.01%;0.045%	A217190	001	May 02, 2025	Oct CAHN
AB			0.01%;0.045%	A217190	001	May 02, 2025	Apr NFTG

HALOPERIDOL

TABLET;ORAL
HALOPERIDOL

AB		APPCO	0.5MG	A211061	001	Jan 08, 2020	Feb CAHN
AB			1MG	A211061	002	Jan 08, 2020	Feb CAHN
AB			2MG	A211061	003	Jan 08, 2020	Feb CAHN
AB			5MG	A211061	004	Jan 08, 2020	Feb CAHN
AB			10MG	A211061	005	Jan 08, 2020	Feb CAHN
AB			20MG	A211061	006	Jan 08, 2020	Feb CAHN

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

AO		CAPLIN	EQ 50MG BASE/ML	A219168	001	May 13, 2025	May NEWA
AO			EQ 100MG BASE/ML	A219168	002	May 13, 2025	May NEWA

HALOPERIDOL LACTATE

INJECTABLE;INJECTION
HALOPERIDOL

	@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Feb DISC

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

	@	B BRAUN MEDICAL	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Jan DISC
AP		EMERGE BIOSCIENCE	1,000 UNITS/ML	A211005	001	Dec 14, 2018	Sep CAHN
AP			1,000 UNITS/ML	A211007	001	May 28, 2019	Sep CAHN
AP			5,000 UNITS/ML	A211007	002	May 28, 2019	Sep CAHN
AP			5,000 UNITS/ML	A212061	001	Jul 15, 2020	Sep CAHN
AP			10,000 UNITS/ML	A211007	003	May 28, 2019	Sep CAHN
AP			20,000 UNITS/ML	A211004	001	Feb 24, 2020	Sep CAHN
		HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jan CTEC
AP		NORVIUM BIOSCIENCE	1,000 UNITS/ML	A203851	001	Nov 30, 2017	May CAHN

		INJECTABLE;INJECTION						
		HEPARIN SODIUM						
	AP		5,000 UNITS/ML	A203851	002	Nov 30, 2017	May	CAHN
	AP		10,000 UNITS/ML	A203851	003	Nov 30, 2017	May	CAHN
	AP		20,000 UNITS/ML	A203852	001	Nov 30, 2017	May	CAHN
>D>		+! PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Oct	DISC
>A>		@ +	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Oct	DISC
>D>		+!	5,000 UNITS/ML	N201370	002	Jul 21, 2011	Oct	DISC
>A>		@ +	5,000 UNITS/ML	N201370	002	Jul 21, 2011	Oct	DISC
		@ PHARMOBEDIENT	20,000 UNITS/ML	A203852	001	Nov 30, 2017	Aug	DISC
	AP	PLANO PHARMS	1,000 UNITS/ML	A091682	001	Jun 08, 2011	Mar	CAHN
	AP		5,000 UNITS/ML	A091682	002	Jun 08, 2011	Mar	CAHN
	AP		10,000 UNITS/ML	A201002	001	Jun 08, 2011	Mar	CAHN
		HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
		+! B BRAUN	5,000 UNITS/100ML	N019953	003	Mar 25, 2025	Mar	NEWA
		+!	10,000 UNITS/100ML	N019953	004	Mar 25, 2025	Mar	NEWA
		HEPARIN SODIUM PRESERVATIVE FREE						
	AP	EMERGE BIOSCIENCE	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Sep	CAHN
>D>		+! PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Oct	DISC
>A>		@ +	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Oct	DISC
		HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE						
		SYRUP;ORAL						
		HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE						
		@ APOZEAL PHARMS	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Apr	CAHN
>D>		@ CHARTWELL	1.5MG/5ML;5MG/5ML	A040613	001	Feb 08, 2008	Oct	CAHN
		@	1.5MG/5ML;5MG/5ML	A040613	001	Feb 08, 2008	Sep	CAHN
>A>		@ GENUS LIFESCIENCES	1.5MG/5ML;5MG/5ML	A040613	001	Feb 08, 2008	Oct	CAHN
		@ SANKALP LIFECARE	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Apr	CAHN
		@ SCIEGEN PHARMS INC	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Sep	CAHN
	AA	XTTRIUM LABS INC	1.5MG/5ML;5MG/5ML	A088008	001	Mar 03, 1983	Feb	CAHN
		HYDRALAZINE HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		HYDRALAZINE HYDROCHLORIDE						
		@ ADRASTEA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Jun	DISC
	AP	BAXTER HLTHCARE CORP	20MG/ML	A219797	001	Jul 17, 2025	Jul	NEWA
	AP	KINDOS	20MG/ML	A217501	001	Jun 02, 2025	May	NEWA
		@ PHARMOBEDIENT	20MG/ML	A203110	001	Jun 29, 2015	Sep	CAHN
		TABLET;ORAL						
		HYDRALAZINE HYDROCHLORIDE						
		@ MACLEODS PHARMS LTD	10MG	A211010	001	Aug 21, 2024	Jun	DISC
		@	25MG	A211010	002	Aug 21, 2024	Jun	DISC
		@	50MG	A211010	003	Aug 21, 2024	Jun	DISC
		@	100MG	A211010	004	Aug 21, 2024	Jun	DISC
		HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE						
		TABLET;ORAL						
		ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE						
	AB	MLV	37.5MG;20MG	A215988	001	Jan 17, 2024	Sep	CAHN
	AB	NOVAST LABS	37.5MG;20MG	A215586	001	Apr 06, 2022	Aug	CAHN
		HYDROCHLOROTHIAZIDE						
		CAPSULE;ORAL						
		HYDROCHLOROTHIAZIDE						
		@ QUAGEN	12.5MG	A075640	001	Jan 28, 2000	Sep	CAHN
		MICROZIDE						
	AB	+! TEVA BRANDED PHARM	12.5MG	N020504	001	Dec 27, 1996	Apr	CAHN
		FOR SUSPENSION;ORAL						
		INZIRQO						
		+! NOVITIUM PHARMA	10MG/ML	N219141	001	Jan 28, 2025	Jan	NEWA
		TABLET;ORAL						
		HYDROCHLOROTHIAZIDE						
	AB	UNICHEM	12.5MG	A040907	003	Apr 03, 2025	Mar	NEWA
		HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE						
		TABLET;ORAL						
		METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE						
	AB	SENORES PHARMS	25MG;50MG	A215789	001	Jan 08, 2025	Jan	NEWA
	AB		25MG;100MG	A215789	002	Jan 08, 2025	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@		GLENMARK PHARMS	12.5MG;7.5MG	A090718	001	Mar 17, 2010	Aug DISC
@			12.5MG;15MG	A090718	002	Mar 17, 2010	Aug DISC
@			25MG;15MG	A090718	003	Mar 17, 2010	Aug DISC
		TEVA	12.5MG;7.5MG	A076980	001	Mar 07, 2007	Aug CTEC
			12.5MG;15MG	A076980	003	Mar 07, 2007	Aug CTEC
	!		25MG;15MG	A076980	002	Mar 07, 2007	Aug CTEC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB		ALKEM LABS LTD	12.5MG;20MG	A207037	001	Jul 11, 2024	Aug CTNA
AB			12.5MG;40MG	A207037	002	Jul 11, 2024	Aug CTNA
AB			25MG;40MG	A207037	003	Jul 11, 2024	Aug CTNA
AB		HANGZHOU BINJIANG	12.5MG;20MG	A214427	001	Aug 20, 2025	Sep CAHN
AB			12.5MG;40MG	A214427	002	Aug 20, 2025	Sep CAHN
AB			25MG;40MG	A214427	003	Aug 20, 2025	Sep CAHN
AB		HETERO LABS LTD V	12.5MG;20MG	A209199	001	Jul 25, 2025	Aug CTNA
AB			12.5MG;20MG	A209199	001	Jul 25, 2025	Jul NEWA
AB			12.5MG;40MG	A209199	002	Jul 25, 2025	Aug CTNA
AB			12.5MG;40MG	A209199	002	Jul 25, 2025	Jul NEWA
AB			25MG;40MG	A209199	003	Jul 25, 2025	Aug CTNA
AB			25MG;40MG	A209199	003	Jul 25, 2025	Jul NEWA
AB		MSN	12.5MG;20MG	A217398	001	Sep 26, 2025	Sep NEWA
AB			12.5MG;40MG	A217398	002	Sep 26, 2025	Sep NEWA
AB			25MG;40MG	A217398	003	Sep 26, 2025	Sep NEWA
AB		ZHEJIANG NUODE	12.5MG;20MG	A214427	001	Aug 20, 2025	Aug NEWA
AB			12.5MG;40MG	A214427	002	Aug 20, 2025	Aug NEWA
AB			25MG;40MG	A214427	003	Aug 20, 2025	Aug NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@		APOTEX	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan DISC
@			12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan DISC
@			25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

@		MANKIND PHARMA	12.5MG;40MG	A218406	001	Mar 03, 2025	Aug DISC
AB			12.5MG;40MG	A218406	001	Mar 03, 2025	Feb NEWA
@			12.5MG;80MG	A218406	002	Mar 03, 2025	Aug DISC
AB			12.5MG;80MG	A218406	002	Mar 03, 2025	Feb NEWA
@			25MG;80MG	A218406	003	Mar 03, 2025	Aug DISC
AB			25MG;80MG	A218406	003	Mar 03, 2025	Feb NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@		MACLEODS PHARMS LTD	25MG;37.5MG	A214611	001	Jan 28, 2025	Jun DISC
AB			25MG;37.5MG	A214611	001	Jan 28, 2025	Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE

@		STRIDES PHARMA	5MG;200MG	A077723	003	Nov 06, 2006	Apr CAHN

HYDROCODONE BITARTRATE AND IBUPROFEN

@		STRIDES PHARMA	7.5MG;200MG	A077723	001	Nov 06, 2006	Apr CAHN
@			10MG;200MG	A077723	002	Nov 06, 2006	Apr CAHN

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@		APOZEAL PHARMS	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Apr CAHN
@		SCIEGEN PHARMS INC	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Sep CAHN

HYDROCORTISONE

GEL;TOPICAL

NUTRACORT

@ +	HEALTHPOINT	1%	A084698	001			Sep CRLD

LOTION;TOPICAL

ALA-SCALP

+	LEGACY PHARMA	2%	A083231	001			Mar CRLD

HYDROCORTISONE

@	TARO	2.5%	A040247	001	Jul 23, 1999		Aug DISC

STIE-CORT

!	PADAGIS US	2.5%	A089074	001	Nov 26, 1985		Aug CTEC

OINTMENT;TOPICAL

HYDROCORTISONE

@	TARO	1%	A086257	001			Aug DISC

SOLUTION;ORAL

KHINDIVI

+!	ETON	1MG/ML	N218980	001	May 28, 2025		May NEWA

TABLET;ORAL

HYDROCORTISONE

AB	NOVITIUM PHARMA	5MG	A217881	001	May 02, 2025		Apr NEWA
AB		10MG	A217881	002	May 02, 2025		Apr NEWA
AB		20MG	A217881	003	May 02, 2025		Apr NEWA

HYDROCORTISONE ACETATE

AEROSOL, METERED;RECTAL

CORTIFOAM

+!	VIATRIS	10%	N017351	001	Feb 10, 1982		Feb CAHN

CREAM;TOPICAL

MICORT-HC

@	LEGACY PHARMA	2%	A040398	001	Mar 29, 2002		Jan CAHN

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL

HYDROCORTISONE BUTYRATE

@	GLENMARK PHARMS LTD	0.1%	A202145	001	Sep 27, 2013		Aug DISC

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

@	GLENMARK PHARMS LTD	0.2%	A211129	001	Oct 12, 2018		Jul DISC

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

@	GLENMARK PHARMS LTD	0.2%	A211750	001	Dec 14, 2018		Aug DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

>A> AT	AMNEAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A217803	001	Oct 29, 2025		Oct NEWA
@	SAPTALIS PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005		Feb CAHN

SUSPENSION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	AMNEAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A217735	001	Sep 30, 2025		Sep NEWA
AT	SAPTALIS PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006		Feb CAHN
AT	SCIEGEN PHARMS INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006		Sep CAHN

HYDROMORPHONE HYDROCHLORIDE

SOLUTION;ORAL

HYDROMORPHONE HYDROCHLORIDE

@	CHARTWELL	5MG/5ML	A207108	001	Apr 22, 2020		Sep CAHN

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

@	CHARTWELL	2MG	A077471	002	Dec 09, 2009		Sep CAHN
@		4MG	A077471	003	Dec 09, 2009		Sep CAHN
@		8MG	A077471	001	Dec 09, 2009		Sep CAHN
@	MPP PHARMA	8MG	A076723	001	Oct 18, 2005		Jun CAHN

HYDROXYUREA

CAPSULE;ORAL

DROXIA

	@ +	WAYLIS THERAP	200MG	N016295	002	Feb 25, 1998	Sep	CAHN
	@ +		300MG	N016295	003	Feb 25, 1998	Sep	CAHN
	@ +		400MG	N016295	004	Feb 25, 1998	Sep	CAHN

HYDREA

AB	+!	WAYLIS THERAP	500MG	N016295	001		Sep	CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

AA		BIONPHARMA	10MG/5ML	A219289	001	Apr 28, 2025	Apr	NEWA
	@	RISING	10MG/5ML	A086880	001		Aug	CAHN

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

	@	APPCO	10MG	A040812	001	Mar 12, 2008	Apr	CAHN
	@		25MG	A040812	002	Mar 12, 2008	Apr	CAHN
	@		50MG	A040812	003	Mar 12, 2008	Apr	CAHN
AB	!	GRAVITI PHARMS	50MG	A217652	003	Aug 17, 2023	Mar	CHRS
AB	+	PLIVA	50MG	A088619	001	Jan 10, 1986	Mar	CHRS
	@	SOMERSET THERAPS LLC	10MG	A040812	001	Mar 12, 2008	Sep	CAHN
	@		25MG	A040812	002	Mar 12, 2008	Sep	CAHN
	@		50MG	A040812	003	Mar 12, 2008	Sep	CAHN
	@ +	STRIDES PHARMA	50MG	A087604	001	Jan 22, 1982	Mar	CRLD

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB		BARR LABS	EQ 50MG HYDROCHLORIDE	A088487	001	Jun 15, 1984	Mar	CAHN
			EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984	Mar	CAHN

SUSPENSION;ORAL

VISTARIL

	@ +	PFIZER	EQ 25MG HYDROCHLORIDE/5ML	N011795	001		Jul	CRLD

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

ICATIBANT ACETATE

	@	CAPLIN	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213054	001	Oct 05, 2020	Apr	CAHN

ICODEXTRIN

SOLUTION;INTRAPERITONEAL

EXTRANEAL

	+!	VANTIVE US HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002	Feb	CAHN

ICOSAPENT ETHYL

CAPSULE;ORAL

ICOSAPENT ETHYL

AB		PHARMOBEDIENT	1GM	A218994	001	Dec 20, 2024	Sep	CAHN
AB		XIAMEN LP PHARM CO	1GM	A219156	001	Aug 06, 2025	Jul	NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

IDAMYCIN

>D>	@	PFIZER	5MG/VIAL	N050661	002	Sep 27, 1990	Oct	CDFR
>D>	@		10MG/VIAL	N050661	001	Sep 27, 1990	Oct	CDFR
>D>	@		20MG/VIAL	N050661	003	Apr 25, 1995	Oct	CDFR

IDAMYCIN PFS

>D> AP	+!	PFIZER	1MG/ML	N050734	001	Feb 17, 1997	Oct	CDFR

IDARUBICIN HYDROCHLORIDE

>D>	@	FRESENIUS KABI USA	1MG/ML	A065440	001	Aug 04, 2009	Oct	CDFR
>D> AP		HIKMA	1MG/ML	A065275	001	Dec 14, 2006	Oct	CDFR
>D> AP			1MG/ML	A065288	001	May 15, 2007	Oct	CDFR
>D> AP		MEITHEAL	1MG/ML	A065036	001	May 01, 2002	Oct	CDFR
>D>	@	RISING	1MG/ML	A200144	001	Oct 11, 2012	Oct	CDFR
>D>	@	SANDOZ	1MG/ML	A091293	001	Mar 29, 2011	Oct	CDFR
>D>	@	TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002	Oct	CDFR
>D>	@		10MG/VIAL	A065037	002	May 01, 2002	Oct	CDFR
>D>	@		20MG/VIAL	A065037	001	May 01, 2002	Oct	CDFR

>A>			POWDER;INTRAVENOUS					
>A>			IDAMYCIN					
>A>		@	PFIZER	5MG/VIAL	N050661	002	Sep 27, 1990	Oct CDFR
>A>		@		10MG/VIAL	N050661	001	Sep 27, 1990	Oct CDFR
>A>		@		20MG/VIAL	N050661	003	Apr 25, 1995	Oct CDFR
>A>			IDARUBICIN HYDROCHLORIDE					
>A>		@	TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002	Oct CDFR
>A>		@		10MG/VIAL	A065037	002	May 01, 2002	Oct CDFR
>A>		@		20MG/VIAL	A065037	001	May 01, 2002	Oct CDFR
>A>			SOLUTION;INTRAVENOUS					
>A>			IDAMYCIN PFS					
>A>	AP	+!	PFIZER	1MG/ML	N050734	001	Feb 17, 1997	Oct CDFR
>A>	AP	+!		5MG/5ML (1MG/ML)	N050734	001	Feb 17, 1997	Oct CPOT
>A>			IDARUBICIN HYDROCHLORIDE					
>A>		@	FRESENIUS KABI USA	1MG/ML	A065440	001	Aug 04, 2009	Oct CDFR
>A>		@		5MG/5ML (1MG/ML)	A065440	001	Aug 04, 2009	Oct CPOT
>A>		@		10MG/10ML (1MG/ML)	A065440	002	Aug 04, 2009	Oct NEWA
>A>		@		20MG/20ML (1MG/ML)	A065440	003	Aug 04, 2009	Oct NEWA
>A>	AP		HIKMA	1MG/ML	A065275	001	Dec 14, 2006	Oct CDFR
>A>	AP			1MG/ML	A065288	001	May 15, 2007	Oct CDFR
>A>	AP			5MG/5ML (1MG/ML)	A065275	001	Dec 14, 2006	Oct CPOT
>A>	AP			5MG/5ML (1MG/ML)	A065288	001	May 15, 2007	Oct CPOT
>A>	AP			10MG/10ML (1MG/ML)	A065275	002	Dec 14, 2006	Oct NEWA
>A>	AP			10MG/10ML (1MG/ML)	A065288	002	May 15, 2007	Oct NEWA
>A>	AP			20MG/20ML (1MG/ML)	A065275	003	Dec 14, 2006	Oct NEWA
>A>	AP			20MG/20ML (1MG/ML)	A065288	003	May 15, 2007	Oct NEWA
>A>	AP		MEITHEAL	1MG/ML	A065036	001	May 01, 2002	Oct CDFR
>A>	AP			5MG/5ML (1MG/ML)	A065036	001	May 01, 2002	Oct CPOT
>A>	AP			10MG/10ML (1MG/ML)	A065036	002	May 01, 2002	Oct NEWA
>A>	AP			20MG/20ML (1MG/ML)	A065036	003	May 01, 2002	Oct NEWA
>A>	AP	+!	PFIZER	10MG/10ML (1MG/ML)	N050734	002	Feb 17, 1997	Oct NEWA
>A>	AP	+!		20MG/20ML (1MG/ML)	N050734	003	Feb 17, 1997	Oct NEWA
>A>		@	RISING	1MG/ML	A200144	001	Oct 11, 2012	Oct CDFR
>A>		@		5MG/5ML (1MG/ML)	A200144	001	Oct 11, 2012	Oct CPOT
>A>		@		10MG/10ML (1MG/ML)	A200144	002	Oct 11, 2012	Oct NEWA
>A>		@		20MG/20ML (1MG/ML)	A200144	003	Oct 11, 2012	Oct NEWA
>A>		@	SANDOZ	1MG/ML	A091293	001	Mar 29, 2011	Oct CDFR
>A>		@		5MG/5ML (1MG/ML)	A091293	001	Mar 29, 2011	Oct CPOT
>A>		@		10MG/10ML (1MG/ML)	A091293	002	Mar 29, 2011	Oct NEWA
>A>		@		20MG/20ML (1MG/ML)	A091293	003	Mar 29, 2011	Oct NEWA

IMATINIB MESYLATE

			TABLET;ORAL					
			IMATINIB MESYLATE					
	AB		CSPC OUYI	EQ 100MG BASE	A212193	001	Apr 21, 2025	Apr NEWA
	AB			EQ 400MG BASE	A212193	002	Apr 21, 2025	Apr NEWA
	AB		HETERO LABS LTD V	EQ 100MG BASE	A212975	001	Apr 14, 2025	Apr NEWA
	AB			EQ 400MG BASE	A212975	002	Apr 14, 2025	Apr NEWA

IMIQUIMOD

			CREAM;TOPICAL					
			IMIQUIMOD					
		@	APOTEX INC	5%	A091308	001	Apr 06, 2012	Mar DISC

IMLUNESTRANT TOSYLATE

			TABLET;ORAL					
			INLURIYO					
		+!	ELI LILLY AND CO	EQ 200MG BASE	N218881	001	Sep 25, 2025	Sep NEWA

INDOCYANINE GREEN

			INJECTABLE;INJECTION					
			IC-GREEN					
	AP	+	RENEW PHARMS	25MG/VIAL	N011525	001		May CMFD
			INDOCYANINE GREEN					
	AP	!	RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007	May CTEC

INDOMETHACIN

			SUPPOSITORY;RECTAL					
			INDOMETHACIN					
	AB		AMNEAL	50MG	A215399	001	Feb 24, 2025	Feb NEWA
	AB		ANNORA PHARMA	50MG	A216905	001	Jul 03, 2025	Jun NEWA

IOBENGUANE SULFATE I-123

SOLUTION;INTRAVENOUS

ADREVIEW							
+!	GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N022290	001	Sep 19, 2008	Jun	CTEC
IOBENGUANE I-123							
@	BWXT MEDCL	10mCi/5ML (2mCi/ML)	A213637	001	Dec 09, 2024	Jun	DISC

IOHEXOL

SOLUTION;INJECTION, ORAL, RECTAL

>A>	IOHEXOL						
>A> AP	AMNEAL	64.7%	A217737	001	Nov 13, 2025	Oct	NFTG
OMNIPAQUE 300							
>D> +!	GE HEALTHCARE	64.7%	N018956	003	Dec 26, 1985	Oct	CFTG
>A> AP +!		64.7%	N018956	003	Dec 26, 1985	Oct	CFTG

IOMEPROL

SOLUTION;INTRA-ARTERIAL

IOMERVU							
@ +	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216016	002	Nov 27, 2024	Mar	DISC
@ +		17.5GM IODINE/50ML (350MG IODINE/ML)	N216016	006	Nov 27, 2024	Mar	DISC
@ +		20GM IODINE/50ML (400MG IODINE/ML)	N216016	010	Nov 27, 2024	Mar	DISC
@ +		25GM IODINE/100ML (250MG IODINE/ML)	N216016	001	Nov 27, 2024	Mar	DISC
@ +		30GM IODINE/100ML (300MG IODINE/ML)	N216016	003	Nov 27, 2024	Mar	DISC
@ +		35GM IODINE/100ML (350MG IODINE/ML)	N216016	007	Nov 27, 2024	Mar	DISC
@ +		40GM IODINE/100ML (400MG IODINE/ML)	N216016	011	Nov 27, 2024	Mar	DISC
@ +		60GM IODINE/150ML (400MG IODINE/ML)	N216016	012	Nov 27, 2024	Mar	DISC
@ +		45GM IODINE/150ML (300MG IODINE/ML)	N216016	004	Nov 27, 2024	Mar	DISC
@ +		52.5GM IODINE/150ML (350MG IODINE/ML	N216016	008	Nov 27, 2024	Mar	DISC
@ +		60GM IODINE/200ML (300MG IODINE/ML)	N216016	005	Nov 27, 2024	Mar	DISC
@ +		70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Mar	DISC
@ +		80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Mar	DISC

SOLUTION;INTRAVENOUS

IOMERVU							
@ +	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216017	002	Nov 27, 2024	Mar	DISC
@ +		17.5GM IODINE/50ML (350MG IODINE/ML)	N216017	006	Nov 27, 2024	Mar	DISC
@ +		20GM IODINE/50ML (400MG IODINE/ML)	N216017	010	Nov 27, 2024	Mar	DISC
@ +		25GM IODINE/100ML (250MG IODINE/ML)	N216017	001	Nov 27, 2024	Mar	DISC
@ +		30GM IODINE/100ML (300MG IODINE/ML)	N216017	003	Nov 27, 2024	Mar	DISC
@ +		35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Mar	DISC
@ +		40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Mar	DISC
@ +		60GM IODINE/150ML (400MG IODINE/ML)	N216017	012	Nov 27, 2024	Mar	DISC
@ +		45GM IODINE/150ML (300MG IODINE/ML)	N216017	004	Nov 27, 2024	Mar	DISC
@ +		52.5GM IODINE/150ML (350MG IODINE/ML)	N216017	008	Nov 27, 2024	Mar	DISC
@ +		60GM IODINE/200ML (300MG IODINE/ML)	N216017	005	Nov 27, 2024	Mar	DISC
@ +		70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Mar	DISC
@ +		80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Mar	DISC

IOVERSOL

INJECTABLE;INJECTION

OPTIRAY 300

	@ +	LIEBEL-FLARSHEIM	64%	N020923	004	May 13, 1999	Jul DISC

IPRATROPIUM BROMIDE

SOLUTION;INHALATION

IPRATROPIUM BROMIDE

	@	PHARMOBEDIENT	0.02%	A074755	001	Jan 10, 1997	Jun CAHN
	@	SUN PHARM	0.02%	A207903	001	Jan 03, 2017	Aug DISC

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

AB		LUPIN	0.021MG/SPRAY	A217912	001	Feb 07, 2025	Jan NEWA
AB			0.042MG/SPRAY	A217886	001	Jan 27, 2025	Jan NEWA
AB		RUBICON	0.021MG/SPRAY	A219222	001	Jan 14, 2025	Jan NEWA

IRBESARTAN

TABLET;ORAL

IRBESARTAN

>A> AB		MSN	75MG	A219539	001	Nov 04, 2025	Oct NEWA
>A> AB			150MG	A219539	002	Nov 04, 2025	Oct NEWA
>A> AB			300MG	A219539	003	Nov 04, 2025	Oct NEWA
	@	YILING	75MG	A200461	001	Sep 27, 2012	Sep CAHN
	@		150MG	A200461	002	Sep 27, 2012	Sep CAHN
	@		300MG	A200461	003	Sep 27, 2012	Sep CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

IRINOTECAN HYDROCHLORIDE

	@	HENGRUI PHARMA	40MG/2ML (20MG/ML)	A090675	002	Dec 16, 2011	Sep DISC
	@		100MG/5ML (20MG/ML)	A090675	001	Dec 16, 2011	Sep DISC
AP		PHARMOBEDIENT	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	Aug CAHN
AP			100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	Aug CAHN

IRON DEXTRAN

INJECTABLE;INJECTION

DEXFERRUM

	@	AM REGENT	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996	Aug CAIN

INFED

BP	+!	ALLERGAN	EQ 100MG IRON/2ML (EQ 50MG IRON/ML)	N017441	001		Aug CAIN

IRON DEXTRAN

	@	SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002		Aug CAIN

PROFERDEX

	@	NEW RIVER	EQ 50MG IRON/ML	N017807	001		Aug CAIN

IRON SUCROSE

INJECTABLE;INTRAVENOUS

IRON SUCROSE

AB		INTL MEDICATION SYS	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	A208977	001	Aug 08, 2025	Aug NFTG
AB			EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	A208977	002	Aug 08, 2025	Aug NFTG
AB			EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	A208977	003	Aug 08, 2025	Aug NFTG
AB		MYLAN LABS LTD	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	A212559	001	Aug 08, 2025	Aug NFTG
AB			EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	A212559	002	Aug 08, 2025	Aug NFTG
AB			EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	A212559	003	Aug 08, 2025	Aug NFTG
AB		SANDOZ	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	A212340	001	Aug 08, 2025	Aug NFTG
AB			EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	A212340	002	Aug 08, 2025	Aug NFTG
AB			EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	A212340	003	Aug 08, 2025	Aug NFTG

VENOFER

AB	+	AM REGENT	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N021135	002	Mar 20, 2005	Aug CFTG
	+		EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N021135	002	Mar 20, 2005	Aug CAIN
	@		EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)	N021135	005	Mar 29, 2013	Aug CAIN

		INJECTABLE;INTRAVENOUS						
		VENOFER						
		@	EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)	N021135	003	Mar 29, 2005	Aug	CAIN
	AB	+!	EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	N021135	001	Nov 06, 2000	Aug	CFTG
		+!	EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	N021135	001	Nov 06, 2000	Aug	CAIN
	AB	+	EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N021135	004	Feb 09, 2007	Aug	CFTG
		+	EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N021135	004	Feb 09, 2007	Aug	CAIN
		ISOCARBOXAZID						
		TABLET;ORAL						
		MARPLAN						
		+! LIFSA DRUGS	10MG	N011961	001		Jun	CAHN
		ISOFLURANE						
		LIQUID;INHALATION						
		ISOFLURANE						
>A>	AN	SHANDONG	99.9%	A216527	001	Nov 04, 2025	Oct	NEWA
		ISONIAZID						
		SYRUP;ORAL						
		ISONIAZID						
	AA	CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997	Feb	CMFD
	AA	+! CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Feb	CTEC
		TABLET;ORAL						
		ISONIAZID						
		@ GENUS	100MG	A080936	001		Aug	DISC
		@	300MG	A080937	002		Aug	DISC
	AA	! OMNIVIUM PHARMS	100MG	A040090	001	Jun 26, 1997	Aug	CHRS
	AA	!	300MG	A040090	002	Jun 26, 1997	Aug	CHRS
		ISOSORBIDE DINITRATE						
		TABLET;ORAL						
		ISOSORBIDE DINITRATE						
	AB	HIKMA INTL PHARMS	5MG	A088088	003	Oct 29, 1987	Jul	CMS1
	AB		10MG	A088088	002	Oct 29, 1987	Jul	CMS1
		TABLET;SUBLINGUAL						
		ISOSORBIDE DINITRATE						
		@ HIKMA INTL PHARMS	2.5MG	A086055	002	Oct 29, 1987	Jul	CMS1
		ISOSULFAN BLUE						
		SOLUTION;SUBCUTANEOUS						
		ISOSULFAN BLUE						
		@ SABA ILAY SANAYI	50MG/5ML (10MG/ML)	A210714	001	Jan 16, 2019	Jun	CAHN
		ISOTRETINOIN						
		CAPSULE;ORAL						
		AMNESTEEM						
	AB1	MYLAN PHARMS INC	30MG	A075945	004	Mar 17, 2025	Mar	NEWA
		ISOTRETINOIN						
	AB2	AMNEAL PHARMS NY	10MG	A216097	001	Oct 07, 2025	Sep	NEWA
	AB2		20MG	A216097	002	Oct 07, 2025	Sep	NEWA
	AB2		25MG	A216097	003	Oct 07, 2025	Sep	NEWA
	AB2		30MG	A216097	004	Oct 07, 2025	Sep	NEWA
	AB2		35MG	A216097	005	Oct 07, 2025	Sep	NEWA
	AB2		40MG	A216097	006	Oct 07, 2025	Sep	NEWA
	AB2	ZYDUS PHARMS	10MG	A216633	001	May 22, 2025	May	NEWA
	AB2		20MG	A216633	002	May 22, 2025	May	NEWA
	AB2		25MG	A216633	003	May 22, 2025	May	NEWA
	AB2		30MG	A216633	004	May 22, 2025	May	NEWA
	AB2		35MG	A216633	005	May 22, 2025	May	NEWA
	AB2		40MG	A216633	006	May 22, 2025	May	NEWA
		ITRACONAZOLE						
		CAPSULE;ORAL						
		ITRACONAZOLE						
	AB	RISING	100MG	A205724	001	Dec 13, 2016	Feb	CMFD

	SOLUTION;ORAL						
	ITRACONAZOLE						
AA	! AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015	Aug CHRS	
	SPORANOX						
	@ + JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997	Aug DISC	
	IVABRADINE HYDROCHLORIDE						
	TABLET;ORAL						
	IVABRADINE HYDROCHLORIDE						
AB	MSN	EQ 5MG BASE	A213483	001	Apr 28, 2025	Apr NEWA	
AB		EQ 7.5MG BASE	A213483	002	Apr 28, 2025	Apr NEWA	
	IVERMECTIN						
	TABLET;ORAL						
	IVERMECTIN						
AB	EPIC PHARMA LLC	3MG	A218805	001	Sep 09, 2025	Aug NEWA	
AB	RUBICON	3MG	A215922	001	Jan 22, 2025	Jan NEWA	
		6MG	A215922	002	Jan 22, 2025	Jan NFTG	
	KETAMINE HYDROCHLORIDE						
	INJECTABLE;INJECTION						
	KETAMINE HYDROCHLORIDE						
AP	CAPLIN	EQ 10MG BASE/ML	A217858	001	Aug 07, 2025	Sep CAHN	
AP	FRESENIUS KABI USA	EQ 100MG BASE/ML	A215808	003	Apr 18, 2025	Apr NEWA	
AP	PHARMATHER	EQ 10MG BASE/ML	A217858	001	Aug 07, 2025	Aug NEWA	
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS						
	KETAMINE HYDROCHLORIDE						
	! BAXTER HLTHCARE CORP	EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A219684	001	Sep 17, 2025	Sep NEWA	
	KETOCONAZOLE						
	AEROSOL, FOAM;TOPICAL						
	EXTINA						
	@ + RISING	2%	N021738	001	Jun 12, 2007	Aug CAHN	
	CREAM;TOPICAL						
	KETOCONAZOLE						
AB	! ENCUBE	2%	A212443	001	May 20, 2021	Sep CHRS	
AB	PADAGIS US	2%	A215185	001	Nov 17, 2021	Sep CAHN	
AB	TEVA	2%	A075581	001	Apr 25, 2000	Sep CHRS	
AB	TP ANDA HOLDINGS	2%	A215185	001	Nov 17, 2021	Sep CAHN	
	GEL;TOPICAL						
	XOLEGEL						
	@ + INA PHARMS	2%	N021946	001	Jul 28, 2006	May CAHN	
	SHAMPOO;TOPICAL						
	KETOCONAZOLE						
AB	ZYDUS LIFESCIENCES	2%	A218559	001	Mar 07, 2025	Feb NEWA	
	TABLET;ORAL						
	KETOCONAZOLE						
AB	ESJAY PHARMA	200MG	A219129	001	Jul 03, 2025	Jun NEWA	
AB	NOVITIUM PHARMA	200MG	A219129	001	Jul 03, 2025	Aug CAHN	
	KETOROLAC TROMETHAMINE						
	INJECTABLE;INJECTION						
	KETOROLAC TROMETHAMINE						
	@ FRESENIUS KABI USA	15MG/ML	A203242	001	Oct 07, 2015	Jul DISC	
	@ HOSPIRA	30MG/ML	A074993	002	Jan 27, 1999	Jul DISC	
	@ SUN PHARM	15MG/ML	A078737	001	Oct 06, 2008	Jul DISC	
	@	30MG/ML	A078737	002	Oct 06, 2008	Jul DISC	
	LABETALOL HYDROCHLORIDE						
	INJECTABLE;INJECTION						
	LABETALOL HYDROCHLORIDE						
AP	AMNEAL	5MG/ML	A218870	001	Oct 02, 2025	Sep NEWA	
	TABLET;ORAL						
	LABETALOL HYDROCHLORIDE						
AB	MACLEODS PHARMS LTD	100MG	A217949	001	Sep 23, 2025	Sep NEWA	
AB		200MG	A217949	002	Sep 23, 2025	Sep NEWA	
AB		300MG	A217949	003	Sep 23, 2025	Sep NEWA	
AB	RUBICON RESEARCH	100MG	A211953	001	Aug 18, 2021	Jul CAHN	
AB		200MG	A211953	002	Aug 18, 2021	Jul CAHN	
AB		300MG	A211953	003	Aug 18, 2021	Jul CAHN	

LACOSAMIDE

SOLUTION;INTRAVENOUS

LACOSAMIDE

AP		WESTMINSTER PHARMS	200MG/20ML (10MG/ML)	A218706	001	May 23, 2025	May NEWA

SOLUTION;ORAL

LACOSAMIDE

AA		AJENAT PHARMS	10MG/ML	A219699	001	Jun 26, 2025	Jun NEWA
AA		APOTEX	10MG/ML	A206355	001	Sep 26, 2022	May CMFD
	@		10MG/ML	A206355	001	Sep 26, 2022	Feb DISC
AA		KANCHAN HLTHCARE	10MG/ML	A216461	001	Feb 06, 2023	Sep CAHN

LACTULOSE

FOR SOLUTION;ORAL

LACTULOSE

AA	!	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997	Mar CTEC
AA	!		20GM/PACKET	A074712	002	Dec 10, 1997	Mar CTEC
AA		PAI HOLDINGS	10GM/PACKET	A217914	001	Mar 14, 2025	Mar NEWA
AA			20GM/PACKET	A217914	002	Mar 14, 2025	Mar NEWA

SOLUTION;ORAL

LACTULOSE

	@	VISTAPHARM LLC	10GM/15ML	A074138	001	Sep 30, 1992	Jan CAHN

SOLUTION;ORAL, RECTAL

LACTULOSE

AA		SCIEGEN PHARMS INC	10GM/15ML	A203762	001	Mar 27, 2015	Sep CAHN

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

AB		APPCO	150MG	A206974	001	Nov 21, 2016	Mar CAHN
AB			300MG	A206974	002	Nov 21, 2016	Mar CAHN
>D> AB		BRECKENRIDGE	150MG	A203586	001	Nov 21, 2016	Oct DISC
>A>	@		150MG	A203586	001	Nov 21, 2016	Oct DISC
	@	NORVIUM BIOSCIENCE	150MG	A078545	001	Mar 05, 2019	Feb CAHN
	@		300MG	A078545	002	Mar 05, 2019	Feb CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

AB		NORVIUM BIOSCIENCE	150MG;300MG	A079128	001	May 13, 2015	May CAHN

LAMOTRIGINE

SUSPENSION;ORAL

SUBVENITE

	+!	OWP PHARMS	10MG/ML	N218879	001	Sep 16, 2025	Sep NEWA

TABLET;ORAL

LAMOTRIGINE

	@	AIPING PHARM INC	25MG	A078645	001	Jan 27, 2009	Jan CAHN
	@		100MG	A078645	002	Jan 27, 2009	Jan CAHN
	@		150MG	A078645	003	Jan 27, 2009	Jan CAHN
	@		200MG	A078645	004	Jan 27, 2009	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB		PH HEALTH	25MG	A201374	001	Dec 26, 2012	Sep CMFD
AB			50MG	A201374	002	Dec 26, 2012	Sep CMFD
AB			100MG	A201374	003	Dec 26, 2012	Sep CMFD
AB			200MG	A201374	004	Dec 26, 2012	Sep CMFD
AB			250MG	A201374	005	Dec 26, 2012	Sep CMFD
AB			300MG	A201374	006	Dec 26, 2012	Sep CMFD

TABLET, FOR SUSPENSION;ORAL

LAMOTRIGINE

	@	TARO	5MG	A079204	001	Feb 04, 2009	Aug DISC
	@		25MG	A079204	002	Feb 04, 2009	Aug DISC

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

AB		TARO	25MG	A219677	001	Oct 07, 2025	Sep NEWA
AB			50MG	A219677	002	Oct 07, 2025	Sep NEWA
AB			100MG	A219677	003	Oct 07, 2025	Sep NEWA
AB			200MG	A219677	004	Oct 07, 2025	Sep NEWA

LANDIOLOL HYDROCHLORIDE

POWDER;INTRAVENOUS

RAPIBLYK

>A>		+!	AOP HLTH US	EQ 280MG BASE/VIAL	N217202	001	Nov 22, 2024	Oct CAHN
>D>		+!	AOP ORPHAN	EQ 280MG BASE/VIAL	N217202	001	Nov 22, 2024	Oct CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

	@		MACLEODS PHARMS LTD	15MG	A208671	001	Nov 04, 2024	Jun DISC
	@			30MG	A208671	002	Nov 04, 2024	Jun DISC

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

LANTHANUM CARBONATE

AB			ALKEM LABS LTD	EQ 500MG BASE	A202329	001	Mar 13, 2025	Mar NEWA
AB				EQ 750MG BASE	A202329	002	Mar 13, 2025	Mar NEWA
AB				EQ 1GM BASE	A202329	003	Mar 13, 2025	Mar NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

	@		CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Apr CAHN
AT			MICRO LABS	0.005%	A219306	001	Apr 14, 2025	Apr NEWA

LATANOPROSTENE BUNOD

SOLUTION/DROPS;OPHTHALMIC

LATANOPROSTENE BUNOD

AB			GLAND	0.024%	A217387	001	Apr 29, 2025	Apr NFTG

VYZULTA

AB		+!	BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017	Apr CFTG

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

AB			FOSUN WANBANG	10MG	A077087	001	Sep 13, 2005	Jan CAHN
AB				20MG	A077087	002	Sep 13, 2005	Jan CAHN

LENACAPAVIR SODIUM

SOLUTION;SUBCUTANEOUS

YEZTUGO

		+!	GILEAD SCIENCES INC	EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)	N220018	001	Jun 18, 2025	Jun NEWA

TABLET;ORAL

YEZTUGO

		+!	GILEAD SCIENCES INC	EQ 300MG BASE	N220020	001	Jun 18, 2025	Jun NEWA

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

	@		AMNEAL	2.5MG	A216213	001	Jan 31, 2025	Jun DISC
AB				2.5MG	A216213	001	Jan 31, 2025	Jan NEWA
	@			5MG	A216213	002	Jan 31, 2025	Jun DISC
AB				5MG	A216213	002	Jan 31, 2025	Jan NEWA
	@			10MG	A216213	003	Jan 31, 2025	Jun DISC
AB				10MG	A216213	003	Jan 31, 2025	Jan NEWA
	@			15MG	A216213	004	Jan 31, 2025	Jun DISC
AB				15MG	A216213	004	Jan 31, 2025	Jan NEWA
	@			20MG	A216213	005	Jan 31, 2025	Jun DISC
AB				20MG	A216213	005	Jan 31, 2025	Jan NEWA
	@			25MG	A216213	006	Jan 31, 2025	Jun DISC
AB				25MG	A216213	006	Jan 31, 2025	Jan NEWA
AB			BIOCON PHARMA	2.5MG	A215759	001	Mar 03, 2025	Feb NEWA
AB				5MG	A215759	002	Mar 03, 2025	Feb NEWA
AB				10MG	A215759	003	Mar 03, 2025	Feb NEWA
AB				15MG	A215759	004	Mar 03, 2025	Feb NEWA
AB				20MG	A215759	005	Mar 03, 2025	Feb NEWA
AB				25MG	A215759	006	Mar 03, 2025	Feb NEWA
AB			DEVA HOLDING AS	2.5MG	A217554	001	May 22, 2025	May NEWA
AB				5MG	A217554	002	May 22, 2025	May NEWA
AB				10MG	A217554	003	May 22, 2025	May NEWA

CAPSULE;ORAL
LENALIDOMIDE

	AB		15MG	A217554	004	May 22, 2025	May	NEWA
	AB		20MG	A217554	005	May 22, 2025	May	NEWA
	AB		25MG	A217554	006	May 22, 2025	May	NEWA
	AB	LUPIN LTD	2.5MG	A214398	001	Sep 16, 2025	Sep	NEWA
	AB		5MG	A214398	002	Sep 16, 2025	Sep	NEWA
	AB		10MG	A214398	003	Sep 16, 2025	Sep	NEWA
	AB		15MG	A214398	004	Sep 16, 2025	Sep	NEWA
	AB		20MG	A214398	005	Sep 16, 2025	Sep	NEWA
	AB		25MG	A214398	006	Sep 16, 2025	Sep	NEWA
>A>	AB	TORRENT	15MG	A213405	004	Nov 04, 2025	Oct	NEWA

LETROZOLE
TABLET;ORAL
LETROZOLE

	@	CARNEGIE	2.5MG	A091191	001	Jun 03, 2011	Sep	CAHN

LEUCOVORIN CALCIUM
INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

>A>	AP	GLAND	EQ 350MG BASE/VIAL	A218200	001	Nov 12, 2025	Oct	NEWA

LEUPROLIDE ACETATE
SOLUTION;SUBCUTANEOUS
LEUPROLIDE ACETATE

	AP	ENDO OPERATIONS	14MG/2.8ML (1MG/0.2ML)	A217437	001	Jun 09, 2025	May	NEWA
	@	PH HEALTH	14MG/2.8ML (1MG/0.2ML)	A217437	001	Jun 09, 2025	Aug	DISC
>A>	AP	ZYDUS PHARMS	14MG/2.8ML (1MG/0.2ML)	A215826	001	Nov 13, 2025	Oct	NEWA

LEUPROLIDE MESYLATE
EMULSION;SUBCUTANEOUS
CAMCEVI ETM

	+!	FORESEE PHARMS	EQ 21MG BASE	N219745	001	Aug 25, 2025	Aug	NEWA

LEVALBUTEROL HYDROCHLORIDE
SOLUTION;INHALATION
LEVALBUTEROL HYDROCHLORIDE

	@	MANKIND PHARMA	EQ 0.0103% BASE	A218770	001	Oct 21, 2024	Apr	DISC
	@		EQ 0.021% BASE	A218770	002	Oct 21, 2024	Apr	DISC
	@		EQ 0.042% BASE	A218770	003	Oct 21, 2024	Apr	DISC

LEVETIRACETAM
INJECTABLE;INTRAVENOUS
LEVETIRACETAM IN SODIUM CHLORIDE

	AP	CAPLIN	500MG/100ML (5MG/ML)	A219562	001	Jan 16, 2025	Jan	NEWA
	AP		1GM/100ML (10MG/ML)	A219562	002	Jan 16, 2025	Jan	NEWA
	AP		1.5GM/100ML (15MG/ML)	A219562	003	Jan 16, 2025	Jan	NEWA
>D>	@	FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Oct	CMFD
>A>	AP		500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Oct	CMFD
>D>	@		1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Oct	CMFD
>A>	AP		1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Oct	CMFD
>D>	@		1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Oct	CMFD
>A>	AP		1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Oct	CMFD

SOLUTION;ORAL
LEVETIRACETAM

	AA	AJENAT PHARMS	100MG/ML	A090461	001	Sep 30, 2010	Jan	CAHN
	AA	BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	May	CMFD

TABLET;ORAL
LEVETIRACETAM

	AB	ANDA REPOSITORY	250MG	A076920	001	Jan 15, 2009	Sep	CAHN
	AB		500MG	A076920	002	Jan 15, 2009	Sep	CAHN
	AB		750MG	A076920	003	Jan 15, 2009	Sep	CAHN
	@	CHINA RESOURCES	500MG	A205102	004	Dec 16, 2015	Jan	CAHN
	@		1GM	A205102	003	Dec 16, 2015	Jan	CAHN
	@	MPP PHARMA	250MG	A090511	001	Aug 18, 2011	Jun	CAHN
	@		500MG	A090511	002	Aug 18, 2011	Jun	CAHN
	@		750MG	A090511	003	Aug 18, 2011	Jun	CAHN
	@		1GM	A090511	004	Aug 18, 2011	Jun	CAHN
	@	TARO	250MG	A078960	004	Feb 01, 2010	Aug	DISC
	@		500MG	A078960	003	Feb 01, 2010	Aug	DISC
	@		750MG	A078960	002	Feb 01, 2010	Aug	DISC

		TABLET;ORAL						
		LEVETIRACETAM						
		@	1GM	A078960	001	Feb 01, 2010	Aug DISC	
		TABLET, EXTENDED RELEASE;ORAL						
		LEVETIRACETAM						
		@ APOTEX	1GM	A202958	001	Feb 25, 2015	Mar DISC	
		TABLET, FOR SUSPENSION;ORAL						
		SPRITAM						
		+! APRECIA PHARMS	500MG	N207958	002	Jul 31, 2015	Apr CHRS	
		@ +	750MG	N207958	003	Jul 31, 2015	Apr DISC	
		@ +	1GM	N207958	004	Jul 31, 2015	Apr DISC	
	LEVOCARNITINE							
		INJECTABLE;INJECTION						
		LEVOCARNITINE						
	AP	DEVA HOLDING AS	200MG/ML	A217430	001	Jun 30, 2025	Jun NEWA	
	LEVOCETIRIZINE DIHYDROCHLORIDE							
		SOLUTION;ORAL						
		LEVOCETIRIZINE DIHYDROCHLORIDE						
		@ TARO	2.5MG/5ML	A202673	001	Jul 26, 2013	Aug DISC	
		TABLET;ORAL						
		LEVOCETIRIZINE DIHYDROCHLORIDE						
	AB	SYNTHON BV	5MG	A090229	001	Nov 26, 2010	Feb CAHN	
	LEVODOPA							
		POWDER;INHALATION						
		INBRIJA						
		+! MERZ	42MG	N209184	001	Dec 21, 2018	Feb CAHN	
	LEVOFLOXACIN							
		TABLET;ORAL						
		LEVOFLOXACIN						
		@ APOTEX INC	250MG	A090787	001	Sep 29, 2011	Mar DISC	
		@	500MG	A090787	002	Sep 29, 2011	Mar DISC	
		@	750MG	A090787	003	Sep 29, 2011	Mar DISC	
		@ CHARTWELL RX	250MG	A090367	001	Jun 20, 2011	Sep CAHN	
		@	500MG	A090367	002	Jun 20, 2011	Sep CAHN	
		@	750MG	A090367	003	Jun 20, 2011	Sep CAHN	
	LEVOMILNACIPRAN HYDROCHLORIDE							
		CAPSULE, EXTENDED RELEASE;ORAL						
		FETZIMA						
>D>		+ ABBVIE	EQ 20MG BASE	N204168	001	Jul 25, 2013	Oct CTEC	
>A>	AB	+	EQ 20MG BASE	N204168	001	Jul 25, 2013	Oct CTEC	
>D>		+	EQ 40MG BASE	N204168	002	Jul 25, 2013	Oct CTEC	
>A>	AB	+	EQ 40MG BASE	N204168	002	Jul 25, 2013	Oct CTEC	
>D>		+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Oct CTEC	
>A>	AB	+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Oct CTEC	
>D>		+!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Oct CTEC	
>A>	AB	+!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Oct CTEC	
	LEVORPHANOL TARTRATE							
		TABLET;ORAL						
		LEVORPHANOL TARTRATE						
	AB	ACERTIS PHARMS	2MG	A211484	001	Dec 13, 2018	Apr CAHN	
	BX	NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021	Mar CTEC	
	BX		2MG	A213479	001	Jul 01, 2020	Mar CTEC	
	BX		3MG	A213479	002	Jan 12, 2021	Mar CTEC	
	AB		3MG	A213479	002	Jan 12, 2021	Mar CHRS	
		! SUN PHARM INDS INC	3MG	A213906	002	Apr 25, 2023	Mar CTEC	
	AB	!	3MG	A213906	002	Apr 25, 2023	Mar CHRS	
	LEVOTHYROXINE SODIUM							
		CAPSULE;ORAL						
		LEVOTHYROXINE SODIUM						
		@ ANI PHARMS	0.075MG	A211369	001	Oct 28, 2020	Jun CAHN	
		@	0.088MG	A213256	001	Jan 06, 2021	Jun CAHN	
		@	0.1MG	A213256	002	Jan 06, 2021	Jun CAHN	
		@	0.112MG	A211369	003	Apr 16, 2021	Jun CAHN	
		@	0.125MG	A213256	003	Jan 06, 2021	Jun CAHN	
		@	0.137MG	A211369	005	May 02, 2023	Jun CAHN	

CAPSULE;ORAL
LEVOTHYROXINE SODIUM

	@		0.15MG	A211369	002	Oct 28, 2020	Jun CAHN
	@		0.175MG	A211369	006	May 02, 2023	Jun CAHN
	@		0.2MG	A211369	004	Nov 09, 2022	Jun CAHN

POWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM

AP		ONESOURCE SPECIALTY	100MCG/VIAL	A216729	001	Mar 05, 2025	May CAHN
AP			200MCG/VIAL	A216729	002	Mar 05, 2025	May CAHN
AP			500MCG/VIAL	A216729	003	Mar 05, 2025	May CAHN
AP		STERISCIENCE	100MCG/VIAL	A216729	001	Mar 05, 2025	Feb NEWA
AP			200MCG/VIAL	A216729	002	Mar 05, 2025	Feb NEWA
AP			500MCG/VIAL	A216729	003	Mar 05, 2025	Feb NEWA

SOLUTION;ORAL
THYQUIDITY

	+!	STEVENS J	100MCG/5ML	N214047	001	Nov 30, 2020	Apr CAHN

LEVOTHYROXINE SODIUM **
**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
TABLET;ORAL
EUTHYROX

AB2		EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr CAHN
AB2			0.05MG	N021292	002	May 31, 2002	Apr CAHN
AB2			0.075MG	N021292	003	May 31, 2002	Apr CAHN
AB2			0.088MG	N021292	004	May 31, 2002	Apr CAHN
AB2			0.1MG	N021292	005	May 31, 2002	Apr CAHN
AB2			0.112MG	N021292	006	May 31, 2002	Apr CAHN
AB2			0.125MG	N021292	007	May 31, 2002	Apr CAHN
AB2			0.137MG	N021292	008	May 31, 2002	Apr CAHN
AB2			0.15MG	N021292	009	May 31, 2002	Apr CAHN
AB2			0.175MG	N021292	010	May 31, 2002	Apr CAHN
AB2			0.2MG	N021292	011	May 31, 2002	Apr CAHN
	@		0.3MG	N021292	012	May 31, 2002	Apr CAHN

LEVOTHYROXINE SODIUM

	@	AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jan DISC
	@		0.15MG	A216414	002	Jul 16, 2024	Jan DISC
	@		0.175MG	A216414	003	Jul 16, 2024	Jan DISC
	@		0.2MG	A216414	004	Jul 16, 2024	Jan DISC
	@		0.3MG	A216414	005	Jul 16, 2024	Jan DISC
AB1,AB2, AB3,AB4		MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4			0.025MG	A211417	001	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4			0.05MG	A211417	002	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4			0.05MG	A211417	002	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4			0.075MG	A211417	003	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4			0.075MG	A211417	003	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4			0.088MG	A211417	004	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4			0.088MG	A211417	004	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4			0.1MG	A211417	005	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4			0.1MG	A211417	005	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4			0.112MG	A211417	006	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4			0.112MG	A211417	006	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4			0.125MG	A211417	007	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4			0.125MG	A211417	007	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4			0.137MG	A211417	008	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4			0.137MG	A211417	008	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4			0.15MG	A211417	009	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4			0.15MG	A211417	009	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4			0.175MG	A211417	010	Dec 21, 2022	Feb CTEC

TABLET;ORAL
LEVOTHYROXINE SODIUM

AB1,AB2, AB4			0.175MG	A211417	010	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4			0.2MG	A211417	011	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4			0.2MG	A211417	011	Dec 21, 2022	Feb CTEC
AB1,AB2, AB3,AB4			0.3MG	A211417	012	Dec 21, 2022	Feb CTEC
AB1,AB2, AB4			0.3MG	A211417	012	Dec 21, 2022	Feb CTEC

LIDOCAINE

OINTMENT;TOPICAL
LIDOCAINE

BX		ALEMBIC	5%	A211469	001	Nov 23, 2018	Mar CTEC
AT		CHARTWELL RX	5%	A208660	001	Jan 05, 2021	Apr CAHN

PATCH;TOPICAL
LIDOCAINE

AB		ALKEM LABS LTD	5%	A216484	001	Oct 06, 2025	Sep NEWA
AB		AVEVA	1.8%	A217221	001	Mar 25, 2025	Mar NFTG
AB		DIFGEN PHARMS	1.8%	A217221	001	Mar 25, 2025	Sep CAHN

ZTLIDO

AB	+!	SCILEX PHARMS	1.8%	N207962	001	Feb 28, 2018	Mar CFTG

SYSTEM;TOPICAL
BONDLIDO

	+!	MEDRX USA	10%	N215029	001	Sep 24, 2025	Sep NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

	@	AFAXYS	1%	A215132	001	Jun 09, 2022	Jul DISC
AP		ANTHEA PHARMA	1%	A219535	001	Apr 02, 2025	Mar NEWA
AP		NEOCUBES PHARMA	1%	A219535	001	Apr 02, 2025	Sep CAHN
AP		YILING	1%	A214267	001	Sep 19, 2022	Sep CAHN
AP			2%	A214267	002	Sep 19, 2022	Sep CAHN
AP			4%	A214269	001	May 05, 2022	Sep CAHN

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

	@	EUGIA PHARMA	1%	A203040	001	Mar 14, 2013	Jul DISC
	@		2%	A203040	002	Mar 14, 2013	Jul DISC

SOLUTION;ORAL
LIDOCAINE HYDROCHLORIDE

AT		AUROBINDO PHARMA LTD	2%	A219759	001	Jul 29, 2025	Jul NEWA
AT		XTTRIUM LABS INC	2%	A087872	001	Nov 18, 1982	Feb CAHN

SOLUTION;TOPICAL
LIDOCAINE HYDROCHLORIDE

AT		XTTRIUM LABS INC	4%	A087881	001	Nov 18, 1982	Feb CAHN

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL
LIDOCAINE AND PRILOCAINE

>A>	@	CHARTWELL RX	2.5%;2.5%	A213253	001	Sep 21, 2020	Oct CAHN
>D>	@	RHODES PHARMS	2.5%;2.5%	A213253	001	Sep 21, 2020	Oct CAHN

LIDOCAINE; TETRACAINE

CREAM;TOPICAL
PLIAGLIS

	+!	CRESCITA THERAP	7%;7%	N021717	001	Jun 29, 2006	Sep CMFD

LINAGLIPTIN

TABLET;ORAL
LINAGLIPTIN

>A>	AB	AUROBINDO PHARMA LTD	5MG	A208415	001	Nov 03, 2025	Oct NEWA
>A>	AB	DR REDDYS	5MG	A208428	001	Nov 03, 2025	Oct NEWA
>A>	AB	MSN	5MG	A208457	001	Nov 03, 2025	Oct NEWA
>A>	AB	MYLAN	5MG	A208431	001	Nov 03, 2025	Oct NEWA
	AB	ZYDUS PHARMS	5MG	A208448	001	Mar 30, 2023	Sep CMFD

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

>A>	AB		DR REDDYS	2.5MG;500MG	A208427	001	Nov 03, 2025	Oct NEWA
>A>	AB			2.5MG;850MG	A208427	002	Nov 03, 2025	Oct NEWA
>A>	AB			2.5MG;1GM	A208427	003	Nov 03, 2025	Oct NEWA
>A>	AB		MSN	2.5MG;500MG	A208459	001	Nov 03, 2025	Oct NEWA
>A>	AB			2.5MG;850MG	A208459	002	Nov 03, 2025	Oct NEWA
>A>	AB			2.5MG;1GM	A208459	003	Nov 03, 2025	Oct NEWA
	AB		ZYDUS PHARMS	2.5MG;500MG	A208449	001	Mar 30, 2023	Sep CMFD
	AB			2.5MG;850MG	A208449	002	Mar 30, 2023	Sep CMFD
	AB			2.5MG;1GM	A208449	003	Mar 30, 2023	Sep CMFD

LINEZOLID

SOLUTION;INTRAVENOUS

LINEZOLID

	AP		NORVIUM BIOSCIENCE	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	Feb CAHN
	AP			600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	Feb CAHN

TABLET;ORAL

LINEZOLID

>D>	AB		ALKEM LABS LTD	600MG	A205517	001	Dec 21, 2015	Oct CHRS
>A>	AB	!		600MG	A205517	001	Dec 21, 2015	Oct CHRS
		@	MACLEODS PHARMS LTD	600MG	A210378	001	Oct 10, 2024	Jun DISC

ZYVOX

>D>	AB	+!	PFIZER	600MG	N021130	002	Apr 18, 2000	Oct DISC
>A>		@ +		600MG	N021130	002	Apr 18, 2000	Oct DISC

LIOTHYRONINE SODIUM

INJECTABLE;INJECTION

TRIOSTAT

		@ +	PH HEALTH	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Jul CAHN

LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS

LIRAGLUTIDE

	AP1		HIKMA	18MG/3ML (6MG/ML)	A215503	001	Dec 23, 2024	Aug CTEC
	AP1		LUPIN LTD	18MG/3ML (6MG/ML)	A215421	001	Jul 22, 2025	Aug CTEC
	AP			18MG/3ML (6MG/ML)	A215421	001	Jul 22, 2025	Jul NEWA
	AP1		NANJING KING FRIEND	18MG/3ML (6MG/ML)	A218115	001	Apr 02, 2025	Aug CTEC
	AP		NANJING KING-FRIEND	18MG/3ML (6MG/ML)	A218115	001	Apr 02, 2025	Mar NEWA
	AP2		TEVA PHARMS	18MG/3ML (6MG/ML)	A214568	001	Aug 27, 2025	Aug NFTG

SAXENDA

	AP2	+!	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014	Aug CFTG

VICTOZA

	AP1	+!	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010	Aug CTEC

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

	AB		GRANULES	10MG	A218987	001	Jan 29, 2025	Jan NEWA
	AB			20MG	A218987	002	Jan 29, 2025	Jan NEWA
	AB			30MG	A218987	003	Jan 29, 2025	Jan NEWA
	AB			40MG	A218987	004	Jan 29, 2025	Jan NEWA
	AB			50MG	A218987	005	Jan 29, 2025	Jan NEWA
	AB			60MG	A218987	006	Jan 29, 2025	Jan NEWA
	AB			70MG	A218987	007	Jan 29, 2025	Jan NEWA
	AB		SANDOZ	20MG	A202836	001	Jul 26, 2024	Jan CMFD
	AB			30MG	A202836	002	Jul 26, 2024	Jan CMFD
	AB			40MG	A202836	003	Jul 26, 2024	Jan CMFD
	AB			50MG	A202836	004	Jul 26, 2024	Jan CMFD
	AB			60MG	A202836	005	Jul 26, 2024	Jan CMFD
	AB			70MG	A202836	006	Jul 26, 2024	Jan CMFD

SOLUTION;ORAL

ARYNTA

		+!	AZURITY	10MG/ML	N219847	001	Jun 16, 2025	Jun NEWA

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

	@	NORVIUM BIOSCIENCE	300MG	A202288	001	Jun 29, 2012	Jul DISC
	@		450MG	A202219	001	Aug 08, 2012	Mar DISC
AB			450MG	A202219	001	Aug 08, 2012	Feb CAHN

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

	@ +	NOVARTIS	EQ 0.1% BASE	N020191	001	Sep 23, 1993	May DISC

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LOFEXIDINE HYDROCHLORIDE

AB		MSN	EQ 0.18MG BASE	A218699	001	Feb 24, 2025	Feb NEWA
>A> AB		NOVITIUM PHARMA	EQ 0.18MG BASE	A219917	001	Oct 22, 2025	Oct NEWA

LUCEMYRA

AB	+!	BIOCORRX PHARMS	EQ 0.18MG BASE	N209229	001	May 16, 2018	May CAHN

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

	@ +	AZURITY	5MG	N017588	004	Dec 19, 2014	Aug CAHN
>D>	+		10MG	N017588	001		Oct CFTG
>A> AB	+		10MG	N017588	001		Oct CFTG
	+		10MG	N017588	001		Aug CAHN
>D>	+!		40MG	N017588	002		Oct CFTG
>A> AB	+!		40MG	N017588	002		Oct CFTG
	+!		40MG	N017588	002		Aug CAHN
>D>	+		100MG	N017588	003		Oct CFTG
>A> AB	+		100MG	N017588	003		Oct CFTG
	+		100MG	N017588	003		Aug CAHN

>A> LOMUSTINE

>A> AB	CARNEGIE	10MG	A219265	001	Oct 27, 2025	Oct NFTG
>A> AB		40MG	A219265	002	Oct 27, 2025	Oct NFTG
>A> AB		100MG	A219265	003	Oct 27, 2025	Oct NFTG

LORAZEPAM

INJECTABLE;INJECTION

LORAZEPAM

@	AVIV PHARMA	1MG/0.5ML	A074551	003	Sep 12, 1996	May CAHN
@		2MG/ML	A074535	001	Sep 12, 1996	Apr CAHN
@		2MG/ML	A074551	001	Sep 12, 1996	May CAHN
@		4MG/ML	A074535	002	Sep 12, 1996	Apr CAHN
@		4MG/ML	A074551	002	Sep 12, 1996	May CAHN
@	HOSPIRA	2MG/ML	A074282	001	May 27, 1994	Apr DISC
@		4MG/ML	A074282	002	May 27, 1994	Apr DISC

TABLET;ORAL

LORAZEPAM

AB	AUROBINDO PHARMA	0.5MG	A203572	001	Dec 22, 2017	Aug CAHN
AB		1MG	A203572	002	Dec 22, 2017	Aug CAHN
AB		2MG	A203572	003	Dec 22, 2017	Aug CAHN
AB	GRAVITI PHARMS	0.5MG	A218597	001	Jul 24, 2025	Jul NEWA
AB		1MG	A218597	002	Jul 24, 2025	Jul NEWA
AB		2MG	A218597	003	Jul 24, 2025	Jul NEWA

LOSARTAN POTASSIUM

SUSPENSION;ORAL

ARBLI

	+!	SCIENTURE	10MG/ML	N218772	001	Mar 13, 2025	Mar NEWA

TABLET;ORAL

LOSARTAN POTASSIUM

AB		AIPING PHARM INC	25MG	A090544	001	Oct 06, 2010	Jul CMFD
AB			50MG	A090544	002	Oct 06, 2010	Jul CMFD
AB			100MG	A090544	003	Oct 06, 2010	Jul CMFD
	@	APOTEX	25MG	A218551	001	Jun 04, 2024	Jan DISC
	@		50MG	A218551	002	Jun 04, 2024	Jan DISC
	@		100MG	A218551	003	Jun 04, 2024	Jan DISC
AB		GRAVITI PHARMS	25MG	A219859	001	Sep 19, 2025	Sep NEWA
AB			50MG	A219859	002	Sep 19, 2025	Sep NEWA

TABLET;ORAL
LOSARTAN POTASSIUM

AB			100MG		A219859	003	Sep 19, 2025	Sep NEWA

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC
LOTEMAX SM

AB		+!	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019	Jun CFTG

LOTEPREDNOL ETABONATE

AB			HIKMA	0.5%	A213956	001	Nov 29, 2023	Sep CMFD
AB			LUPIN LTD	0.38%	A218087	001	Jun 30, 2025	Jun NFTG

SUSPENSION/DROPS;OPHTHALMIC
LOTEPREDNOL ETABONATE

AB			AMNEAL	0.5%	A217484	001	May 20, 2025	May NEWA
AB			PADAGIS US	0.5%	A215204	001	Jan 29, 2025	Jan NEWA

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL
ALTOPREV

	@	+	COVIS	20MG	N021316	002	Jun 26, 2002	May DISC
	@	+		40MG	N021316	003	Jun 26, 2002	May DISC
	@	+		60MG	N021316	004	Jun 26, 2002	May DISC

LUBIPROSTONE

CAPSULE;ORAL
LUBIPROSTONE

	@		AMNEAL	8MCG	A209450	001	Nov 30, 2021	Sep DISC
	@			24MCG	A209450	002	Nov 30, 2021	Sep DISC

LURASIDONE HYDROCHLORIDE

TABLET;ORAL
LURASIDONE HYDROCHLORIDE

AB			CHARTWELL RX	20MG	A212091	001	Dec 28, 2020	Mar CAHN
AB				40MG	A212091	002	Dec 28, 2020	Mar CAHN
AB				60MG	A212091	003	Dec 28, 2020	Mar CAHN
AB				80MG	A212091	004	Dec 28, 2020	Mar CAHN
AB				120MG	A212091	005	Dec 28, 2020	Mar CAHN
>D> AB			SUN PHARM	120MG	A208066	005	Jan 04, 2019	Oct DISC
>A>	@			120MG	A208066	005	Jan 04, 2019	Oct DISC
AB			TORRENT	60MG	A208055	005	Jan 13, 2025	Jan NEWA

MACITENTAN

TABLET;ORAL
MACITENTAN

AB			ALEMBIC	10MG	A211128	001	Aug 18, 2025	Aug NEWA
>A> AB			LAURUS	10MG	A211120	001	Nov 05, 2025	Oct NEWA
AB			MSN	10MG	A211136	001	Aug 20, 2025	Aug NEWA
AB			SUN PHARM	10MG	A211123	001	Aug 26, 2025	Aug NEWA

OPSUMIT

AB		+!	ACTELION	10MG	N204410	001	Oct 18, 2013	Aug CTEC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

	@		FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Jun DISC

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

		+!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017378	001		Jun CTEC

MAGNESIUM SULFATE

INJECTABLE;INJECTION
MAGNESIUM SULFATE IN PLASTIC CONTAINER

>D> AP			MYLAN LABS LTD	4GM/100ML (40MG/ML)	A209911	002	Sep 14, 2018	Oct DISC
>A>	@			4GM/100ML (40MG/ML)	A209911	002	Sep 14, 2018	Oct DISC

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

AP			ASPIRO	1GM/2ML (500MG/ML)	A219777	001	May 28, 2025	May NFTG
AP				5GM/10ML (500MG/ML)	A219777	002	May 28, 2025	May NEWA
AP				10GM/20ML (500MG/ML)	A219777	003	May 28, 2025	May NEWA

SOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

AP			25GM/50ML (500MG/ML)	A219777	004	May 28, 2025	May NFTG
AP	+!	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	May CFTG
AP	+!		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	May CFTG

MANGANESE CHLORIDE
INJECTABLE;INJECTION
MANGANESE CHLORIDE

AP		FRESENIUS KABI USA	EQ 0.1MG MANGANESE/ML	A217583	001	Jul 07, 2025	Jun NFTG

MANGANESE CHLORIDE IN PLASTIC CONTAINER

AP	+!	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Jun CFTG

MARALIXIBAT CHLORIDE
TABLET;ORAL
LIVMARLI

	+	MIRUM	EQ 10MG BASE	N219485	001	Apr 10, 2025	Apr NEWA
	+		EQ 15MG BASE	N219485	002	Apr 10, 2025	Apr NEWA
	+		EQ 20MG BASE	N219485	003	Apr 10, 2025	Apr NEWA
	+!		EQ 30MG BASE	N219485	004	Apr 10, 2025	Apr NEWA

MARAVIROC
TABLET;ORAL
MARAVIROC

AB		NAVINTA LLC	150MG	A217880	001	May 13, 2025	May NEWA
AB			300MG	A217880	002	May 13, 2025	May NEWA
>A> AB		RHODES PHARMS	150MG	A216143	001	Nov 04, 2025	Oct NEWA
>A> AB			300MG	A216143	002	Nov 04, 2025	Oct NEWA

MECLIZINE HYDROCHLORIDE
TABLET;ORAL
MECLIZINE HYDROCHLORIDE

AA		ALLIED	25MG	A084092	003	May 22, 1989	Jul CAHN
	@	HERITAGE	12.5MG	A205136	001	Feb 22, 2019	Jul CAHN
	@		25MG	A205136	002	Feb 22, 2019	Jul CAHN
	@		50MG	A205136	003	Feb 22, 2019	Jul CAHN
	@	INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	Jun CAHN
	@		25MG	A205136	002	Feb 22, 2019	Jun CAHN
	@		50MG	A205136	003	Feb 22, 2019	Jun CAHN
AA		SCIEGEN PHARMS INC	25MG	A084092	003	May 22, 1989	Sep CAHN

MEFENAMIC ACID
CAPSULE;ORAL
MEFENAMIC ACID

AB		AJENAT PHARMS	250MG	A091608	001	Jun 02, 2014	Jan CAHN
	@	MPP PHARMA	250MG	A090359	001	Feb 05, 2013	Jun CAHN

MEFLOQUINE HYDROCHLORIDE
TABLET;ORAL
MEFLOQUINE HYDROCHLORIDE

AB		CHARTWELL RX	250MG	A076175	001	Feb 20, 2002	Jun CMFD
	@	HIKMA	250MG	A076523	001	Oct 01, 2004	Sep DISC

MEGESTROL ACETATE
SUSPENSION;ORAL
MEGACE ES

	@ +	ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	Feb DISC

MEGESTROL ACETATE

	!	TWI PHARMS	125MG/ML	A203139	001	Aug 27, 2014	Feb CTEC
AB	!		125MG/ML	A203139	001	Aug 27, 2014	Feb CHRS
AB		XTTRIUM LABS INC	40MG/ML	A076721	001	Nov 01, 2004	Apr CMFD

MELOXICAM
SOLUTION;INTRAVENOUS
QAMZOVA

	+!	NANJING DELOVA	30MG/ML (30MG/ML)	N217593	001	Apr 22, 2025	Apr NEWA

XIFYRM

	+!	AZURITY	30MG/ML (30MG/ML)	N218395	001	Jun 05, 2025	Jun NEWA

TABLET;ORAL
MELOXICAM

AB		GRAVITI PHARMS	7.5MG	A077931	001	Jul 25, 2006	Feb CAHN
AB			15MG	A077931	002	Jul 25, 2006	Feb CAHN

TABLET;ORAL
MELOXICAM

@	TARO	7.5MG	A078102	001	Nov 07, 2006	Aug DISC
@		15MG	A078102	002	Nov 07, 2006	Aug DISC

MELOXICAM; RIZATRIPTAN BENZOATE

TABLET;ORAL
SYMBRAVO

+!	AXSOME	20MG;EQ 10MG BASE	N215431	001	Jan 30, 2025	Jan NEWA

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION
MELPHALAN HYDROCHLORIDE

>D> AP		ALMAJECT	EQ 50MG BASE/VIAL	A204817	001	May 17, 2019	Oct DISC
>A>	@		EQ 50MG BASE/VIAL	A204817	001	May 17, 2019	Oct DISC
	@	NOVAST LABS	EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020	Sep DISC
AP			EQ 50MG BASE/VIAL	A210947	001	Feb 18, 2020	Aug CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE

@	APOTEX	7MG	A206135	001	Nov 22, 2016	Mar DISC
@		14MG	A206135	002	Nov 22, 2016	Mar DISC
@		21MG	A206135	003	Nov 22, 2016	Mar DISC
@		28MG	A206135	004	Nov 22, 2016	Mar DISC
AB	MACLEODS PHARMS LTD	7MG	A206310	001	Aug 28, 2025	Aug NEWA
AB		14MG	A206310	002	Aug 28, 2025	Aug NEWA
AB		21MG	A206310	003	Aug 28, 2025	Aug NEWA
AB		28MG	A206310	004	Aug 28, 2025	Aug NEWA
AB	RISING	7MG	A206032	001	Sep 28, 2016	May CMFD
AB		14MG	A206032	002	Sep 28, 2016	May CMFD
AB		21MG	A206032	003	Sep 28, 2016	May CMFD
AB		28MG	A206032	004	Sep 28, 2016	May CMFD
AB	VITRUVIAS	7MG	A213985	001	Oct 11, 2022	Sep CAHN
AB		14MG	A213985	002	Oct 11, 2022	Sep CAHN
AB		21MG	A213985	004	Feb 06, 2024	Sep CAHN
AB		28MG	A213985	003	Oct 11, 2022	Sep CAHN

SOLUTION;ORAL
MEMANTINE HYDROCHLORIDE

@	APOZEAL PHARMS	2MG/ML	A205446	001	Dec 07, 2015	Apr CAHN
@	SCIEGEN PHARMS INC	2MG/ML	A205446	001	Dec 07, 2015	Sep CAHN

TABLET;ORAL
MEMANTINE HYDROCHLORIDE

@	POINTVIEW HLDINGS	5MG	A090073	001	Sep 04, 2015	Apr CAHN
@		10MG	A090073	002	Sep 04, 2015	Apr CAHN
AB	RENATA	5MG	A209527	001	May 07, 2018	Aug CAHN
AB		10MG	A209527	002	May 07, 2018	Aug CAHN
AB	SOMERSET THERAPS LLC	5MG	A209527	001	May 07, 2018	Sep CAHN
AB		10MG	A209527	002	May 07, 2018	Sep CAHN
AB	YILING	5MG	A212947	001	Apr 03, 2020	Apr CMFD
AB		10MG	A212947	002	Apr 03, 2020	Apr CMFD

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION
CARBOCAINE

@ +	HOSPIRA	1%	N012250	001		Jul DISC
@ +		1.5%	N012250	005		Jul DISC
@ +		2%	N012250	002		Jul DISC

POLOCAINE

FRESENIUS KABI USA	1%	A089407	001	Dec 01, 1986	Jul CTEC
	2%	A089410	001	Dec 01, 1986	Jul CTEC

POLOCAINE-MPF

FRESENIUS KABI USA	1%	A089406	001	Dec 01, 1986	Jul CTEC
	1.5%	A089408	001	Dec 01, 1986	Jul CTEC
	2%	A089409	001	Dec 01, 1986	Jul CTEC

MERCAPTOPURINE

SUSPENSION;ORAL
MERCAPTOPURINE

AB	HIKMA	20MG/ML	A216418	001	Feb 26, 2025	Feb NFTG

PURIXAN

AB +!	NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014	Feb CFTG

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

AP	!	ACS DOBFAR	500MG/VIAL	A091404	001	Oct 26, 2011	Apr	CHRS
AP	!		1GM/VIAL	A091404	002	Oct 26, 2011	Apr	CHRS

MERREM IV

	@ +	PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Apr	DISC
	@ +		1GM/VIAL	N050706	001	Jun 21, 1996	Apr	DISC

POWDER;INTRAVENOUS

MEROPENEM

AP		BROOKS STERISCIENCE	2GM/VIAL	A219084	001	Jun 23, 2025	Jun	NFTG
AP	+!	HQ SPCLT PHARMA	2GM/VIAL	N215212	001	Jul 26, 2023	Jun	CFTG

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL

MESALAMINE

AB		ANNORA PHARMA	375MG	A219864	001	Aug 13, 2025	Aug	NEWA
AB		NOVAST LABS	375MG	A218410	001	Aug 22, 2024	Sep	CAHN

ENEMA;RECTAL

MESALAMINE

AB		NOVITIUM PHARMA	4GM/60ML	A215269	001	Apr 16, 2025	Apr	NEWA

SUPPOSITORY;RECTAL

MESALAMINE

AB		NORVIUM BIOSCIENCE	1GM	A204354	001	Nov 24, 2015	May	CAHN
AB		QUAGEN	1GM	A204354	001	Nov 24, 2015	Sep	CAHN
AB		RISING	1GM	A219028	001	Apr 14, 2025	Apr	NEWA

TABLET, DELAYED RELEASE;ORAL

MESALAMINE

AB		AMNEAL	800MG	A215067	001	Feb 18, 2025	Feb	NEWA

MESNA

TABLET;ORAL

MESNA

AB		NOVAST LABS	400MG	A218871	001	Jan 13, 2025	Aug	CAHN
AB		RICONPHARMA LLC	400MG	A218871	001	Jan 13, 2025	Jan	NFTG

MESNEX

AB	+!	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002	Jan	CFTG

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

	!	CHARTWELL	10MG/5ML	A073632	001	Jul 22, 1992	Sep	CAHN

METAXALONE

TABLET;ORAL

METAXALONE

	@	NOVAST LABS	800MG	A213836	001	Oct 21, 2020	Sep	CAHN
>D>	@ +	PRIMUS PHARMS	640MG	N022503	001	Jun 01, 2015	Oct	CMFD
>A>	+!		640MG	N022503	001	Jun 01, 2015	Oct	CMFD

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

METFORMIN HYDROCHLORIDE

AB		ANNORA PHARMA	500MG/5ML	A215008	001	Mar 13, 2025	Mar	NEWA
AB		BIONPHARMA	500MG/5ML	A219151	001	Apr 14, 2025	Apr	NEWA
AB		VISTAPHARM LLC	500MG/5ML	A212677	001	Aug 19, 2022	Jan	CAHN

TABLET;ORAL

METFORMIN HYDROCHLORIDE

>A>	@	AARXION ANDA HLDING	500MG	A205330	001	Oct 31, 2017	Oct	CAHN
>A>	@		850MG	A205330	002	Oct 31, 2017	Oct	CAHN
>A>	@		1GM	A205330	003	Oct 31, 2017	Oct	CAHN
AB		ANDA REPOSITORY	500MG	A076033	001	Jan 24, 2002	Sep	CAHN
AB			850MG	A076033	002	Jan 24, 2002	Sep	CAHN
AB			1GM	A076033	003	Jan 24, 2002	Sep	CAHN
	@	APOTEX	500MG	A075984	001	Apr 23, 2002	Mar	DISC
	@		500MG	A090666	001	Dec 07, 2011	Mar	DISC
	@		850MG	A075984	002	Apr 23, 2002	Mar	DISC
	@		850MG	A090666	002	Dec 07, 2011	Mar	DISC
	@		1GM	A075984	003	Apr 23, 2002	Mar	DISC
	@		1GM	A090666	003	Dec 07, 2011	Mar	DISC
	@	GLENMARK PHARMS LTD	500MG	A078170	001	May 23, 2008	Aug	DISC

TABLET;ORAL
METFORMIN HYDROCHLORIDE

		@		850MG	A078170	002	May 23, 2008	Aug DISC
		@		1GM	A078170	003	May 23, 2008	Aug DISC
>D>		@	MACLEODS PHARMS LTD	500MG	A205330	001	Oct 31, 2017	Oct CAHN
>D>		@		850MG	A205330	002	Oct 31, 2017	Oct CAHN
>D>		@		1GM	A205330	003	Oct 31, 2017	Oct CAHN

TABLET, EXTENDED RELEASE;ORAL
FORTAMET

		@ +	ANDRX LABS LLC	1GM	N021574	002	Apr 27, 2004	Jul DISC

METFORMIN HYDROCHLORIDE

	AB1		MEDICAP LABS	500MG	A202306	001	Feb 23, 2017	Feb CAHN
	AB			750MG	A202306	002	Feb 23, 2017	Feb CAHN
	AB2		MPP PHARMA	500MG	A203832	001	Dec 26, 2017	May CAHN
	AB2			1GM	A203832	002	Dec 26, 2017	May CAHN
		@	SUN PHARM	500MG	A202917	001	Aug 01, 2016	Jan DISC
		@		1GM	A202917	002	Aug 01, 2016	Jan DISC
>D>	AB1		SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006	Oct DISC
>A>		@		500MG	A077336	001	Feb 09, 2006	Oct DISC
		@		750MG	A077336	002	Feb 09, 2006	Sep DISC
>D>	AB2		TWI PHARMS	500MG	A213247	001	Sep 29, 2021	Oct DISC
>A>		@		500MG	A213247	001	Sep 29, 2021	Oct DISC
>D>	AB2			1GM	A213247	002	Sep 29, 2021	Oct DISC
>A>		@		1GM	A213247	002	Sep 29, 2021	Oct DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

	AB		TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	May CMFD
	AB			850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	May CMFD

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

	AB		DR REDDYS LABS SA	500MG;EQ 5MG BASE	A207678	001	Aug 09, 2023	Jan CTNA
	AB			1GM;EQ 2.5MG BASE	A207678	002	Aug 09, 2023	Jan CTNA
	AB	!		1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Jan CTNA
		@	SUN PHARM	500MG;EQ 5MG BASE	A206081	001	Jul 31, 2023	Jul DISC
		@		1GM;EQ 2.5MG BASE	A206081	002	Jul 31, 2023	Jul DISC
		@		1GM;EQ 5MG BASE	A206081	003	Jul 31, 2023	Jul DISC

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL
JANUMET XR

		+	MSD SUB MERCK	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Jun CTEC
	AB	+		500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	May CFTG
		+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Jun CTEC
	AB	+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	May CFTG
		+!		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Jun CTEC
	AB	+!		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	May CFTG

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

		@	ENDO OPERATIONS	500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	Jun DISC
	AB			500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	May NFTG
		@		1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	Jun DISC
	AB			1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	May NFTG
		@		1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	Jun DISC
	AB			1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	May NFTG

METHADONE HYDROCHLORIDE

INJECTABLE;INJECTION
METHADONE HYDROCHLORIDE

	AP		HIKMA	10MG/ML	A218609	001	May 05, 2025	Apr NEWA

TABLET;ORAL
METHADONE HYDROCHLORIDE

	AA		HIKMA	5MG	A088109	002	Mar 08, 1983	Jul CMS1
		@	VISTAPHARM LLC	10MG	A040241	002	May 29, 1998	Aug DISC

TABLET, FOR SUSPENSION;ORAL
METHADONE HYDROCHLORIDE

	AA		VISTAPHARM LLC	40MG	A075082	001	Mar 25, 1998	Jan CAHN

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB		ANDA REPOSITORY	25MG	A040062	001	Jan 27, 1994	Sep CAHN
AB	!		50MG	A040062	002	Jan 27, 1994	Sep CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB	+	ESJAY PHARMA	1GM	N017681	001		Jul CMFD
	@ +		1GM	N017681	001		May DISC

METHENAMINE HIPPURATE

AB		ZYDUS LIFESCIENCES	1GM	A219661	001	Mar 10, 2025	Feb NEWA

UREX

AB		QUAGEN	1GM	N016151	001		Jul CAHN

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB		AIPING PHARM INC	5MG	A040547	001	Feb 18, 2005	Mar CAHN
AB			10MG	A040547	002	Feb 18, 2005	Mar CAHN
	@		20MG	A040547	004	Feb 18, 2005	Mar CAHN
AB		SQUARE PHARMS PLC	5MG	A218830	001	Feb 05, 2025	Aug CMFD
	@		5MG	A218830	001	Feb 05, 2025	Jul DISC
AB			5MG	A218830	001	Feb 05, 2025	Jan NEWA
AB			10MG	A218830	002	Feb 05, 2025	Aug CMFD
	@		10MG	A218830	002	Feb 05, 2025	Jul DISC
AB			10MG	A218830	002	Feb 05, 2025	Jan NEWA

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

	@	PHARMOBEDIENT	1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Jun CAHN

SUSPENSION;ORAL

ATMEKSI

	+!	ROSEMONT PHARMS	750MG/5ML	N219843	001	Jul 30, 2025	Jul NEWA

TABLET;ORAL

METHOCARBAMOL

AA		BOSTAL	500MG	A200958	001	Oct 21, 2011	May CAHN
AA			750MG	A200958	002	Oct 21, 2011	May CAHN
AB	!		1GM	A200958	003	Dec 06, 2021	May CAHN
AA		PHARMOBEDIENT	500MG	A203550	001	Feb 08, 2017	Sep CAHN
AA			750MG	A203550	002	Feb 08, 2017	Sep CAHN
AA		POINTVIEW HLDINGS	500MG	A212623	001	Apr 30, 2021	Apr CAHN
AA			750MG	A212623	002	Apr 30, 2021	Apr CAHN

METHOTREXATE

SOLUTION;SUBCUTANEOUS

OTREXUP

	@ +	ASSERTIO SPECLTY	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Aug CAHN
	@ +		10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Aug CAHN
	@ +		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Aug CAHN
	@ +		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Aug CAHN
	@ +		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Aug CAHN
	@ +		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Aug CAHN
	@ +		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Aug CAHN
	@ +		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013	Aug CAHN
	@ +	OTTER PHARMS	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Jul DISC
	@ +		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Jul DISC
	@ +		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Jul DISC
	@ +		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Jul DISC
	@ +		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Jul DISC
	@ +		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Jul DISC
	@ +		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013	Jul DISC

OTREXUP PFS

	@ +	ASSERTIO SPECLTY	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Aug CAHN
	@ +		15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Aug CAHN
	@ +		17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Aug CAHN
	@ +		20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Aug CAHN
	@ +		22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Aug CAHN
	@ +		25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Aug CAHN

METHYLENE BLUE

SOLUTION;INTRAVENOUS

METHYLENE BLUE

AP		HIKMA	50MG/10ML (5MG/ML)	A216959	001	Dec 17, 2024	Jan CAHN
AP		MEITHEAL	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan CAHN
AP		NANJING KING-FRIEND	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan NEWA
AP		XIROMED	50MG/10ML (5MG/ML)	A219363	001	Jul 30, 2025	Jul NEWA

METHYLNALTREXONE BROMIDE

SOLUTION;SUBCUTANEOUS

METHYLNALTREXONE BROMIDE

	@	ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)	A208112	001	Aug 26, 2024	Mar DISC
	@		12MG/0.6ML (12MG/0.6ML)	A208112	002	Aug 26, 2024	Mar DISC
	@	MYLAN LABS LTD	12MG/0.6ML (12MG/0.6ML)	A208592	001	May 28, 2025	Jun DISC
AP			12MG/0.6ML (12MG/0.6ML)	A208592	001	May 28, 2025	May NFTG

RELISTOR

	+!	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Mar CTEC
	+!		12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008	Jun CTEC
AP	+!		12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008	May CFTG
	+!		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Mar CTEC

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

COTEMPLA XR-ODT

	@ +	NEOS THERAPS INC	34.6MG	N205489	004	Aug 19, 2024	Jun DISC
	+		34.6MG	N205489	004	Aug 19, 2024	Apr CMFD

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

	@	ESJAY PHARMA	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
	@		10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN
AA		HIBROW HLTHCARE	5MG/5ML	A210139	001	Oct 03, 2018	Sep CAHN
AA			10MG/5ML	A210139	002	Oct 03, 2018	Sep CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

	@	MPP PHARMA	5MG	A207587	001	Mar 03, 2017	Jun CAHN
	@		10MG	A207587	002	Mar 03, 2017	Jun CAHN
	@		20MG	A207587	003	Mar 03, 2017	Jun CAHN

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

	@	STRIDES PHARMA	2.5MG	A204954	001	Jan 26, 2017	Apr CAHN
	@		5MG	A204954	002	Jan 26, 2017	Apr CAHN
	@		10MG	A204954	003	Jan 26, 2017	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		GRANULES	18MG	A213473	001	Jul 29, 2020	Sep CAHN
AB			27MG	A213473	002	Jul 29, 2020	Sep CAHN
AB			36MG	A213473	003	Jul 29, 2020	Sep CAHN
AB			54MG	A213473	004	Jul 29, 2020	Sep CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB		HIKMA	80MG/ML	A219145	001	Apr 16, 2025	Apr NEWA

METHYLTESTOSTERONE

TABLET;ORAL

ANDROID 25

	@	BAUSCH	25MG	A087147	001		Apr DISC
BP			25MG	A087147	001		Mar CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

	@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Jul DISC

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

	@	VISTAPHARM LLC	EQ 5MG BASE/5ML	A075051	001	Jan 26, 2001	Jan CAHN

TABLET;ORAL
METOCLOPRAMIDE HYDROCHLORIDE

@	IMPAX LABS INC	EQ 5MG BASE	A071250	002	Dec 28, 1995	Jul	DISC
@		EQ 10MG BASE	A071250	001	Feb 03, 1988	Jul	DISC

METOLAZONE

TABLET;ORAL
METOLAZONE

AB	IXORA LIFESCIENCE	2.5MG	A218606	001	Apr 17, 2024	Aug	CAHN
AB		5MG	A218606	002	Apr 17, 2024	Aug	CAHN
AB		10MG	A218606	003	Apr 17, 2024	Aug	CAHN
AB	LEADING	2.5MG	A218606	001	Apr 17, 2024	Jun	CAHN
AB		5MG	A218606	002	Apr 17, 2024	Jun	CAHN
AB		10MG	A218606	003	Apr 17, 2024	Jun	CAHN
AB	RENATA	2.5MG	A215616	001	Oct 24, 2022	Aug	CAHN
AB		5MG	A215616	002	Oct 24, 2022	Aug	CAHN
AB		10MG	A215616	003	Oct 24, 2022	Aug	CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

AB	IPCA LABS LTD	EQ 25MG TARTRATE	A206980	001	Jun 25, 2025	Jun	NEWA
AB		EQ 50MG TARTRATE	A206980	002	Jun 25, 2025	Jun	NEWA
AB		EQ 100MG TARTRATE	A206980	003	Jun 25, 2025	Jun	NEWA
AB		EQ 200MG TARTRATE	A206980	004	Jun 25, 2025	Jun	NEWA

METOPROLOL TARTRATE

SOLUTION;ORAL
LOPRESSOR

+!	RUBICON	10MG/ML	N219373	001	Apr 10, 2025	Apr	NEWA

TABLET;ORAL
LOPRESSOR

+!	XTM CONSULTING	12.5MG	N218698	001	Aug 28, 2025	Aug	NEWA

METOPROLOL TARTRATE

@	PHARMOBEDIENT	50MG	A073666	001	Dec 21, 1993	Jun	CAHN
@		100MG	A073666	002	Dec 21, 1993	Jun	CAHN
AB	RENATA	50MG	A074453	001	Apr 27, 1995	Aug	CAHN
AB		100MG	A074453	002	Apr 27, 1995	Aug	CAHN
AB	SCIEGEN PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan	CAHN
AB		50MG	A208955	002	Feb 05, 2020	Jan	CAHN
AB		100MG	A208955	003	Feb 05, 2020	Jan	CAHN
@	SUN PHARM INDS INC	25MG	A076670	001	Jan 15, 2004	Apr	DISC

METRONIDAZOLE

CREAM;TOPICAL
METROCREAM

AB +	GALDERMA LABS LP	0.75%	N020531	001	Sep 20, 1995	Jun	CHRS

METRONIDAZOLE

AB	AUROBINDO PHARMA LTD	0.75%	A219295	001	Jul 09, 2025	Jun	NEWA
AB !	FOUGERA PHARMS	0.75%	A076408	001	May 28, 2004	Jun	CHRS
BX	ZYDUS LIFESCIENCES	0.75%	A217128	001	Apr 21, 2023	Mar	CTEC

GEL;VAGINAL
METROGEL-VAGINAL

@ +	BAUSCH	0.75%	N020208	001	Aug 17, 1992	Aug	DISC

METRONIDAZOLE

AB !	ENCUBE	0.75%	A215610	001	Jun 16, 2023	Aug	CHRS
@		1.3%	A216795	001	Mar 18, 2024	Jan	DISC
AB	SCIEGEN PHARMS INC	0.75%	A216750	001	Dec 31, 2024	Sep	CAHN

NUVESSA

+!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Jan	CTEC

INJECTABLE;INJECTION
METRONIDAZOLE IN PLASTIC CONTAINER

>D> AP	BAXTER HLTHCARE CORP	500MG/100ML	A078084	001	Mar 31, 2008	Oct	DISC
>A> @		500MG/100ML	A078084	001	Mar 31, 2008	Oct	DISC

METYRAPONE

CAPSULE;ORAL
METOPIRONE

+!	ESTEVE	250MG	N012911	002	Aug 09, 1996	Jul	CAHN

TABLET;ORAL
METOPIRONE

@	ESTEVE	250MG	N012911	001		Jul	CAHN

METYROSINE

CAPSULE;ORAL
METYROSINE

AB	CEROVENE INC	250MG	A218620	001	Apr 09, 2025	Mar	NEWA
AB	DR REDDYS LABS SA	250MG	A218620	001	Apr 09, 2025	Sep	CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

>D> AB	IXORA LIFESCIENCE	150MG	A215876	001	Feb 27, 2023	Oct	CAHN
AB		150MG	A215876	001	Feb 27, 2023	Aug	CAHN
>D> AB		200MG	A215876	002	Feb 27, 2023	Oct	CAHN
AB		200MG	A215876	002	Feb 27, 2023	Aug	CAHN
>D> AB		250MG	A215876	003	Feb 27, 2023	Oct	CAHN
AB		250MG	A215876	003	Feb 27, 2023	Aug	CAHN
>A> AB	LEADING	150MG	A215876	001	Feb 27, 2023	Oct	CAHN
>A> AB		200MG	A215876	002	Feb 27, 2023	Oct	CAHN
>A> AB		250MG	A215876	003	Feb 27, 2023	Oct	CAHN

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS
MICAFUNGIN SODIUM

AP	QILU PHARM HAINAN	EQ 50MG BASE/VIAL	A219273	001	Apr 03, 2025	Mar	NEWA
AP		EQ 100MG BASE/VIAL	A219273	002	Apr 03, 2025	Mar	NEWA

MIDAZOLAM

SOLUTION;INTRAVENOUS
MIDAZOLAM IN 0.8% SODIUM CHLORIDE

!	B BRAUN MEDICAL	50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	Jul	CHRS
		50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	May	CAHN
!		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	Jul	CHRS
		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	May	CAHN
	STERINOVA INC	50MG/50ML (1MG/ML)	A218454	001	May 01, 2025	Apr	NFTG
		100MG/100ML (1MG/ML)	A218454	002	May 01, 2025	Apr	NFTG

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE

@	EPIC PHARMA LLC	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jun	CAHN
AP	HIKMA	EQ 1MG BASE/ML	A212847	001	Dec 11, 2020	Jun	CAHN
AP		EQ 5MG BASE/ML	A212847	002	Dec 11, 2020	Jun	CAHN
AP	RISING	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jun	CAHN
AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jun	CAHN

SOLUTION;INTRAMUSCULAR
SEIZALAM

@ +	MMT	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566	001	Sep 14, 2018	Jul	DISC

MIDODRINE HYDROCHLORIDE

TABLET;ORAL
ORVATEN

AB	BEIJING YILING	2.5MG	A076725	001	Nov 03, 2004	Jun	CAHN
AB !		5MG	A076725	002	Nov 03, 2004	Jun	CAHN
AB		10MG	A076725	003	Nov 03, 2004	Jun	CAHN

MIFEPRISTONE

TABLET;ORAL
MIFEPRISTONE

AB	EVITA SOLUTIONS	200MG	A216616	001	Sep 30, 2025	Sep	NEWA

MIGLUSTAT

CAPSULE;ORAL
MIGLUSTAT

@	CHARTWELL RX	100MG	A209325	001	Feb 03, 2022	Mar	CAHN
AB	NAVINTA LLC	100MG	A219111	001	Mar 14, 2025	Mar	NEWA
@	VERANOVA	100MG	A209325	001	Feb 03, 2022	Feb	CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

	@	BRECKENRIDGE	12.5MG		A205071	001	Jan 27, 2016	Sep CAHN
	@		25MG		A205071	002	Jan 27, 2016	Sep CAHN
	@		50MG		A205071	003	Jan 27, 2016	Sep CAHN
	@		100MG		A205071	004	Jan 27, 2016	Sep CAHN
	@	CENTAUR PHARMS PVT	12.5MG		A205071	001	Jan 27, 2016	Sep CAHN
	@		25MG		A205071	002	Jan 27, 2016	Sep CAHN
	@		50MG		A205071	003	Jan 27, 2016	Sep CAHN
	@		100MG		A205071	004	Jan 27, 2016	Sep CAHN
	@	HETERO LABS LTD V	12.5MG		A205147	001	Oct 03, 2024	Apr DISC
	@		25MG		A205147	002	Oct 03, 2024	Apr DISC
	@		50MG		A205147	003	Oct 03, 2024	Apr DISC
	@		100MG		A205147	004	Oct 03, 2024	Apr DISC

SAVELLA

	+	ABBVIE	12.5MG		N022256	001	Jan 14, 2009	Apr CTEC
	+		25MG		N022256	002	Jan 14, 2009	Apr CTEC
	+!		50MG		N022256	003	Jan 14, 2009	Apr CTEC
	+		100MG		N022256	004	Jan 14, 2009	Apr CTEC

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE IN DEXTROSE 5%

AP		CAPLIN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)		A219170	001	Sep 02, 2025	Aug NEWA
AP			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)		A219170	002	Sep 02, 2025	Aug NEWA

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

MINOCYCLINE HYDROCHLORIDE

>D> AB		SUN PHARM INDS INC	EQ 50MG BASE		A090867	001	May 13, 2013	Oct DISC
>A>	@		EQ 50MG BASE		A090867	001	May 13, 2013	Oct DISC
>D> AB			EQ 75MG BASE		A090867	002	May 13, 2013	Oct DISC
>A>	@		EQ 75MG BASE		A090867	002	May 13, 2013	Oct DISC
>D> AB			EQ 100MG BASE		A090867	003	May 13, 2013	Oct DISC
>A>	@		EQ 100MG BASE		A090867	003	May 13, 2013	Oct DISC

CAPSULE, EXTENDED RELEASE;ORAL

EMROSI

	+!	JOURNEY	EQ 40MG BASE		N219015	001	Nov 01, 2024	Mar CPOT

INJECTABLE;INJECTION

MINOCIN

	+!	REMPEX	EQ 100MG BASE/VIAL		N050444	001		May CTEC

MINOCYCLINE HYDROCHLORIDE

AP		NEXUS	EQ 100MG BASE/VIAL		A214934	001	Oct 24, 2024	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

	@	SUN PHARM	EQ 45MG BASE		A204394	001	Dec 30, 2015	Aug DISC
	@		EQ 55MG BASE		A204394	002	Oct 07, 2022	Aug DISC
	@		EQ 65MG BASE		A204394	003	Oct 07, 2022	Aug DISC
	@		EQ 80MG BASE		A204394	004	Dec 30, 2015	Aug DISC
	@		EQ 105MG BASE		A204394	005	Dec 30, 2015	Aug DISC
	@		EQ 115MG BASE		A204394	006	Oct 07, 2022	Aug DISC
	@		EQ 135MG BASE		A204394	007	Dec 30, 2015	Aug DISC

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

	@	APOTEX	25MG		A209434	001	Jan 02, 2025	May DISC
	@		50MG		A209434	002	Jan 02, 2025	May DISC
AB		ASCENT PHARMS INC	25MG		A218172	001	Sep 24, 2025	Sep NEWA
AB			50MG		A218172	002	Sep 24, 2025	Sep NEWA
>A> AB		MSN	25MG		A218543	001	Nov 04, 2025	Oct NEWA
>A> AB			50MG		A218543	002	Nov 04, 2025	Oct NEWA
AB		QILU	25MG		A217989	001	Jun 30, 2025	Jun NEWA
AB			50MG		A217989	002	Jun 30, 2025	Jun NEWA
	@	SAWAI USA	50MG		A217061	001	May 06, 2025	Jun DISC
AB			50MG		A217061	001	May 06, 2025	Apr NEWA

MIRDAMETINIB

CAPSULE;ORAL

GOMEKLI

	+	SPRINGWORKS	1MG	N219389	001	Feb 11, 2025	Feb NEWA
	+!		2MG	N219389	002	Feb 11, 2025	Feb NEWA

TABLET, FOR SUSPENSION;ORAL

GOMEKLI

	+!	SPRINGWORKS	1MG	N219379	001	Feb 11, 2025	Feb NEWA

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB		ANNORA PHARMA	7.5MG	A219721	001	Oct 02, 2025	Sep NEWA
AB			15MG	A219721	002	Oct 02, 2025	Sep NEWA
AB			30MG	A219721	003	Oct 02, 2025	Sep NEWA
AB			45MG	A219721	004	Oct 02, 2025	Sep NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

AB		ACME LABS	15MG	A205798	001	Jun 01, 2017	Sep CAHN
AB			30MG	A205798	002	Jun 01, 2017	Sep CAHN
AB			45MG	A205798	003	Jun 01, 2017	Sep CAHN

MITOMYCIN

FOR SOLUTION;TOPICAL

MITOSOL

	+!	GLAUKOS	0.2MG/VIAL	N022572	001	Feb 07, 2012	Aug CAHN

INJECTABLE;INJECTION

MITOMYCIN

AP		ACCORD HLTHCARE	20MG/VIAL	A064144	002	Apr 30, 1998	Apr CMFD
	@		20MG/VIAL	A064144	002	Apr 30, 1998	Jan DISC
	@	EUGIA PHARMA	5MG/VIAL	A216732	001	Oct 30, 2023	Aug DISC
	@		20MG/VIAL	A216732	002	Oct 30, 2023	Aug DISC
	@		40MG/VIAL	A216732	003	Oct 30, 2023	Aug DISC
AP	!	MEITHEAL	20MG/VIAL	A214505	002	Sep 08, 2022	Jan CHRS

POWDER;INTRAVESICAL

ZUSDURI

	+!	UROGEN PHARMA	40MG/VIAL	N215793	001	Jun 12, 2025	Jun NEWA

MITOTANE

TABLET;ORAL

LYSODREN

	+!	ESTEVE	500MG	N016885	001		Jul CAHN

MODAFINIL

TABLET;ORAL

MODAFINIL

	@	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jun DISC
	@		200MG	A076715	002	Nov 01, 2012	Jun DISC

PROVIGIL

AB	+	NUVO PHARMS	100MG	N020717	001	Dec 24, 1998	Jan CAHN
AB	+!		200MG	N020717	002	Dec 24, 1998	Jan CAHN

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

	@	APOTEX INC	7.5MG	A078454	001	Jun 02, 2008	Mar DISC
	@		15MG	A078454	002	Jun 02, 2008	Mar DISC

MOMETASONE FUROATE

CREAM;TOPICAL

MOMETASONE FUROATE

	@	CHARTWELL MOLECULAR	0.1%	A076591	001	Apr 18, 2007	Feb CAHN
AB	!	COSETTE	0.1%	A077447	001	May 22, 2006	Jun CHRS
	@	GLENMARK PHARMS INC	0.1%	A078541	001	May 28, 2008	Jun DISC

LOTION;TOPICAL

MOMETASONE FUROATE

	@	GLENMARK PHARMS LTD	0.1%	A090506	001	Aug 09, 2010	Jul DISC
	@	SUN PHARMA CANADA	0.1%	A076788	001	Mar 15, 2006	Sep CAHN
	@	TARO	0.1%	A076788	001	Mar 15, 2006	Aug DISC

		OINTMENT;TOPICAL						
		MOMETASONE FUROATE						
	@	GLENMARK PHARMS INC	0.1%	A078571	001	May 28, 2008	Jun DISC
AB	!	PADAGIS US	0.1%	A076067	001	Mar 18, 2002	Jun CHRS
		SPRAY, METERED;NASAL						
		MOMETASONE FUROATE						
>D> AB		NASPRESS	0.05MG/SPRAY	A211706	001	May 15, 2025	Oct DISC
>A>	@		0.05MG/SPRAY	A211706	001	May 15, 2025	Oct DISC
AB			0.05MG/SPRAY	A211706	001	May 15, 2025	May NEWA
		MONTELUKAST SODIUM						
		TABLET;ORAL						
		MONTELUKAST SODIUM						
AB		PHARMOBEDIENT	EQ 10MG BASE	A202859	001	Oct 30, 2014	Sep CAHN
AB		SANDOZ INC	EQ 10MG BASE	A200889	001	Aug 03, 2012	Sep CMFD
		TABLET, CHEWABLE;ORAL						
		MONTELUKAST SODIUM						
>A>	@	AIPING PHARM INC	EQ 4MG BASE	A091414	001	Aug 03, 2012	Oct CAHN
>A>	@		EQ 5MG BASE	A091414	002	Aug 03, 2012	Oct CAHN
	@	NEW HEIGHTSRX	EQ 4MG BASE	A091588	001	Aug 03, 2012	Aug CAHN
	@		EQ 5MG BASE	A091588	002	Aug 03, 2012	Aug CAHN
	@	PHARMACO	EQ 4MG BASE	A091588	001	Aug 03, 2012	Sep CAHN
	@		EQ 5MG BASE	A091588	002	Aug 03, 2012	Sep CAHN
AB		PHARMOBEDIENT	EQ 4MG BASE	A203037	001	Oct 30, 2014	Sep CAHN
AB			EQ 5MG BASE	A203037	002	Oct 30, 2014	Sep CAHN
>D>	@	SANDOZ INC	EQ 4MG BASE	A091414	001	Aug 03, 2012	Oct CAHN
>D>	@		EQ 5MG BASE	A091414	002	Aug 03, 2012	Oct CAHN
AB		UNICHEM	EQ 4MG BASE	A208621	001	Jul 02, 2018	Aug CMFD
AB			EQ 5MG BASE	A208621	002	Jul 02, 2018	Aug CMFD
		MORPHINE SULFATE						
		CAPSULE, EXTENDED RELEASE;ORAL						
		MORPHINE SULFATE						
	@	ANDA REPOSITORY	20MG	A203158	001	Aug 04, 2021	Sep CAHN
	@		30MG	A203158	002	Aug 04, 2021	Sep CAHN
	@		50MG	A203158	003	Aug 04, 2021	Sep CAHN
	@		60MG	A203158	004	Aug 04, 2021	Sep CAHN
	@		80MG	A203158	005	Aug 04, 2021	Sep CAHN
	@		100MG	A203158	006	Aug 04, 2021	Sep CAHN
		SOLUTION;ORAL						
		MORPHINE SULFATE						
AA	+	HIKMA	20MG/5ML	N022195	002	Mar 17, 2008	Apr CTEC
	+		20MG/5ML	N022195	002	Mar 17, 2008	Feb CTEC
AA		PHARM ASSOC	10MG/5ML	A206573	002	Sep 12, 2023	Jun CMFD
AA			100MG/5ML	A206573	001	Nov 14, 2016	Jun CMFD
	@	RHODES PHARMS	10MG/5ML	A206308	001	Jun 22, 2017	Jan DISC
	@		20MG/5ML	A206420	001	Jul 12, 2016	Jan DISC
	@		100MG/5ML	A206308	002	Jun 22, 2017	Jan DISC
	@	SANKALP LIFECARE	10MG/5ML	A201011	001	Feb 05, 2014	Apr CAHN
	@		20MG/5ML	A201011	002	Feb 05, 2014	Apr CAHN
	@		100MG/5ML	A201011	003	Oct 06, 2016	Apr CAHN
AA		WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Apr CMFD
	@		10MG/5ML	A211454	001	Feb 12, 2021	Feb DISC
AA			20MG/5ML	A211454	002	Feb 12, 2021	Apr CMFD
	@		20MG/5ML	A211454	002	Feb 12, 2021	Feb DISC
AA			100MG/5ML	A211454	003	Feb 12, 2021	Apr CMFD
	@		100MG/5ML	A211454	003	Feb 12, 2021	Feb DISC
		TABLET;ORAL						
		MORPHINE SULFATE						
AB	+	HIKMA	15MG	N022207	001	Mar 17, 2008	Jun CAHN
AB	+!		30MG	N022207	002	Mar 17, 2008	Jun CAHN
		TABLET, EXTENDED RELEASE;ORAL						
		MORPHINE SULFATE						
	@	NOVEL LABS INC	15MG	A203602	001	Dec 16, 2015	Feb DISC
	@		30MG	A203602	002	Dec 16, 2015	Feb DISC
	@		60MG	A203602	003	Dec 16, 2015	Feb DISC
	@		100MG	A203602	004	Dec 16, 2015	Feb DISC
	@		200MG	A203602	005	Dec 16, 2015	Feb DISC

MOTIXAFORTIDE ACETATE

POWDER;SUBCUTANEOUS

APHEXDA

	+!	AYRMID PHARMA	EQ 62MG BASE/VIAL	N217159	001	Sep 08, 2023	Mar	CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1		FDC LTD	EQ 0.5% BASE	A219475	001	Aug 04, 2025	Jul	NEWA
AT1		MANKIND PHARMA	EQ 0.5% BASE	A217988	001	Jan 27, 2025	Jan	NEWA
	@	NORVIUM BIOSCIENCE	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Feb	CAHN
AT1		REGCON HOLDINGS	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Sep	CAHN

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

>D>	@	SUNSHINE	EQ 400MG BASE	A206295	001	Sep 28, 2018	Oct	CMFD
>A> AB			EQ 400MG BASE	A206295	001	Sep 28, 2018	Oct	CMFD
AB		TORRENT	EQ 400MG BASE	A200160	001	Apr 03, 2014	Sep	CMFD

MUPIROCIN

OINTMENT;TOPICAL

MUPIROCIN

AB		ENCUBE	2%	A217943	001	May 13, 2025	May	NEWA
AB		SUN PHARMA CANADA	2%	A065170	001	Sep 23, 2005	Sep	CAHN

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

BX		ALEMBIC	EQ 2% BASE	A213053	001	Nov 16, 2021	Mar	CTEC

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

	@	TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Apr	DISC
AB		VISTAPHARM LLC	200MG/ML	A210370	001	Feb 12, 2019	Jan	CAHN

MYCOPHENOLATE SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLATE SODIUM

AB		ACCORD HLTHCARE	EQ 180MG BASE	A202555	001	Aug 23, 2017	Aug	CAIN
AB			EQ 360MG BASE	A202555	002	Aug 23, 2017	Aug	CAIN
AB		ALKEM LABS LTD	EQ 180MG BASE	A208315	001	Sep 23, 2021	Aug	CAIN
AB			EQ 360MG BASE	A208315	002	Sep 23, 2021	Aug	CAIN
AB		APOTEX INC	EQ 180MG BASE	A091558	001	Aug 21, 2012	Aug	CAIN
AB			EQ 360MG BASE	A091558	002	Aug 19, 2014	Aug	CAIN
AB		AUROBINDO PHARMA LTD	EQ 180MG BASE	A218603	001	Feb 27, 2024	Aug	CAIN
AB			EQ 360MG BASE	A218603	002	Feb 27, 2024	Aug	CAIN
AB		BIOCON PHARMA	EQ 180MG BASE	A214630	001	Nov 29, 2021	Aug	CAIN
AB			EQ 180MG BASE	A217031	001	Nov 29, 2023	Aug	CAIN
AB			EQ 360MG BASE	A214630	002	Nov 29, 2021	Aug	CAIN
AB			EQ 360MG BASE	A217031	002	Nov 29, 2023	Aug	CAIN
AB		CONCORD BIOTECH LTD	EQ 180MG BASE	A211173	001	Dec 13, 2019	Aug	CAIN
AB			EQ 360MG BASE	A211173	002	Dec 13, 2019	Aug	CAIN
AB		FOSUN WANBANG	EQ 180MG BASE	A216637	001	May 29, 2024	Aug	CAIN
AB			EQ 360MG BASE	A216637	002	May 29, 2024	Aug	CAIN
AB		RK PHARMA	EQ 180MG BASE	A091248	002	Jan 08, 2014	Aug	CAIN
AB			EQ 360MG BASE	A091248	001	Jan 08, 2014	Aug	CAIN
	@	TEVA PHARMS USA	EQ 180MG BASE	A202720	001	Oct 30, 2014	Aug	CAIN
	@		EQ 360MG BASE	A202720	002	Oct 30, 2014	Aug	CAIN
AB		TWI PHARMS	EQ 180MG BASE	A214289	001	Nov 03, 2021	Aug	CAIN
AB			EQ 360MG BASE	A214289	002	Nov 03, 2021	Aug	CAIN
AB		YICHANG HUMANWELL	EQ 180MG BASE	A214376	001	Feb 10, 2021	Aug	CAIN
AB			EQ 360MG BASE	A214376	002	Feb 10, 2021	Aug	CAIN

MYFORTIC

AB	+	NOVARTIS	EQ 180MG BASE	N050791	001	Feb 27, 2004	Aug	CAIN
AB	+!		EQ 360MG BASE	N050791	002	Feb 27, 2004	Aug	CAIN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC SODIUM

AB		FOSUN WANBANG	EQ 180MG BASE	A216637	001	May 29, 2024	Jan CAHN
AB			EQ 360MG BASE	A216637	002	May 29, 2024	Jan CAHN
AB		YICHANG HUMANWELL	EQ 180MG BASE	A214376	001	Feb 10, 2021	Jul CAHN
AB			EQ 360MG BASE	A214376	002	Feb 10, 2021	Jul CAHN

NABUMETONE

TABLET;ORAL

NABUMETONE

	@	MPP PHARMA	500MG	A090427	001	Dec 30, 2011	Jun CAHN
	@		750MG	A090427	002	Dec 30, 2011	Jun CAHN

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

	@	FRESENIUS	EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020	Apr DISC

NALBUPHINE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALBUPHINE

	@	ABRAXIS PHARM	10MG/ML (10MG/ML)	A070751	001	Jul 02, 1986	Mar CPOT
	@		10MG/ML	A070751	001	Jul 02, 1986	Mar CDFR
	@		20MG/ML (20MG/ML)	A070752	001	Sep 24, 1986	Mar CPOT
	@		20MG/ML	A070752	001	Sep 24, 1986	Mar CDFR
	@		200MG/10ML (20MG/ML)	A070752	002	Sep 24, 1986	Mar NEWA

NALBUPHINE HYDROCHLORIDE

	@	ABBOTT	20MG/ML (20MG/ML)	A070917	001	Feb 03, 1989	Mar CPOT
	@		20MG/ML	A070917	001	Feb 03, 1989	Mar CDFR
	@	ABRAXIS PHARM	100MG/10ML (10MG/ML)	A070751	002	Jul 02, 1986	Mar NEWA
	@	DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	Mar CDFR
	@		20MG/ML	A074471	002	Mar 19, 1998	Mar CDFR
	@		100MG/10ML (10MG/ML)	A074471	001	Mar 19, 1998	Mar CPOT
	@		200MG/10ML (20MG/ML)	A074471	002	Mar 19, 1998	Mar CPOT
AP	!	HOSPIRA	10MG/ML (10MG/ML)	A070914	001	Feb 03, 1989	Mar CPOT
AP	!		10MG/ML	A070914	001	Feb 03, 1989	Mar CDFR
AP	!		10MG/ML	A070915	001	Feb 03, 1989	Mar CDFR
AP	!		20MG/ML (20MG/ML)	A070916	001	Feb 03, 1989	Mar CPOT
AP	!		20MG/ML	A070916	001	Feb 03, 1989	Mar CDFR
AP	!		20MG/ML	A070918	001	Feb 03, 1989	Mar CDFR
AP	!		100MG/10ML (10MG/ML)	A070915	001	Feb 03, 1989	Mar CPOT
AP	!		200MG/10ML (20MG/ML)	A070918	001	Feb 03, 1989	Mar CPOT
	@	IGI LABS INC	10MG/ML (10MG/ML)	A072070	001	Apr 10, 1989	Mar CPOT
	@		10MG/ML	A072070	001	Apr 10, 1989	Mar CDFR
	@		10MG/ML (10MG/ML)	A072071	001	Apr 10, 1989	Mar CPOT
	@		10MG/ML	A072071	001	Apr 10, 1989	Mar CDFR
	@		10MG/ML (10MG/ML)	A072072	001	Apr 10, 1989	Mar CPOT
	@		10MG/ML	A072072	001	Apr 10, 1989	Mar CDFR
	@		20MG/ML (20MG/ML)	A072073	001	Apr 10, 1989	Mar CPOT
	@		20MG/ML	A072073	001	Apr 10, 1989	Mar CDFR
	@		20MG/ML (20MG/ML)	A072074	001	Apr 10, 1989	Mar CPOT
	@		20MG/ML	A072074	001	Apr 10, 1989	Mar CDFR
	@		20MG/ML (20MG/ML)	A072075	001	Apr 10, 1989	Mar CPOT
	@		20MG/ML	A072075	001	Apr 10, 1989	Mar CDFR
	@		100MG/10ML (10MG/ML)	A072070	002	Apr 10, 1989	Mar NEWA
	@		200MG/10ML (20MG/ML)	A072073	002	Apr 10, 1989	Mar NEWA
	@	RISING	10MG/ML	A206506	001	Feb 06, 2019	Mar CDFR
	@		10MG/ML (10MG/ML)	A207595	001	Jan 11, 2019	Mar CPOT
	@		10MG/ML	A207595	001	Jan 11, 2019	Mar CDFR
	@		20MG/ML	A206506	002	Feb 06, 2019	Mar CDFR
	@		20MG/ML (20MG/ML)	A207595	002	Jan 11, 2019	Mar CPOT
	@		20MG/ML	A207595	002	Jan 11, 2019	Mar CDFR
	@		100MG/10ML (10MG/ML)	A206506	001	Feb 06, 2019	Mar CPOT
	@		200MG/10ML (20MG/ML)	A206506	002	Feb 06, 2019	Mar CPOT
AP		SOMERSET THERAPS LLC	10MG/ML	A216049	001	Sep 19, 2024	Mar CDFR
AP			10MG/ML (10MG/ML)	A216050	001	Sep 19, 2024	Mar CPOT
AP			10MG/ML	A216050	001	Sep 19, 2024	Mar CDFR
AP			20MG/ML	A216049	002	Sep 19, 2024	Mar CDFR
AP			20MG/ML (20MG/ML)	A216050	002	Sep 19, 2024	Mar CPOT
AP			20MG/ML	A216050	002	Sep 19, 2024	Mar CDFR
AP			100MG/10ML (10MG/ML)	A216049	001	Sep 19, 2024	Mar CPOT

	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
	NALBUPHINE HYDROCHLORIDE							
AP			200MG/10ML (20MG/ML)	A216049	002	Sep 19, 2024	Mar CPOT	
	NUBAIN							
	@ +	ENDO OPERATIONS	10MG/ML	N018024	001		Mar CDFR	
	@ +		10MG/ML (10MG/ML)	N018024	001		Mar CPOT	
	@ +		20MG/ML	N018024	002	May 27, 1982	Mar CDFR	
	@ +		20MG/ML (20MG/ML)	N018024	002	May 27, 1982	Mar CPOT	
	@ +		20MG/2ML (10MG/ML)	N018024	004		Mar NEWA	
	@ +		100MG/10ML (10MG/ML)	N018024	003		Mar NEWA	
	@ +		200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Mar NEWA	
	@ +	PH HEALTH	10MG/ML (10MG/ML)	N018024	001		Jul CAHN	
	@ +		20MG/ML (20MG/ML)	N018024	002	May 27, 1982	Jul CAHN	
	@ +		20MG/2ML (10MG/ML)	N018024	004		Jul CAHN	
	@ +		100MG/10ML (10MG/ML)	N018024	003		Jul CAHN	
	@ +		200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Jul CAHN	
	NALMEFENE HYDROCHLORIDE							
	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS							
	ZURNAI (AUTOINJECTOR)							
	+!	PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Sep CMFD	
	@ +		EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Jan DISC	
	NALOXEGOL OXALATE							
	TABLET;ORAL							
	MOVANTIK							
	+	AVERITAS	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Sep CAHN	
	+!		EQ 25MG BASE	N204760	002	Sep 16, 2014	Sep CAHN	
	NALOXONE HYDROCHLORIDE							
	INJECTABLE;INJECTION							
	NALOXONE HYDROCHLORIDE							
AP		BAXTER HLTHCARE CORP	1MG/ML	A214785	002	Jun 03, 2025	May NEWA	
	@	PH HEALTH	0.4MG/ML	A211286	001	Jan 17, 2020	Jul CAHN	
AP		STERINOVA INC	0.4MG/ML	A214211	001	Aug 21, 2025	Aug NEWA	
	SPRAY;NASAL							
	KLOXXADO							
	+	HIKMA	4MG/SPRAY	N212045	002	Aug 25, 2025	Aug NEWA	
	+!		8MG/SPRAY	N212045	001	Apr 29, 2021	May CTEC	
AB	+!		8MG/SPRAY	N212045	001	Apr 29, 2021	Apr CFTG	
	NALOXONE HYDROCHLORIDE							
	@	PADAGIS ISRAEL	8MG/SPRAY	A216719	001	Apr 24, 2025	May DISC	
AB			8MG/SPRAY	A216719	001	Apr 24, 2025	Apr NFTG	
	REZENOPY							
	@ +	SCIENTURE	10MG/SPRAY	N215487	001	Apr 19, 2024	Aug CAHN	
	@ +	SUMMIT BIOSCI	10MG/SPRAY	N215487	001	Apr 19, 2024	Jul DISC	
	NALTREXONE HYDROCHLORIDE							
	TABLET;ORAL							
	NALTREXONE HYDROCHLORIDE							
	@	ALLIED	50MG	A075434	001	Mar 08, 2000	Jul CAHN	
	@	ESJAY PHARMA	50MG	A075434	001	Mar 08, 2000	Jul CAHN	
	NAPROXEN							
	SUSPENSION;ORAL							
	NAPROXEN							
AB		AUROBINDO PHARMA	25MG/ML	A216504	001	Oct 03, 2025	Sep NEWA	
	TABLET, DELAYED RELEASE;ORAL							
	NAPROXEN							
AB		AUROBINDO PHARMA USA	375MG	A075390	001	Apr 19, 2001	Aug CMFD	
AB			500MG	A075390	002	Apr 19, 2001	Aug CMFD	
	NEBIVOLOL HYDROCHLORIDE							
	TABLET;ORAL							
	NEBIVOLOL HYDROCHLORIDE							
AB		MACLEODS PHARMS LTD	EQ 2.5MG BASE	A212661	001	Jan 28, 2025	Jan NEWA	
AB			EQ 5MG BASE	A212661	002	Jan 28, 2025	Jan NEWA	
AB			EQ 10MG BASE	A212661	003	Jan 28, 2025	Jan NEWA	
AB			EQ 20MG BASE	A212661	004	Jan 28, 2025	Jan NEWA	

NELARABINE

INJECTABLE;INTRAVENOUS

NELARABINE

	!	SHORLA	375MG/75ML (5MG/ML)	A214809	002	Jul 16, 2025	Jul NFTG

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA		AARXION ANDA HLDING	500MG	A065220	001	Jul 28, 2006	Sep CAHN
	@	AVIV PHARMA	500MG	A065468	001	Mar 29, 2010	May CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP		AVET LIFESCIENCES	5MG/10ML (0.5MG/ML)	A208230	001	Nov 25, 2022	May CTNA
AP			10MG/10ML (1MG/ML)	A208230	002	Nov 25, 2022	May CTNA
AP		REGCON HOLDINGS	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Sep CAHN
AP			10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Sep CAHN

>A> NERANDOMILAST

>A> TABLET;ORAL

>A> JASCAYD

>A>	+	BOEHRINGER INGELHEIM	9MG	N218764	001	Oct 07, 2025	Oct NEWA
>A>	+!		18MG	N218764	002	Oct 07, 2025	Oct NEWA

NEVIRAPINE

TABLET;ORAL

NEVIRAPINE

	@	PHARMOBEDIENT	200MG	A078864	001	May 22, 2012	Sep CAHN

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

AB		MPP PHARMA	500MG	A207726	001	Jul 25, 2025	Jul NEWA
AB			750MG	A207726	002	Jul 25, 2025	Jul NEWA
AB			1GM	A207726	003	Jul 25, 2025	Jul NEWA
	@	ZYDUS PHARMS	500MG	A203285	001	Apr 28, 2025	Sep DISC
AB			500MG	A203285	001	Apr 28, 2025	Apr NEWA
	@		750MG	A203285	002	Apr 28, 2025	Sep DISC
AB			750MG	A203285	002	Apr 28, 2025	Apr NEWA
	@		1GM	A203285	003	Apr 28, 2025	Sep DISC
AB			1GM	A203285	003	Apr 28, 2025	Apr NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB		AMNEAL	20MG	A218202	001	Apr 10, 2024	Sep CAHN
AB			30MG	A218202	002	Apr 10, 2024	Sep CAHN
AB		NAVINTA LLC	20MG	A218638	001	Jun 25, 2025	Jun NEWA
AB			30MG	A218638	002	Jun 25, 2025	Jun NEWA

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

	@	AMNEAL	25MG/10ML (2.5MG/ML)	A215406	001	Oct 31, 2024	Jan DISC
AP		MANKIND PHARMA	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	Jun CAHN
AP		NANJING KING FRIEND	25MG/10ML (2.5MG/ML)	A216819	001	Aug 20, 2025	Aug NEWA
>A> AP		QILU PHARM HAINAN	25MG/10ML (2.5MG/ML)	A219608	001	Oct 28, 2025	Oct NEWA

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

>A> AP		CAPLIN	20MG/200ML (0.1MG/ML)	A220243	001	Oct 22, 2025	Oct NEWA
>A> AP			40MG/200ML (0.2MG/ML)	A220243	002	Oct 22, 2025	Oct NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

>D> AB2		SPIL	30MG	A210838	001	Apr 16, 2019	Oct DISC
>A>	@		30MG	A210838	001	Apr 16, 2019	Oct DISC
>D> AB2			60MG	A210838	002	Apr 16, 2019	Oct DISC
>A>	@		60MG	A210838	002	Apr 16, 2019	Oct DISC
>D> AB2			90MG	A210838	003	Apr 16, 2019	Oct DISC
>A>	@		90MG	A210838	003	Apr 16, 2019	Oct DISC

NILOTINIB D-TARTRATE

CAPSULE;ORAL

NILOTINIB D-TARTRATE

	+	CIPLA	EQ 50MG BASE	N218922	001	Feb 19, 2025	Feb NEWA
	+		EQ 150MG BASE	N218922	002	Feb 19, 2025	Feb NEWA
	+!		EQ 200MG BASE	N218922	003	Feb 19, 2025	Feb NEWA

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

AB		APOTEX	EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr CMFD
AB			EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr CMFD
AB			EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr CMFD

TASIGNA

AB	+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr CTEC
AB	+		EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr CTEC
AB	+!		EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr CTEC

NIMODIPINE

SOLUTION;ORAL

NIMODIPINE

AB		ALKEM LABS LTD	6MG/ML	A213409	001	Jan 22, 2025	Jan NFTG

NYMALIZE

AB	+!	AZURITY	6MG/ML	N203340	002	Apr 08, 2020	Jan CFTG

NITAZOXANIDE

TABLET;ORAL

NITAZOXANIDE

AB		ANI PHARMS	500MG	A214844	001	Feb 03, 2025	Apr CAHN
AB		ANNORA PHARMA	500MG	A218701	001	Apr 15, 2025	Apr NEWA
AB	!	RISING	500MG	A213820	001	Nov 27, 2020	Jan CTEC
AB		ZENARA	500MG	A214844	001	Feb 03, 2025	Jan NEWA

NITISINONE

TABLET;ORAL

HARLIKU

	+!	CYCLE	2MG	N209449	004	Jun 10, 2025	Jul NEWA

NITRIC OXIDE

GAS;INHALATION

INOMAX

	@ +	MALLINCKRODT IRELAND	100PPM	N020845	002	Dec 23, 1999	Jul CAHN
AA	+!		800PPM	N020845	003	Dec 23, 1999	Jul CAHN
	+!		4880PPM	N020845	004	Jan 17, 2023	Jul CAHN

NOXIVENT

	@	LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	Apr DISC

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

AB		ANNORA PHARMA	25MG/5ML	A219495	001	Jul 02, 2025	Jun NEWA
AB		APPCO	25MG/5ML	A208909	001	Jan 14, 2025	Jan NEWA
AB		STRIDES PHARMA	25MG/5ML	A201355	001	Aug 14, 2013	Apr CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

	@	AMNEAL PHARMS	75MG;25MG	A207372	001	May 15, 2017	Jul DISC
AB		MICRO LABS	75MG;25MG	A217073	001	Nov 03, 2023	Sep CAHN

NITROGLYCERIN

OINTMENT;INTRA-ANAL

NITROGLYCERIN

AB		TP ANDA HOLDINGS	0.4%	A212222	001	Nov 29, 2024	Aug CAHN

OINTMENT;TRANSDERMAL

NITROGLYCERIN

AB		ENCUBE	2%	A218235	001	Apr 15, 2025	Apr NFTG
AB	+!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	Apr CFTG

TABLET;SUBLINGUAL
NITROGLYCERIN

AB		RUBICON RESEARCH	0.3MG	A209779	001	May 03, 2021	Jul CAHN
AB			0.4MG	A209779	002	May 03, 2021	Jul CAHN
AB			0.6MG	A209779	003	May 03, 2021	Jul CAHN

NIZATIDINE

CAPSULE;ORAL
NIZATIDINE

@		GLENMARK PHARMS INC	150MG	A090618	001	Jul 15, 2011	Jul DISC
@			300MG	A090618	002	Jul 15, 2011	Jul DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP		ASPIRO	EQ 1MG BASE/ML	A219163	001	Jan 31, 2025	Jan NEWA
AP		BIOCON PHARMA	EQ 1MG BASE/ML	A219443	001	Mar 21, 2025	Mar NEWA

SOLUTION;INTRAVENOUS
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

>A>	+!	INFORLIFE	EQ 32MG BASE/250ML (EQ 128MCG BASE/ML)	N215700	004	Oct 15, 2025	Oct NEWA

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

AP	+!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Aug CFTG
AP	+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Aug CFTG
AP		SAGENT	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	A219692	001	Aug 11, 2025	Aug NFTG
AP			EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	A219692	002	Aug 11, 2025	Aug NFTG

NYSTATIN

CREAM;TOPICAL
NYSTATIN

AT		AUROBINDO PHARMA	100,000 UNITS/GM	A219527	001	Mar 21, 2025	Mar NEWA
@		CHARTWELL RX	100,000 UNITS/GM	A065315	001	May 31, 2006	Apr CAHN

POWDER;TOPICAL
KLAYESTA

>A>							
>A> AT		EPIC PHARMA LLC	100,000 UNITS/GM	A210532	001	Apr 30, 2018	Oct CTNA

NYSTATIN

@		ADRASTEA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Jun DISC
>D> AT		EPIC PHARMA LLC	100,000 UNITS/GM	A210532	001	Apr 30, 2018	Oct CTNA
@		PHARMOBEDIENT	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Sep CAHN

SUSPENSION;ORAL
NYSTATIN

AA		MLV	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Aug CMFD
AA		PHARMOBEDIENT	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Aug CAHN
AA	!	SENORES PHARMS	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Sep CAHN
@		TARO	100,000 UNITS/ML	A062876	001	Feb 29, 1988	Aug DISC
AA		XTTRIUM LABS INC	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jan CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		CHARTWELL RX	100,000 UNITS/GM;0.1%	A208326	001	Oct 26, 2016	Apr CAHN
@		GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208136	001	Oct 24, 2016	Jul DISC

OINTMENT;TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

@		GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208300	001	Jun 23, 2016	Jul DISC

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

@		AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb DISC

SOLUTION/DROPS;OTIC
OFLOXACIN

AT		FDC LTD	0.3%	A215038	001	Jan 19, 2022	Aug CMFD

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

AP		QILU	10MG/VIAL	A218116	001	May 16, 2025	May NEWA
AP		UBI	10MG/VIAL	A211072	001	Jun 11, 2025	May NEWA

OLICERIDINE

SOLUTION;INTRAVENOUS

OLINVYK

	@ +	TREVENA	1MG/ML (1MG/ML)	N210730	001	Oct 30, 2020	Jan DISC
	@ +		2MG/2ML (1MG/ML)	N210730	002	Oct 30, 2020	Jan DISC

OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

CLINOLIPID 20%

	+!	BAXTER HLTHCARE CORP	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun CMFD

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB		JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Mar CMFD
AB			20MG	A205482	002	Apr 24, 2017	Mar CMFD
AB			40MG	A205482	003	Apr 24, 2017	Mar CMFD

OMAVELOXOLONE

CAPSULE;ORAL

SKYCLARYS

	+!	BIOGEN US	50MG	N216718	001	Feb 28, 2023	Jan CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

LOVAZA

AB	+!	WAYLIS THERAP	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb CAHN

OMEGA-3-ACID ETHYL ESTERS

	@	SUN PHARM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210834	001	Jan 09, 2020	Jul DISC

OMIDENEPAG ISOPROPYL

SOLUTION;OPHTHALMIC

OMLONTI

	+!	OCUVEX THERAP	0.002%	N215092	001	Sep 22, 2022	Jun CMFD

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB		IPCA LABS LTD	4MG	A209389	001	Oct 30, 2023	May CMFD
AB			8MG	A209389	002	Oct 30, 2023	May CMFD
	@	NORVIUM BIOSCIENCE	4MG	A078139	001	Jun 25, 2007	Feb CAHN
	@		8MG	A078139	002	Jun 25, 2007	Feb CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

	@	HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076781	001	Dec 26, 2006	Mar DISC

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

	@	APOTEX	EQ 4MG BASE	A077306	001	Jun 25, 2007	Mar DISC
	@		EQ 8MG BASE	A077306	002	Jun 25, 2007	Mar DISC
AB		IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	May CMFD
AB			EQ 8MG BASE	A203761	002	Jan 23, 2014	May CMFD

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB		BEIJING JIALIN	EQ 30MG BASE	A217133	001	Oct 30, 2024	Sep CAHN
AB			EQ 75MG BASE	A217133	002	Oct 30, 2024	Sep CAHN
AB		SHANDONG	EQ 30MG BASE	A217274	001	Jul 09, 2025	Jun NEWA
AB			EQ 45MG BASE	A217274	002	Jul 09, 2025	Jun NEWA

		CAPSULE;ORAL						
		OSELTAMIVIR PHOSPHATE						
	AB		EQ 75MG BASE	A217274	003	Jul 09, 2025	Jun	NEWA
	AB	ZHEJIANG POLY PHARM	EQ 30MG BASE	A218009	002	Oct 02, 2025	Sep	NEWA
	AB		EQ 45MG BASE	A218009	003	Oct 02, 2025	Sep	NEWA
	AB		EQ 75MG BASE	A218009	001	Nov 24, 2023	Mar	CAHN
		TAMIFLU						
>D>	AB	+ ROCHE	EQ 30MG BASE	N021087	003	Jul 02, 2007	Oct	DISC
>A>		@ +	EQ 30MG BASE	N021087	003	Jul 02, 2007	Oct	DISC
		FOR SUSPENSION;ORAL						
		OSELTAMIVIR PHOSPHATE						
	AB	JUBILANT GENERICS	EQ 6MG BASE/ML	A213695	001	Mar 03, 2025	Feb	NEWA
	AB	PHARMOBEDIENT	EQ 6MG BASE/ML	A217303	001	Jul 02, 2024	Sep	CAHN
		OSPEMIFENE						
		TABLET;ORAL						
		OSPEMIFENE						
		@ HETERO LABS LTD V	60MG	A215574	001	Feb 13, 2024	Apr	DISC
		OSPHENA						
		+! DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Apr	CTEC
		OXALIPLATIN						
		INJECTABLE;INTRAVENOUS						
		OXALIPLATIN						
		@ FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Aug	DISC
		@	100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Aug	DISC
	AP	HETERO LABS LTD VI	50MG/10ML (5MG/ML)	A217925	001	Jan 27, 2025	Jan	NEWA
	AP		100MG/20ML (5MG/ML)	A217925	002	Jan 27, 2025	Jan	NEWA
>D>	AP	NOVAST LABS	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Oct	DISC
>A>		@	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Oct	DISC
		OXAZEPAM						
		CAPSULE;ORAL						
		OXAZEPAM						
	AB	EPIC PHARMA LLC	10MG	A071756	002	Apr 19, 1988	Jul	CMS1
	AB		30MG	A071756	003	Apr 19, 1988	Jul	CMS1
	AB	LEADING	10MG	A218261	001	Mar 03, 2025	Feb	NEWA
	AB		15MG	A218261	002	Mar 03, 2025	Feb	NEWA
	AB		30MG	A218261	003	Mar 03, 2025	Feb	NEWA
		OXCARBAZEPINE						
		SUSPENSION;ORAL						
		OXCARBAZEPINE						
	AB	MACLEODS PHARMS LTD	300MG/5ML	A207300	001	Jul 11, 2025	Jul	NEWA
		@ PAI HOLDINGS	300MG/5ML	A211420	001	Jul 09, 2021	Jul	CAHN
		TABLET, EXTENDED RELEASE;ORAL						
		OXCARBAZEPINE						
	AB	AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Apr	CMFD
	AB		300MG	A217659	002	Feb 22, 2024	Apr	CMFD
	AB		600MG	A217659	003	Feb 22, 2024	Apr	CMFD
		@ AUROBINDO PHARMA LTD	150MG	A219241	001	Apr 30, 2025	May	DISC
	AB		150MG	A219241	001	Apr 30, 2025	Apr	NEWA
		@	300MG	A219241	002	Apr 30, 2025	May	DISC
	AB		300MG	A219241	002	Apr 30, 2025	Apr	NEWA
		@	600MG	A219241	003	Apr 30, 2025	May	DISC
	AB		600MG	A219241	003	Apr 30, 2025	Apr	NEWA
	AB	RICONPHARMA LLC	150MG	A215796	001	Nov 22, 2024	Apr	CMFD
	AB		300MG	A215796	002	Nov 22, 2024	Apr	CMFD
	AB		600MG	A215796	003	Nov 22, 2024	Apr	CMFD
		OXYBUTYNIN CHLORIDE						
		TABLET;ORAL						
		OXYBUTYNIN CHLORIDE						
	AB	AIPING PHARM INC	5MG	A074625	001	Jul 31, 1996	Jul	CAHN
		OXYCODONE HYDROCHLORIDE						
		SOLUTION;ORAL						
		OXYCODONE HYDROCHLORIDE						
	AA	HIBROW HLTHCARE	5MG/5ML	A207511	001	Nov 23, 2016	Sep	CAHN
	AA		100MG/5ML	A209897	001	Sep 06, 2017	Sep	CAHN
		@ PHARM ASSOC	100MG/5ML	A206822	001	Aug 15, 2017	Apr	DISC
		@ PHARMOBEDIENT	5MG/5ML	A206456	001	Jun 16, 2015	Aug	CAHN

SOLUTION;ORAL
OXYCODONE HYDROCHLORIDE

		@	VISTAPHARM LLC	100MG/5ML	A202537	001	Jul 30, 2012	Jan CAHN

TABLET;ORAL
OXYCODONE HYDROCHLORIDE

		@	NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017	Feb DISC
		@		10MG	A204021	002	Jun 12, 2017	Feb DISC
		@		15MG	A204021	003	Jun 12, 2017	Feb DISC
		@		20MG	A204021	004	Jun 12, 2017	Feb DISC
		@		30MG	A204021	005	Jun 12, 2017	Feb DISC

PACLITAXEL
POWDER;INTRAVENOUS
PACLITAXEL

	AB		CIPLA	100MG/VIAL	A209657	001	Apr 10, 2025	Mar NEWA
	AB		MYLAN	100MG/VIAL	A217877	001	Aug 19, 2025	Aug NEWA
	AB		SHUANGCHENG	100MG/VIAL	A216355	001	May 15, 2025	May NEWA

PALBOCICLIB
TABLET;ORAL
PALBOCICLIB

		@	ZYDUS LIFESCIENCES	75MG	A215570	001	Jun 05, 2024	Apr CAHN
		@		100MG	A215570	002	Jun 05, 2024	Apr CAHN
		@		125MG	A215570	003	Jun 05, 2024	Apr CAHN

PALIPERIDONE
TABLET, EXTENDED RELEASE;ORAL
PALIPERIDONE

	AB		DR REDDYS	3MG	A205559	001	Feb 19, 2025	Feb NEWA
	AB			6MG	A205559	002	Feb 19, 2025	Feb NEWA
	AB			9MG	A205559	003	Feb 19, 2025	Feb NEWA
>A>	AB		ESKAYEF	1.5MG	A218755	001	Sep 04, 2025	Oct CAHN
	AB			1.5MG	A218755	001	Sep 04, 2025	Aug NEWA
>A>	AB			3MG	A218755	002	Sep 04, 2025	Oct CAHN
	AB			3MG	A218755	002	Sep 04, 2025	Aug NEWA
>A>	AB			6MG	A218755	003	Sep 04, 2025	Oct CAHN
	AB			6MG	A218755	003	Sep 04, 2025	Aug NEWA
>A>	AB			9MG	A218755	004	Sep 04, 2025	Oct CAHN
	AB			9MG	A218755	004	Sep 04, 2025	Aug NEWA
>D>	AB		EVEREST LIFESCIENCES	1.5MG	A218755	001	Sep 04, 2025	Oct CAHN
>A>	AB			1.5MG	A218755	001	Sep 04, 2025	Oct CAHN
	AB			1.5MG	A218755	001	Sep 04, 2025	Sep CAHN
>D>	AB			3MG	A218755	002	Sep 04, 2025	Oct CAHN
>A>	AB			3MG	A218755	002	Sep 04, 2025	Oct CAHN
	AB			3MG	A218755	002	Sep 04, 2025	Sep CAHN
>D>	AB			6MG	A218755	003	Sep 04, 2025	Oct CAHN
>A>	AB			6MG	A218755	003	Sep 04, 2025	Oct CAHN
	AB			6MG	A218755	003	Sep 04, 2025	Sep CAHN
>D>	AB			9MG	A218755	004	Sep 04, 2025	Oct CAHN
>A>	AB			9MG	A218755	004	Sep 04, 2025	Oct CAHN
	AB			9MG	A218755	004	Sep 04, 2025	Sep CAHN
>D>	BX		LUPIN LTD	1.5MG	A208643	001	Jun 29, 2022	Oct DISC
>A>		@		1.5MG	A208643	001	Jun 29, 2022	Oct DISC
>D>	BX			3MG	A208643	002	Jun 29, 2022	Oct DISC
>A>		@		3MG	A208643	002	Jun 29, 2022	Oct DISC
>D>	BX			6MG	A208643	003	Jun 29, 2022	Oct DISC
>A>		@		6MG	A208643	003	Jun 29, 2022	Oct DISC
>D>	BX			9MG	A208643	004	Jun 29, 2022	Oct DISC
>A>		@		9MG	A208643	004	Jun 29, 2022	Oct DISC

PALIPERIDONE PALMITATE
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA SUSTENNA

>D>	AB	+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Oct CTEC
>A>		+		39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Oct CTEC
>D>	AB	+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Oct CTEC
>A>		+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Oct CTEC
>D>	AB	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Oct CTEC
>A>		+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Oct CTEC
>D>	AB	+!		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Oct CTEC
>A>		+!		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Oct CTEC
>D>	AB	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Oct CTEC
>A>		+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Oct CTEC

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@	NOVAST LABS	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Sep	CAHN

PALTUSOTINE HYDROCHLORIDE

TABLET;ORAL

PALSONIFY

+	CRINETICS	EQ 20MG BASE	N219070	001	Sep 25, 2025	Sep	NEWA
+!		EQ 30MG BASE	N219070	002	Sep 25, 2025	Sep	NEWA

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB	AUROBINDO PHARMA LTD	EQ 40MG BASE	A217923	001	Mar 31, 2025	Mar	NEWA
AB	CIPLA	EQ 40MG BASE	A217458	001	Mar 31, 2025	Mar	NEWA

INJECTABLE;INTRAVENOUS

PANTOPRAZOLE SODIUM

AP	ALEMBIC	EQ 40MG BASE/VIAL	A219230	001	Mar 31, 2025	Mar	NEWA
AP	DEVA HOLDING AS	EQ 40MG BASE/VIAL	A215074	001	May 16, 2025	May	NEWA

POWDER;INTRAVENOUS

PANTOPRAZOLE SODIUM

AP	FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	May	CMFD
@		EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Feb	DISC
AP +!	HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	May	CTEC
+!		EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Feb	CTEC

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB	GRAVITI PHARMS	EQ 20MG BASE	A219087	001	Jan 16, 2025	Jan	NEWA
AB		EQ 40MG BASE	A219087	002	Jan 16, 2025	Jan	NEWA
@	INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Jan	DISC

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB	CHARTWELL RX	1MCG	A091412	001	Jun 24, 2014	Apr	CAHN
AB		2MCG	A091412	002	Jun 24, 2014	Apr	CAHN
AB		4MCG	A091412	003	Jun 24, 2014	Apr	CAHN

SOLUTION;INTRAVENOUS

PARICALCITOL

AP	CAPLIN	0.002MG/ML (0.002MG/ML)	A204910	001	Aug 17, 2016	Apr	CAHN
AP		0.005MG/ML (0.005MG/ML)	A204910	002	Aug 17, 2016	Apr	CAHN
AP		0.01MG/2ML (0.005MG/ML)	A204910	003	Aug 17, 2016	Apr	CAHN
@	HIKMA PHARMS	0.002MG/ML (0.002MG/ML)	N205917	001	Nov 18, 2014	Jul	DISC
@		0.005MG/ML (0.005MG/ML)	N205917	002	Nov 18, 2014	Jul	DISC
@		0.01MG/2ML (0.005MG/ML)	N205917	003	Nov 18, 2014	Jul	DISC

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

AB	ALEMBIC	EQ 25MG BASE	A217280	001	Sep 24, 2025	Sep	NEWA
AB		EQ 37.5MG BASE	A217280	002	Sep 24, 2025	Sep	NEWA

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

PAZOPANIB HYDROCHLORIDE

	TORRENT	EQ 400MG BASE	A219922	001	Sep 04, 2025	Aug	NFTG

PEGULICIANINE ACETATE

POWDER;INTRAVENOUS

LUMISIGHT

+!	LUMICELL	EQ 39MG BASE/VIAL	N214511	001	Apr 17, 2024	Aug	CPOT

PEMETREXED DISODIUM

POWDER;INTRAVENOUS

PEMETREXED DISODIUM

@	BAXTER HLTHCARE CORP	EQ 100MG BASE/VIAL	A214436	001	Aug 18, 2022	May	DISC
@		EQ 500MG BASE/VIAL	A214436	002	Aug 18, 2022	May	DISC

		SOLUTION;INTRAVENOUS						
		PEMETREXED DISODIUM						
	@ +	ACCORD HLTHCARE	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214408	001	Jul 19, 2022	Jun DISC
	@ +		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408	002	Jul 19, 2022	Jun DISC
	@ +		EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408	003	Jul 19, 2022	Jun DISC
	@ +		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408	004	Jul 19, 2022	Jun DISC
>D>	PEMETREXED DITROMETHAMINE						
>D>	POWDER;INTRAVENOUS						
>D>	PEMETREXED DITROMETHAMINE						
>D>	+!	HOSPIRA	EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Oct DISC
>A>	@ +		EQ 100MG BASE/VIAL	N208746	001	Jun 10, 2022	Oct DISC
>D>	+!		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Oct DISC
>A>	@ +		EQ 500MG BASE/VIAL	N208746	002	Jun 10, 2022	Oct DISC
	PENCICLOVIR						
	CREAM;TOPICAL						
	PENCICLOVIR						
AB		AMNEAL	1%	A214100	001	Aug 22, 2025	Aug NEWA
BX		TORRENT	1%	A216981	001	Aug 07, 2023	Mar CTEC
	PENICILLAMINE						
	CAPSULE;ORAL						
	PENICILLAMINE						
	@	APOTEX	250MG	A213310	001	Apr 28, 2020	Sep DISC
	PENTAMIDINE ISETHIONATE						
	INJECTABLE;INJECTION						
	PENTAMIDINE ISETHIONATE						
AP		PHARMOBEDIENT	300MG/VIAL	A206982	001	Mar 17, 2022	Sep CAHN
	PENTOXIFYLLINE						
	TABLET, EXTENDED RELEASE;ORAL						
	PENTOXIFYLLINE						
	@	BAUSCH	400MG	A075028	001	Jul 20, 1998	Sep DISC
AB			400MG	A075028	001	Jul 20, 1998	Sep CAHN
	PERAMPANEL						
	SUSPENSION;ORAL						
	FYCOMPA						
AB	+!	CATALYST PHARMS	0.5MG/ML	N208277	001	Apr 29, 2016	Jul CFTG
	PERAMPANEL						
AB		MSN	0.5MG/ML	A218152	001	Jul 11, 2025	Jul NFTG
	TABLET;ORAL						
	FYCOMPA						
AB	+	CATALYST PHARMS	2MG	N202834	001	Oct 22, 2012	May CFTG
AB	+		4MG	N202834	002	Oct 22, 2012	May CFTG
AB	+		6MG	N202834	003	Oct 22, 2012	May CFTG
AB	+		8MG	N202834	004	Oct 22, 2012	May CFTG
AB	+		10MG	N202834	005	Oct 22, 2012	May CFTG
AB	+!		12MG	N202834	006	Oct 22, 2012	May CFTG
	PERAMPANEL						
AB		TEVA PHARMS USA INC	2MG	A209801	001	May 23, 2025	May NFTG
AB			4MG	A209801	002	May 23, 2025	May NFTG
AB			6MG	A209801	003	May 23, 2025	May NFTG
AB			8MG	A209801	004	May 23, 2025	May NFTG
AB			10MG	A209801	005	May 23, 2025	May NFTG
AB			12MG	A209801	006	May 23, 2025	May NFTG
	PERPHENAZINE						
	TABLET;ORAL						
	PERPHENAZINE						
AB		JUBILANT GENERICS	2MG	A213694	001	Mar 18, 2025	Mar NEWA
AB			4MG	A213694	002	Mar 18, 2025	Mar NEWA
AB			8MG	A213694	003	Mar 18, 2025	Mar NEWA
AB			16MG	A213694	004	Mar 18, 2025	Mar NEWA

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENDIMETRAZINE TARTRATE

		+!	ACERTIS PHARMS	105MG	N018074	001		May CAHN

TABLET;ORAL

BONTRIL PDM

	AA	+!	BAUSCH	35MG	A085272	001		Mar CAHN

PHENDIMETRAZINE TARTRATE

	AA		ACERTIS PHARMS	35MG	A085588	001		May CAHN
		@	MPP PHARMA	35MG	A203600	001	Dec 27, 2017	May CAHN

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

>D>	AA		MERRO PHARM USA	37.5MG	A206342	001	Nov 18, 2016	Oct CAHN
>A>	AA		PURACAP LABS BLU	37.5MG	A206342	001	Nov 18, 2016	Oct CAHN

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE

	AB		DR REDDYS LABS SA	EQ 7.5MG BASE;46MG	A208175	002	Jun 12, 2025	Jun NEWA
	AB			EQ 11.25MG BASE;69MG	A208175	003	Jun 12, 2025	Jun NEWA
	AB			EQ 15MG BASE;92MG	A208175	004	Jun 12, 2025	Jun NEWA
	AB			EQ 3.75MG BASE;23MG	A208175	001	Jun 12, 2025	Jun NEWA

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

BIORPHEN

	AP	+!	DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb CFTG

PHENYLEPHRINE HYDROCHLORIDE

>D>		+!	HIKMA	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Oct CTEC
>A>	AP2	+!		50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Oct CTEC
>D>		+!		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Oct CTEC
>A>	AP2	+!		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Oct CTEC
	AP1		MILLA PHARMS	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Sep CAHN
	AP1			50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Sep CAHN
	AP1			100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Sep CAHN
>D>		@	SANDOZ	10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Oct CMFD
>A>	AP1	!		10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Oct CMFD
		@		10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Aug CHRS
>D>		@		50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Oct CMFD
>A>	AP1	!		50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Oct CMFD
		@		50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Aug CHRS
>D>		@		100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Oct CMFD
>A>	AP1	!		100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Oct CMFD
		@		100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Aug CHRS
	AP		SOMERSET THERAPS LLC	0.5MG/5ML (0.1MG/ML)	A215617	001	Feb 14, 2025	Feb NFTG

PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

		+!	DR REDDYS LABS SA	20MG/250ML (0.08MG/ML)	N216830	001	May 30, 2025	Jun CAHN
		+!	SINTETICA SA	20MG/250ML (0.08MG/ML)	N216830	001	May 30, 2025	May NEWA

VAZCULEP

		@ +	EXELA PHARMA	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Aug DISC
		@ +		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Aug DISC
		@ +		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Aug DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

		@	VISTAPHARM LLC	125MG/5ML	A040342	001	Jan 31, 2001	Jan CAHN
		@		125MG/5ML	A040342	002	Aug 18, 2005	Jan CAHN

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

	AB		ALEMBIC	1MG/0.5ML	A216444	001	Sep 08, 2025	Aug NEWA
>A>	AB		AMNEAL	1MG/0.5ML	A216601	001	Nov 04, 2025	Oct NEWA
	AB1		CAPLIN	10MG/ML	A219212	001	Apr 17, 2025	Apr NEWA

TABLET;ORAL

PHYTONADIONE

		@	HIKMA	5MG	A212112	001	Dec 19, 2024	Feb DISC

PILOCARPINE HYDROCHLORIDE

>D>		SOLUTION;OPHTHALMIC						
>D>		ISOPTO CARPINE						
>D>	AT	+! SANDOZ	1%	N200890	001	Jun 22, 2010	Oct CDFR	
>D>	AT	+!	2%	N200890	002	Jun 22, 2010	Oct CDFR	
>D>	AT	+!	4%	N200890	003	Jun 22, 2010	Oct CDFR	
>D>		PILOCARPINE HYDROCHLORIDE						
>D>	AT	AMNEAL	1%	A214193	001	Sep 21, 2020	Oct CDFR	
>D>	AB		1.25%	A217733	001	Apr 28, 2025	Oct CDFR	
	AB		1.25%	A217733	001	Apr 28, 2025	Apr NFTG	
>D>	AT		2%	A214193	002	Sep 21, 2020	Oct CDFR	
>D>	AT		4%	A214193	003	Sep 21, 2020	Oct CDFR	
>D>	AT	FDC LTD	1%	A217052	001	Oct 02, 2025	Oct CDFR	
	AT		1%	A217052	001	Oct 02, 2025	Sep NEWA	
>D>	AT		2%	A217052	002	Oct 02, 2025	Oct CDFR	
	AT		2%	A217052	002	Oct 02, 2025	Sep NEWA	
>D>	AT		4%	A217052	003	Oct 02, 2025	Oct CDFR	
	AT		4%	A217052	003	Oct 02, 2025	Sep NEWA	
>D>	AT	RISING	1%	A204398	001	Sep 27, 2017	Oct CDFR	
>D>	AT		2%	A204398	002	Sep 27, 2017	Oct CDFR	
>D>	AT		4%	A204398	003	Sep 27, 2017	Oct CDFR	
>D>	AT	SOMERSET THERAPS LLC	1%	A210384	001	Nov 25, 2019	Oct CDFR	
>D>	AT		2%	A210384	002	Nov 25, 2019	Oct CDFR	
>D>	AT		4%	A210384	003	Nov 25, 2019	Oct CDFR	
>D>		QLOSI						
>D>		+! ORASIS PHARMS	0.4%	N217836	001	Oct 17, 2023	Oct CDFR	
>D>		VUITY						
>D>	AB	+! ABBVIE	1.25%	N214028	001	Oct 28, 2021	Oct CDFR	
	AB	+!	1.25%	N214028	001	Oct 28, 2021	Apr CFTG	
>A>		SOLUTION/DROPS;OPHTHALMIC						
>A>		ISOPTO CARPINE						
>A>	AT	+! SANDOZ	1%	N200890	001	Jun 22, 2010	Oct CDFR	
>A>	AT	+!	2%	N200890	002	Jun 22, 2010	Oct CDFR	
>A>	AT	+!	4%	N200890	003	Jun 22, 2010	Oct CDFR	
>A>		PILOCARPINE HYDROCHLORIDE						
>A>	AT	AMNEAL	1%	A214193	001	Sep 21, 2020	Oct CDFR	
>A>	AB		1.25%	A217733	001	Apr 28, 2025	Oct CDFR	
>A>	AT		2%	A214193	002	Sep 21, 2020	Oct CDFR	
>A>	AT		4%	A214193	003	Sep 21, 2020	Oct CDFR	
>A>	AT	FDC LTD	1%	A217052	001	Oct 02, 2025	Oct CDFR	
>A>	AT		2%	A217052	002	Oct 02, 2025	Oct CDFR	
>A>	AT		4%	A217052	003	Oct 02, 2025	Oct CDFR	
>A>	AT	RISING	1%	A204398	001	Sep 27, 2017	Oct CDFR	
>A>	AT		2%	A204398	002	Sep 27, 2017	Oct CDFR	
>A>	AT		4%	A204398	003	Sep 27, 2017	Oct CDFR	
>A>	AT	SOMERSET THERAPS LLC	1%	A210384	001	Nov 25, 2019	Oct CDFR	
>A>	AT		2%	A210384	002	Nov 25, 2019	Oct CDFR	
>A>	AT		4%	A210384	003	Nov 25, 2019	Oct CDFR	
>A>		QLOSI						
>A>		+! ORASIS PHARMS	0.4%	N217836	001	Oct 17, 2023	Oct CDFR	
>A>		VUITY						
>A>	AB	+! ABBVIE	1.25%	N214028	001	Oct 28, 2021	Oct CDFR	

PINDOLOL

	TABLET;ORAL						
	PINDOLOL						
AB	MPP PHARMA	5MG	A205415	001	Jan 13, 2016	May CAHN	
AB		10MG	A205415	002	Jan 13, 2016	May CAHN	

PIOGLITAZONE HYDROCHLORIDE

	TABLET;ORAL						
	PIOGLITAZONE HYDROCHLORIDE						
	@ AVIV PHARMA	EQ 15MG BASE	A078472	001	Feb 13, 2013	May CAHN	
	@	EQ 30MG BASE	A078472	002	Feb 13, 2013	May CAHN	
	@	EQ 45MG BASE	A078472	003	Feb 13, 2013	May CAHN	

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	MILLA PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Sep	CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Sep	CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Sep	CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Sep	CAHN
AP		EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Sep	CAHN

POWDER;INTRAVENOUS

PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

+!	B BRAUN MEDICAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N206056	001	Apr 03, 2025	Apr	NEWA
+!		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N206056	002	Apr 03, 2025	Apr	NEWA
+!		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N206056	003	Apr 03, 2025	Apr	NEWA

PIRFENIDONE

TABLET;ORAL

PIRFENIDONE

AB	AUROBINDO PHARMA	267MG	A212596	001	Aug 11, 2025	Aug	NEWA
AB		801MG	A212596	002	Aug 11, 2025	Aug	NEWA

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB	SOLIS PHARMS	10MG	A074118	002	Jun 15, 1993	Apr	CAHN
AB		20MG	A074118	001	Jun 15, 1993	Apr	CAHN

PITOLISANT HYDROCHLORIDE

TABLET;ORAL

WAKIX

+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Feb	CAHN
+!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Feb	CAHN

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

PLERIXAFOR

AP	HETERO LABS LTD VI	24MG/1.2ML (20MG/ML)	A217560	001	Jun 16, 2025	Jun	NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

@	SOLIS PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017	Apr	CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

@	QUAGEN	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Sep	CAHN
@		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Sep	CAHN
@		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Sep	CAHN
@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Sep	CAHN
@		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Sep	CAHN

COLYTE WITH FLAVOR PACKS

@	QUAGEN	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Sep	CAHN

COLYTE-FLAVORED

@	QUAGEN	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Sep	CAHN
@		240GM/BOT;2.98GM/BOT;6.72	N018983	009	Nov 14, 1991	Sep	CAHN

FOR SOLUTION;ORAL
COLYTE-FLAVORED

				GM/BOT;5.84GM/BOT;22.72GM/BOT				

POLYMYXIN B SULFATE

INJECTABLE;INJECTION
POLYMYXIN B SULFATE

	@		ADRASTEA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Jun DISC
	@		PHARMOBEDIENT	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Sep CAHN

POMALIDOMIDE

CAPSULE;ORAL
POMALIDOMIDE

	@		APOTEX	1MG	A210164	001	Jun 11, 2024	Jan DISC
	@			2MG	A210164	002	Jun 11, 2024	Jan DISC
	@			3MG	A210164	003	Jun 11, 2024	Jan DISC
	@			4MG	A210164	004	Jun 11, 2024	Jan DISC
	@		HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Apr DISC
	@			2MG	A210236	002	Sep 26, 2024	Apr DISC
	@			3MG	A210236	003	Sep 26, 2024	Apr DISC
	@			4MG	A210236	004	Sep 26, 2024	Apr DISC

POMALYST

	+		BRISTOL	1MG	N204026	001	Feb 08, 2013	Apr CTEC
	+			2MG	N204026	002	Feb 08, 2013	Apr CTEC
	+			3MG	N204026	003	Feb 08, 2013	Apr CTEC
	+!			4MG	N204026	004	Feb 08, 2013	Apr CTEC

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL
POSACONAZOLE

AB			MSN	100MG	A218434	001	Feb 24, 2025	Feb NEWA
AB			QILU PHARM HAINAN	100MG	A217720	001	Apr 23, 2025	Apr NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
KLOR-CON

>D>	AB		UPSHER SMITH LABS	8MEQ	A203106	001	Jul 10, 2015	Oct DISC
>A>		@		8MEQ	A203106	001	Jul 10, 2015	Oct DISC
>D>	AB			10MEQ	A203106	002	Jul 10, 2015	Oct DISC
>A>		@		10MEQ	A203106	002	Jul 10, 2015	Oct DISC

FOR SOLUTION;ORAL
POTASSIUM CHLORIDE

	AA		AJENAT PHARMS	20MEQ	A212183	001	May 06, 2019	Jan CAHN
	AA		ANDA REPOSITORY	20MEQ	A219009	001	Jul 11, 2025	Sep CAHN
	AA	+!	GENUS	20MEQ	N208019	001	Aug 19, 2015	Jan CHRS
		@ +		40MEQ	N208019	003	Aug 25, 2023	Jan DISC
	AA		GUARDIAN DRUG	20MEQ	A219009	001	Jul 11, 2025	Jul NEWA

INJECTABLE;INJECTION
POTASSIUM CHLORIDE

	AP		NEXUS	2MEQ/ML	A217704	001	Aug 14, 2023	Mar CAHN

SOLUTION;ORAL
POTASSIUM CHLORIDE

	AA		AJENAT PHARMS	20MEQ/15ML	A216156	001	Mar 07, 2023	Jan CAHN
	AA			40MEQ/15ML	A216156	002	Mar 07, 2023	Jan CAHN
	AA		ASCENT PHARMS INC	20MEQ/15ML	A211992	001	Apr 09, 2025	Mar NEWA
	AA			40MEQ/15ML	A211992	002	Apr 09, 2025	Mar NEWA
	AA		MACLEODS PHARMS LTD	20MEQ/15ML	A218733	001	Sep 10, 2025	Aug NEWA
	AA			40MEQ/15ML	A218733	002	Sep 10, 2025	Aug NEWA
	AA		TARO	20MEQ/15ML	A218960	001	Jul 22, 2025	Jul NEWA

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

>D>	AB1		AMNEAL	10MEQ	A212861	001	May 08, 2020	Oct DISC
>A>		@		10MEQ	A212861	001	May 08, 2020	Oct DISC
>D>	AB1			20MEQ	A212861	003	May 08, 2020	Oct DISC
>A>		@		20MEQ	A212861	003	May 08, 2020	Oct DISC
	AB1		GUANGZHOU NOVAKEN	10MEQ	A214395	001	Jan 28, 2021	Apr CAHN
	AB1			20MEQ	A214395	002	Jan 28, 2021	Apr CAHN
	AB2		NORVIUM BIOSCIENCE	8MEQ	A204662	001	Aug 21, 2014	May CAHN
	AB2			10MEQ	A204662	002	Aug 21, 2014	May CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		OTSUKA ICU MEDCL	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	May CAHN

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES

AP		CIPLA	1.18GM/5ML(236MG/ML); 1.12GM/5ML(224MG/ML)	A217892	001	Jan 24, 2025	Jan NEWA
AP			3.54GM/15ML(236MG/ML); 3.36GM/15ML(224MG/ML)	A217892	002	Jan 24, 2025	Jan NEWA
AP			11.8GM/50ML(236MG/ML); 11.2GM/50ML(224MG/ML)	A217892	003	Jan 24, 2025	Jan NEWA
AP		HOSPIRA	3.54GM/15ML (236MG/ML);3.36GM/15ML	A217459	001	Sep 11, 2025	Sep NEWA

POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE

	+!	FRESENIUS KABI USA	1.18GM/100ML(11.8MG/ML); 1.12GM/100ML(11.2MG/ML)	N212832	004	May 09, 2025	May NEWA
	+!		1.18GM/250ML(4.72MG/ML); 1.12GM/250ML(4.48MG/ML)	N212832	005	May 09, 2025	May NEWA

PRALATREXATE

SOLUTION;INTRAVENOUS

FOLOTYN

AP	+	ACROTECH BIOPHARMA	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Feb CFTG
AP	+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Feb CFTG

PRALATREXATE

AP		DR REDDYS	20MG/ML (20MG/ML)	A206183	001	Mar 10, 2025	Feb NFTG
AP			40MG/2ML (20MG/ML)	A206183	002	Mar 10, 2025	Feb NFTG

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

	@	AVIV PHARMA	0.125MG	A091450	001	Oct 08, 2010	May CAHN
	@		0.25MG	A091450	002	Oct 08, 2010	May CAHN
	@		0.5MG	A091450	003	Oct 08, 2010	May CAHN
	@		1MG	A091450	004	Oct 08, 2010	May CAHN
	@		1.5MG	A091450	005	Oct 08, 2010	May CAHN
AB		PHARMOBEDIENT	0.125MG	A090151	001	Apr 30, 2012	Aug CAHN
AB			0.25MG	A090151	002	Apr 30, 2012	Aug CAHN
AB			0.5MG	A090151	003	Apr 30, 2012	Aug CAHN
AB			0.75MG	A090151	006	Apr 30, 2012	Aug CAHN
AB			1MG	A090151	004	Apr 30, 2012	Aug CAHN
AB			1.5MG	A090151	005	Apr 30, 2012	Aug CAHN

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

>D>	+	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Oct DISC
>A>	@ +		EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Oct DISC
>D>	+!		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Oct DISC
>A>	@ +		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Oct DISC

PREDNISOLONE

SOLUTION;ORAL

PREDNISOLONE

AA	!	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Jun CDFR
	@	HIKMA	15MG/5ML	A040401	001	Feb 27, 2003	Jun CDFR
	@	IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999	Jun CDFR
AA		LANNETT CO INC	15MG/5ML	A040775	001	Sep 21, 2007	Jun CDFR
	@	NESHER PHARMS	15MG/5ML	A040364	001	Apr 10, 2002	Jun CDFR
	@	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	Jun CDFR
AA			15MG/5ML	A040571	001	Aug 25, 2005	Jun CDFR
	@	PHARMOBEDIENT CNSLTG	15MG/5ML	A040313	001	Sep 10, 2003	Jun CDFR
	@	TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000	Jun CDFR
AA		TP ANDA HOLDINGS	15MG/5ML	A219509	001	Jun 23, 2025	Aug CAHN
AA		TULEX PHARMS INC	15MG/5ML	A219509	001	Jun 23, 2025	Jun NEWA
	@	WE PHARMS	15MG/5ML	A040192	001	May 28, 1998	Jun CDFR

		SOLUTION;ORAL						
		PRELONE						
AA		TEVA	15MG/5ML	A089081	001	Feb 04, 1986	Jun	CDFR
		PREDNISOLONE ACETATE						
		SUSPENSION;ORAL						
		FLO-PRED						
	@	SUN PHARMA CANADA	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008	Aug	CAHN
	@		EQ 15MG BASE/5ML	N022067	002	Jan 17, 2008	Aug	CAHN
		SUSPENSION/DROPS;OPHTHALMIC						
		PREDNISOLONE ACETATE						
AB		AMNEAL	1%	A218256	001	Jun 11, 2025	May	NEWA
		PREDNISONE						
		TABLET;ORAL						
		PREDNISONE						
	@	AIPING PHARM INC	5MG	A080336	002		Jan	CAHN
AB	+!	HIKMA	1MG	A080352	002	Apr 22, 1982	Apr	CMS1
AB	+!		2.5MG	A080352	003	Apr 22, 1982	Apr	CMS1
AB	+!		10MG	A080352	004		Apr	CMS1
AB	+!		20MG	A080352	005		Apr	CMS1
AB	+!		50MG	A080352	006		Apr	CMS1
AB		MYLAN	5MG	A083677	002		Aug	CMS1
AB			10MG	A083677	003	Dec 04, 1985	Aug	CMS1
AB		POINTVIEW HLDINGS	5MG	A212629	001	Dec 05, 2023	Apr	CAHN
AB			10MG	A212629	002	Dec 05, 2023	Apr	CAHN
AB			20MG	A212629	003	Dec 05, 2023	Apr	CAHN
		TABLET, DELAYED RELEASE;ORAL						
		PREDNISONE						
	!	DR REDDYS	1MG	A219477	001	Oct 01, 2025	Sep	NEWA
			2MG	A219477	002	Oct 01, 2025	Sep	NEWA
		PREGABALIN						
		CAPSULE;ORAL						
		PREGABALIN						
	@	ACTAVIS ELIZABETH	25MG	A091025	001	Jul 09, 2020	Apr	DISC
	@		50MG	A091025	002	Jul 09, 2020	Apr	DISC
	@		75MG	A091025	003	Jul 09, 2020	Apr	DISC
	@		100MG	A091025	004	Jul 09, 2020	Apr	DISC
	@		150MG	A091025	005	Jul 09, 2020	Apr	DISC
	@		200MG	A091025	006	Jul 09, 2020	Apr	DISC
	@		225MG	A091025	007	Jul 09, 2020	Apr	DISC
	@		300MG	A091025	008	Jul 09, 2020	Apr	DISC
	@	APOTEX	25MG	A211685	001	Jul 07, 2021	Apr	DISC
	@		50MG	A211685	002	Jul 07, 2021	Apr	DISC
	@		75MG	A211685	003	Jul 07, 2021	Apr	DISC
	@		100MG	A211685	004	Jul 07, 2021	Apr	DISC
	@		150MG	A211685	005	Jul 07, 2021	Apr	DISC
	@		200MG	A211685	006	Jul 07, 2021	Apr	DISC
	@		225MG	A211685	007	Jul 07, 2021	Apr	DISC
	@		300MG	A211685	008	Jul 07, 2021	Apr	DISC
>A> AB		ESKAYEF	25MG	A212988	001	Mar 08, 2022	Oct	CAHN
>A> AB			50MG	A212988	002	Mar 08, 2022	Oct	CAHN
>A> AB			75MG	A212988	003	Mar 08, 2022	Oct	CAHN
>A> AB			100MG	A212988	004	Mar 08, 2022	Oct	CAHN
>A> AB			150MG	A212988	005	Mar 08, 2022	Oct	CAHN
>A> AB			200MG	A212988	006	Mar 08, 2022	Oct	CAHN
>A> AB			225MG	A212988	007	Mar 08, 2022	Oct	CAHN
>A> AB			300MG	A212988	008	Mar 08, 2022	Oct	CAHN
AB		HLTHCARE	25MG	A091222	001	Feb 21, 2025	Feb	NEWA
AB			50MG	A091222	002	Feb 21, 2025	Feb	NEWA
AB			75MG	A091222	003	Feb 21, 2025	Feb	NEWA
AB			100MG	A091222	004	Feb 21, 2025	Feb	NEWA
AB			150MG	A091222	005	Feb 21, 2025	Feb	NEWA
AB			200MG	A091222	006	Feb 21, 2025	Feb	NEWA
AB			225MG	A091222	007	Feb 21, 2025	Feb	NEWA
AB			300MG	A091222	008	Feb 21, 2025	Feb	NEWA
AB		JUBILANT GENERICS	25MG	A209530	001	May 20, 2025	May	NEWA
AB			50MG	A209530	002	May 20, 2025	May	NEWA
AB			75MG	A209530	003	May 20, 2025	May	NEWA
AB			100MG	A209530	004	May 20, 2025	May	NEWA
AB			150MG	A209530	005	May 20, 2025	May	NEWA
AB			200MG	A209530	006	May 20, 2025	May	NEWA

CAPSULE;ORAL
PREGABALIN

AB			225MG	A209530	007	May 20, 2025	May NEWA
AB			300MG	A209530	008	May 20, 2025	May NEWA
	@	MACLEODS PHARMS LTD	25MG	A205924	001	Nov 12, 2024	Jun DISC
	@		50MG	A205924	002	Nov 12, 2024	Jun DISC
	@		75MG	A205924	003	Nov 12, 2024	Jun DISC
	@		100MG	A205924	004	Nov 12, 2024	Jun DISC
	@		150MG	A205924	005	Nov 12, 2024	Jun DISC
	@		200MG	A205924	006	Nov 12, 2024	Jun DISC
	@		225MG	A205924	007	Nov 12, 2024	Jun DISC
	@		300MG	A205924	008	Nov 12, 2024	Jun DISC
AB		PHARMOBEDIENT	25MG	A091222	001	Feb 21, 2025	Sep CAHN
AB			50MG	A091222	002	Feb 21, 2025	Sep CAHN
AB			75MG	A091222	003	Feb 21, 2025	Sep CAHN
AB			100MG	A091222	004	Feb 21, 2025	Sep CAHN
AB			150MG	A091222	005	Feb 21, 2025	Sep CAHN
AB			200MG	A091222	006	Feb 21, 2025	Sep CAHN
AB			225MG	A091222	007	Feb 21, 2025	Sep CAHN
AB			300MG	A091222	008	Feb 21, 2025	Sep CAHN
AB		REGCON HOLDINGS	25MG	A208113	001	May 17, 2024	Sep CAHN
AB			50MG	A208113	002	May 17, 2024	Sep CAHN
AB			75MG	A208113	004	May 17, 2024	Sep CAHN
AB			100MG	A208113	005	May 17, 2024	Sep CAHN
AB			150MG	A208113	003	May 17, 2024	Sep CAHN
AB			200MG	A208113	006	May 17, 2024	Sep CAHN
AB			225MG	A208113	007	May 17, 2024	Sep CAHN
AB			300MG	A208113	008	May 17, 2024	Sep CAHN
AB		RENATA	50MG	A210585	001	Dec 26, 2019	Aug CAHN
AB			75MG	A210585	002	Dec 26, 2019	Aug CAHN
AB			100MG	A210585	003	Dec 26, 2019	Aug CAHN
AB			150MG	A210585	004	Dec 26, 2019	Aug CAHN
AB			200MG	A210585	005	Dec 26, 2019	Aug CAHN
AB			300MG	A210585	006	Dec 26, 2019	Aug CAHN
AB		SOMERSET THERAPS LLC	50MG	A210585	001	Dec 26, 2019	Sep CAHN
AB			75MG	A210585	002	Dec 26, 2019	Sep CAHN
AB			100MG	A210585	003	Dec 26, 2019	Sep CAHN
AB			150MG	A210585	004	Dec 26, 2019	Sep CAHN
AB			200MG	A210585	005	Dec 26, 2019	Sep CAHN
AB			300MG	A210585	006	Dec 26, 2019	Sep CAHN
AB		TORRENT	25MG	A206942	001	Feb 21, 2025	Feb NEWA
AB			50MG	A206942	002	Feb 21, 2025	Feb NEWA
AB			75MG	A206942	003	Feb 21, 2025	Feb NEWA
AB			100MG	A206942	004	Feb 21, 2025	Feb NEWA
AB			150MG	A206942	005	Feb 21, 2025	Feb NEWA
AB			200MG	A206942	006	Feb 21, 2025	Feb NEWA
AB			225MG	A206942	007	Feb 21, 2025	Feb NEWA
AB			300MG	A206942	008	Feb 21, 2025	Feb NEWA
>D> AB		WESTMINSTER PHARMS	25MG	A212988	001	Mar 08, 2022	Oct CAHN
AB			25MG	A212988	001	Mar 08, 2022	Aug CAHN
>D> AB			50MG	A212988	002	Mar 08, 2022	Oct CAHN
AB			50MG	A212988	002	Mar 08, 2022	Aug CAHN
>D> AB			75MG	A212988	003	Mar 08, 2022	Oct CAHN
AB			75MG	A212988	003	Mar 08, 2022	Aug CAHN
>D> AB			100MG	A212988	004	Mar 08, 2022	Oct CAHN
AB			100MG	A212988	004	Mar 08, 2022	Aug CAHN
>D> AB			150MG	A212988	005	Mar 08, 2022	Oct CAHN
AB			150MG	A212988	005	Mar 08, 2022	Aug CAHN
>D> AB			200MG	A212988	006	Mar 08, 2022	Oct CAHN
AB			200MG	A212988	006	Mar 08, 2022	Aug CAHN
>D> AB			225MG	A212988	007	Mar 08, 2022	Oct CAHN
AB			225MG	A212988	007	Mar 08, 2022	Aug CAHN
>D> AB			300MG	A212988	008	Mar 08, 2022	Oct CAHN
AB			300MG	A212988	008	Mar 08, 2022	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL
PREGABALIN

AB		AIPING PHARM INC	330MG	A217857	001	Jan 28, 2025	Sep CAHN
	@	ALVOGEN	82.5MG	A211593	001	Apr 13, 2021	Feb DISC
	@		165MG	A211593	002	Apr 13, 2021	Feb DISC
	@		330MG	A211593	003	Apr 13, 2021	Feb DISC
	@	APOTEX	165MG	A213313	001	Apr 13, 2021	Jan DISC
	@		330MG	A213313	002	Apr 13, 2021	Jan DISC
AB		HQ PHARMA	330MG	A217857	001	Jan 28, 2025	Jan NEWA

PRIMIDONE

TABLET;ORAL

PRIMIDONE

	@		CHARTWELL RX	50MG	A040862	001	Oct 03, 2008	Apr CAHN
	@			250MG	A040862	002	Oct 03, 2008	Apr CAHN

PROBENECID; SULOPENEM ETZADROXIL

TABLET;ORAL

ORLYNVAH

>D>	@	+	ITERUM THERAP	500MG;500MG	N213972	001	Oct 25, 2024	Oct CMFD
>A>		+!		500MG;500MG	N213972	001	Oct 25, 2024	Oct CMFD
	@	+		500MG;500MG	N213972	001	Oct 25, 2024	Apr DISC

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP			CAPLIN	100MG/ML	A218674	001	Feb 04, 2025	Jan NEWA
AP				500MG/ML	A218674	002	Feb 04, 2025	Jan NEWA

PROCHLORPERAZINE

SUPPOSITORY;RECTAL

COMPAZINE

	@	+	GLAXOSMITHKLINE	2.5MG	N011127	003		Mar CRLD
	@	+		5MG	N011127	001		Mar CMS1
	@	+		5MG	N011127	001		Mar CRLD
	@	+		25MG	N011127	002		Mar CMS1
	@	+		25MG	N011127	002		Mar CRLD

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

	@		NEXUS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Apr DISC

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

AB			AUROBINDO PHARMA LTD	EQ 5MG BASE	A218734	001	Sep 08, 2025	Aug NEWA
AB				EQ 10MG BASE	A218734	002	Sep 08, 2025	Aug NEWA
AB			CEROVENE INC	EQ 5MG BASE	A217847	001	May 19, 2025	May NEWA
AB				EQ 10MG BASE	A217847	002	May 19, 2025	May NEWA
AB			DR REDDYS LABS SA	EQ 5MG BASE	A217847	001	May 19, 2025	Sep CAHN
AB				EQ 10MG BASE	A217847	002	May 19, 2025	Sep CAHN

PROGESTERONE

CAPSULE;ORAL

PROMETRIUM

AB		+	ACERTIS PHARMS	100MG	N019781	001	May 14, 1998	May CAHN
AB		+!		200MG	N019781	002	Oct 15, 1999	May CAHN
	@			300MG	N019781	003	Oct 15, 1999	May CAHN

INSERT;VAGINAL

ENDOMETRIN

AB		+!	FERRING	100MG	N022057	001	Jun 21, 2007	Sep CFTG

PROGESTERONE

AB			XIROMED	100MG	A218391	001	Sep 19, 2025	Sep NFTG

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL

PROMETHAZINE HYDROCHLORIDE

	@		TARO	12.5MG	A040603	001	Oct 26, 2006	Aug DISC
	@			25MG	A040603	002	Oct 26, 2006	Aug DISC

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

AA			COSETTE	6.25MG/5ML	A091675	001	Jun 28, 2012	Jun CAHN
AA			PHARM ASSOC	6.25MG/5ML	A040643	001	Apr 26, 2006	Aug CMFD
AA			STRIDES PHARMA	6.25MG/5ML	A040891	001	Mar 13, 2009	Apr CAHN
	@		TARO	6.25MG/5ML	A040718	001	Apr 04, 2007	Aug DISC

PROMETHAZINE PLAIN

AA		+!	XTTRIUM LABS INC	6.25MG/5ML	A087953	001	Nov 15, 1982	Feb CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PROPARACAINE HYDROCHLORIDE

	AT		MANKIND PHARMA	0.5%	A219136	001	May 21, 2025	May NEWA
>A>	AT		MICRO LABS	0.5%	A219294	001	Oct 20, 2025	Oct NEWA

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPRANOLOL HYDROCHLORIDE

	AB		ANDA REPOSITORY	60MG	A078065	001	Jan 26, 2007	Sep CAHN
	AB			80MG	A078065	002	Jan 26, 2007	Sep CAHN
	AB			120MG	A078065	003	Jan 26, 2007	Sep CAHN
	AB			160MG	A078065	004	Jan 26, 2007	Sep CAHN

SOLUTION;ORAL

HEMANGEOL

>A>		+!	PIERRE	4.28MG/ML	N205410	001	Mar 14, 2014	Oct CAHN
>D>		+!	PIERRE FABRE	4.28MG/ML	N205410	001	Mar 14, 2014	Oct CAHN

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

>D>	AB		NORTHSTAR HLTHCARE	10MG	A078213	001	Jan 10, 2008	Oct DISC
>A>		@		10MG	A078213	001	Jan 10, 2008	Oct DISC
>D>	AB			20MG	A078213	002	Jan 10, 2008	Oct DISC
>A>		@		20MG	A078213	002	Jan 10, 2008	Oct DISC
>D>	AB			40MG	A078213	003	Jan 10, 2008	Oct DISC
>A>		@		40MG	A078213	003	Jan 10, 2008	Oct DISC
>D>	AB			60MG	A078213	004	Jan 10, 2008	Oct DISC
>A>		@		60MG	A078213	004	Jan 10, 2008	Oct DISC
>D>	AB			80MG	A078213	005	Jan 10, 2008	Oct DISC
>A>		@		80MG	A078213	005	Jan 10, 2008	Oct DISC

PROTAMINE SULFATE

POWDER;INTRAVENOUS

PROTAMINE SULFATE

		@	PHARMACIA AND UPJOHN	50MG/VIAL	N007413	001		Aug CDFR
		@		250MG/VIAL	N007413	002	Aug 02, 1984	Aug CDFR

SOLUTION;INTRAVENOUS

PROTAMINE SULFATE

		!	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987	Aug CDFR
		!		50MG/5ML (10MG/ML)	A089454	001	Apr 07, 1987	Aug CPOT
		!		250MG/25ML (10MG/ML)	A089454	002	Apr 07, 1987	Aug NEWA
		@	HIKMA	10MG/ML	A089474	001	Nov 05, 1986	Aug CDFR
		@		10MG/ML	A089475	001	Nov 05, 1986	Aug CDFR
		@		50MG/5ML (10MG/ML)	A089474	001	Nov 05, 1986	Aug CPOT
		@		50MG/5ML (10MG/ML)	A089475	002	Jun 07, 1988	Aug NEWA
		@		250MG/25ML (10MG/ML)	A089475	001	Nov 05, 1986	Aug CPOT
		@ +	LILLY	10MG/ML	N006460	002		Aug CDFR
		@ +		50MG/5ML (10MG/ML)	N006460	002		Aug CPOT
		@ +		250MG/25ML (10MG/ML)	N006460	003		Aug DISC
		+		250MG/25ML (10MG/ML)	N006460	003		Aug NEWA

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

PROTRIPTYLINE HYDROCHLORIDE

	AB	!	EPIC PHARMA LLC	10MG	A202220	002	Nov 19, 2012	Apr CHRS
		@	HIKMA	5MG	A078913	001	Sep 16, 2008	Apr DISC
		@		10MG	A078913	002	Sep 16, 2008	Apr DISC

PRUCALOPRIDE SUCCINATE

TABLET;ORAL

PRUCALOPRIDE SUCCINATE

	AB		AGGREGA	EQ 1MG BASE	A219193	001	Jun 24, 2025	Jun NEWA
	AB			EQ 2MG BASE	A219193	002	Jun 24, 2025	Jun NEWA
	AB		ALKEM LABS LTD	EQ 1MG BASE	A218295	001	Jun 24, 2025	Jun NEWA
	AB			EQ 2MG BASE	A218295	002	Jun 24, 2025	Jun NEWA
	AB		AMNEAL	EQ 1MG BASE	A218812	001	Jun 24, 2025	Sep CAHN
	AB			EQ 2MG BASE	A218812	002	Jun 24, 2025	Sep CAHN
	AB		ANNORA PHARMA	EQ 1MG BASE	A219160	001	Jun 24, 2025	Jun NEWA
	AB			EQ 2MG BASE	A219160	002	Jun 24, 2025	Jun NEWA
	AB		APOTEX	EQ 1MG BASE	A218977	001	Jun 24, 2025	Jun NEWA
	AB			EQ 2MG BASE	A218977	002	Jun 24, 2025	Jun NEWA
	AB		APPCO	EQ 1MG BASE	A218963	001	Jun 24, 2025	Jun NEWA

TABLET;ORAL
PRUCALOPRIDE SUCCINATE

AB		EQ 2MG BASE	A218963	002	Jun 24, 2025	Jun	NEWA
AB	H2-PHARMA	EQ 1MG BASE	A219216	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A219216	002	Jun 24, 2025	Jun	NEWA
AB	HIKMA	EQ 1MG BASE	A217662	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A217662	002	Jun 24, 2025	Jun	NEWA
AB	LUPIN LTD	EQ 1MG BASE	A218847	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A218847	002	Jun 24, 2025	Jun	NEWA
AB	MSN	EQ 1MG BASE	A218177	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A218177	002	Jun 24, 2025	Jun	NEWA
AB	SKG PHARMA	EQ 1MG BASE	A218812	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A218812	002	Jun 24, 2025	Jun	NEWA
AB	SOMERSET THERAP	EQ 1MG BASE	A219078	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A219078	002	Jun 24, 2025	Jun	NEWA
AB	SPECGX LLC	EQ 1MG BASE	A219193	001	Jun 24, 2025	Aug	CAHN
AB		EQ 2MG BASE	A219193	002	Jun 24, 2025	Aug	CAHN
@	TORRENT	EQ 1MG BASE	A218778	001	Jun 24, 2025	Jul	DISC
AB		EQ 1MG BASE	A218778	001	Jun 24, 2025	Jun	NEWA
@		EQ 2MG BASE	A218778	002	Jun 24, 2025	Jul	DISC
AB		EQ 2MG BASE	A218778	002	Jun 24, 2025	Jun	NEWA
AB	ZENARA	EQ 1MG BASE	A218795	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A218795	002	Jun 24, 2025	Jun	NEWA
AB	ZYDUS LIFESCIENCES	EQ 1MG BASE	A218056	001	Aug 07, 2025	Sep	CAHN
AB		EQ 2MG BASE	A218056	002	Aug 07, 2025	Sep	CAHN
AB	ZYDUS PHARMS	EQ 1MG BASE	A218056	001	Aug 07, 2025	Aug	NEWA
AB		EQ 2MG BASE	A218056	002	Aug 07, 2025	Aug	NEWA

PYRIMETHAMINE

TABLET;ORAL
PYRIMETHAMINE

@	ALVOGEN	25MG	A211271	001	Jul 27, 2021	May	DISC

QUETIAPINE FUMARATE

TABLET;ORAL
QUETIAPINE FUMARATE

AB	GRAVITI PHARMS	EQ 25MG BASE	A077380	001	Mar 27, 2012	Feb	CAHN
AB		EQ 50MG BASE	A077380	002	Mar 27, 2012	Feb	CAHN
AB		EQ 100MG BASE	A077380	003	Mar 27, 2012	Feb	CAHN
AB		EQ 150MG BASE	A077380	004	Mar 27, 2012	Feb	CAHN
AB		EQ 200MG BASE	A077380	005	Mar 27, 2012	Feb	CAHN
AB		EQ 300MG BASE	A077380	006	Mar 27, 2012	Feb	CAHN
AB		EQ 400MG BASE	A077380	007	Mar 27, 2012	Feb	CAHN
@	SUN PHARM	EQ 200MG BASE	A201190	004	Mar 27, 2012	Sep	DISC

SEROQUEL

AB	+! CHEPLAPHARM	EQ 25MG BASE	N020639	001	Sep 26, 1997	Mar	CAHN
AB	+	EQ 50MG BASE	N020639	007	Oct 04, 2005	Mar	CAHN
AB	+	EQ 100MG BASE	N020639	002	Sep 26, 1997	Mar	CAHN
@	+	EQ 150MG BASE	N020639	004	Dec 20, 1998	Mar	CAHN
AB	+	EQ 200MG BASE	N020639	003	Sep 26, 1997	Mar	CAHN
AB	+!	EQ 300MG BASE	N020639	005	Jul 26, 2000	Mar	CAHN
AB	+	EQ 400MG BASE	N020639	006	Oct 04, 2005	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL
QUETIAPINE FUMARATE

AB	MEDICAP LABS	EQ 50MG BASE	A202939	001	May 09, 2017	Feb	CAHN
AB		EQ 150MG BASE	A202939	002	May 09, 2017	Feb	CAHN
AB		EQ 200MG BASE	A202939	003	May 09, 2017	Feb	CAHN
AB		EQ 300MG BASE	A202939	004	May 09, 2017	Feb	CAHN
AB		EQ 400MG BASE	A202939	005	May 09, 2017	Feb	CAHN

SEROQUEL XR

AB	+ CHEPLAPHARM	EQ 50MG BASE	N022047	001	May 17, 2007	Mar	CAHN
AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Mar	CAHN
AB	+!	EQ 200MG BASE	N022047	002	May 17, 2007	Mar	CAHN
AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Mar	CAHN
AB	+	EQ 400MG BASE	N022047	004	May 17, 2007	Mar	CAHN

RALTEGRAVIR POTASSIUM

TABLET;ORAL
ISENTRESS

	+! MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Jan	CTEC

ISENTRESS HD

AB	+! MSD SUB MERCK	EQ 600MG BASE	N022145	002	May 26, 2017	Apr	CFTG

TABLET;ORAL
RALTEGRAVIR POTASSIUM

	@	HETERO LABS LTD III	EQ 400MG BASE	A203540	001	Dec 19, 2024	Jan DISC
AB		LUPIN LTD	EQ 600MG BASE	A217990	001	May 06, 2025	Apr NFTG

RAMELTEON

TABLET;ORAL
RAMELTEON

AB		APPCO	8MG	A213815	001	Oct 26, 2020	Mar CAHN
BX		AURO BINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Mar CTEC
BX		I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar CTEC
BX		XIROMED	8MG	A216209	001	Nov 25, 2022	Mar CTEC

RAMIPRIL

CAPSULE;ORAL
ALTACE

	@ +	KING PHARMS LLC	1.25MG	N019901	001	Jan 28, 1991	Jul DISC
	@ +		2.5MG	N019901	002	Jan 28, 1991	Jul DISC
	@ +		5MG	N019901	003	Jan 28, 1991	Jul DISC
	@ +		10MG	N019901	004	Jan 28, 1991	Jul DISC

RAMIPRIL

AB	!	LUPIN	10MG	A077626	004	Jun 09, 2008	Jul CHRS

SOLUTION;ORAL
VOSTALLY

	+!	ROSEMONT PHARMS	1MG/ML	N219757	001	Jul 23, 2025	Jul NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
RANITIDINE HYDROCHLORIDE

	@	APOTEX	EQ 150MG BASE	A074680	001	Sep 12, 1997	Mar DISC
	@		EQ 300MG BASE	A074680	002	Sep 12, 1997	Mar DISC
	@	GLENMARK PHARMS INC	EQ 150MG BASE	A078542	001	Nov 19, 2008	Aug DISC
	@		EQ 300MG BASE	A078542	002	Nov 19, 2008	Aug DISC
	@	MPP PHARMA	EQ 150MG BASE	A203694	001	Nov 30, 2017	Jun CAHN
	@		EQ 300MG BASE	A203694	002	Nov 30, 2017	Jun CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL
RANOLAZINE

AB		ARTHUR GRP	500MG	A212781	001	Mar 23, 2020	Jan CAHN
AB			1GM	A212781	002	Mar 23, 2020	Jan CAHN
AB	!	CADILA	1GM	A210188	002	Aug 19, 2019	Mar CHRS
AB		JUBILANT GENERICS	500MG	A211361	001	Apr 15, 2025	Apr NEWA
AB			1GM	A211361	002	Apr 15, 2025	Apr NEWA
	@	SUN PHARM	500MG	A211707	001	May 28, 2019	Mar DISC
	@		1GM	A211707	002	May 28, 2019	Mar DISC
	@	TORRENT	500MG	A210407	001	Feb 04, 2025	Jun DISC
AB			500MG	A210407	001	Feb 04, 2025	Jan NEWA
	@		1GM	A210407	002	Feb 04, 2025	Jun DISC
AB			1GM	A210407	002	Feb 04, 2025	Jan NEWA

RASAGILINE MESYLATE

TABLET;ORAL
RASAGILINE MESYLATE

	@	CARNEGIE	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Apr CAHN
	@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Apr CAHN
AB		RISING	EQ 0.5MG BASE	A218163	001	Apr 09, 2024	Sep CAHN
AB			EQ 1MG BASE	A218163	002	Apr 09, 2024	Sep CAHN
AB		TORRENT	EQ 0.5MG BASE	A210150	001	May 05, 2025	Apr NEWA
AB			EQ 1MG BASE	A210150	002	May 05, 2025	Apr NEWA

REGORAFENIB

TABLET;ORAL
REGORAFENIB

	@	ACTAVIS LABS FL	40MG	A209728	001	Jan 13, 2025	Jul DISC
AB			40MG	A209728	001	Jan 13, 2025	Jan NFTG

STIVARGA

	+!	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012	Jul CTEC
AB	+!		40MG	N203085	001	Sep 27, 2012	Jan CFTG

RELUGOLIX
TABLET;ORAL
ORGOVYX
+! SUMITOMO PHARMA AM 120MG N214621 001 Dec 18, 2020 Aug CAHN

REMDESIVIR
SOLUTION;INTRAVENOUS
VEKLURY
@ + GILEAD SCIENCES INC 100MG/20ML (5MG/ML) N214787 002 Oct 22, 2020 Jun DISC

REMIBRUTINIB
TABLET;ORAL
RHAPSIDO
+! NOVARTIS 25MG N218436 001 Sep 30, 2025 Sep NEWA

REPAGLINIDE
TABLET;ORAL
REPAGLINIDE
@ QUAGEN 0.5MG A090252 001 Aug 23, 2013 Sep CAHN
@ 1MG A090252 002 Jan 22, 2014 Sep CAHN
@ 2MG A090252 003 Jan 22, 2014 Sep CAHN
@ SUN PHARM INDS INC 1MG A077571 002 Jul 11, 2013 Feb DISC
@ 2MG A077571 003 Jul 11, 2013 Feb DISC

REPOTRECTINIB
CAPSULE;ORAL
AUGTYRO
+! BRISTOL 160MG N218213 002 Jun 11, 2024 Jul CHRS

RIBAVIRIN
FOR SOLUTION;INHALATION
RIBAVIRIN
! NAVINTA LLC 6GM/VIAL A207366 001 Oct 06, 2016 Aug CHRS
6GM/VIAL A207366 001 Oct 06, 2016 Aug CTEC
VIRAZOLE
@ + BAUSCH 6GM/VIAL N018859 001 Dec 31, 1985 Aug DISC

RIBOFLAVIN 5'-PHOSPHATE
SOLUTION/DROPS;OPHTHALMIC
>A> EPIOXA HD/EPIOXA KIT
>A> +! GLAUKOS 0.239%;0.177% N219910 001 Oct 17, 2025 Oct NEWA

RIFAMPIN
CAPSULE;ORAL
RIFADIN
@ + SANOFI AVENTIS US 150MG N050420 002 Apr CMS1

RILPIVIRINE HYDROCHLORIDE
TABLET, FOR SUSPENSION;ORAL
EDURANT PED
+! JANSSEN PRODS EQ 2.5MG BASE N219016 001 Mar 15, 2024 May CMFD

RILUZOLE
TABLET;ORAL
RILUZOLE
AB NORVIUM BIOSCIENCE 50MG A203042 001 Jul 01, 2013 Feb CAHN
@ PHARMOBEDIENT 50MG A203042 001 Jul 01, 2013 Aug DISC

RILZABRUTINIB
TABLET;ORAL
WAYRILZ
+! GENZYME CORP 400MG N219685 001 Aug 29, 2025 Aug NEWA

RISDIPLAM
TABLET;ORAL
EVRYSDI
+! GENENTECH INC 5MG N219285 001 Feb 11, 2025 Feb NEWA

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM

>D>	BX		AUROBINDO PHARMA	150MG	A206768	001	Oct 21, 2016	Oct CTEC
>A>	AB			150MG	A206768	001	Oct 21, 2016	Oct CTEC

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

		@	SUN PHARM	35MG	A203925	001	Jul 09, 2019	Apr DISC

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

RYKINDO

		@ +	SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023	Jul DISC

INJECTABLE;INTRAMUSCULAR

RISPERIDONE

	AB		AMNEAL	12.5MG/VIAL	A218586	001	Sep 02, 2025	Aug NEWA
	AB			25MG/VIAL	A218586	002	Sep 02, 2025	Aug NEWA
	AB			37.5MG/VIAL	A218586	003	Sep 02, 2025	Aug NEWA
	AB			50MG/VIAL	A218586	004	Sep 02, 2025	Aug NEWA
	AB		NANOMI	25MG/VIAL	A211220	001	Sep 02, 2025	Aug NEWA
	AB			37.5MG/VIAL	A211220	002	Sep 02, 2025	Aug NEWA
	AB			50MG/VIAL	A211220	003	Sep 02, 2025	Aug NEWA

SOLUTION;ORAL

RISPERIDONE

>D>		@	ANI PHARMS	1MG/ML	A076440	001	Jan 30, 2009	Oct CMFD
>A>	AA			1MG/ML	A076440	001	Jan 30, 2009	Oct CMFD
	AA		APOZEAL PHARMS	1MG/ML	A078909	001	Jul 29, 2009	Jul CMFD
		@		1MG/ML	A078909	001	Jul 29, 2009	Apr CAHN
		@	LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	Feb DISC
		@	TARO	1MG/ML	A090347	001	Feb 07, 2011	Jul DISC

TABLET;ORAL

RISPERIDONE

		@	APOTEX INC	0.25MG	A077953	001	Sep 15, 2008	Mar DISC
		@		0.5MG	A077953	002	Sep 15, 2008	Mar DISC
		@		1MG	A077953	003	Sep 15, 2008	Mar DISC
		@		2MG	A077953	004	Sep 15, 2008	Mar DISC
		@		3MG	A077953	005	Sep 15, 2008	Mar DISC
		@		4MG	A077953	006	Sep 15, 2008	Mar DISC
	AB		RENATA	0.25MG	A078707	001	Dec 29, 2008	Aug CAHN
	AB			0.5MG	A078707	002	Dec 29, 2008	Aug CAHN
	AB			1MG	A078707	003	Dec 29, 2008	Aug CAHN
	AB			2MG	A078707	004	Dec 29, 2008	Aug CAHN
	AB			3MG	A078707	005	Dec 29, 2008	Aug CAHN
	AB			4MG	A078707	006	Dec 29, 2008	Aug CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

		@	SUN PHARM INDS LTD	0.5MG	A078464	001	Apr 08, 2013	Jul DISC
		@		1MG	A078464	002	Apr 08, 2013	Jul DISC
		@		2MG	A078464	003	Apr 08, 2013	Jul DISC
		@		3MG	A078464	004	Apr 08, 2013	Jul DISC
		@		4MG	A078464	005	Apr 08, 2013	Jul DISC

RITONAVIR

CAPSULE;ORAL

RITONAVIR

			QUAGEN	100MG	A205024	001	Feb 16, 2024	Sep CAHN

RIVAROXABAN

FOR SUSPENSION;ORAL

RIVAROXABAN

	AB		ALKEM LABS LTD	1MG/ML	A218502	001	Jun 26, 2025	Jun NFTG
	AB		LUPIN LTD	1MG/ML	A218195	001	Sep 25, 2025	Sep NEWA

XARELTO

	AB	+!	JANSSEN PHARMS	1MG/ML	N215859	001	Dec 20, 2021	Jun CFTG

TABLET;ORAL

RIVAROXABAN

	AB		AIPING PHARM INC	10MG	A216995	001	May 14, 2025	Sep CAHN
	AB			15MG	A216995	002	May 14, 2025	Sep CAHN
	AB			20MG	A216995	003	May 14, 2025	Sep CAHN
	AB		ALEMBIC	2.5MG	A210301	001	May 14, 2025	May NEWA
	AB			10MG	A210301	002	May 14, 2025	May NFTG

TABLET;ORAL

RIVAROXABAN

	AB			15MG	A210301	003	May 14, 2025	May NFTG
	AB			20MG	A210301	004	May 14, 2025	May NFTG
	AB		APOTEX	2.5MG	A217810	001	May 02, 2025	Apr NEWA
	AB		ASCENT PHARMS INC	2.5MG	A219332	001	May 14, 2025	May NEWA
	AB			10MG	A219332	002	May 14, 2025	May NFTG
	AB			15MG	A219332	003	May 14, 2025	May NFTG
	AB			20MG	A219332	004	May 14, 2025	May NFTG
	AB		AUROBINDO PHARMA LTD	2.5MG	A208544	001	Apr 10, 2025	Apr NEWA
	AB			10MG	A208544	002	May 15, 2025	May NEWA
	AB			15MG	A208544	003	May 15, 2025	May NEWA
	AB			20MG	A208544	004	May 15, 2025	May NEWA
	AB		BIOCON PHARMA	2.5MG	A218107	001	May 14, 2025	May NEWA
	AB			10MG	A218107	002	May 14, 2025	May NFTG
	AB			15MG	A218107	003	May 14, 2025	May NFTG
	AB			20MG	A218107	004	May 14, 2025	May NFTG
	AB		BRECKENRIDGE	10MG	A208220	001	May 15, 2025	May NEWA
	AB			15MG	A208220	002	May 15, 2025	May NEWA
	AB			20MG	A208220	003	May 15, 2025	May NEWA
	AB		CHANGZHOU PHARM	10MG	A216995	001	May 14, 2025	May NFTG
	AB			15MG	A216995	002	May 14, 2025	May NFTG
	AB			20MG	A216995	003	May 14, 2025	May NFTG
	AB		DR REDDYS	2.5MG	A208534	001	May 14, 2025	May NEWA
	AB			10MG	A208534	002	May 14, 2025	May NFTG
	AB			15MG	A208534	003	May 14, 2025	May NFTG
	AB			20MG	A208534	004	May 14, 2025	May NFTG
	AB		INDOCO	2.5MG	A218445	001	Aug 11, 2025	Aug NEWA
	AB			10MG	A218445	002	Aug 11, 2025	Aug NEWA
	AB			15MG	A218445	003	Aug 11, 2025	Aug NEWA
	AB			20MG	A218445	004	Aug 11, 2025	Aug NEWA
		@	INVAGEN PHARMS	10MG	A208543	001	May 14, 2025	Aug DISC
	AB			10MG	A208543	001	May 14, 2025	May NFTG
		@		15MG	A208543	002	May 14, 2025	Aug DISC
	AB			15MG	A208543	002	May 14, 2025	May NFTG
		@		20MG	A208543	003	May 14, 2025	Aug DISC
	AB			20MG	A208543	003	May 14, 2025	May NFTG
	AB		LUPIN LTD	2.5MG	A208555	001	Mar 03, 2025	Feb NFTG
	AB			10MG	A208555	002	May 14, 2025	May NFTG
	AB			15MG	A208555	003	May 14, 2025	May NFTG
	AB			20MG	A208555	004	May 14, 2025	May NFTG
	AB		MACLEODS PHARMS LTD	2.5MG	A213114	001	May 14, 2025	May NEWA
	AB			10MG	A213114	002	May 14, 2025	May NFTG
	AB			15MG	A213114	003	May 14, 2025	May NFTG
	AB			20MG	A213114	004	May 14, 2025	May NFTG
>A>	AB		MSN	2.5MG	A208546	001	Oct 24, 2025	Oct NEWA
>A>	AB			10MG	A208546	002	Oct 24, 2025	Oct NEWA
>A>		@		10MG	A208546	002	Oct 24, 2025	Oct DISC
>A>	AB			15MG	A208546	003	Oct 24, 2025	Oct NEWA
>A>		@		15MG	A208546	003	Oct 24, 2025	Oct DISC
>A>	AB			20MG	A208546	004	Oct 24, 2025	Oct NEWA
>A>		@		20MG	A208546	004	Oct 24, 2025	Oct DISC
	AB		SCIEGEN PHARMS INC	2.5MG	A218117	001	Jul 31, 2025	Jul NEWA
	AB			10MG	A218117	002	Jul 31, 2025	Jul NEWA
	AB			15MG	A218117	003	Jul 31, 2025	Jul NEWA
	AB			20MG	A218117	004	Jul 31, 2025	Jul NEWA
	AB		SUNSHINE	10MG	A213348	001	May 14, 2025	May NFTG
	AB			15MG	A213348	002	May 14, 2025	May NFTG
	AB			20MG	A213348	003	May 14, 2025	May NFTG
	AB		TARO	2.5MG	A208557	001	Mar 03, 2025	Feb NFTG
	AB			10MG	A208557	002	Oct 07, 2025	Sep NEWA
	AB			15MG	A208557	003	Oct 07, 2025	Sep NEWA
	AB			20MG	A208557	004	Oct 07, 2025	Sep NEWA

XARELTO

	AB	+	JANSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018	Feb CFTG
	AB	+		10MG	N022406	001	Jul 01, 2011	May CFTG
	AB	+		15MG	N022406	002	Nov 04, 2011	May CFTG
	AB	+!		20MG	N022406	003	Nov 04, 2011	May CFTG

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

	@	ALVOGEN	4.6MG/24HR	A204403	001	Sep 03, 2015	Mar DISC
	@		9.5MG/24HR	A204403	002	Sep 03, 2015	Mar DISC
	@		13.3MG/24HR	A204403	003	Aug 31, 2015	Mar DISC
AB		YICHANG HUMANWELL	4.6MG/24HR	A215445	001	Sep 23, 2025	Sep NEWA
AB			9.5MG/24HR	A215445	002	Sep 23, 2025	Sep NEWA
AB			13.3MG/24HR	A215445	003	Sep 23, 2025	Sep NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB		NORVIUM BIOSCIENCE	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb CAHN
AB			EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

	@	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun DISC
	@		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP		MANKIND PHARMA	50MG/5ML (10MG/ML)	A219674	001	May 29, 2025	May NEWA
AP			100MG/10ML (10MG/ML)	A219674	002	May 29, 2025	May NEWA
	@	RISING	50MG/5ML (10MG/ML)	A204918	001	Jul 12, 2024	Sep CAHN
	@		100MG/10ML (10MG/ML)	A204918	002	Jul 12, 2024	Sep CAHN

SOLUTION;INTRAVENOUS

ROCURONIUM BROMIDE

	+!	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	N217472	001	Jun 09, 2025	Jun NEWA
	+!		100MG/10ML (10MG/ML)	N217472	002	Jun 09, 2025	Jun NEWA
>A>	+!	STERINOVA INC	50MG/5ML (10MG/ML)	N219108	001	Oct 24, 2025	Oct NEWA

ROFLUMILAST

CREAM;TOPICAL

ZORYVE

>A>	+!	ARCUTIS	0.05%	N215985	003	Oct 04, 2025	Oct NEWA

TABLET;ORAL

ROFLUMILAST

AB		AUROBINDO PHARMA LTD	250MCG	A213298	002	Jan 31, 2025	Jan NEWA
	@	SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023	Feb CAHN
	@		500MCG	A208236	001	Oct 03, 2018	Feb CAHN
	@	TORRENT	250MCG	A208272	002	Oct 18, 2024	Sep DISC

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

	@	AUROBINDO PHARMA USA	EQ 2MG BASE	A200462	001	Oct 15, 2012	Aug CAHN
	@		EQ 3MG BASE	A200462	002	Oct 15, 2012	Aug CAHN
	@		EQ 4MG BASE	A200462	003	Oct 15, 2012	Aug CAHN
	@		EQ 6MG BASE	A200462	004	Oct 15, 2012	Aug CAHN
	@		EQ 8MG BASE	A200462	005	Oct 15, 2012	Aug CAHN
	@		EQ 12MG BASE	A200462	006	Oct 15, 2012	Aug CAHN
>A> AB		ELITE LABS INC	EQ 2MG BASE	A217862	001	Nov 10, 2025	Oct NEWA
>A> AB			EQ 4MG BASE	A217862	002	Nov 10, 2025	Oct NEWA
>A> AB			EQ 6MG BASE	A217862	003	Nov 10, 2025	Oct NEWA
>A> AB			EQ 8MG BASE	A217862	004	Nov 10, 2025	Oct NEWA
>A> AB			EQ 12MG BASE	A217862	005	Nov 10, 2025	Oct NEWA

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		ANTHEA PHARMA	40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Mar NEWA
AP			150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Mar NEWA
AP			200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Mar NEWA
AP		NEOCUBES PHARMA	20MG/10ML (2MG/ML)	A219883	004	Oct 08, 2025	Sep NEWA
AP			40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Sep CAHN
AP			100MG/20ML (5MG/ML)	A219883	005	Oct 08, 2025	Sep NEWA
AP			150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Sep CAHN
AP			200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Sep CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB	+	ASTRAZENECA	EQ 5MG BASE	N021366	002	Aug 12, 2003	Jan	CAHN
AB	+		EQ 10MG BASE	N021366	003	Aug 12, 2003	Jan	CAHN
AB	+		EQ 20MG BASE	N021366	004	Aug 12, 2003	Jan	CAHN
AB	+!		EQ 40MG BASE	N021366	005	Aug 12, 2003	Jan	CAHN

ROSUVASTATIN CALCIUM

	@	MACLEODS PHARMS LTD	EQ 5MG BASE	A207296	001	Nov 06, 2024	Jun	DISC
	@		EQ 10MG BASE	A207296	002	Nov 06, 2024	Jun	DISC
	@		EQ 20MG BASE	A207296	003	Nov 06, 2024	Jun	DISC
	@		EQ 40MG BASE	A207296	004	Nov 06, 2024	Jun	DISC
	@	MANKIND PHARMA	EQ 5MG BASE	A206603	001	May 16, 2025	Sep	DISC
AB			EQ 5MG BASE	A206603	001	May 16, 2025	May	NEWA
	@		EQ 10MG BASE	A206603	002	May 16, 2025	Sep	DISC
AB			EQ 10MG BASE	A206603	002	May 16, 2025	May	NEWA
	@		EQ 20MG BASE	A206603	003	May 16, 2025	Sep	DISC
AB			EQ 20MG BASE	A206603	003	May 16, 2025	May	NEWA
	@		EQ 40MG BASE	A206603	004	May 16, 2025	Sep	DISC
AB			EQ 40MG BASE	A206603	004	May 16, 2025	May	NEWA
AB		RENATA	EQ 5MG BASE	A207062	001	Oct 31, 2016	Aug	CAHN
AB			EQ 10MG BASE	A207062	002	Oct 31, 2016	Aug	CAHN
AB			EQ 20MG BASE	A207062	003	Oct 31, 2016	Aug	CAHN
AB			EQ 40MG BASE	A207062	004	Oct 31, 2016	Aug	CAHN
AB		ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	May	CMFD
AB			EQ 10MG BASE	A206513	002	Mar 01, 2019	May	CMFD
AB			EQ 20MG BASE	A206513	003	Mar 01, 2019	May	CMFD
AB			EQ 40MG BASE	A206513	004	Mar 01, 2019	May	CMFD

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

AB		HIKMA	40MG/ML	A207363	001	Apr 23, 2019	Jun	CAHN
AB		MSN	40MG/ML	A214817	001	Apr 15, 2025	Apr	NEWA

SACUBITRIL; VALSARTAN

TABLET;ORAL

SACUBITRIL AND VALSARTAN

AB		DR REDDYS	24MG;26MG	A213627	001	Jan 13, 2025	Jan	NEWA
AB			49MG;51MG	A213627	002	Jan 13, 2025	Jan	NEWA
AB			97MG;103MG	A213627	003	Jan 13, 2025	Jan	NEWA
AB		HETERO LABS LTD III	24MG;26MG	A213668	001	Jul 17, 2025	Jul	NEWA
AB			49MG;51MG	A213668	002	Jul 17, 2025	Jul	NEWA
AB			97MG;103MG	A213668	003	Jul 17, 2025	Jul	NEWA
AB		LUPIN	24MG;26MG	A213808	001	Jan 08, 2025	Jan	NEWA
AB			49MG;51MG	A213808	002	Jan 08, 2025	Jan	NEWA
AB			97MG;103MG	A213808	003	Jan 08, 2025	Jan	NEWA
AB		MSN	24MG;26MG	A213748	001	Jul 16, 2025	Jul	NEWA
AB			49MG;51MG	A213748	002	Jul 16, 2025	Jul	NEWA
AB			97MG;103MG	A213748	003	Jul 16, 2025	Jul	NEWA
AB		NOVUGEN PHARMA SDN	24MG;26MG	A213611	001	Jul 16, 2025	Jul	NEWA
AB			49MG;51MG	A213611	002	Jul 16, 2025	Jul	NEWA
AB			97MG;103MG	A213611	003	Jul 16, 2025	Jul	NEWA

SAFINAMIDE MESYLATE

TABLET;ORAL

SAFINAMIDE MESYLATE

AB		ZENARA	EQ 50MG BASE	A215913	001	Jun 13, 2025	Jun	NEWA
AB			EQ 100MG BASE	A215913	002	Jun 13, 2025	Jun	NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

SAPROPTERIN DIHYDROCHLORIDE

AB		HOPEWELL PHARMA	100MG/PACKET	A216432	001	Sep 03, 2025	Aug	NEWA
AB			500MG/PACKET	A216432	002	Sep 03, 2025	Aug	NEWA

ZELVYSIA

AB		AUCTA	100MG/PACKET	A218645	001	Apr 29, 2025	Jun	CAHN
AB			500MG/PACKET	A218645	002	Apr 29, 2025	Jun	CAHN
AB		SHANGHAI AUCYUN	100MG/PACKET	A218645	001	Apr 29, 2025	Apr	NEWA
AB			500MG/PACKET	A218645	002	Apr 29, 2025	Apr	NEWA

TABLET;ORAL
SAPROPTERIN DIHYDROCHLORIDE

AB		AUROBINDO PHARMA	100MG	A216797	001	Jun 09, 2025	May NEWA
AB		ZENARA	100MG	A218797	001	Jun 11, 2025	May NEWA

SAXAGLIPTIN HYDROCHLORIDE
TABLET;ORAL
SAXAGLIPTIN

	@	SUN PHARM	EQ 2.5MG BASE	A206078	001	Jul 31, 2023	Jul DISC
	@		EQ 5MG BASE	A206078	002	Jul 31, 2023	Jul DISC

SCOPOLAMINE
SYSTEM;TRANSDERMAL
SCOPOLAMINE

AB		AMNEALS PHARMS	1MG/72HR	A218384	001	Jun 09, 2025	May NEWA
AB	!	RICONPHARMA LLC	1MG/72HR	A212342	001	Nov 24, 2020	Apr CHRS

TRANSDERM SCOP

AB	+	BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Apr CHRS

SEBETRALSTAT
TABLET;ORAL
EKTERLY

	+!	KALVISTA	300MG	N219301	001	Jul 03, 2025	Jul NEWA

SELEGILINE HYDROCHLORIDE
CAPSULE;ORAL
ELDEPRYL

	@ +	QUAGEN	5MG	N020647	001	May 15, 1996	Sep CAHN

TABLET;ORAL
SELEGILINE HYDROCHLORIDE

AB		MLV	5MG	A074672	001	Apr 01, 1997	Sep CAHN
	@ +	QUAGEN	5MG	N019334	001	Jun 05, 1989	Sep CAHN

SELENIOUS ACID
SOLUTION;INTRAVENOUS
SELENIOUS ACID

AP	+!	AM REGENT	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	N209379	003	Aug 30, 2021	May CFTG
	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Feb CTEC
AP	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Jan CFTG
AP	+!		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	N209379	001	Apr 30, 2019	Feb CFTG
AP		ASPIRO	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A219633	001	Jun 11, 2025	May NFTG
AP			EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219633	002	Jun 11, 2025	May NEWA
AP		CIPLA	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A218661	001	Jul 21, 2025	Jul NEWA
AP			EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218661	002	Jul 21, 2025	Jul NEWA
AP		FRESENIUS KABI USA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jan NFTG
	@		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jul DISC
AP			EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Feb CMS1
AP		GLAND	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219629	001	Jul 08, 2025	Jun NEWA
AP		SUN PHARM	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219547	001	Feb 20, 2025	Feb NEWA

SELINEXOR
TABLET;ORAL
XPOVIO

	+	KARYOPHARM THERAPS	10MG	N212306	005	Mar 10, 2025	Mar NEWA
>A>	+		80MG	N212306	006	Oct 20, 2025	Oct NEWA

SELPERCATINIB

CAPSULE;ORAL

RETEVMO

	+	ELI LILLY AND CO	40MG	N213246	001	May 08, 2020	Jan CAHN
	+!		80MG	N213246	002	May 08, 2020	Jan CAHN

TABLET;ORAL

RETEVMO

	+	ELI LILLY AND CO	40MG	N218160	001	Apr 10, 2024	Jan CAHN
	+		80MG	N218160	002	Apr 10, 2024	Jan CAHN
	+		120MG	N218160	003	Apr 10, 2024	Jan CAHN
	+!		160MG	N218160	004	Apr 10, 2024	Jan CAHN

SELUMETINIB SULFATE

GRANULE;ORAL

KOSELUGO

	+	ASTRAZENECA	EQ 5MG BASE	N219943	001	Sep 10, 2025	Sep NEWA
	+!		EQ 7.5MG BASE	N219943	002	Sep 10, 2025	Sep NEWA

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS

OZEMPIC

	@ +	NOVO	2MG/1.5ML (1.34MG/ML)	N209637	001	Dec 05, 2017	Sep DISC

TABLET;ORAL

RYBELSUS

>D>	+	NOVO	1.5MG	N213051	004	Dec 09, 2024	Oct CHRS
>A>	+!		1.5MG	N213051	004	Dec 09, 2024	Oct CHRS
>D>	+		4MG	N213051	005	Dec 09, 2024	Oct CHRS
>A>	+!		4MG	N213051	005	Dec 09, 2024	Oct CHRS

SEPIAPTERIN

POWDER;ORAL

SEPHIENCE

	+	PTC THERAP	250MG/PACKET	N219666	001	Jul 28, 2025	Jul NEWA
	+!		1GM/PACKET	N219666	002	Jul 28, 2025	Jul NEWA

SERTRALINE HYDROCHLORIDE

CAPSULE;ORAL

SERTRALINE HYDROCHLORIDE

AB	+!	ALMATICA	EQ 150MG BASE	N215133	001	Oct 04, 2021	Jul CFTG
AB	+		EQ 200MG BASE	N215133	002	Oct 04, 2021	Jul CFTG
AB		ZENARA	EQ 150MG BASE	A218853	001	Jul 16, 2025	Jul NFTG
AB			EQ 200MG BASE	A218853	002	Jul 16, 2025	Jul NFTG

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB		PHARMACO	EQ 25MG BASE	A076882	001	Feb 06, 2007	Sep CAHN
AB			EQ 50MG BASE	A076882	002	Feb 06, 2007	Sep CAHN
AB			EQ 100MG BASE	A076882	003	Feb 06, 2007	Sep CAHN
	@	QUAGEN	EQ 25MG BASE	A078626	001	Jan 31, 2008	Sep CAHN
	@		EQ 50MG BASE	A078626	002	Jan 31, 2008	Sep CAHN
	@		EQ 100MG BASE	A078626	003	Jan 31, 2008	Sep CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

	@	INVAGEN PHARMS	800MG/PACKET	A206234	001	Jul 12, 2024	Jan DISC
	@		2.4GM/PACKET	A206234	002	Jul 12, 2024	Jan DISC
	@	TORRENT	800MG/PACKET	A215909	001	Feb 27, 2025	Jun DISC
AB			800MG/PACKET	A215909	001	Feb 27, 2025	Feb NEWA
	@		2.4GM/PACKET	A215909	002	Feb 27, 2025	Jun DISC
AB			2.4GM/PACKET	A215909	002	Feb 27, 2025	Feb NEWA

TABLET;ORAL

SEVELAMER CARBONATE

	@	EPIC PHARMA LLC	800MG	A212970	001	Apr 09, 2020	Jun CAHN
>A> AB		NAVINTA LLC	800MG	A219931	001	Oct 27, 2025	Oct NEWA

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

SEVELAMER HYDROCHLORIDE

BX		AUROBINDO PHARMA LTD	400MG	A212599	001	Jul 11, 2023	Mar CTEC
BX			800MG	A212599	002	Jul 11, 2023	Mar CTEC
AB		NAVINTA LLC	800MG	A218966	001	Feb 03, 2025	Jan NEWA

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

SILDENAFIL CITRATE

AB			APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN
AB			CHARTWELL RX	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN
	@		TARO	EQ 10MG BASE/ML	A215522	001	Nov 16, 2021	Aug DISC

TABLET;ORAL

SILDENAFIL CITRATE

AB			JUBILANT GENERICS	EQ 20MG BASE	A202954	001	Mar 06, 2025	Feb NEWA
	@		MYLAN	EQ 25MG BASE	A201171	001	Mar 25, 2019	Aug DISC
	@			EQ 50MG BASE	A201171	002	Mar 25, 2019	Sep DISC
>D> AB				EQ 100MG BASE	A201171	003	Mar 25, 2019	Oct DISC
>A>	@			EQ 100MG BASE	A201171	003	Mar 25, 2019	Oct DISC
AB			UMEDICA	EQ 25MG BASE	A209302	003	Jun 15, 2021	Sep CTEC
AB				EQ 50MG BASE	A209302	001	Aug 25, 2020	Sep CTEC
AB				EQ 100MG BASE	A209302	002	Aug 25, 2020	Sep CTEC

SILODOSIN

CAPSULE;ORAL

RAPAFLO

	@	+	ABBVIE	4MG	N022206	001	Oct 08, 2008	Jul DISC
	@	+		8MG	N022206	002	Oct 08, 2008	Jul DISC

SILODOSIN

AB		!	LUPIN LTD	4MG	A206541	001	Dec 03, 2018	Jul CHRS
	@		TORRENT	4MG	A210396	001	Feb 10, 2025	Jun DISC
AB				4MG	A210396	001	Feb 10, 2025	Jan NEWA
	@			8MG	A210396	002	Feb 10, 2025	Jun DISC
AB				8MG	A210396	002	Feb 10, 2025	Jan NEWA

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

AB			GRAVITI PHARMS	5MG	A077752	005	Jan 23, 2008	Feb CAHN
AB				10MG	A077752	001	Dec 20, 2006	Feb CAHN
AB				20MG	A077752	002	Dec 20, 2006	Feb CAHN
AB				40MG	A077752	003	Dec 20, 2006	Feb CAHN
AB				80MG	A077752	004	Dec 20, 2006	Feb CAHN
>A> AB			INVAGEN PHARMS	5MG	A206557	005	Oct 27, 2025	Oct NEWA

SIPONIMOD

TABLET;ORAL

MAYZENT

		+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	May CTEC
AB		+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr CFTG
		+		EQ 1MG BASE	N209884	003	Aug 24, 2021	May CTEC
AB		+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Apr CFTG
		+!		EQ 2MG BASE	N209884	002	Mar 26, 2019	May CTEC
AB		+!		EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr CFTG

SIPONIMOD

	@		RICONPHARMA LLC	EQ 0.25MG BASE	A218444	001	Apr 22, 2025	May DISC
AB				EQ 0.25MG BASE	A218444	001	Apr 22, 2025	Apr NFTG
	@			EQ 1MG BASE	A218444	002	Apr 22, 2025	May DISC
AB				EQ 1MG BASE	A218444	002	Apr 22, 2025	Apr NFTG
	@			EQ 2MG BASE	A218444	003	Apr 22, 2025	May DISC
AB				EQ 2MG BASE	A218444	003	Apr 22, 2025	Apr NFTG

SIROLIMUS

POWDER;INTRAVENOUS

FYARRO

		+!	AADI SUB	100MG/VIAL	N213312	001	Nov 22, 2021	Mar CAHN

SOLUTION;ORAL

SIROLIMUS

AA			RISING	1MG/ML	A215116	001	Jul 15, 2025	Jul NEWA

SITAGLIPTIN HYDROCHLORIDE

SOLUTION;ORAL

BRYNOVIN

		+!	AZURITY	EQ 25MG BASE/ML	N219122	001	Jan 16, 2025	Jan NEWA

SODIUM ACETATE

SOLUTION;INTRAVENOUS

SODIUM ACETATE

	AP		AMNEAL	100MEQ/50ML (2MEQ/ML)	A218469	001	Aug 08, 2025	Aug NEWA
	AP			200MEQ/100ML (2MEQ/ML)	A218469	002	Aug 08, 2025	Aug NEWA
	AP		SOMERSET THERAPS LLC	100MEQ/50ML (2MEQ/ML)	A219826	001	Sep 18, 2025	Sep NEWA
	AP			200MEQ/100ML (2MEQ/ML)	A219826	002	Sep 18, 2025	Sep NEWA

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

	AP		ANTHEA PHARMA	1MEQ/ML	A219701	001	Jun 26, 2025	Jun NEWA
	AP		FRESENIUS KABI USA	0.5MEQ/ML	A206688	001	Aug 25, 2025	Aug NEWA
	AP			1MEQ/ML	A206688	002	Aug 25, 2025	Aug NEWA
	AP		NEOCUBES PHARMA	1MEQ/ML	A219701	001	Jun 26, 2025	Sep CAHN

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9%

		@ +	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Aug DISC
		@ +		18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Aug DISC
		@ +		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Aug DISC
		@ +		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Aug DISC
		@ +		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Aug DISC

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	AP		GVS TM	900MG/100ML	A076316	001	Oct 27, 2004	Sep CAHN
	AP	+!	OTSUKA ICU MEDCL	900MG/100ML	N016366	001		May CAHN

SOLUTION;INJECTION

SODIUM CHLORIDE 0.9%

	AP		NEXUS	90MG/10ML (9MG/ML)	A217535	001	Aug 23, 2023	Mar CAHN
	AP			180MG/20ML (9MG/ML)	A217535	002	Aug 23, 2023	Mar CAHN

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE;INJECTION

FERRLECIT

	AB	+!	SANOFI AVENTIS US	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	N020955	001	Feb 18, 1999	Aug CAIN

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

	AB		HIKMA	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	A078215	001	Mar 31, 2011	Aug CAIN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

>D>	AP		ESSENTIAL ISOTOPES	10-200mCi/ML	A204541	001	Oct 29, 2014	Oct DISC
>A>		@		10-200mCi/ML	A204541	001	Oct 29, 2014	Oct DISC
>D>	AP		HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015	Oct DISC
>A>		@		10-200mCi/ML	A204530	001	Jul 29, 2015	Oct DISC

SODIUM IODIDE I-131

SOLUTION;ORAL

SODIUM IODIDE I 131

	AA		CARDINAL HLTH 414	250-1000mCi	A213615	001	Jun 12, 2025	Jun NEWA

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

		@	XIROMED	25MG/ML	A211277	001	Oct 29, 2020	Jan DISC

SODIUM OXYBATE

SOLUTION;ORAL

SODIUM OXYBATE

	AA		AMNEAL	0.5GM/ML	A203631	001	Sep 10, 2025	Aug NEWA
>A>	AA		ASCENT PHARMS INC	0.5GM/ML	A210523	001	Nov 05, 2025	Oct NEWA

XYREM

	AA	+!	JAZZ PHARMS	0.5GM/ML	N021196	001	Jul 17, 2002	Aug CTEC

SODIUM PHENYLBUTYRATE

FOR SUSPENSION;ORAL

OLPRUVA

>A>		+	ACER	0.5GM/PACKET	N214860	007	Oct 10, 2025	Oct NEWA
>A>		+		1GM/PACKET	N214860	008	Oct 10, 2025	Oct NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA			AJENAT PHARMS	454GM/BOT	A205727	001	Feb 23, 2016	Jan CAHN

SUSPENSION;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA			LYNE	15GM/60ML	A214912	001	Jun 10, 2025	May NEWA

SOLIFENACIN SUCCINATE

SUSPENSION;ORAL

VESICARE LS

	@	+	ASTELLAS	1MG/ML	N209529	001	May 26, 2020	Jul DISC

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB			BOSTAL	5MG	A210281	001	May 20, 2019	Aug CAHN
AB				10MG	A210281	002	May 20, 2019	Aug CAHN
	@		TORRENT	5MG	A209424	001	Mar 04, 2025	Jun DISC
AB				5MG	A209424	001	Mar 04, 2025	Feb NEWA
	@			10MG	A209424	002	Mar 04, 2025	Jun DISC
AB				10MG	A209424	002	Mar 04, 2025	Feb NEWA

SORAFENIB TOSYLATE

TABLET;ORAL

SORAFENIB TOSYLATE

	@		APOTEX	EQ 200MG BASE	A212228	001	Jan 27, 2025	Mar DISC
AB				EQ 200MG BASE	A212228	001	Jan 27, 2025	Jan NEWA

SPIRONOLACTONE

SUSPENSION;ORAL

SPIRONOLACTONE

AB			HETERO LABS LTD III	25MG/5ML	A218085	001	Feb 21, 2025	Feb NEWA

TABLET;ORAL

SPIRONOLACTONE

AB			ANNORA PHARMA	25MG	A217761	001	Jul 25, 2025	Jul NEWA
AB				50MG	A217761	002	Jul 25, 2025	Jul NEWA
AB				100MG	A217761	003	Jul 25, 2025	Jul NEWA
AB			GRAVITI PHARMS	25MG	A219494	001	Jan 23, 2025	Jan NEWA
AB				50MG	A219494	002	Jan 23, 2025	Jan NEWA
AB				100MG	A219494	003	Jan 23, 2025	Jan NEWA

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

		+!	HOSPIRA	100% (5.2ML)	N018801	006	May 02, 2023	Sep CMFD

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

	@		TARO	100%	A077393	001	Aug 11, 2006	Aug DISC

STREPTOZOCIN

INJECTABLE;INJECTION

ZANOSAR

	@	+	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982	Feb DISC

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

AP			FRESENIUS KABI USA	20MG/ML	A217885	001	Feb 21, 2025	Feb NEWA
AP			REGCON HOLDINGS	20MG/ML	A214308	001	May 22, 2020	Sep CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

AP			FRESENIUS KABI USA	100MG/5ML (20MG/ML)	A217884	001	Feb 11, 2025	Jan NEWA

SUCRALFATE

SUSPENSION;ORAL

SUCRALFATE

AB		PADAGIS US	1GM/10ML	A211780	001	Apr 14, 2025	Apr	NEWA

TABLET;ORAL

SUCRALFATE

AB		CHARTWELL RX	1GM	A074415	001	Jun 08, 1998	Apr	CAHN

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

SUGAMMADEX SODIUM

AP		B BRAUN MEDICAL	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214279	001	Aug 05, 2025	Sep	CAHN
AP		FISIOPHARMA	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214279	001	Aug 05, 2025	Jul	NEWA

SULFACETAMIDE SODIUM

LOTION;TOPICAL

SULFACETAMIDE SODIUM

@		TARO	10%	A078668	001	May 20, 2009	Jul	DISC

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

@		PHARMOBEDIENT	10%	A040215	001	May 25, 1999	Sep	CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@		AIPING PHARM INC	400MG;80MG	A070890	002	Nov 13, 1986	Aug	CMS1

SULFANILAMIDE

CREAM;VAGINAL

AVC

@ +		PHARMOBEDIENT	15%	N006530	003	Jan 27, 1987	Sep	CAHN

SUPPOSITORY;VAGINAL

AVC

@		PHARMOBEDIENT	1.05GM	N006530	004	Jan 27, 1987	Sep	CAHN

SULFASALAZINE

TABLET;ORAL

SULFASALAZINE

>A>	AB	RISING	500MG	A219046	001	Nov 04, 2025	Oct	NEWA

SULINDAC

TABLET;ORAL

SULINDAC

AB		EPIC PHARMA	150MG	A072711	002	Mar 25, 1991	Mar	CMS1

SUMATRIPTAN

SPRAY;NASAL

SUMATRIPTAN

AB		REGCON HOLDINGS	20MG/SPRAY	A208967	001	Feb 17, 2021	Sep	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

IMITREX STATDOSE

>D>		+! GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080	002	Feb 01, 2006	Oct	CTEC
>A>	AB	+!	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080	002	Feb 01, 2006	Oct	CTEC

SUMATRIPTAN SUCCINATE

>A>	AB	ALEMBIC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A213518	001	Nov 06, 2025	Oct	NEWA
>A>	AB		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A213518	002	Nov 06, 2025	Oct	NEWA
	AB	SUN PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Jun	CMFD

TABLET;ORAL

SUMATRIPTAN SUCCINATE

AB		IPCA LABS LTD	EQ 25MG BASE	A206019	001	Jul 15, 2025	Jul	NEWA
AB			EQ 50MG BASE	A206019	002	Jul 15, 2025	Jul	NEWA
AB			EQ 100MG BASE	A206019	003	Jul 15, 2025	Jul	NEWA
@		SUN PHARM INDS	EQ 25MG BASE	A078295	001	Aug 10, 2009	Jul	DISC

TABLET;ORAL
SUMATRIPTAN SUCCINATE

	@		EQ 50MG BASE	A078295	002	Aug 10, 2009	Jul DISC
	@		EQ 100MG BASE	A078295	003	Aug 10, 2009	Jul DISC
AB		ZHEJIANG	EQ 25MG BASE	A200263	001	Jun 19, 2012	Sep CAHN
AB			EQ 50MG BASE	A200263	002	Jun 19, 2012	Sep CAHN
AB			EQ 100MG BASE	A200263	003	Jun 19, 2012	Sep CAHN

SUNITINIB MALATE

CAPSULE;ORAL
SUNITINIB MALATE

AB		FOSUN WANBANG	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Jan CAHN
AB			EQ 25MG BASE	A218012	002	Aug 21, 2023	Jan CAHN
AB			EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Jan CAHN
AB			EQ 50MG BASE	A218012	004	Aug 21, 2023	Jan CAHN
AB		MSN	EQ 12.5MG BASE	A214824	001	Feb 14, 2025	Feb NEWA
AB			EQ 25MG BASE	A214824	002	Feb 14, 2025	Feb NEWA
AB			EQ 37.5MG BASE	A214824	003	Feb 14, 2025	Feb NEWA
AB			EQ 50MG BASE	A214824	004	Feb 14, 2025	Feb NEWA

SUNVOZERTINIB

TABLET;ORAL
ZEGFROVY

	+	DIZAL JIANGSU	150MG	N219839	001	Jul 02, 2025	Jul NEWA
	+!		200MG	N219839	002	Jul 02, 2025	Jul NEWA

SUZETRIGINE

TABLET;ORAL
JOURNAVX

	+!	VERTEX PHARMS INC	50MG	N219209	001	Jan 30, 2025	Jan NEWA

TACROLIMUS

CAPSULE;ORAL
TACROLIMUS

AB		AJENAT PHARMS	EQ 0.5MG BASE	A206651	001	Nov 30, 2017	Jan CAHN
AB			EQ 1MG BASE	A206651	002	Nov 30, 2017	Jan CAHN
AB			EQ 5MG BASE	A206651	003	Nov 30, 2017	Jan CAHN
	@	HANGZHOU ZHONGMEI	EQ 0.5MG BASE	A210929	001	Apr 17, 2023	Jul DISC
	@		EQ 1MG BASE	A210929	002	Apr 17, 2023	Jul DISC
	@		EQ 5MG BASE	A210929	003	Apr 17, 2023	Jul DISC

INJECTABLE;INJECTION
PROGRAF

AP	+!	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Jan CTEC

TACROLIMUS

AP		NEXUS	EQ 5MG BASE/ML	A217108	001	Feb 12, 2025	Jan NEWA

OINTMENT;TOPICAL
TACROLIMUS

BX		ENCUBE	0.1%	A212387	001	Oct 10, 2023	Mar CTEC

TADALAFIL

TABLET;ORAL
TADALAFIL

AB1		HIBROW HLTHCARE	2.5MG	A217606	001	Aug 13, 2024	Sep CAHN
AB1			5MG	A217606	002	Aug 13, 2024	Sep CAHN
AB1			10MG	A217606	003	Aug 13, 2024	Sep CAHN
AB1			20MG	A217606	004	Aug 13, 2024	Sep CAHN
AB1		UMEDICA	2.5MG	A211298	001	Oct 23, 2020	Sep CTEC
AB1			5MG	A211298	002	Oct 23, 2020	Sep CTEC
AB1			10MG	A211298	003	Oct 23, 2020	Sep CTEC
AB1			20MG	A211298	004	Oct 23, 2020	Sep CTEC

TALAZOPARIB TOSYLATE

CAPSULE;ORAL
TALZENNA

	@ +	PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023	Feb DISC
	@ +		EQ 0.25MG BASE	N211651	001	Oct 16, 2018	Feb DISC
	@ +		EQ 0.35MG BASE	N211651	006	Jun 20, 2023	Feb DISC
	@ +		EQ 0.5MG BASE	N211651	003	Sep 20, 2021	Feb DISC
	@ +		EQ 0.75MG BASE	N211651	004	Sep 20, 2021	Feb DISC
	@ +		EQ 1MG BASE	N211651	002	Oct 16, 2018	Feb DISC

TALETRECTINIB ADIPATE

CAPSULE;ORAL

IBTROZI

		+!	NUVATION	EQ 200MG BASE	N219713	001	Jun 11, 2025	Jun NEWA

TAMOXIFEN CITRATE

TABLET;ORAL

TAMOXIFEN CITRATE

		@	APOTEX	EQ 10MG BASE	A090878	001	Sep 23, 2011	Mar DISC
		@		EQ 20MG BASE	A090878	002	Sep 23, 2011	Mar DISC

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

FLOMAX

		@ +	SANOFI	0.4MG	N020579	001	Apr 15, 1997	Feb DISC

TAMSULOSIN HYDROCHLORIDE

	AB		ASCENT PHARMS INC	0.4MG	A214730	001	May 04, 2022	Feb CMFD
	AB		GRAVITI PHARMS	0.4MG	A219767	001	May 01, 2025	Apr NEWA
	AB	!	ZYDUS PHARMS USA INC	0.4MG	A078225	001	Apr 27, 2010	Feb CHRS

TAPINAROF

CREAM;TOPICAL

VTAMA

		+!	ORGANON LLC	1%	N215272	001	May 23, 2022	May CAHN

TAVABOROLE

SOLUTION;TOPICAL

TAVABOROLE

		@	AMNEAL	5%	A212256	001	Nov 25, 2020	Jul DISC
		@	TARO	5%	A212215	001	May 07, 2021	Jul DISC

TAZAROTENE

CREAM;TOPICAL

AVAGE

>D>	AB	+!	ALLERGAN	0.1%	N021184	003	Sep 30, 2002	Oct CAHN
>A>	AB	+!	ALMIRALL	0.1%	N021184	003	Sep 30, 2002	Oct CAHN

TAZAROTENE

	AB		COSETTE	0.05%	A208662	002	Mar 10, 2025	Feb NEWA
	AB		SUN PHARMA CANADA	0.1%	A208258	001	Apr 03, 2017	Sep CAHN

TAZORAC

>D>	AB	+!	ALLERGAN	0.05%	N021184	001	Sep 29, 2000	Oct CAHN
>D>	AB	+!		0.1%	N021184	002	Sep 29, 2000	Oct CAHN
>A>	AB	+!	ALMIRALL	0.05%	N021184	001	Sep 29, 2000	Oct CAHN
>A>	AB	+!		0.1%	N021184	002	Sep 29, 2000	Oct CAHN

GEL;TOPICAL

TAZORAC

>D>	AB	+!	ABBVIE	0.05%	N020600	001	Jun 13, 1997	Oct CAHN
	AB	+!		0.05%	N020600	001	Jun 13, 1997	Aug CAHN
>D>	AB	+!		0.1%	N020600	002	Jun 13, 1997	Oct CAHN
	AB	+!		0.1%	N020600	002	Jun 13, 1997	Aug CAHN
>A>	AB	+!	ALMIRALL	0.05%	N020600	001	Jun 13, 1997	Oct CAHN
>A>	AB	+!		0.1%	N020600	002	Jun 13, 1997	Oct CAHN

LOTION;TOPICAL

ARAZLO

		+!	BAUSCH	0.045%	N211882	001	Dec 18, 2019	Aug CTEC
	AB	+!		0.045%	N211882	001	Dec 18, 2019	Jul CFTG

TAZAROTENE

		@	PADAGIS ISRAEL	0.045%	A215393	001	Jul 29, 2025	Aug DISC
	AB			0.045%	A215393	001	Jul 29, 2025	Jul NFTG

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION

OSTEOLITE

		@	SUN PHARM INDS INC	N/A	N017972	001		Feb CAHN

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE;INJECTION

DRAXIMAGE DTPA

AP		+!	JUBILANT	N/A	N018511	001	Dec 29, 1989	Mar CFTG

TECHNETIUM TC-99M PENTETATE KIT

AP			CURIUM	N/A	A215146	001	Mar 26, 2025	Mar NFTG

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE;INJECTION

TECHNETIUM TC 99M SESTAMIBI

		@	SUN PHARM INDS INC	10-30mCi	A079157	001	Jul 10, 2009	May DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION;INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

		@	SUN PHARM INDS INC	12mCi/ML	N017321	001		May CAHN
		@		24mCi/ML	N017321	002		May CAHN
		@		48mCi/ML	N017321	003		May CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INTRAVENOUS

ULTRA-TECHNEKOW V4

		+!	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jun CTNA
		@		0.25-3 CI/GENERATOR	N017243	002		Jun CTNA

SOLUTION;INTRAVENOUS, ORAL

DRYTEC

		@ +	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	Jun CTNA
		@		830-16600mCi/GENERATOR	N017693	001		Jun CTNA

TELMISARTAN

TABLET;ORAL

MICARDIS

>D>	AB		+	BOEHRINGER INGELHEIM	20MG	N020850	003	Apr 04, 2000	Oct DISC
>A>			@ +		20MG	N020850	003	Apr 04, 2000	Oct DISC
			@ +		80MG	N020850	002	Nov 10, 1998	Jul DISC
	AB		+		80MG	N020850	002	Nov 10, 1998	Feb CHRS

TELMISARTAN

>D>	AB			HETERO LABS LTD V	20MG	A205901	001	Apr 22, 2016	Oct DISC
>A>			@		20MG	A205901	001	Apr 22, 2016	Oct DISC
>D>	AB				40MG	A205901	002	Apr 22, 2016	Oct DISC
>A>			@		40MG	A205901	002	Apr 22, 2016	Oct DISC
>D>	AB				80MG	A205901	003	Apr 22, 2016	Oct DISC
>A>			@		80MG	A205901	003	Apr 22, 2016	Oct DISC
	AB		!	INVENTIA	80MG	A205150	003	Oct 30, 2015	Feb CHRS
	AB			MACLEODS PHARMS LTD	20MG	A203986	001	Jan 15, 2025	Jan NEWA
	AB				40MG	A203986	002	Jan 15, 2025	Jan NEWA
	AB				80MG	A203986	003	Jan 15, 2025	Jan NEWA
	AB			TORRENT	20MG	A203171	001	Jul 07, 2014	Sep CMFD
	AB				40MG	A203171	002	Jul 07, 2014	Sep CMFD
	AB				80MG	A203171	003	Jul 07, 2014	Sep CMFD

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

		@	SUN PHARM INDUSTRIES	7.5MG	A078581	001	Sep 08, 2009	Mar DISC

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

		@	EIRGEN	5MG	A203898	001	Feb 10, 2016	Aug CAHN
		@		20MG	A203898	002	Feb 10, 2016	Aug CAHN
	AB			100MG	A203898	003	Feb 10, 2016	Aug CAHN
	AB			140MG	A203898	004	Feb 10, 2016	Aug CAHN
	AB			180MG	A203898	005	Feb 10, 2016	Aug CAHN
	AB			250MG	A203898	006	Feb 10, 2016	Aug CAHN
		@	NEXTSOURCE	5MG	A203898	001	Feb 10, 2016	Mar CAHN
		@		20MG	A203898	002	Feb 10, 2016	Mar CAHN
		@		100MG	A203898	003	Feb 10, 2016	Mar CAHN
	AB			100MG	A203898	003	Feb 10, 2016	Mar CMFD
		@		140MG	A203898	004	Feb 10, 2016	Mar CAHN
	AB			140MG	A203898	004	Feb 10, 2016	Mar CMFD

	CAPSULE;ORAL						
	TEMOZOLOMIDE						
	@		180MG	A203898	005	Feb 10, 2016	Mar CAHN
AB			180MG	A203898	005	Feb 10, 2016	Mar CMFD
	@		250MG	A203898	006	Feb 10, 2016	Mar CAHN
AB			250MG	A203898	006	Feb 10, 2016	Mar CMFD
	@	TRI-SOURCE PHARMA	5MG	A203898	001	Feb 10, 2016	Apr CAHN
	@		20MG	A203898	002	Feb 10, 2016	Apr CAHN
AB			100MG	A203898	003	Feb 10, 2016	Apr CAHN
AB			140MG	A203898	004	Feb 10, 2016	Apr CAHN
AB			180MG	A203898	005	Feb 10, 2016	Apr CAHN
AB			250MG	A203898	006	Feb 10, 2016	Apr CAHN
	TERAZOSIN HYDROCHLORIDE						
	CAPSULE;ORAL						
	TERAZOSIN HYDROCHLORIDE						
AB		AJANTA PHARMA LTD	EQ 1MG BASE	A219482	001	May 12, 2025	May NEWA
AB			EQ 2MG BASE	A219482	002	May 12, 2025	May NEWA
AB			EQ 5MG BASE	A219482	003	May 12, 2025	May NEWA
AB			EQ 10MG BASE	A219482	004	May 12, 2025	May NEWA
	@	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun CAHN
	@		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun CAHN
	@		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun CAHN
	@		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun CAHN
	SOLUTION;ORAL						
	TEZRULY						
>D>	+!	NOVITIUM PHARMA	EQ 1MG BASE/ML	N218139	001	Jul 29, 2024	Oct DISC
>A>	@ +		EQ 1MG BASE/ML	N218139	001	Jul 29, 2024	Oct DISC
	TERBINAFINE HYDROCHLORIDE						
	TABLET;ORAL						
	TERBINAFINE HYDROCHLORIDE						
	@	BRECKENRIDGE PHARM	EQ 250MG BASE	A077714	001	Jun 04, 2010	Mar DISC
	TERIFLUNOMIDE						
	TABLET;ORAL						
	TERIFLUNOMIDE						
	@	APOTEX	7MG	A209601	001	Nov 02, 2018	Feb DISC
	@		14MG	A209601	002	Nov 02, 2018	Feb DISC
AB		CONCORD BIOTECH LTD	7MG	A218663	001	Apr 07, 2025	Mar NEWA
AB			14MG	A218663	002	Apr 07, 2025	Mar NEWA
	@	SOMERSET THERAPS LLC	7MG	A209702	001	Feb 28, 2020	Sep CAHN
	@		14MG	A209702	002	Feb 28, 2020	Sep CAHN
	@	WELDING	7MG	A209702	001	Feb 28, 2020	Jun CAHN
	@		14MG	A209702	002	Feb 28, 2020	Jun CAHN
	TERIPARATIDE						
	SOLUTION;SUBCUTANEOUS						
	BONSITY						
		ALVOGEN	0.56MG/2.24ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Feb CPOT
	FORTEO						
AP	+!	LILLY	0.56MG/2.24ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Feb CPOT
	TERIPARATIDE						
AP	+!	ALMAJECT	0.56MG/2.24ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Feb CPOT
AP	+!		0.6MG/2.4ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Feb CTEC
AP		APOTEX	0.56MG/2.24ML (0.25MG/ML)	A211097	001	Nov 16, 2023	Feb CPOT
AP		TEVA PHARMS USA	0.56MG/2.24ML (0.25MG/ML)	A208569	001	Nov 16, 2023	Feb CPOT
	TESTOSTERONE						
	GEL, METERED;TRANSDERMAL						
	TESTOSTERONE						
	@	TWI PHARMS	1.62% (20.25MG/1.25GM ACTUATION)	A209390	001	Sep 23, 2019	Aug DISC
	SOLUTION, METERED;TRANSDERMAL						
	TESTOSTERONE						
	@	ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jan DISC
	@	TWI PHARMS	30MG/1.5ML ACTUATION	A209836	001	Sep 03, 2021	Jun DISC

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL

KYZATREX

	@ +	MARIUS	100MG	N213953	001	Jul 27, 2022	Sep	DISC
	+		100MG	N213953	001	Jul 27, 2022	Aug	CAHN
	+		150MG	N213953	002	Jul 27, 2022	Aug	CAHN
	+!		200MG	N213953	003	Jul 27, 2022	Aug	CAHN

THEOPHYLLINE

SOLUTION, ELIXIR;ORAL

ELIXOPHYLLIN

AA	+!	SOLIS PHARMS	80MG/15ML	A085186	001		Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

	@	AJANTA PHARMA LTD	300MG	A218401	002	Mar 26, 2025	Jul	DISC
AB			300MG	A218401	002	Mar 26, 2025	Mar	NEWA
	@		450MG	A218401	001	Jan 13, 2025	Jul	DISC
AB			450MG	A218401	001	Jan 13, 2025	Jan	NEWA
AB		MPP PHARMA	400MG	A040560	003	Apr 21, 2006	Jun	CAHN
AB	!		600MG	A040560	002	Apr 21, 2006	Jun	CAHN
	@	RHODES PHARMS	300MG	A214113	001	May 11, 2023	Jan	DISC

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP		GLAND	100MG/ML	A217800	001	Feb 24, 2025	Feb	NEWA

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

>D> AP		BELOTECA	15MG/VIAL	A211831	001	Dec 08, 2021	Oct	CAHN
>A> AP		REGCON HOLDINGS	15MG/VIAL	A211831	001	Dec 08, 2021	Oct	CAHN

POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

THIOTEPA

AP		REGCON HOLDINGS	15MG/VIAL	A217559	001	Aug 20, 2024	Sep	CAHN

POWDER;INTRAVENOUS

TEPADINA AND SODIUM CHLORIDE

	+!	ADIENNE SA	200MG	N208264	003	Apr 10, 2025	May	NEWA

SOLUTION;INTRAVENOUS

TEPYLUTE

	+!	SHORLA	100MG/10ML (10MG/ML)	N216984	002	Feb 26, 2025	Mar	NEWA

TIAGABINE HYDROCHLORIDE

TABLET;ORAL

TIAGABINE HYDROCHLORIDE

	@	SUN PHARM INDS	2MG	A077555	001	Nov 04, 2011	Jun	DISC
	@		4MG	A077555	002	Nov 04, 2011	Jun	DISC

TICAGRELOR

TABLET;ORAL

BRILINTA

AB	+	ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Mar	CTEC

TICAGRELOR

>A> AB		ALEMBIC	60MG	A208576	002	Oct 28, 2025	Oct	NEWA
AB			90MG	A208576	001	May 01, 2025	Apr	NEWA
>A> AB		ALKEM LABS LTD	60MG	A210219	001	Oct 28, 2025	Oct	NEWA
>A> AB		AMNEAL	60MG	A208531	002	Oct 28, 2025	Oct	NEWA
>A> AB		APOTEX	60MG	A208584	002	Oct 28, 2025	Oct	NEWA
AB			90MG	A208584	001	May 01, 2025	Apr	NEWA
>A> AB		CHANGZHOU PHARM	60MG	A216187	001	Oct 28, 2025	Oct	NEWA
>A> AB			90MG	A216187	002	Oct 28, 2025	Oct	NEWA
>A> AB		DR REDDYS	60MG	A208541	002	Oct 28, 2025	Oct	NEWA
>A> AB		INVAGEN PHARMS	60MG	A208537	002	Oct 28, 2025	Oct	NEWA
AB			90MG	A208537	001	May 05, 2025	Apr	NEWA
>A> AB		MACLEODS PHARMS LTD	60MG	A212258	001	Oct 28, 2025	Oct	NEWA
>A> AB			90MG	A212258	002	Oct 28, 2025	Oct	NEWA
>A> AB		MSN	60MG	A208596	002	Oct 28, 2025	Oct	NEWA
AB			90MG	A208596	001	Apr 07, 2020	Mar	CMFD
	@		90MG	A208596	001	Apr 07, 2020	Feb	CAHN
AB		MYLAN	60MG	A208597	001	Jul 09, 2021	Jul	CMFD
AB			90MG	A208597	002	Jul 09, 2021	Jul	CMFD

TABLET;ORAL
TICAGRELOR

>A>	AB	SCIEGEN PHARMS INC	60MG	A218962	001	Oct 28, 2025	Oct	NEWA
>A>	AB		90MG	A218962	002	Oct 28, 2025	Oct	NEWA
>A>	AB	SUNSHINE	60MG	A208508	002	Oct 28, 2025	Oct	NEWA
	AB		90MG	A208508	001	Apr 06, 2020	Mar	CMFD
>A>	AB	TARO	60MG	A211498	001	Oct 28, 2025	Oct	NEWA
>A>	AB		90MG	A211498	002	Oct 28, 2025	Oct	NEWA
	AB	WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Mar	CMFD
	AB		90MG	A208390	002	Sep 04, 2018	Mar	CMFD

TICLOPIDINE HYDROCHLORIDE
TABLET;ORAL
TICLOPIDINE HYDROCHLORIDE

	@	APOTEX	250MG	A075089	001	Jul 01, 1999	Mar	DISC

TIMOLOL
SOLUTION/DROPS;OPHTHALMIC
BETIMOL

	@ +	THEA PHARMA	0.25%	N020439	001	Mar 31, 1995	Jun	DISC

TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC
TIMOLOL MALEATE

	@	APOTEX	EQ 0.5% BASE	A204936	001	Apr 17, 2015	May	DISC
	@	PHARMOBEDIENT	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Sep	CAHN

TIOPRONIN
TABLET, DELAYED RELEASE;ORAL
TIOPRONIN

AB		AMNEAL	100MG	A216278	002	Aug 29, 2025	Aug	NEWA

VENXXIVA

AB		TORRENT	100MG	A216990	001	Jan 30, 2024	Aug	CTNA
AB			300MG	A216990	002	Jan 30, 2024	Aug	CTNA

TIZANIDINE HYDROCHLORIDE
CAPSULE;ORAL
TIZANIDINE HYDROCHLORIDE

AB		ANDA REPOSITORY	EQ 4MG BASE	A213365	001	May 13, 2024	Sep	CAHN
AB			EQ 6MG BASE	A213365	002	May 13, 2024	Sep	CAHN
AB		RUBICON RESEARCH	EQ 2MG BASE	A213798	001	May 27, 2020	Aug	CAHN
AB			EQ 4MG BASE	A213798	002	May 27, 2020	Aug	CAHN
AB			EQ 6MG BASE	A213798	003	May 27, 2020	Aug	CAHN
	!		EQ 8MG BASE	A213798	004	Aug 28, 2025	Aug	NFTG

TABLET;ORAL
TIZANIDINE HYDROCHLORIDE

AB		RISING	EQ 2MG BASE	A076354	001	Mar 28, 2003	Aug	CMFD
AB			EQ 4MG BASE	A076354	002	Mar 28, 2003	Aug	CMFD

TOBRAMYCIN
POWDER;INHALATION
TOBI PODHALER

	+!	VIATRIS	28MG	N201688	001	Mar 22, 2013	Feb	CAHN

SOLUTION;INHALATION
TOBI

AN	+!	VIATRIS	300MG/5ML	N050753	001	Dec 22, 1997	Feb	CAHN

TOBRAMYCIN SULFATE
INJECTABLE;INJECTION
TOBRAMYCIN SULFATE

	@	EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Aug	DISC

TOFACITINIB CITRATE
TABLET, EXTENDED RELEASE;ORAL
TOFACITINIB CITRATE

AB		AJANTA PHARMA LTD	EQ 11MG BASE	A219542	001	Aug 19, 2025	Aug	NEWA
	@	AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024	Aug	CTNA
	@	DEXCEL	EQ 11MG BASE	A218668	001	Dec 16, 2024	Apr	DISC
AB		SINOTHERAPEUTICS INC	EQ 11MG BASE	A216001	001	Sep 30, 2025	Sep	NEWA
	@	ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Aug	CTNA
	@		EQ 22MG BASE	A214264	002	Aug 19, 2021	Aug	CTNA

TABLET, EXTENDED RELEASE;ORAL
XELJANZ XR

AB	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Aug CTEC
	+		EQ 11MG BASE	N208246	001	Feb 23, 2016	Apr CTEC

TOLMETIN SODIUM

CAPSULE;ORAL
TOLMETIN SODIUM

	@	ANDA REPOSITORY	EQ 400MG BASE	A073290	001	Nov 27, 1991	Sep CAHN

TOLTERODINE TARTRATE

TABLET;ORAL
TOLTERODINE TARTRATE

AB		PTS CONSULTING	1MG	A204721	001	Jan 24, 2020	Mar CAHN
AB			2MG	A204721	002	Jan 24, 2020	Mar CAHN
AB		RISING	1MG	A210775	001	Dec 30, 2019	Jul CAHN
AB			2MG	A210775	002	Dec 30, 2019	Jul CAHN

TOLVAPTAN

TABLET;ORAL
JYNARQUE

AB2	+	OTSUKA	15MG	N204441	001	Apr 23, 2018	Apr CFTG
AB2	+		30MG	N204441	002	Apr 23, 2018	Apr CFTG
AB	+!		45MG	N204441	003	Apr 23, 2018	Apr CFTG
AB2	+		60MG	N204441	004	Apr 23, 2018	Apr CFTG
AB	+		90MG	N204441	005	Apr 23, 2018	Apr CFTG

SAMSCA

AB1	+	OTSUKA	15MG	N022275	001	May 19, 2009	Apr CTEC
AB1	+!		30MG	N022275	002	May 19, 2009	Apr CTEC

TOLVAPTAN

AB1		ALKEM LABS LTD	15MG	A211891	003	Sep 06, 2022	Apr CTEC
AB1			30MG	A211891	001	May 19, 2020	Apr CTEC
AB1		APOTEX	15MG	A207605	002	Sep 06, 2022	Apr CTEC
>A> AB2			15MG	A218381	001	Nov 10, 2025	Oct NEWA
AB1			30MG	A207605	001	May 19, 2020	Apr CTEC
>A> AB2			30MG	A218381	002	Nov 10, 2025	Oct NEWA
>A> AB			45MG	A218381	003	Nov 10, 2025	Oct NEWA
>A> AB2			60MG	A218381	004	Nov 10, 2025	Oct NEWA
>A> AB			90MG	A218381	005	Nov 10, 2025	Oct NEWA
AB1		ENDO OPERATIONS	15MG	A206119	001	Feb 15, 2022	Apr CTEC
AB1			30MG	A206119	002	Feb 15, 2022	Apr CTEC
AB1		HETERO LABS LTD V	15MG	A205646	002	Sep 06, 2022	Apr CTEC
AB1			30MG	A205646	001	Jul 16, 2021	Apr CTEC
AB2		LUPIN LTD	15MG	A216063	001	Apr 23, 2025	Apr NFTG
AB2			30MG	A216063	002	Apr 23, 2025	Apr NFTG
AB			45MG	A216063	003	Apr 23, 2025	Apr NFTG
AB2			60MG	A216063	004	Apr 23, 2025	Apr NFTG
AB			90MG	A216063	005	Apr 23, 2025	Apr NFTG
AB1		MSN	15MG	A216949	001	Jun 21, 2023	Apr CTEC
AB1			30MG	A216949	002	Jun 21, 2023	Apr CTEC

TOPIRAMATE

CAPSULE;ORAL
TOPIRAMATE

AB		RUBICON	15MG	A216683	001	May 27, 2025	May NEWA
AB			25MG	A216683	002	May 27, 2025	May NEWA
AB			50MG	A216683	003	May 27, 2025	May NEWA
AB		ZYDUS PHARMS USA INC	50MG	A078877	003	Oct 23, 2024	May CTEC

CAPSULE, EXTENDED RELEASE;ORAL
TOPIRAMATE

AB2		AJANTA PHARMA LTD	25MG	A219564	001	Sep 02, 2025	Aug NEWA
AB2			50MG	A219564	002	Sep 02, 2025	Aug NEWA
AB2			100MG	A219564	003	Sep 02, 2025	Aug NEWA
AB2			150MG	A219564	004	Sep 02, 2025	Aug NEWA
AB2			200MG	A219564	005	Sep 02, 2025	Aug NEWA

TABLET;ORAL
TOPIRAMATE

AB		PHARMACO	25MG	A077733	001	Mar 27, 2009	Sep CAHN
AB			50MG	A077733	002	Mar 27, 2009	Sep CAHN
AB			100MG	A077733	003	Mar 27, 2009	Sep CAHN
AB			200MG	A077733	004	Mar 27, 2009	Sep CAHN
	@	SENORES PHARMS	25MG	A090353	001	Sep 01, 2010	May CAHN

TABLET;ORAL
TOPIRAMATE

	@		50MG	A090353	002	Sep 01, 2010	May CAHN
	@		100MG	A090353	003	Sep 01, 2010	May CAHN
	@		200MG	A090353	004	Sep 01, 2010	May CAHN
	@	SUN PHARM	200MG	A090278	004	Mar 27, 2009	May DISC

TORSEMIDE

TABLET;ORAL
TORSEMIDE

AB		COREPHARMA	5MG	A076894	001	May 31, 2005	Apr CAHN
AB			10MG	A076894	002	May 31, 2005	Apr CAHN
AB			20MG	A076894	003	May 31, 2005	Apr CAHN
AB			100MG	A076894	004	May 31, 2005	Apr CAHN
	@	HIKMA	5MG	A076943	001	Mar 01, 2005	Sep DISC
	@		10MG	A076943	002	Mar 01, 2005	Sep DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL
TRAMADOL HYDROCHLORIDE

AB		APDM PHARMS	50MG	A090404	001	Jan 31, 2011	Feb CAHN
	@	APOTEX	50MG	A075981	001	Jul 10, 2002	Mar DISC
AB		GRAVITI PHARMS	50MG	A075968	001	Jun 25, 2002	Sep CMFD
>D>	@	MERRO PHARM USA	50MG	A206706	001	Jul 02, 2019	Oct CAHN
	@		50MG	A206706	001	Jul 02, 2019	Feb DISC
>A>	@	PURACAP LABS BLU	50MG	A206706	001	Jul 02, 2019	Oct CAHN
AB		SENORES PHARMS	50MG	A090404	001	Jan 31, 2011	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
TRAMADOL HYDROCHLORIDE

AB1	!	LUPIN LTD	100MG	A200503	001	Aug 29, 2011	Jan CTEC
AB1			200MG	A200503	002	Aug 29, 2011	Jan CTEC
AB1			300MG	A200503	003	Aug 29, 2011	Jan CTEC
AB1		MACLEODS PHARMS LTD	100MG	A209404	001	Jan 31, 2025	Jan NEWA
AB1			200MG	A209404	002	Jan 31, 2025	Jan NEWA
AB1			300MG	A209404	003	Jan 31, 2025	Jan NEWA

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL
TRAMETINIB DIMETHYL SULFOXIDE

	@	HIKMA	EQ 0.5MG	A219002	001	Aug 06, 2024	Feb CAHN
	@		EQ 2MG	A219002	002	Aug 06, 2024	Feb CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION
TRANEXAMIC ACID

	@	FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Jan DISC
AP		MILLA PHARMS	100MG/ML	A212676	001	Jul 17, 2019	Sep CAHN

SOLUTION;INTRAVENOUS
TRANEXAMIC ACID

AP		HERITAGE	1GM/100ML (10MG/ML)	A218896	001	Jun 02, 2025	Aug CAHN
AP		RTU PHARMA SA	1GM/100ML (10MG/ML)	A218896	001	Jun 02, 2025	May NEWA

TABLET;ORAL
TRANEXAMIC ACID

AB		APPCO	650MG	A218729	001	Jun 11, 2025	May NEWA
AB		BIONPHARMA	650MG	A219123	001	Aug 19, 2025	Aug NEWA

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC
TRAVATAN Z

AT2	+!	SANDOZ	0.004%	N021994	001	Sep 21, 2006	Feb CTEC

TRAVOPROST

	@	ALEMBIC	0.004%	A210458	001	Dec 20, 2019	Feb DISC
AT2		APOTEX	0.004%	A203431	001	Jul 10, 2015	Feb CTEC
	!	CHARTWELL RX	0.004%	A091340	001	Mar 01, 2013	Feb CTEC
AT2		GLAND	0.004%	A218159	001	Jul 12, 2024	Feb CTEC
AT2		MICRO LABS	0.004%	A203767	001	Mar 19, 2021	Feb CTEC
AT2		MYLAN	0.004%	A205050	001	Jul 07, 2017	Feb CTEC
AT2		SOMERSET THERAPS LLC	0.004%	A217228	001	Sep 23, 2024	Feb CTEC

TREOSULFAN

POWDER;INTRAVENOUS

GRAFAPEX

	+!	MEDEXUS	1GM/VIAL	N214759	001	Jan 21, 2025	Jan CAHN
	+!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan CAHN
	+!	MGFKSMB	1GM/VIAL	N214759	001	Jan 21, 2025	Jan NEWA
	+!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan NEWA

TREPROSTINIL

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

REMODULIN

	@ +	UNITED THERAP	0.1MG/ML	N021272	006	Sep 28, 2023	Jun DISC
	@ +		0.2MG/ML	N021272	007	Sep 28, 2023	Jun DISC
	@ +		20MG/ML	N021272	005	Jul 30, 2021	Jun DISC

TREPROSTINIL

>D> AP		PH HEALTH	1MG/ML	A209382	001	Sep 24, 2019	Oct DISC
>A>	@		1MG/ML	A209382	001	Sep 24, 2019	Oct DISC
>D> AP			2.5MG/ML	A209382	002	Sep 24, 2019	Oct DISC
>A>	@		2.5MG/ML	A209382	002	Sep 24, 2019	Oct DISC
>D> AP			5MG/ML	A209382	003	Sep 24, 2019	Oct DISC
>A>	@		5MG/ML	A209382	003	Sep 24, 2019	Oct DISC
>D> AP			10MG/ML	A209382	004	Sep 24, 2019	Oct DISC
>A>	@		10MG/ML	A209382	004	Sep 24, 2019	Oct DISC

POWDER;INHALATION

TYVASO DPI

	+!	UNITED THERAP	0.032MG/INH	N214324	002	May 23, 2022	Jan CHRS
	+!		0.048MG/INH	N214324	003	May 23, 2022	Jan CHRS
	+!		0.08MG/INH	N214324	005	Oct 24, 2024	Jan CHRS

TREPROSTINIL SODIUM

POWDER;INHALATION

YUTREPIA

	+!	LIQUIDIA TECH	EQ 0.0265MG BASE/INH	N213005	001	May 23, 2025	May NEWA
	+!		EQ 0.053MG BASE/INH	N213005	002	May 23, 2025	May NEWA
	+!		EQ 0.0795MG BASE/INH	N213005	003	May 23, 2025	May NEWA
	+!		EQ 0.106MG BASE/INH	N213005	004	May 23, 2025	May NEWA

TRETINOIN

CAPSULE;ORAL

TRETINOIN

	@	BARR LABS INC	10MG	A077684	001	Jun 22, 2007	Feb DISC
AB	!	ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Feb CHRS

CREAM;TOPICAL

TRETINOIN

AB		ALEMBIC	0.025%	A218399	001	Aug 14, 2025	Aug NEWA
AB		ENCUBE	0.025%	A217831	001	Jul 10, 2025	Jul NEWA

GEL;TOPICAL

AVITA

	@	RISING	0.025%	N020400	001	Jan 29, 1998	Aug CAHN

RETIN-A

AB	+!	BAUSCH	0.01%	N017955	001		Jan CAHN

TRETINOIN

AB		AUROBINDO PHARMA LTD	0.01%	A218246	001	Jan 13, 2025	Jan NEWA
AB			0.025%	A218245	001	Feb 27, 2025	Feb NEWA
AB		ENCUBE	0.01%	A217588	001	Mar 03, 2025	Feb NEWA
AB			0.025%	A217587	001	Mar 03, 2025	Feb NEWA
	@	RISING	0.04%	A202567	001	Jul 17, 2013	Aug CAHN
	@		0.1%	A202026	001	Jul 17, 2013	Aug CAHN

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

	@	GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016	Jul DISC

GEL;TOPICAL

ARISTOGEL

	@ +	ASTELLAS	0.1%	A083380	001		Feb CRLD

INJECTABLE;INJECTION

KENALOG-10

AB	+	APOTHECON	10MG/ML	N012041	001		Feb CTEC

		INJECTABLE;INJECTION						
		TRIAMCINOLONE ACETONIDE						
>A>	AB	ALEMBIC	40MG/ML	A218601	001	Oct 17, 2025	Oct	NEWA
	AB	DR REDDYS	10MG/ML	A218773	001	Mar 12, 2025	Feb	NEWA
	AB		40MG/ML	A218421	001	Apr 11, 2025	Apr	NEWA
		LOTION;TOPICAL						
		TRIAMCINOLONE ACETONIDE						
	@	BEACH PRODS	0.025%	A204608	001	Jul 07, 2016	May	CAHN
	AT !	XTTRIUM LABS INC	0.025%	A088450	001	Apr 01, 1985	Feb	CAHN
	AT !		0.1%	A088451	001	Apr 03, 1985	Feb	CAHN
		OINTMENT;TOPICAL						
		TRIAMCINOLONE ACETONIDE						
	@	GLENMARK PHARMS LTD	0.5%	A206379	001	Jul 22, 2016	Jul	DISC
	@	GLENMARK SPECLT	0.1%	A208320	001	Aug 22, 2017	Jul	DISC
	AT	SENORES PHARMS	0.05%	A213619	001	Nov 10, 2020	Sep	CAHN
	AT	SUN PHARMA CANADA	0.1%	A040037	001	Sep 30, 1994	Aug	CAHN
		TRIAMCINOLONE HEXACETONIDE						
		INJECTABLE;INJECTION						
		ARISTOSPAN						
	@ +	ETHYPHARM INC	5MG/ML	N016466	001		May	CAHN
	@ +		20MG/ML	N016466	002		May	CAHN
		TRIHEXYPHENIDYL HYDROCHLORIDE						
		ELIXIR;ORAL						
		TRIHEXYPHENIDYL HYDROCHLORIDE						
	AA	CHARTWELL RX	2MG/5ML	A040251	001	Sep 27, 1999	Aug	CAHN
		TRIMETHOBENZAMIDE HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		TIGAN						
>D>	+!	PH HEALTH	100MG/ML	N017530	001		Oct	CTEC
>A>	AP +!		100MG/ML	N017530	001		Oct	CTEC
	+!		100MG/ML	N017530	001		Aug	CAHN
		TRIMETHOBENZAMIDE HYDROCHLORIDE						
>A>	AP	BPI LABS	100MG/ML	A219606	001	Oct 16, 2025	Oct	NEWA
		TRIMIPRAMINE MALEATE						
		CAPSULE;ORAL						
		SURMONTIL						
	@ +	TEVA WOMENS	EQ 25MG BASE	N016792	001		Jun	CAHN
	@ +		EQ 50MG BASE	N016792	002		Jun	CAHN
	@ +		EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun	CAHN
		TROSPIUM CHLORIDE						
		TABLET;ORAL						
		TROSPIUM CHLORIDE						
	AB	CHARTWELL RX	20MG	A215781	001	Feb 16, 2022	Sep	CAHN
	AB	ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb	CAHN
		URSODIOL						
		CAPSULE;ORAL						
		URSODIOL						
	@	QUAGEN	300MG	A090530	001	Feb 17, 2010	Sep	CAHN
		TABLET;ORAL						
		URSO 250						
	@ +	ABBVIE	250MG	N020675	001	Dec 10, 1997	Jun	DISC
	AB +		250MG	N020675	001	Dec 10, 1997	Jun	CAHN
		URSO FORTE						
	@ +	ABBVIE	500MG	N020675	002	Jul 21, 2004	Jun	DISC
	AB +!		500MG	N020675	002	Jul 21, 2004	Jun	CAHN
		URSODIOL						
	AB !	ZYDUS LIFESCIENCES	500MG	A211145	002	Oct 30, 2018	Jun	CHRS
		VALACYCLOVIR HYDROCHLORIDE						
		TABLET;ORAL						
		VALACYCLOVIR HYDROCHLORIDE						
	@	APOTEX	EQ 500MG BASE	A090500	001	Apr 04, 2014	Mar	DISC

VALBENAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

+	NEUROCRINE	EQ 60MG BASE	N209241	003	Apr 23, 2021	Feb	CTEC

VALBENAZINE TOSYLATE

@	ZYDUS LIFESCIENCES	EQ 40MG BASE	A216137	001	Aug 07, 2024	Feb	DISC
@		EQ 60MG BASE	A216137	002	Aug 07, 2024	Feb	DISC
@		EQ 80MG BASE	A216137	003	Aug 07, 2024	Feb	DISC

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	SPH ZHONGXI PHARM	EQ 450MG BASE	A218027	001	Apr 16, 2025	Apr	NEWA

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

@	PAI HOLDINGS	250MG/5ML	A077105	001	Jul 29, 2005	Apr	CAHN

VALSARTAN

SOLUTION;ORAL

PREXXARTAN

@ +	CARMEL BIOSCIENCES	4MG/ML	N209139	001	Dec 19, 2017	May	CPOT

VALSARTAN

AB !	NOVITIUM PHARMA	4MG/ML	A214102	001	Nov 02, 2021	May	CTEC
!		4MG/ML	A214102	001	Nov 02, 2021	May	CPOT
AB	RUBICON	4MG/ML	A216460	001	Jun 05, 2025	May	NEWA

TABLET;ORAL

VALSARTAN

AB	ACME LABS	40MG	A205347	001	Apr 09, 2018	Sep	CAHN
AB		80MG	A205347	002	Apr 09, 2018	Sep	CAHN
AB		160MG	A205347	003	Apr 09, 2018	Sep	CAHN
AB		320MG	A205347	004	Apr 09, 2018	Sep	CAHN
@	RENATA	40MG	A218169	001	Aug 05, 2024	Aug	CAHN
@		40MG	A218169	001	Aug 05, 2024	Feb	DISC
AB		40MG	A218169	001	Aug 05, 2024	Jan	CAHN
@		80MG	A218169	002	Aug 05, 2024	Aug	CAHN
@		80MG	A218169	002	Aug 05, 2024	Feb	DISC
AB		80MG	A218169	002	Aug 05, 2024	Jan	CAHN
@		160MG	A218169	003	Aug 05, 2024	Aug	CAHN
@		160MG	A218169	003	Aug 05, 2024	Feb	DISC
AB		160MG	A218169	003	Aug 05, 2024	Jan	CAHN
@		320MG	A218169	004	Aug 05, 2024	Aug	CAHN
@		320MG	A218169	004	Aug 05, 2024	Feb	DISC
AB		320MG	A218169	004	Aug 05, 2024	Jan	CAHN
@	SOMERSET THERAPS LLC	40MG	A218169	001	Aug 05, 2024	Sep	CAHN
@		80MG	A218169	002	Aug 05, 2024	Sep	CAHN
@		160MG	A218169	003	Aug 05, 2024	Sep	CAHN
@		320MG	A218169	004	Aug 05, 2024	Sep	CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

@	ABON PHARMS LLC	EQ 125MG BASE	A065478	001	Apr 09, 2012	Jul	CAHN
@		EQ 250MG BASE	A065478	002	Apr 09, 2012	Jul	CAHN

INJECTABLE;INJECTION

VANCOCIN HYDROCHLORIDE

@	STERISCIENCE	EQ 500MG BASE/VIAL	A060180	001		Apr	CAHN
@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Apr	CAHN
@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Apr	CAHN
@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Apr	CAHN
@		EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Apr	CAHN
@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Apr	CAHN
@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Apr	CAHN
@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Apr	CAHN
@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Apr	CAHN

VANCOMYCIN HYDROCHLORIDE

@	HOSPIRA INC	EQ 10GM BASE/VIAL	A065455	001	Apr 29, 2009	Jul	DISC
AP	MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan	CMFD
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan	CMFD
@	PLANO PHARMS	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010	Mar	CAHN

			INJECTABLE;INJECTION					
			VANCOMYCIN HYDROCHLORIDE					
		@		EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010	Mar CAHN
		@		EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Mar CAHN
		@		EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Mar CAHN
			POWDER;INTRAVENOUS					
			VANCOMYCIN HYDROCHLORIDE					
	AP		GLAND	EQ 750MG BASE/VIAL	A218140	001	Mar 21, 2025	Mar NEWA
	AP			EQ 1.25GM BASE/VIAL	A218140	002	Mar 21, 2025	Mar NEWA
	AP			EQ 1.5GM BASE/VIAL	A218140	003	Mar 21, 2025	Mar NEWA
	AP	+!	MYLAN LABS LTD	EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018	Mar CFTG
	AP		STERISCIENCE	EQ 750MG BASE/VIAL	A215324	001	Oct 02, 2025	Sep NEWA
	AP			EQ 1.25GM BASE/VIAL	A215324	002	Oct 02, 2025	Sep NEWA
	AP			EQ 1.5GM BASE/VIAL	A215324	003	Oct 02, 2025	Sep NEWA
			POWDER;INTRAVENOUS, ORAL					
			VANCOMYCIN HYDROCHLORIDE					
		+!	ZHEJIANG NOVUS PHARM	EQ 1.5MG BASE/VIAL	N210274	007	Aug 01, 2025	Aug NEWA
		+!		EQ 750MG BASE/VIAL	N210274	005	Aug 01, 2025	Aug NEWA
		+!		EQ 1.25GM BASE/VIAL	N210274	006	Aug 01, 2025	Aug NEWA
			SOLUTION;INTRAVENOUS					
			TYZAVAN					
		+!	HIKMA	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019	Jul CTNA
		+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020	Jul CTNA
		+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	Jul CTNA
		+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020	Jul CTNA
		+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019	Jul CTNA
		+!		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020	Jul CTNA
		+!		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	Jul CTNA
			VARENICLINE TARTRATE					
			TABLET;ORAL					
			CHANTIX					
	AB	+	PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Sep CMFD
	AB	+		EQ 1MG BASE	N021928	002	May 10, 2006	Sep CMFD
			VARENICLINE TARTRATE					
	AB		AUROBINDO PHARMA	EQ 0.5MG BASE	A214595	001	May 02, 2025	Apr NEWA
	AB			EQ 1MG BASE	A214595	002	May 02, 2025	Apr NEWA
	AB		HANDA PHARMS LLC	EQ 0.5MG BASE	A213268	001	May 21, 2025	May NEWA
	AB			EQ 1MG BASE	A213268	002	May 21, 2025	May NEWA
	AB		KANCHAN HLTHCARE	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Sep CAHN
	AB			EQ 1MG BASE	A217151	002	Jul 25, 2023	Sep CAHN
>A>	AB		MICRO LABS	EQ 0.5MG BASE	A218302	001	Oct 29, 2025	Oct NEWA
>A>	AB			EQ 1MG BASE	A218302	002	Oct 29, 2025	Oct NEWA
	AB		NORVIUM BIOSCIENCE	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	May CAHN
	AB			EQ 1MG BASE	A202019	002	Feb 28, 2024	May CAHN
	AB		PHARMOBEDIENT	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Jul CAHN
	AB			EQ 1MG BASE	A202019	002	Feb 28, 2024	Jul CAHN
		@	PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Feb DISC
		@		EQ 1MG BASE	A217115	002	Jul 23, 2024	Feb DISC
>D>	AB		RHODES PHARMS	EQ 0.5MG BASE	A213268	001	May 21, 2025	Oct DISC
>A>		@		EQ 0.5MG BASE	A213268	001	May 21, 2025	Oct DISC
	AB			EQ 0.5MG BASE	A213268	001	May 21, 2025	Jul CAHN
>D>	AB			EQ 1MG BASE	A213268	002	May 21, 2025	Oct DISC
>A>		@		EQ 1MG BASE	A213268	002	May 21, 2025	Oct DISC
	AB			EQ 1MG BASE	A213268	002	May 21, 2025	Jul CAHN
	AB		SHILPA	EQ 0.5MG BASE	A216615	001	Apr 08, 2025	Mar NEWA
	AB			EQ 1MG BASE	A216615	002	Apr 08, 2025	Mar NEWA
	AB		VIWIT PHARM	EQ 0.5MG BASE	A212879	001	May 06, 2025	Apr NEWA
	AB			EQ 1MG BASE	A212879	002	May 06, 2025	Apr NEWA
			VASOPRESSIN					
			SOLUTION;INTRAVENOUS					
			VASOPRESSIN IN DEXTROSE 5%					
	AP		GLAND	40UNITS/100ML (0.4UNITS/ML)	A216963	002	Aug 22, 2025	Aug NFTG
			VASOPRESSIN IN SODIUM CHLORIDE 0.9%					
		@ +	LONG GROVE PHARMS	50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	May DISC

	SOLUTION;INTRAVENOUS						
	VASOSTRICT						
AP	+! PH HEALTH	40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020	Aug	CFTG
	VENLAFAXINE HYDROCHLORIDE						
	CAPSULE, EXTENDED RELEASE;ORAL						
	VENLAFAXINE HYDROCHLORIDE						
AB	MEDICAP LABS	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Feb	CAHN
AB		EQ 75MG BASE	A201272	002	Nov 23, 2018	Feb	CAHN
AB		EQ 150MG BASE	A201272	003	Nov 23, 2018	Feb	CAHN
AB	SCIEGEN PHARMS INC	EQ 37.5MG BASE	A078865	001	Apr 14, 2011	Jul	CAHN
AB		EQ 75MG BASE	A078865	002	Apr 14, 2011	Jul	CAHN
AB		EQ 150MG BASE	A078865	003	Apr 14, 2011	Jul	CAHN
	TABLET;ORAL						
	VENLAFAXINE HYDROCHLORIDE						
	@ PHARMOBEDIENT	EQ 25MG BASE	A077166	001	Jun 13, 2008	Sep	CAHN
	@	EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Sep	CAHN
	@	EQ 50MG BASE	A077166	003	Jun 13, 2008	Sep	CAHN
	@	EQ 75MG BASE	A077166	004	Jun 13, 2008	Sep	CAHN
	@	EQ 100MG BASE	A077166	005	Jun 13, 2008	Sep	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	VENLAFAXINE HYDROCHLORIDE						
AB	ABON PHARMS LLC	EQ 150MG BASE	A217841	001	Feb 07, 2025	Jan	NEWA
AB		EQ 225MG BASE	A217841	002	Feb 07, 2025	Jan	NEWA
AB	ADAPTIS	EQ 75MG BASE	A213927	001	Jan 21, 2021	Sep	CAHN
AB	MPP PHARMA	EQ 150MG BASE	A205468	002	Mar 24, 2017	May	CAHN
AB		EQ 225MG BASE	A205468	003	Mar 24, 2017	May	CAHN
	@ TORRENT	EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jun	DISC
AB		EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jan	NEWA
	@	EQ 75MG BASE	A218180	002	Jan 28, 2025	Jun	DISC
AB		EQ 75MG BASE	A218180	002	Jan 28, 2025	Jan	NEWA
	@	EQ 150MG BASE	A218180	003	Jan 28, 2025	Jun	DISC
AB		EQ 150MG BASE	A218180	003	Jan 28, 2025	Jan	NEWA
	@	EQ 225MG BASE	A218180	004	Jan 28, 2025	Jun	DISC
AB		EQ 225MG BASE	A218180	004	Jan 28, 2025	Jan	NEWA
	VIBEGRON						
	TABLET;ORAL						
	GEMTESA						
	+! SUMITOMO PHARMA AM	75MG	N213006	001	Dec 23, 2020	Aug	CAHN
	VIGABATRIN						
	FOR SOLUTION;ORAL						
	VIGABATRIN						
	@ DEXCEL	500MG/PACKET	A214992	001	May 13, 2021	Sep	DISC
	TABLET;ORAL						
	VIGABATRIN						
	@ AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Feb	DISC
	@ CARNEGIE	500MG	A215519	001	Apr 28, 2023	May	CAHN
	@ RYAN LABS	500MG	A215519	001	Apr 28, 2023	Jan	DISC
	VIMSELTINIB						
	CAPSULE;ORAL						
	ROMVIMZA						
	+ DECIPHERA PHARMS	14MG	N219304	001	Feb 14, 2025	Feb	NEWA
	+	20MG	N219304	002	Feb 14, 2025	Feb	NEWA
	+!	30MG	N219304	003	Feb 14, 2025	Feb	NEWA
	VORICONAZOLE						
	FOR SUSPENSION;ORAL						
	VORICONAZOLE						
AB	HETERO LABS LTD V	200MG/5ML	A211598	001	Aug 08, 2025	Aug	NEWA
AB	ZHEJIANG POLY PHARM	200MG/5ML	A216805	001	Jan 02, 2024	Mar	CAHN
	POWDER;INTRAVENOUS						
	VFEND						
AP	+! PF PRISM CV	200MG/VIAL	N021267	001	May 24, 2002	Sep	CDFR
	VORICONAZOLE						
AP	ALMAJECT	200MG/VIAL	A206398	001	Mar 23, 2016	Sep	CDFR
AP	ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Sep	CDFR
	@ EUGIA PHARMA	200MG/VIAL	A212162	001	Feb 02, 2023	Sep	CDFR
AP	GLAND	200MG/VIAL	A211099	001	Mar 31, 2020	Sep	CDFR
AP	HIKMA	200MG/VIAL	N208562	001	Mar 09, 2017	Sep	CDFR

POWDER;INTRAVENOUS
VORICONAZOLE

AP		MEITHEAL	200MG/VIAL	A214516	001	May 09, 2022	Sep CDFR
	@	PHARMOBEDIENT	200MG/VIAL	A210849	001	Oct 11, 2022	Sep CDFR
AP		SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012	Sep CDFR
AP		SLATE RUN PHARMA	200MG/VIAL	A211661	001	Nov 30, 2018	Sep CDFR
AP		UBI	200MG/VIAL	A211264	001	Mar 09, 2023	Sep CDFR
AP		ZYDUS PHARMS	200MG/VIAL	A208983	001	Jul 16, 2018	Sep CDFR

WARFARIN SODIUM

TABLET;ORAL
WARFARIN SODIUM

	@	AIPING PHARM INC	1MG	A200104	001	Jun 27, 2013	Jul CAHN
	@		2MG	A200104	002	Jun 27, 2013	Jul CAHN
	@		2.5MG	A200104	003	Jun 27, 2013	Jul CAHN
	@		3MG	A200104	004	Jun 27, 2013	Jul CAHN
	@		4MG	A200104	005	Jun 27, 2013	Jul CAHN
	@		5MG	A200104	006	Jun 27, 2013	Jul CAHN
	@		6MG	A200104	007	Jun 27, 2013	Jul CAHN
	@		7.5MG	A200104	008	Jun 27, 2013	Jul CAHN
	@		10MG	A200104	009	Jun 27, 2013	Jul CAHN

ZALEPLON

CAPSULE;ORAL
SONATA

	@ +	PFIZER	5MG	N020859	001	Aug 13, 1999	Aug DISC
	@ +		10MG	N020859	002	Aug 13, 1999	Aug DISC

ZALEPLON

AB	!	UNICHEM	10MG	A078989	002	Jun 06, 2008	Aug CHRS

ZANUBRUTINIB

CAPSULE;ORAL
BRUKINSA

	@ +	BEONE MEDICINES USA	80MG	N213217	001	Nov 14, 2019	Aug DISC
	+!		80MG	N213217	001	Nov 14, 2019	Apr CAHN

TABLET;ORAL
BRUKINSA

	+!	BEONE MEDICINES USA	160MG	N218785	001	Jun 10, 2025	Jun NEWA

ZILEUTON

TABLET;ORAL
ZYFLO

>D>	@	CHIESI	300MG	N020471	001	Dec 09, 1996	Oct CRLD
>A>	@ +		300MG	N020471	001	Dec 09, 1996	Oct CRLD
>D>	+!		600MG	N020471	003	Dec 09, 1996	Oct DISC
>A>	@ +		600MG	N020471	003	Dec 09, 1996	Oct DISC

ZINC ACETATE

CAPSULE;ORAL
GALZIN

	+	ETON	EQ 25MG ZINC	N020458	001	Jan 28, 1997	Jan CAHN
	+!		EQ 50MG ZINC	N020458	002	Jan 28, 1997	Jan CAHN

ZINC CHLORIDE

INJECTABLE;INJECTION
ZINC CHLORIDE

AP		RK PHARMA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	May CAHN
AP		STIRA	EQ 1MG ZINC/ML	A217625	001	Apr 14, 2025	Apr NEWA

ZINC SULFATE

SOLUTION;INTRAVENOUS
ZINC SULFATE

AP		ASPIRO	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A219585	001	May 01, 2025	Apr NEWA
AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A219585	002	May 01, 2025	Apr NEWA
AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A219585	003	May 01, 2025	Apr NEWA
AP		RK PHARMA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	Sep CAHN
AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	Sep CAHN
AP			EQ 30MG BASE/10ML (EQ 3MG	A217624	003	Jun 10, 2025	Sep CAHN

SOLUTION;INTRAVENOUS
ZINC SULFATE

			BASE/ML)				
AP		STIRA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A217624	001	Jun 10, 2025	May NEWA
AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A217624	002	Jun 10, 2025	May NEWA
AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A217624	003	Jun 10, 2025	May NEWA

ZIPRASIDONE MESYLATE

POWDER;INTRAMUSCULAR
ZIPRASIDONE MESYLATE

AP		STERISCIENCE	EQ 20MG BASE/VIAL	A217595	001	Sep 03, 2025	Aug NEWA

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS
ZOLEDRONIC ACID

	@	APOTEX	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar DISC
	@	NOVAST LABS	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Sep CAHN

SOLUTION;INTRAVENOUS
ZOLEDRONIC ACID

	@	HOSPIRA	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Aug DISC

ZOLMITRIPTAN

SPRAY;NASAL
ZOLMITRIPTAN

AB		PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Apr CHRS

ZOMIG

AB	+!	AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Apr CHRS

TABLET;ORAL
ZOLMITRIPTAN

>A>	AB		CHARTWELL RX	2.5MG	A206973	001	Jun 30, 2017	Oct CAHN
>A>	AB			5MG	A206973	002	Jun 30, 2017	Oct CAHN
>D>	AB		SOMERSET THERAPS LLC	2.5MG	A206973	001	Jun 30, 2017	Oct CAHN
>D>	AB			5MG	A206973	002	Jun 30, 2017	Oct CAHN

ZOLPIDEM TARTRATE

TABLET;ORAL
AMBIEN

AB	+	COSETTE	5MG	N019908	001	Dec 16, 1992	Jan CAHN
AB	+!		10MG	N019908	002	Dec 16, 1992	Jan CAHN

ZOLPIDEM TARTRATE

	@	APOTEX INC	5MG	A077884	001	Apr 23, 2007	Mar DISC
	@		10MG	A077884	002	Apr 23, 2007	Mar DISC

TABLET;SUBLINGUAL
EDLUAR

AB	+	VIATRIS	5MG	N021997	001	Mar 13, 2009	Feb CAHN
AB	+!		10MG	N021997	002	Mar 13, 2009	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL
AMBIEN CR

AB	+	COSETTE	6.25MG	N021774	002	Sep 02, 2005	Jan CAHN
AB	+!		12.5MG	N021774	001	Sep 02, 2005	Jan CAHN

ZOLPIDEM TARTRATE

	@	APOTEX	6.25MG	A200266	001	Sep 10, 2013	Mar DISC
	@		12.5MG	A200266	002	Sep 10, 2013	Mar DISC

ZONGERTINIB

TABLET;ORAL
HERNEXEOS

	+!	BOEHRINGER INGELHEIM	60MG	N219042	001	Aug 08, 2025	Aug NEWA

ZONISAMIDE

CAPSULE;ORAL
ZONISAMIDE

	@	APOTEX	25MG	A077642	001	Dec 22, 2005	Mar DISC
	@		50MG	A077642	002	Dec 22, 2005	Mar DISC
	@		100MG	A077642	003	Dec 22, 2005	Mar DISC
	@	CHARTWELL RX	25MG	A077650	001	Apr 20, 2006	Aug CAHN
	@		50MG	A077650	002	Apr 20, 2006	Aug CAHN
	@		100MG	A077650	003	Apr 20, 2006	Aug CAHN

CAPSULE;ORAL

ZONISAMIDE

@	MACLEODS PHARMS LTD	25MG	A219507	001	May 12, 2025	Jul	DISC
AB		25MG	A219507	001	May 12, 2025	May	NEWA
@		50MG	A219507	002	May 12, 2025	Jul	DISC
AB		50MG	A219507	002	May 12, 2025	May	NEWA
@		100MG	A219507	003	May 12, 2025	Jul	DISC
AB		100MG	A219507	003	May 12, 2025	May	NEWA
@	SUN PHARM INDS (IN)	25MG	A077634	001	Mar 17, 2006	Jul	DISC
@		50MG	A077634	002	Mar 17, 2006	Jul	DISC
@		100MG	A077634	003	Mar 17, 2006	Jul	DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

@	STRIDES PHARMA	250MG;125MG	A217241	001	Jan 17, 2025	Jul DISC
		250MG;125MG	A217241	001	Jan 17, 2025	Jan NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE ALLERGY

	AUROBINDO PHARMA	0.2055MG/SPRAY	A216561	001	Jan 27, 2025	Jan NEWA

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@	AIPING PHARM INC	5MG	A202277	002	Mar 11, 2014	Jul CAHN
@		10MG	A202277	004	Mar 11, 2014	Jul CAHN
@	TARO	5MG	A078072	001	Jul 22, 2009	Aug DISC
@		5MG	A078072	003	Jul 22, 2009	Aug DISC

CETIRIZINE HYDROCHLORIDE HIVES

@	AIPING PHARM INC	5MG	A202277	001	Mar 11, 2014	Jul CAHN
@		10MG	A202277	003	Mar 11, 2014	Jul CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	TARO	10MG	A078072	002	Jul 22, 2009	Aug DISC
@		10MG	A078072	004	Jul 22, 2009	Aug DISC

ZYRTEC ALLERGY

+	KENVUE BRANDS	5MG	N019835	003	Nov 16, 2007	Apr CMFD

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	UNICHEM	5MG;120MG	A210507	001	Sep 10, 2024	Jun DISC

CHLORHEXIDINE GLUCONATE

CLOTH;TOPICAL

READYPREP CHG

+!	MEDLINE INDUSTRIES	2%	N207964	001	Nov 20, 2018	Aug CHRS
+		2%	N207964	001	Nov 20, 2018	Aug CRLD

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@	APOTEX	100MG	A074948	001	Jun 19, 1998	Mar DISC
@		200MG	A074948	002	Jul 26, 2002	Mar DISC

CLOTRIMAZOLE

CREAM;VAGINAL

TRIVAGIZOLE 3

	SUN PHARMA CANADA	2%	N021143	001	Apr 12, 2000	Aug CAHN

DOCOSANOL

CREAM;TOPICAL

DOCOSANOL

	DR REDDYS	10%	A214613	001	Oct 03, 2025	Sep NEWA
>A>		10%	A215505	001	Oct 23, 2025	Oct NEWA
	SUN PHARMA CANADA	10%	A214454	001	Oct 26, 2023	Sep CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

@	AMNEAL PHARMS NY	EQ 20MG BASE	A209716	001	Jun 05, 2019	Aug DISC
	GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	May CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

	CONTRACT PHARMACAL	60MG	A219032	001	Feb 28, 2025	Feb NEWA
		180MG	A219032	002	Feb 28, 2025	Feb NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>D>		AUROBINDO PHARMA LTD	180MG;240MG	A215232	001	Apr 17, 2025	Oct DISC
>A>	@		180MG;240MG	A215232	001	Apr 17, 2025	Oct DISC
			180MG;240MG	A215232	001	Apr 17, 2025	Apr NEWA
		L PERRIGO CO	60MG;120MG	A216792	001	Oct 07, 2025	Sep NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

		RUBICON	0.05MG/SPRAY	A219060	001	Aug 15, 2025	Aug NEWA

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

		STRIDES PHARMA	100MG/5ML	A211666	001	Feb 22, 2021	Aug CMFD

SUSPENSION/DROPS;ORAL

IBUPROFEN

		AUROBINDO PHARMA LTD	40MG/ML	A213506	001	Apr 08, 2024	May CMFD

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

		AUROBINDO PHARMA LTD	200MG;30MG	A213565	001	Mar 10, 2023	Sep CMFD
		STRIDES PHARMA	200MG;30MG	A077628	001	Aug 14, 2006	Apr CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	@	APOTEX	5MG	A211443	001	Apr 21, 2021	Jan DISC
		SANKALP LIFECARE	5MG	A211551	001	Nov 20, 2018	Jul CAHN

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

		ANNORA PHARMA	1.5MG	A219102	001	Sep 30, 2025	Sep NEWA

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

IMODIUM A-D

	@ +	KENVUE BRANDS	1MG/5ML	N019487	001	Mar 01, 1988	Apr DISC
	+!		1MG/7.5ML	N019487	002	Jul 08, 2004	Sep CDFR

LOPERAMIDE HYDROCHLORIDE

		BIONPHARMA	1MG/7.5ML	A220100	001	Sep 19, 2025	Sep NEWA
	@	PAI HOLDINGS	1MG/5ML	A074352	001	Nov 17, 1995	Feb CAHN
		PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011	Sep CDFR
	@	WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997	Apr DISC

LORATADINE

CAPSULE;ORAL

LORATADINE

		AUROBINDO PHARMA	10MG	A211900	001	Mar 24, 2023	Jun CMFD
	@	CATALENT PHARMA	10MG	A215127	001	Feb 28, 2025	Jun DISC
			10MG	A215127	001	Feb 28, 2025	Feb NEWA

SUSPENSION;ORAL

LORATADINE

	@ +	SUN PHARMA CANADA	1MG/ML	N021734	001	Oct 04, 2005	Aug CAHN
	@ +	TARO	1MG/ML	N021734	001	Oct 04, 2005	Aug DISC

TABLET;ORAL

LORATADINE

		ADAPTIS	10MG	A219223	001	Nov 21, 2024	Sep CAHN

TABLET, CHEWABLE;ORAL

LORATADINE

		SUN PHARM	10MG	A210088	002	Apr 25, 2025	Apr NEWA

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

	TARO	5%	A217998	001	Jun 30, 2025	Jun NEWA

MOMETASONE FUROATE

SPRAY, METERED;NASAL

MOMETASONE FUROATE

@	AUROBINDO PHARMA	0.05MG/SPRAY	A217498	001	Nov 22, 2024	May DISC

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

	ADAPTIS	220MG	A074635	001	Jan 13, 1997	Sep CAHN
@	NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018	Apr DISC

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

	DR REDDYS LABS SA	EQ 2MG BASE	A215276	001	Jul 17, 2025	Jul NEWA
		EQ 4MG BASE	A215276	002	Jul 17, 2025	Jul NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

	BAUSCH AND LOMB INC	EQ 0.1% BASE	A206046	001	Jul 26, 2017	May CMFD
		EQ 0.2% BASE	A206087	001	Dec 05, 2017	Feb CMFD
	FDC LTD	EQ 0.2% BASE	A217051	001	Jul 14, 2025	Jul NEWA
	GLENMARK PHARMS INC	EQ 0.2% BASE	A219557	001	Feb 28, 2025	Feb NEWA
	RISING	EQ 0.1% BASE	A204392	001	Mar 21, 2018	May CMFD
		EQ 0.2% BASE	A204620	001	Jun 16, 2020	Apr CMFD

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

@	APOTEX	20MG	A210070	001	Feb 11, 2019	Jan DISC

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

	MARKSANS PHARMA	EQ 20MG BASE	A218829	001	Aug 07, 2025	Aug NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

MIRALAX

+!	BAYER HEALTHCARE LLC	17GM/PACKET	N022015	002	Oct 06, 2006	Aug NEWA

POLYETHYLENE GLYCOL 3350

	ANI PHARMS	17GM/PACKET	A202850	002	Nov 30, 2021	Aug NEWA
	ANNORA PHARMA	17GM/PACKET	A214990	002	Apr 14, 2021	Aug NEWA
	AUROBINDO PHARMA LTD	17GM/PACKET	A209017	002	Apr 23, 2024	Aug NEWA
	NOVEL LABS INC	17GM/PACKET	A091077	002	Jun 27, 2011	Aug NEWA
	SHREE HARI INTL	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Aug CAHN

POTASSIUM IODIDE

TABLET;ORAL

THYROSAFE

	BTG INTL	130MG	A076350	002	Apr 02, 2025	Mar NFTG

>D> PSEUDOEPHEDRINE HYDROCHLORIDE

>D> TABLET, EXTENDED RELEASE;ORAL

>D> SUDAFED 24 HOUR

>D> +!	KENVUE BRANDS	240MG	N020021	002	Dec 15, 1992	Oct DISC
>A> @ +		240MG	N020021	002	Dec 15, 1992	Oct DISC

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2025

NO OCTOBER 2025 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO OCTOBER 2025 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA						
N 216793 001	11673877	Mar 27, 2038	DS DP U-2830			
	12383543	Jul 28, 2037	U-2830			
ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA						
N 216793 002	11673877	Mar 27, 2038	DS DP U-2830			
	12383543	Jul 28, 2037	U-2830			
ACALABRUTINIB - CALQUENCE						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		I-960	Jan 16, 2028
	10167291	Jul 01, 2036	DP U-2519			
	10167291	Jul 01, 2036	DP U-2666			
	10167291	Jul 01, 2036	DP U-2667			
	10167291	Jul 01, 2036	DP U-2668			
	10167291	Jul 01, 2036	DP U-2669			
	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10167291	Jul 01, 2036	DP U-2682			
	10167291	Jul 01, 2036	DP U-2683			
	10167291	Jul 01, 2036	DP U-2684			
	10167291	Jul 01, 2036	DP U-2685			
	10167291	Jul 01, 2036	DP U-2686			
	10167291	Jul 01, 2036	DP U-2687			
	10167291	Jul 01, 2036	DP U-4109			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
	9796721	Jul 01, 2036	DS DP U-4108			
ACALABRUTINIB MALEATE - CALQUENCE						
N 216387 001	10272083	Jan 21, 2035	U-2519		I-960	Jan 16, 2028
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	11059829	Jul 01, 2036	DS DP U-4108			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
ACECLIDINE HYDROCHLORIDE - VIZZ						
N 218585 001	10052313	Mar 24, 2034	DP U-3741		NCE	Jul 31, 2030
	11179328	Mar 24, 2034	U-3741			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACECLIDINE HYDROCHLORIDE - VIZZ							
N 218585	001	12128036	Oct 08, 2039	U-3741			
		12414942	Mar 15, 2044	U-3741			
		9844537	Mar 24, 2034	DP U-3741			
ACETAMINOPHEN - ACETAMINOPHEN							
A 214331	002					PC	Jan 07, 2026
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ							
N 208653	002	8748413	Jul 01, 2030	DS DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ							
N 208653	003	8748413	Jul 01, 2030	DS DP			
ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV							
N 215320	001	>A> 12220392	Oct 26, 2031	U-4306			
		>A> 12220392	Oct 26, 2031	U-4307			
ACETYLCYSTEINE - ACETADOTE							
N 021539	001					D-196	Nov 26, 2027
ACOLTREMON - TRYPTYR							
N 217370	001	10028920	Sep 08, 2031	U-1900		NCE	May 28, 2030
		11850221	Dec 16, 2042	DP U-1900			
		12336971	Dec 16, 2042	U-1900			
		9095609	Sep 08, 2031	DP U-1900			
		9433679	Sep 08, 2031	U-1900			
ACORAMIDIS HYDROCHLORIDE - ATTRUBY							
N 216540	001	9913826	May 05, 2031	U-4046		ODE-506	Nov 22, 2031
ADAGRASIB - KRAZATI							
N 216340	001	12281113	Sep 10, 2041	DS DP			
		12336995	Feb 05, 2041	U-3953			
		12383503	Aug 21, 2043	DP			
AFAMELANOTIDE - SCENESSE							
N 210797	001	8334265	Jan 20, 2033	U-2638			
ALBUMIN HUMAN - OPTISON							
N 020899	001					NPP	May 09, 2028
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT							
N 021747	001	7396341	Oct 10, 2026	DP	Y		
		7837235	Mar 13, 2028	DP	Y		
		8733341	Oct 16, 2030	DP	Y		
		9027967	Mar 31, 2027	DP	Y		
ALPELISIB - VIJOICE							
N 215039	001	>A> 12427141	Feb 17, 2037	U-4288			
ALPELISIB - VIJOICE							
N 215039	002	>A> 12427141	Feb 17, 2037	U-4288			
ALPELISIB - VIJOICE							
N 215039	003	>A> 12427141	Feb 17, 2037	U-4288			
ALPELISIB - VIJOICE							
N 218466	001	>A> 12427141	Feb 17, 2037	U-4288			
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	001	12233033	Aug 23, 2038	U-2106			
		12233033	Aug 23, 2038	U-2224			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	001	12233033	Aug 23, 2038	U-3180			
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	002	12233033	Aug 23, 2038	U-2106			
		12233033	Aug 23, 2038	U-2224			
		12233033	Aug 23, 2038	U-3180			
AMIKACIN SULFATE - ARIKAYCE KIT							
N 207356	001	12168021	May 15, 2035	U-2414			
		12168022	May 15, 2035	U-2414			
		12377114	May 15, 2035	U-2414			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER							
N 200656	001	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER							
N 200656	002	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER							
N 200656	003	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER							
N 200656	004	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER							
N 200656	005	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER							
N 200656	006	12390398	May 03, 2036	DP			
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER							
N 200656	007	12390398	May 03, 2036	DP			
AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN							
N 020965	001	11179574	Oct 13, 2036	U-804			
		11446512	Jan 17, 2037	U-804			
		11697028	Oct 13, 2036	U-804			
		12290700	Oct 13, 2036	U-804			
		12296011	Jan 12, 2038	U-3163			
AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ							
N 208081	001	12280146	Dec 08, 2043	DP			
AMISULPRIDE - BARHEMSYS							
N 209510	001	12005042	Feb 09, 2038	U-1744			
		12005042	Feb 09, 2038	U-2754			
		12005042	Feb 09, 2038	U-3467			
		12194022	Mar 10, 2031	U-1744			
		12194022	Mar 10, 2031	U-3467			
		12329740	Feb 09, 2038	U-2754			
		12329740	Feb 09, 2038	U-3467			
AMISULPRIDE - BARHEMSYS							
N 209510	002	12005042	Feb 09, 2038	U-1744			
		12005042	Feb 09, 2038	U-2754			
		12005042	Feb 09, 2038	U-3467			
		12194022	Mar 10, 2031	U-1744			
		12194022	Mar 10, 2031	U-3467			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMISULPRIDE - BARHEMSYS								
N 209510	002	12329740	Feb 09, 2038		U-2754			
		12329740	Feb 09, 2038		U-3467			
AMLODIPINE BENZOATE - KATERZIA								
N 211340	001	12336984	Oct 06, 2037		U-3447			
		12336984	Oct 06, 2037		U-3448			
	>A>	12383498	Oct 06, 2037		DP			
AMLODIPINE BESYLATE - NORLIQVA								
N 214439	001	12005141	Feb 24, 2041		DP U-3309			
		12005141	Feb 24, 2041		DP U-3310			
		12005141	Feb 24, 2041		DP U-3311			
		12226528	Feb 24, 2041		DP U-3309			
		12226528	Feb 24, 2041		DP U-3310			
		12226528	Feb 24, 2041		DP U-3311			
	>A>	12440441	Feb 24, 2041		DP U-3309			
	>A>	12440441	Feb 24, 2041		DP U-3310			
	>A>	12440441	Feb 24, 2041		DP U-3311			
AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK								
N 219423	001	10322117	Jan 23, 2038		DP		NP	Jun 05, 2028
		10799487	Jan 23, 2038		DP U-3448			
AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK								
N 219423	002	10322117	Jan 23, 2038		DP		NP	Jun 05, 2028
		10799487	Jan 23, 2038		DP U-3448			
AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK								
N 219423	003	10322117	Jan 23, 2038		DP		NP	Jun 05, 2028
		10799487	Jan 23, 2038		DP U-3448			
APALUTAMIDE - ERLEADA								
N 210951	001	12303493	Dec 03, 2035		DP			
		12303497	Jan 30, 2040		U-4201			
		12303497	Jan 30, 2040		U-4202			
APALUTAMIDE - ERLEADA								
N 210951	002	12303493	Dec 03, 2035		DP			
		12303497	Jan 30, 2040		U-4201			
		12303497	Jan 30, 2040		U-4202			
APIXABAN - ELIQUIS								
N 202155	001	6967208	Nov 21, 2026	DS	DP U-1167		NPP	Apr 17, 2028
		6967208	Nov 21, 2026	DS	DP U-1200		PED	Oct 17, 2028
		6967208	Nov 21, 2026	DS	DP U-1301			
		6967208	Nov 21, 2026	DS	DP U-1302			
		6967208	Nov 21, 2026	DS	DP U-1323			
		6967208	Nov 21, 2026	DS	DP U-1501			
		6967208	Nov 21, 2026	DS	DP U-1502			
		6967208	Nov 21, 2026	DS	DP U-1729			
		6967208	Nov 21, 2026	DS	DP U-1730			
		6967208	Nov 21, 2026	DS	DP U-4178			
		6967208*PED	May 21, 2027					
		9326945	Feb 24, 2031		DP			
		9326945*PED	Aug 24, 2031					
APIXABAN - ELIQUIS								
N 202155	002	6967208	Nov 21, 2026	DS	DP U-1200		NPP	Apr 17, 2028
		6967208	Nov 21, 2026	DS	DP U-1301		PED	Oct 17, 2028
		6967208	Nov 21, 2026	DS	DP U-1302			
		6967208	Nov 21, 2026	DS	DP U-1323			
		6967208	Nov 21, 2026	DS	DP U-4178			
		6967208*PED	May 21, 2027					
		9326945	Feb 24, 2031		DP			
		9326945*PED	Aug 24, 2031					

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APIXABAN - ELIQUIS							
N 202155	002	6967208	Nov 21, 2026	DS DP U-1200		NPP	Apr 17, 2028
		6967208	Nov 21, 2026	DS DP U-1301		PED	Oct 17, 2028
		6967208	Nov 21, 2026	DS DP U-1302			
		6967208	Nov 21, 2026	DS DP U-1323			
		6967208	Nov 21, 2026	DS DP U-4178			
		6967208*PED	May 21, 2027				
		9326945	Feb 24, 2031	DP			
		9326945*PED	Aug 24, 2031				
APIXABAN - ELIQUIS							
N 202155	003	6967208	Nov 21, 2026	DS DP U-4179		NS	Apr 17, 2028
		6967208*PED	May 21, 2027			PED	Oct 17, 2028
		9326945	Feb 24, 2031	DP			
		9326945*PED	Aug 24, 2031				
APIXABAN - ELIQUIS SPRINKLE							
N 220073	001	11896586	Nov 22, 2040	DP U-4180		NP	Apr 17, 2028
		11896586*PED	May 22, 2041			PED	Oct 17, 2028
		6967208	Nov 21, 2026	DS DP U-4180			
		6967208*PED	May 21, 2027				
APOMORPHINE HYDROCHLORIDE - ONAPGO							
N 214056	001					NP	Feb 03, 2028
APREMILAST - OTEZLA XR							
N 210745	001	10092541	May 29, 2034	U-2659		>A> M-299	Jul 20, 2026
		11752129	May 27, 2042	DP U-4264		>A> ODE*	Jul 19, 2026
		11752129	May 27, 2042	DP U-4265		>A> PED	Jan 19, 2027
		11752129	May 27, 2042	DP U-4266		>A> PED	Jan 20, 2027
		11969409	May 27, 2042	DP			
	>A>	12427136	May 27, 2042	U-1858			
	>A>	12427136	May 27, 2042	U-4290			
	>A>	12427136	May 27, 2042	U-4291			
		7427638	Feb 16, 2028	DS DP			
APREPITANT - CINVANTI							
N 209296	001	12290520	Sep 18, 2035	DP			
APREPITANT - APONVIE							
N 216457	001	12290520	Sep 18, 2035	DP			
APROCITENTAN - TRYVIO							
N 217686	001	12297189	Feb 26, 2038	DP			
ARIPIPRAZOLE - MEZOFY							
N 211448	001	9694008	Aug 07, 2033	DP			
ARIPIPRAZOLE - MEZOFY							
N 211448	002	9694008	Aug 07, 2033	DP			
ARIPIPRAZOLE - MEZOFY							
N 211448	003	9694008	Aug 07, 2033	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA							
N 207533	001	11969469	Oct 24, 2033	DP			
		12251381	Apr 06, 2039	U-543			
		12311027	Sep 19, 2033	DP U-543			
ARIPIPRAZOLE LAUROXIL - ARISTADA							
N 207533	002	11969469	Oct 24, 2033	DP			
		12251381	Apr 06, 2039	U-543			
		12311027	Sep 19, 2033	DP U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039	U-543			
	12311027	Sep 19, 2033	DP U-543			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 004	11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039	U-543			
	12311027	Sep 19, 2033	DP U-543			
ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT						
N 209830 001	12251381	Apr 06, 2039	U-543			
ARTICAINE HYDROCHLORIDE - CYKLX						
N 218643 001					NP	Aug 15, 2028
ASCIMINIB HYDROCHLORIDE - SCEMBLIX						
N 215358 001	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
ASCIMINIB HYDROCHLORIDE - SCEMBLIX						
N 215358 002	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
ASCIMINIB HYDROCHLORIDE - SCEMBLIX						
N 215358 003	12252478	May 14, 2040	DP			
	12252479	May 17, 2040	U-1374			
ATOGEPANT - QULIPTA						
N 215206 001	12090148	Jul 29, 2041	U-3534			
	12350259	Feb 27, 2043	U-4234			
	12383545	Jun 06, 2039	U-3534			
ATOGEPANT - QULIPTA						
N 215206 002	12090148	Jul 29, 2041	U-3534			
	12383545	Jun 06, 2039	U-3534			
ATOGEPANT - QULIPTA						
N 215206 003	12383545	Jun 06, 2039	U-3534			
ATORVASTATIN CALCIUM - ATORVALIQ						
N 213260 001	12370136	Jun 07, 2037	DP			
ATRASENTAN HYDROCHLORIDE - VANRAFIA						
N 219208 001	10016393	Jul 07, 2034	DP		NCE	Apr 02, 2030
	11491137	Dec 16, 2040	U-3980			
	11874283	Feb 18, 2032	U-3980			
	11998526	Dec 16, 2040	U-3980			
	12121509	Dec 16, 2040	U-3980			
	12370174	Dec 16, 2040	U-3980			
	8623819	Aug 22, 2028	U-3980			
	9364458	Jul 07, 2034	DP U-3980			
AVACINCAPTAD PEGOL SODIUM - IZERVAY						
N 217225 001	7579456	Feb 14, 2026	DS			
	9617546	Feb 14, 2026	DS U-3673			
AVAPRITINIB - AYVAKIT						
N 212608 004	12252494	Apr 10, 2040	U-3506			
AVATROMBOPAG MALEATE - DOPTELET						
N 210238 001					>A> I-974	Jul 24, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AVATROMBOPAG MALEATE - DOPTELET SPRINKLE									
N 219696	001		7638536	Jul 28, 2027	DS	DP	>A>	NP	Jul 24, 2028
AVIBACTAM SODIUM; AZTREONAM - EMBLAVEO									
N 217906	001		7112592	Jan 07, 2026	DS	DP U-4147		NP	Feb 07, 2028
			7612087	Nov 12, 2026		DP		GAIN	Feb 07, 2033
			8471025	Aug 12, 2031	DS				
			8835455	Oct 08, 2030		DP			
			8969566	Jun 15, 2032	DS				
			9284314	Jun 15, 2032	DS				
			9695122	Jun 15, 2032	DS	DP			
AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)									
N 219616	001		11400090	Oct 29, 2038		U-4196		NCE	May 08, 2030
			11517573	Sep 11, 2040		U-4196			
			11517573	Sep 11, 2040		U-4205			
			11873296	Dec 29, 2042		DP U-4196			
			7897792	Feb 09, 2027	DS	DP			
			7928109	Aug 21, 2029	DS	DP			
			8247411	Apr 17, 2028	DS	DP			
BACLOFEN - BACLOFEN									
A 214445	001							PC	Jul 14, 2025
BALOXAVIR MARBOXIL - XOFLUZA									
N 210854	001							M-187	Dec 19, 2027
BALOXAVIR MARBOXIL - XOFLUZA									
N 210854	002							M-187	Dec 19, 2027
BALOXAVIR MARBOXIL - XOFLUZA									
N 210854	003							M-187	Dec 19, 2027
BALOXAVIR MARBOXIL - XOFLUZA									
N 214410	001							M-187	Dec 19, 2027
BALOXAVIR MARBOXIL - XOFLUZA									
N 214410	002		10392406	Apr 27, 2036	DS				
			10633397	Apr 27, 2036		U-2816			
			10633397	Apr 27, 2036		U-3000			
			10759814	Aug 09, 2037	DS	DP			
			11261198	Sep 25, 2038		DP			
			11306106	Aug 09, 2037		U-2816			
			11306106	Aug 09, 2037		U-3000			
			11925648	Apr 21, 2041		DP			
			8927710	May 05, 2031		DP			
			8987441	Sep 21, 2031	DS	DP			
			9815835	Jun 14, 2030		DP			
BALOXAVIR MARBOXIL - XOFLUZA									
N 214410	003		10392406	Apr 27, 2036	DS				
			10633397	Apr 27, 2036		U-2816			
			10633397	Apr 27, 2036		U-3000			
			10759814	Aug 09, 2037	DS	DP			
			11261198	Sep 25, 2038		DP			
			11306106	Aug 09, 2037		U-2816			
			11306106	Aug 09, 2037		U-3000			
			11925648	Apr 21, 2041		DP			
			8927710	May 05, 2031		DP			
			8987441	Sep 21, 2031	DS	DP			
			9815835	Jun 14, 2030		DP			
BECLOMETHASONE DIPROPIONATE - QVAR 80									
N 020911	001	>A>	10022509	May 18, 2031		DP	Y		
		>A>	10022510	May 18, 2031		DP	Y		
		>A>	10086156	May 18, 2031		DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BECLOMETHASONE DIPROPIONATE - QVAR 80							
N 020911	001	9463289	May 18, 2031	DP	Y		
		9808587	May 18, 2031	DP	Y		
BECLOMETHASONE DIPROPIONATE - QVAR 40							
N 020911	002	>A> 10022509	May 18, 2031	DP	Y		
		>A> 10022510	May 18, 2031	DP	Y		
		>A> 10086156	May 18, 2031	DP	Y		
		9463289	May 18, 2031	DP	Y		
		9808587	May 18, 2031	DP	Y		
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER							
N 207921	001	>A> 10022509	May 18, 2031	DP	Y		
		>A> 10022510	May 18, 2031	DP	Y		
		>A> 10086156	May 18, 2031	DP	Y		
		10561808	Jan 01, 2032	DP	Y		
		>A> 10695512	May 18, 2031	DP	Y		
		11395889	May 18, 2031	DP	Y		
		12296089	Jan 26, 2038	DP			
		8132712	Sep 07, 2028	DP	Y		
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER							
N 207921	002	>A> 10022509	May 18, 2031	DP	Y		
		>A> 10022510	May 18, 2031	DP	Y		
		>A> 10086156	May 18, 2031	DP	Y		
		10561808	Jan 01, 2032	DP	Y		
		>A> 10695512	May 18, 2031	DP	Y		
		11395889	May 18, 2031	DP	Y		
		>A> 11865247	Jan 26, 2038	DP	Y		
		>A> 11896759	Jan 26, 2038	DP	Y		
		12296089	Jan 26, 2038	DP			
		8132712	Sep 07, 2028	DP	Y		
BEDAQUILINE FUMARATE - SIRTURO							
N 204384	002					ODE*	Aug 09, 2026
BELUMOSUDIL MESYLATE - REZUROCK							
N 214783	001	10183931	Oct 07, 2033	U-3246			
		10183931	Oct 07, 2033	U-4260			
		10696660	Oct 07, 2033	U-3246			
		10696660	Oct 07, 2033	U-4260			
		8357693	Oct 30, 2029	DS DP U-4259			
BELZUTIFAN - WELIREG							
N 215383	001	12358870	Jun 30, 2042	DP		I-968	May 14, 2028
		9908845	Sep 05, 2034	DS DP U-3201			
		9908845	Sep 05, 2034	DS DP U-4176			
		9908845	Sep 05, 2034	DS DP U-4195			
		RE49948	Sep 05, 2034	DS DP U-3201			
		RE49948	Sep 05, 2034	DS DP U-4176			
		RE49948	Sep 05, 2034	DS DP U-4195			
BEMPEDOIC ACID - NEXLETOL							
N 211616	001	12398087	Jun 19, 2040	DS DP			
		12404227	Jun 19, 2040	DS U-4258			
BEMPEDOIC ACID; EZETIMIBE - NEXLIZET							
N 211617	001	12398087	Jun 19, 2040	DS DP			
		12404227	Jun 19, 2040	DS U-4258			
BENDAMUSTINE HYDROCHLORIDE - BELRAPZO							
N 205580	001	12138248	Jan 28, 2031	DP			
		12350257	Jan 28, 2031	DP U-1542			
		12350257	Jan 28, 2031	DP U-1971			
		12350257	Jan 28, 2031	DP U-1972			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - BENDEKA						
N 208194 001	12138248	Jan 28, 2031	DP			
	12350257	Jan 28, 2031	DP U-1542			
	12350257	Jan 28, 2031	DP U-1971			
	12350257	Jan 28, 2031	DP U-1972			
BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA						
N 212209 001	12208086	Jul 29, 2042	DP			
BENZGALANTAMINE GLUCONATE - ZUNVEYL						
N 218549 001	12208167	Feb 26, 2044	DP U-713			
BENZGALANTAMINE GLUCONATE - ZUNVEYL						
N 218549 002	12208167	Feb 26, 2044	DP U-713			
BENZGALANTAMINE GLUCONATE - ZUNVEYL						
N 218549 003	12208167	Feb 26, 2044	DP U-713			
BENZOYL PEROXIDE - EPSOLAY						
N 214510 001	12257348	May 23, 2041	DP U-3947			
	12295935	Dec 27, 2040	U-3356			
	12350382	Feb 03, 2028	DP			
BENZOYL PEROXIDE; TRETINOIN - TWYNEO						
N 214902 001	12257348	May 23, 2041	DP U-3987			
	12295935	Dec 27, 2040	U-3987			
	12357602	Jul 12, 2038	DP U-3987			
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO						
N 214094 001	10125102	Apr 07, 2035	DS U-3010		ODE-333	Dec 03, 2027
	10125102*PED	Oct 07, 2035			PED	Jun 03, 2028
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS U-3010			
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035	U-3010			
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039	DP U-3010			
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035	U-3300			
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039	U-3300			
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035	U-3300			
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039	U-3010			
	12344585*PED	May 01, 2040				
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO						
N 214094 002	10125102	Apr 07, 2035	DS U-3010		ODE-333	Dec 03, 2027
	10125102*PED	Oct 07, 2035			PED	Jun 03, 2028
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS U-3010			
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035	U-3010			
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039	DP U-3010			
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035	U-3300			
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039	U-3300			
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035	U-3300			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO								
N 214094	002		11708333*PED	Sep 09, 2035				
			12116346	Mar 09, 2035	DS			
			12116346*PED	Sep 09, 2035				
			12344585	Nov 01, 2039	U-3010			
			12344585*PED	May 01, 2040				
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY								
N 210251	001		7390791	Jan 07, 2025	DS DP			
			7390791*PED	Jul 07, 2025				
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY								
N 210251	002		7390791	Jan 07, 2025	DS DP			
			7390791*PED	Jul 07, 2025				
BIMATOPROST - ZOLYMBUS								
N 217307	001	>A>	10314780	Jun 08, 2036	DP U-1295			
BINIMETINIB - MEKTOVI								
N 210498	001		7777050	Mar 13, 2026	DS DP			
BIRCH TRITERPENES - FILSUVEZ								
N 215064	001		12268695	Jan 04, 2039	U-3811			
			8828444	Jun 21, 2026	DP			
BOSENTAN - BOSENTAN								
A 213154	001						PC	Feb 14, 2026
BRENSOCATIB - BRINSUPRI								
N 217673	001		10287258	Jan 21, 2035	DS U-4257		NCE	Aug 12, 2030
			10669245	Jan 21, 2035	DS U-4257			
			11655221	Jan 21, 2035	DP U-4257			
			11655222	Jan 21, 2035	DS U-4257			
			11655223	Jan 21, 2035	DS U-4257			
			11655224	Jan 21, 2035	DP U-4257			
			11673871	Jan 21, 2035	DP U-4257			
			11773069	Jan 21, 2035	DP U-4257			
			11814359	Jan 21, 2035	DS U-4257			
			12054465	Jan 21, 2035	DS U-4257			
			12059424	Feb 21, 2040	DP			
			12201638	Mar 01, 2039	DP			
			9522894	Mar 12, 2035	DS			
			9815805	Jan 21, 2035	U-4257			
BRENSOCATIB - BRINSUPRI								
N 217673	002		10287258	Jan 21, 2035	DS U-4257		NCE	Aug 12, 2030
			10669245	Jan 21, 2035	DS U-4257			
			11655221	Jan 21, 2035	DP U-4257			
			11655222	Jan 21, 2035	DS U-4257			
			11655223	Jan 21, 2035	DS U-4257			
			11655224	Jan 21, 2035	DP U-4257			
			11673871	Jan 21, 2035	DP U-4257			
			11773069	Jan 21, 2035	DP U-4257			
			11814359	Jan 21, 2035	DS U-4257			
			12054465	Jan 21, 2035	DS U-4257			
			12059424	Feb 21, 2040	DP			
			12201638	Mar 01, 2039	DP			
			9522894	Mar 12, 2035	DS			
			9815805	Jan 21, 2035	U-4257			
BREXPIPRAZOLE - REXULTI								
N 205422	001						M-315	May 09, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BREXPIPRAZOLE - REXULTI						
N 205422 002					M-315	May 09, 2028
BREXPIPRAZOLE - REXULTI						
N 205422 003					M-315	May 09, 2028
BREXPIPRAZOLE - REXULTI						
N 205422 004					M-315	May 09, 2028
BREXPIPRAZOLE - REXULTI						
N 205422 005					M-315	May 09, 2028
BREXPIPRAZOLE - REXULTI						
N 205422 006					M-315	May 09, 2028
BUDESONIDE - TARPEYO						
N 215935 001	12171882	Jan 23, 2043	U-4085			
	12171882	Jan 23, 2043	U-4086			
	12171883	Jan 23, 2043	DP			
	12311057	Jan 23, 2043	DP U-4085			
	12311057	Jan 23, 2043	DP U-4086			
	12311057	Jan 23, 2043	DP U-4204			
BUMETANIDE - ENBUMYST						
N 219500 001	11123319	Dec 04, 2040	DP			
	>A> 11260038	Dec 04, 2040	U-4279			
	>A> 12329731	Dec 04, 2040	DP U-4279			
BUPIVACAINE - EXPAREL						
N 022496 001	12226610	Feb 02, 2043	U-4148			
	12226610	Feb 02, 2043	U-4149			
	12226610	Feb 02, 2043	U-4150			
	12251468	Jul 02, 2044	DP U-4152			
	12296047	Jan 22, 2041	DP U-4184			
	12318483	Jul 02, 2044	U-4152			
	12370142	Jul 02, 2044	DP U-4152			
BUPIVACAINE - EXPAREL						
N 022496 002	12226610	Feb 02, 2043	U-4148			
	12226610	Feb 02, 2043	U-4149			
	12226610	Feb 02, 2043	U-4150			
	12251468	Jul 02, 2044	DP U-4152			
	12296047	Jan 22, 2041	DP U-4184			
	12318483	Jul 02, 2044	U-4152			
	12370142	Jul 02, 2044	DP U-4152			
BUPRENORPHINE - SUBLOCADE						
N 209819 001					M-314	Feb 21, 2028
BUPRENORPHINE - SUBLOCADE						
N 209819 002					M-314	Feb 21, 2028
BUPRENORPHINE - BRIXADI						
N 210136 001	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
BUPRENORPHINE - BRIXADI						
N 210136 002	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
BUPRENORPHINE - BRIXADI						
N 210136 003	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE - BRIXADI						
N 210136 004	12161640	Jul 26, 2032	DP		U-4100	
	12318379	Jul 26, 2032	DP		U-4100	
BUPRENORPHINE - BRIXADI						
N 210136 005	12161640	Jul 26, 2032	DP		U-4100	
	12318379	Jul 26, 2032	DP		U-4100	
BUPRENORPHINE - BRIXADI						
N 210136 006	12161640	Jul 26, 2032	DP		U-4100	
	12318379	Jul 26, 2032	DP		U-4100	
BUPRENORPHINE - BRIXADI						
N 210136 007	12161640	Jul 26, 2032	DP		U-4100	
	12318379	Jul 26, 2032	DP		U-4100	
BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY						
N 215430 001	12310961	Jan 20, 2043			U-3419	
	12357697	Jan 20, 2043			U-3419	
	12390428	Dec 01, 2041			U-3419	
CABOTEGRAVIR - APRETUDE						
N 215499 001	8410103	Feb 04, 2031	DS	DP		
CABOTEGRAVIR SODIUM - VOCABRIA						
N 212887 001	8410103	Feb 04, 2031	DS	DP	U-3348	
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT						
N 212888 001	11389448	Apr 13, 2032		DP		
	12178815	Jul 18, 2038			U-3348	
	8410103	Feb 04, 2031	DS	DP	U-3348	
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT						
N 212888 002	11389448	Apr 13, 2032		DP		
	12178815	Jul 18, 2038			U-3348	
	8410103	Feb 04, 2031	DS	DP	U-3348	
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 001	11098015	Jan 15, 2030			U-1220	
	11098015	Jan 15, 2030			U-1480	
	11098015	Jan 15, 2030			U-2488	
	11098015	Jan 15, 2030			U-3225	
	11098015	Jan 15, 2030			U-4131	
	11098015	Jan 15, 2030			U-4156	
	12128039	Feb 10, 2032		DP	U-1220	
	12128039	Feb 10, 2032		DP	U-1480	
	12128039	Feb 10, 2032		DP	U-2488	
	12128039	Feb 10, 2032		DP	U-3225	
	12128039	Feb 10, 2032		DP	U-4131	
	12128039	Feb 10, 2032		DP	U-4156	
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 002	11098015	Jan 15, 2030			U-1220	
	11098015	Jan 15, 2030			U-1480	
	11098015	Jan 15, 2030			U-2488	
	11098015	Jan 15, 2030			U-3225	
	11098015	Jan 15, 2030			U-4131	
	11098015	Jan 15, 2030			U-4156	
	12128039	Feb 10, 2032		DP	U-1220	
	12128039	Feb 10, 2032		DP	U-1480	
	12128039	Feb 10, 2032		DP	U-2488	
	12128039	Feb 10, 2032		DP	U-3225	
	12128039	Feb 10, 2032		DP	U-4131	
	12128039	Feb 10, 2032		DP	U-4156	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 003	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 208418 004	10130646	Jul 25, 2037	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE						
N 208418 005	10130646	Jul 25, 2037	DP			
CANAGLIFLOZIN - INVOKANA						
N 204042 001					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN - INVOKANA						
N 204042 002					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 001					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 002					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 003					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 004					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 001					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 002					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 003					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 004					NPP	Dec 18, 2027
					PED	Jun 18, 2028
CANTHARIDIN - YCANTH						
N 212905 001	12233042	Aug 22, 2038	DP U-3663			
	12290651	Feb 19, 2041	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CAPIVASERTIB - TRUQAP							
N 218197	001	12252495	Oct 10, 2028	U-3762			
CAPIVASERTIB - TRUQAP							
N 218197	002	12252495	Oct 10, 2028	U-3762			
CAPMATINIB HYDROCHLORIDE - TABRECTA							
N 213591	001	10596178	Jul 22, 2035	DP			
		12208101	Jul 22, 2035	DP			
CAPMATINIB HYDROCHLORIDE - TABRECTA							
N 213591	002	10596178	Jul 22, 2035	DP			
		12208101	Jul 22, 2035	DP			
CARBIDOPA; LEVODOPA - CREXONT							
N 217186	001	12194150	Dec 21, 2041	U-219			
		12201596	Dec 21, 2041	U-1649			
		12201596	Dec 21, 2041	U-4004			
		12201596	Dec 21, 2041	U-4005			
		12263148	Dec 21, 2041	U-1649			
		12263148	Dec 21, 2041	U-219			
		12263148	Dec 21, 2041	U-4004			
		12263148	Dec 21, 2041	U-4005			
		12263149	Dec 21, 2041	U-1649			
		12263149	Dec 21, 2041	U-219			
		12263149	Dec 21, 2041	U-4004			
		12263149	Dec 21, 2041	U-4005			
		12274793	Oct 07, 2034	DP			
		12295931	Dec 21, 2041	U-1649			
		12295931	Dec 21, 2041	U-219			
		12295931	Dec 21, 2041	U-4004			
		12295931	Dec 21, 2041	U-4005			
		12303481	Dec 21, 2041	U-1649			
		12303481	Dec 21, 2041	U-219			
		12303481	Dec 21, 2041	U-4004			
		12303481	Dec 21, 2041	U-4005			
		12303482	Dec 21, 2041	U-1649			
		12303482	Dec 21, 2041	U-219			
		12303482	Dec 21, 2041	U-4004			
		12303482	Dec 21, 2041	U-4005			
		12303605	Oct 07, 2034	DP			
		12370163	Dec 21, 2041	U-1649			
		12370163	Dec 21, 2041	U-219			
		12370163	Dec 21, 2041	U-4004			
		12370163	Dec 21, 2041	U-4005			
		12403099	Oct 07, 2034	DP			
CARBIDOPA; LEVODOPA - CREXONT							
N 217186	002	12194150	Dec 21, 2041	U-219			
		12201596	Dec 21, 2041	U-1649			
		12201596	Dec 21, 2041	U-4004			
		12201596	Dec 21, 2041	U-4005			
		12263148	Dec 21, 2041	U-1649			
		12263148	Dec 21, 2041	U-219			
		12263148	Dec 21, 2041	U-4004			
		12263148	Dec 21, 2041	U-4005			
		12263149	Dec 21, 2041	U-1649			
		12263149	Dec 21, 2041	U-219			
		12263149	Dec 21, 2041	U-4004			
		12263149	Dec 21, 2041	U-4005			
		12274793	Oct 07, 2034	DP			
		12295931	Dec 21, 2041	U-1649			
		12295931	Dec 21, 2041	U-219			
		12295931	Dec 21, 2041	U-4004			
		12295931	Dec 21, 2041	U-4005			
		12303481	Dec 21, 2041	U-1649			
		12303481	Dec 21, 2041	U-219			
		12303481	Dec 21, 2041	U-4004			

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 002	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	12403099	Oct 07, 2034	DP			
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 003	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	12403099	Oct 07, 2034	DP			
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 004	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - CREXONT						
N 217186 004	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	12403099	Oct 07, 2034	DP			
CARBOPLATIN - KYXATA						
N 219921 001	12427104	Apr 01, 2045	DP			
CARBOPLATIN - KYXATA						
N 219921 002	12427104	Apr 01, 2045	DP			
CARBOPLATIN - KYXATA						
N 219921 003	12427104	Apr 01, 2045	DP			
CARFILZOMIB - KYPROLIS						
N 202714 001	7417042	Jul 20, 2026	DS DP		M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
CARFILZOMIB - KYPROLIS						
N 202714 002	7417042	Jul 20, 2026	DS DP		M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
CARFILZOMIB - KYPROLIS						
N 202714 003	7417042	Jul 20, 2026	DS DP		M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
CASIMERSEN - AMONDYS 45						
N 213026 001	RE48960	Feb 16, 2029	DS DP U-3087			
	RE48960	Feb 16, 2029	DS DP U-3088			
CEDAZURIDINE; DECITABINE - INQOVI						
N 212576 001	12195496	Oct 07, 2040	DP			
	12239653	Feb 24, 2041	U-2865			
	12239653	Feb 24, 2041	U-2866			
CERITINIB - ZYKADIA						
N 211225 001	12357630	Dec 13, 2037	U-3096			
CHENODIOL - CTEXLI						
N 219488 001					NP	Feb 21, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CHLOROPROCAINE HYDROCHLORIDE - IHEEZO							
N 216227	001	11969403	May 14, 2039	DP			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIQ							
N 209589	001	>A> 12458634	Jan 27, 2038	DP			
CLASCOTERONE - WINLEVI							
N 213433	001	12337002	Jul 24, 2028	DP U-3280			
		8865690	Dec 27, 2025	U-2942			
CLINDAMYCIN PHOSPHATE - XACIATO							
N 215650	001	12303563	Sep 22, 2036	DP			
CLOBAZAM - SYMPAZAN							
N 210833	001	>A> 12290597	Sep 05, 2039	DP U-724			
		>A> 12403090	Sep 05, 2039	DP U-724			
CLOBAZAM - SYMPAZAN							
N 210833	002	>A> 12290597	Sep 05, 2039	DP U-724			
		>A> 12403090	Sep 05, 2039	DP U-724			
CLONIDINE HYDROCHLORIDE - JAVADIN							
N 220256	001	>A> 12233049	Jul 15, 2042	DP			
		>A> 12440474	Jul 15, 2042	DP			
CLOTRIMAZOLE - CLOTIC							
N 217628	001	>A> 12246006	May 26, 2042	DP U-4276		>A> NP	Sep 26, 2028
						>A> GAIN	Sep 26, 2033
COBICISTAT - TYBOST							
N 203094	002	10039718	Oct 06, 2032	DP			
		10039718*PED	Apr 06, 2033				
		8148374	Sep 03, 2029	DS DP U-1279			
		8148374*PED	Mar 03, 2030				
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX							
N 205395	001	8148374	Sep 03, 2029	DS DP U-1279			
		8148374	Sep 03, 2029	DS DP U-2939			
		8148374	Sep 03, 2029	DS DP U-4162			
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX							
N 205395	002	10039718	Oct 06, 2032	DP			
		7700645	Dec 26, 2026	DS DP			
		7700645*PED	Jun 26, 2027				
		8148374	Sep 03, 2029	DS DP U-4162			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA							
N 207561	001	7390791	Jan 07, 2025	DS DP			
		7390791*PED	Jul 07, 2025				
COLCHICINE - GLOPERBA							
N 210942	001	12274751	Nov 22, 2036	U-2814			
COLCHICINE - LODOCO							
N 215727	001	12233035	Nov 01, 2033	U-4132			
		12280025	Nov 01, 2033	U-4168			
		12364675	Nov 01, 2033	U-3639			
COPPER - MIUDELLA							
N 218201	001	10022264	Mar 22, 2034	DP		NP	Feb 24, 2028
		10159596	Aug 14, 2032	DP			
		10166141	Jun 13, 2034	DP			
		10188546	Aug 14, 2032	DP			
		10398588	Feb 24, 2034	DP U-4155			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COPPER - MIUDELLA							
N 218201	001	10918516	Jan 23, 2037	DP			
		11207209	Aug 16, 2034	DP			
		11850181	Aug 14, 2032	DP			
		12138199	Oct 18, 2033	DP			
		9089418	Apr 09, 2033	DP			
		9265652	Apr 28, 2034			U-4155	
		9427351	Aug 14, 2032	DP			
		9610191	Feb 24, 2034			U-4155	
COPPER CU-64 DOTATATE - DETECTNET							
N 213227	001	10383961	Jul 02, 2033			U-2951	
CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)							
N 008372	003	11752199	Jul 18, 2041			U-3686	
		11752199	Jul 18, 2041			U-3687	
		11752199	Jul 18, 2041			U-3688	
CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)							
N 008372	004	11752199	Jul 18, 2041			U-3686	
		11752199	Jul 18, 2041			U-3687	
		11752199	Jul 18, 2041			U-3688	
CORTICOTROPIN - ACTHAR GEL							
N 008372	008	11752199	Jul 18, 2041			U-3686	
		11752199	Jul 18, 2041			U-3687	
		11752199	Jul 18, 2041			U-3688	
CORTICOTROPIN - PURIFIED CORTROPHIN GEL							
N 008975	002	12233105	Oct 27, 2043			U-3904	
		12233105	Oct 27, 2043			U-3905	
		12233105	Oct 27, 2043			U-3906	
		12233105	Oct 27, 2043			U-3907	
		12233105	Oct 27, 2043			U-3908	
		12233105	Oct 27, 2043			U-3909	
		12233105	Oct 27, 2043			U-3910	
		12233105	Oct 27, 2043			U-3911	
		12233105	Oct 27, 2043			U-3912	
		12233105	Oct 27, 2043			U-3913	
		12233105	Oct 27, 2043			U-3914	
		12233105	Oct 27, 2043			U-3915	
		12233105	Oct 27, 2043			U-3916	
		12233105	Oct 27, 2043			U-3917	
		12233105	Oct 27, 2043			U-3918	
		12233105	Oct 27, 2043			U-3919	
		12233105	Oct 27, 2043			U-3920	
		12233105	Oct 27, 2043			U-3921	
		12233105	Oct 27, 2043			U-3922	
		12233105	Oct 27, 2043			U-3923	
		12233105	Oct 27, 2043			U-3924	
		12233105	Oct 27, 2043			U-3925	
		12233105	Oct 27, 2043			U-3926	
		12324787	Oct 27, 2043	DP			
	>A>	12440542	Oct 27, 2043	DP		U-3904	
	>A>	12440542	Oct 27, 2043	DP		U-3905	
	>A>	12440542	Oct 27, 2043	DP		U-3906	
	>A>	12440542	Oct 27, 2043	DP		U-3907	
	>A>	12440542	Oct 27, 2043	DP		U-3908	
	>A>	12440542	Oct 27, 2043	DP		U-3909	
	>A>	12440542	Oct 27, 2043	DP		U-3910	
	>A>	12440542	Oct 27, 2043	DP		U-3911	
	>A>	12440542	Oct 27, 2043	DP		U-3912	
	>A>	12440542	Oct 27, 2043	DP		U-3913	
	>A>	12440542	Oct 27, 2043	DP		U-3914	
	>A>	12440542	Oct 27, 2043	DP		U-3915	
	>A>	12440542	Oct 27, 2043	DP		U-3916	
	>A>	12440542	Oct 27, 2043	DP		U-3917	
	>A>	12440542	Oct 27, 2043	DP		U-3918	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CORTICOTROPIN - PURIFIED CORTROPHIN GEL							
N 008975 002	>A>	12440542	Oct 27, 2043	DP U-3919			
	>A>	12440542	Oct 27, 2043	DP U-3920			
	>A>	12440542	Oct 27, 2043	DP U-3921			
	>A>	12440542	Oct 27, 2043	DP U-3922			
	>A>	12440542	Oct 27, 2043	DP U-3923			
	>A>	12440542	Oct 27, 2043	DP U-3924			
	>A>	12440542	Oct 27, 2043	DP U-3925			
	>A>	12440542	Oct 27, 2043	DP U-3926			
CRINECERFONT - CRENESSITY							
N 218808 001		10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
		11311544	Jan 21, 2035	U-4049			
		11730739	Jan 21, 2035	U-4049			
		12128033	Jun 09, 2041	DS U-4049			
CRINECERFONT - CRENESSITY							
N 218808 002		10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
		11311544	Jan 21, 2035	U-4049			
		11730739	Jan 21, 2035	U-4049			
		12128033	Jun 09, 2041	DS U-4049			
CRINECERFONT - CRENESSITY							
N 218808 003		10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
		11311544	Jan 21, 2035	U-4049			
		11730739	Jan 21, 2035	U-4049			
		12128033	Jun 09, 2041	DS U-4049			
CRINECERFONT - CRENESSITY							
N 218820 001		10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
		11311544	Jan 21, 2035	U-4049			
		11730739	Jan 21, 2035	U-4049			
		12128033	Jun 09, 2041	DS U-4049			
CYCLOBENZAPRINE HYDROCHLORIDE - TONMYA							
N 219428 001		10117936	Mar 14, 2034	DP		NP	Aug 15, 2028
		10864175	Mar 14, 2034	DP			
		9636408	Mar 14, 2034	DP			
		9956188	Mar 14, 2034	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE							
N 212501 001		12329767	Feb 15, 2036	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE							
N 212501 002		12329767	Feb 15, 2036	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE							
N 212501 003		12329767	Feb 15, 2036	DP			
CYCLOSPORINE - RESTASIS MULTIDOSE							
N 050790 002		8292129	Feb 25, 2031	DP	Y		
		8561859	Apr 16, 2032	DP	Y		
		9669974	May 11, 2034	DP	Y		
		9676525	Feb 07, 2034	DP	Y		
DACOMITINIB - VIZIMPRO							
N 211288 001		7772243	May 05, 2028	DS DP			
DACOMITINIB - VIZIMPRO							
N 211288 002		7772243	May 05, 2028	DS DP			
DACOMITINIB - VIZIMPRO							
N 211288 003		7772243	May 05, 2028	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN - FARXIGA							
N 202293	002	12213988	Apr 01, 2041	U-4140			
		12409186	Apr 01, 2041	U-4140			
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ							
N 214985	001					M-200	Sep 30, 2027
DARIDOREXANT HYDROCHLORIDE - QUVIVIQ							
N 214985	002					M-200	Sep 30, 2027
DAROLUTAMIDE - NUBEQA							
N 212099	001	10835515	Jan 28, 2036	DP U-2605		I-971	Jun 03, 2028
		10835515	Jan 28, 2036	DP U-4208			
		10835515	Jan 28, 2036	DP U-4209			
		10835515	Jan 28, 2036	DP U-4210			
		12329742	May 14, 2042	DP			
		8975254	Mar 25, 2033	DS DP U-4208			
		8975254	Mar 25, 2033	DS DP U-4209			
		8975254	Mar 25, 2033	DS DP U-4210			
		9657003	Oct 27, 2030	DS DP U-4208			
		9657003	Oct 27, 2030	DS DP U-4209			
		9657003	Oct 27, 2030	DS DP U-4210			
DASATINIB - PHYRAGO							
N 216099	001	>A> 12433891	Jan 22, 2041	U-3767			
		>A> 12433891	Jan 22, 2041	U-3768			
		>A> 12433891	Jan 22, 2041	U-3769			
		>A> 12433891	Jan 22, 2041	U-3770			
		>A> 12433891	Jan 22, 2041	U-3771			
		>A> 12433891	Jan 22, 2041	U-3772			
DASATINIB - PHYRAGO							
N 216099	002	>A> 12433891	Jan 22, 2041	U-3767			
		>A> 12433891	Jan 22, 2041	U-3768			
		>A> 12433891	Jan 22, 2041	U-3769			
		>A> 12433891	Jan 22, 2041	U-3770			
		>A> 12433891	Jan 22, 2041	U-3771			
		>A> 12433891	Jan 22, 2041	U-3772			
DASATINIB - PHYRAGO							
N 216099	003	>A> 12433891	Jan 22, 2041	U-3767			
		>A> 12433891	Jan 22, 2041	U-3768			
		>A> 12433891	Jan 22, 2041	U-3769			
		>A> 12433891	Jan 22, 2041	U-3770			
		>A> 12433891	Jan 22, 2041	U-3771			
		>A> 12433891	Jan 22, 2041	U-3772			
DASATINIB - PHYRAGO							
N 216099	004	>A> 12433891	Jan 22, 2041	U-3767			
		>A> 12433891	Jan 22, 2041	U-3768			
		>A> 12433891	Jan 22, 2041	U-3769			
		>A> 12433891	Jan 22, 2041	U-3770			
		>A> 12433891	Jan 22, 2041	U-3771			
		>A> 12433891	Jan 22, 2041	U-3772			
DASATINIB - PHYRAGO							
N 216099	005	>A> 12433891	Jan 22, 2041	U-3767			
		>A> 12433891	Jan 22, 2041	U-3768			
		>A> 12433891	Jan 22, 2041	U-3769			
		>A> 12433891	Jan 22, 2041	U-3770			
		>A> 12433891	Jan 22, 2041	U-3771			
		>A> 12433891	Jan 22, 2041	U-3772			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASATINIB - PHYRAGO								
N 216099	006	>A>	12433891	Jan 22, 2041	U-3767			
		>A>	12433891	Jan 22, 2041	U-3768			
		>A>	12433891	Jan 22, 2041	U-3769			
		>A>	12433891	Jan 22, 2041	U-3770			
		>A>	12433891	Jan 22, 2041	U-3771			
		>A>	12433891	Jan 22, 2041	U-3772			
DELGOCITINIB - ANZUPGO								
N 219155	001		8609647	Sep 19, 2031	DS DP U-4237		NCE	Jul 23, 2030
DEOXYCHOLIC ACID - KYBELLA								
N 206333	001		12161653	Feb 17, 2032	U-1940			
DEURUXOLITINIB PHOSPHATE - LEQSELVI								
N 217900	001		12247034	May 10, 2044	DS DP			
			12285432	Aug 11, 2042	U-3976			
			12364699	Oct 10, 2044	U-3976			
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK								
N 218730	001		10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
			10047053	May 17, 2032	DS			
			10081621	Mar 25, 2031	DP U-4087			
			10239867	Apr 09, 2027	DS DP U-4090			
			10646481	Aug 13, 2029	DP			
			11066417	Feb 14, 2039	DS DP			
			11564916	Aug 13, 2029	U-4095			
			11578062	Mar 25, 2031	DP U-4096			
			11639347	Apr 09, 2027	DS DP U-4090			
			11866450	Feb 14, 2039	U-4082			
			11873300	Aug 13, 2040	DS DP U-4083			
			7495103	May 20, 2027	DS DP			
			7645789	May 01, 2027	DS DP			
			7776905	Jun 03, 2027	DS DP			
			8324242	Aug 05, 2027	U-4090			
			8354427	Jul 06, 2026	U-4091			
			8410274	Dec 28, 2026	DP			
			8415387	Nov 12, 2027	U-4082			
			8598181	May 01, 2027	U-4090			
			8623905	May 01, 2027	DS DP			
			8629162	Jun 24, 2025	U-4084			
			8754224	Dec 28, 2026	DS DP			
			8865902	May 17, 2032	DS DP			
			9181192	May 17, 2032	DS DP U-4094			
			9512079	May 17, 2032	DS DP U-4098			
			9670163	Dec 28, 2026	DP U-4080			
			9931334	Dec 28, 2026	DP U-4080			
			9974781	Apr 09, 2027	DP U-4082			
			RE50453	May 01, 2027	DS DP			
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK								
N 218730	002		10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
			10047053	May 17, 2032	DS			
			10058546	Jul 15, 2033	U-4218			
			10081621	Mar 25, 2031	DP U-4087			
			10206877	Apr 14, 2035	DP U-4092			
			10239867	Apr 09, 2027	DS DP U-4090			
			10646481	Aug 13, 2029	DP			
			11066417	Feb 14, 2039	DS DP			
			11564916	Aug 13, 2029	U-4095			
			11578062	Mar 25, 2031	DP U-4096			
			11639347	Apr 09, 2027	DS DP U-4090			
			11866450	Feb 14, 2039	U-4082			
			11873300	Aug 13, 2040	DS DP U-4083			
			11951212	Apr 14, 2035	DP U-4089			
			12186306	Jan 10, 2043	U-4088			
			7495103	May 20, 2027	DS DP			
			7645789	May 01, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK						
N 218730 002	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9012496	Jul 15, 2033	U-4097			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
	RE50453	May 01, 2027	DS DP			
DEXAMETHASONE - DEXTENZA						
N 208742 001					NPP	Apr 07, 2028
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI						
N 215390 001	12364683	Jan 12, 2043	U-4029			
DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI						
N 215390 002	12364683	Jan 12, 2043	U-4029			
DIAZEPAM - VALTOCO						
N 211635 001	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	12324852	Oct 16, 2032	U-4173			
	12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
DIAZEPAM - VALTOCO						
N 211635 002	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	12324852	Oct 16, 2032	U-4173			
	12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
DIAZEPAM - VALTOCO						
N 211635 003	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	12324852	Oct 16, 2032	U-4173			
	12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
DIAZOXIDE CHOLINE - VYKAT XR						
N 216665 001	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
	12343348	Nov 12, 2035	U-4211			
	12419895	Nov 12, 2035	U-4275			
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
DIAZOXIDE CHOLINE - VYKAT XR						
N 216665 002	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
	12343348	Nov 12, 2035	U-4211			
	12419895	Nov 12, 2035	U-4275			
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
DIAZOXIDE CHOLINE - VYKAT XR						
N 216665 003	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
	12343348	Nov 12, 2035	U-4211			
	12419895	Nov 12, 2035	U-4275			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DIAZOXIDE CHOLINE - VYKAT XR						
N 216665 003	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)						
N 215400 001	10532049	Feb 26, 2039	DP			
	11304942	Feb 26, 2039	DP			
	11819501	Feb 26, 2039	U-4188			
	11819501	Feb 26, 2039	U-848			
DIHYDROERGOTAMINE MESYLATE - ATZUMI						
N 217901 001	10758532	Dec 11, 2039	DP		NP	Apr 30, 2028
	10792253	Aug 04, 2037	DP			
	11744967	Oct 12, 2041	DP			
	11872314	Aug 04, 2037	DP			
	12102754	Oct 12, 2041	DP			
	12263162	Dec 11, 2039	DP			
DIROXIMEL FUMARATE - VUMERITY						
N 211855 001	8669281	Oct 29, 2033	DS DP			
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 001	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			
DONEPEZIL HYDROCHLORIDE - ADLARITY						
N 212304 002	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE						
A 208328 001					PC	Jul 15, 2025
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE						
A 208328 002					PC	Jul 15, 2025
DONIDALORSEN SODIUM - DAWNZERA (AUTOINJECTOR)						
N 219407 001	10294477	May 01, 2035	DS DP U-3010			
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
	9315811	Oct 21, 2032	U-3010			
	9670492	Aug 28, 2034	DS			
DORDAVIPRONE HYDROCHLORIDE - MODEYSO						
N 219876 001	10172862	Jan 30, 2037	U-4254		NCE	Aug 06, 2030
	10369154	Jan 30, 2037	U-4254			
	11976068	Mar 01, 2036	DP			
	12102639	Jan 30, 2037	U-4254			
	9265765	Jul 26, 2034	DP			
	9629842	Apr 30, 2032	U-4254			
	RE46290	Apr 30, 2032	U-4254			
DOXERCALCIFEROL - HECTOROL						
N 020862 001					M-14	Jun 11, 2028
DOXERCALCIFEROL - HECTOROL						
N 020862 002					M-14	Jun 11, 2028
DOXERCALCIFEROL - HECTOROL						
N 020862 003					M-14	Jun 11, 2028
DROSPIRENONE - SLYND						
N 211367 001	12280151	Jun 28, 2031	DP			

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DROSPIRENONE; ESTETROL - NEXTSTELLIS							
N 214154 001		12233074	Feb 09, 2043	DP U-3152			
	>A>	12427114	Jun 17, 2036	DP U-3152			
	>A>	12458649	Oct 01, 2043	U-3152			
		7732430	Jan 15, 2028	DP U-3152			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516 001		12171742	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516 002		12171742	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516 003		12171742	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE							
N 212516 004		12171742	Apr 13, 2037	DP			
DUVELISIB - COPIKTRA							
N 211155 001		12213983	Apr 26, 2035	U-2412			
DUVELISIB - COPIKTRA							
N 211155 002		12213983	Apr 26, 2035	U-2412			
EDARAVONE - RADICAVA ORS							
N 215446 001		12194025	Nov 12, 2041	U-4111			
		12285409	Nov 01, 2039	DP			
		12310946	Nov 12, 2041	U-4111			
ELACESTRANT HYDROCHLORIDE - ORSERDU							
N 217639 001		11819480	Feb 28, 2037	U-3523			
ELACESTRANT HYDROCHLORIDE - ORSERDU							
N 217639 002		11819480	Feb 28, 2037	U-3523			
ELAFIBRANOR - IQIRVO							
N 218860 001		12233038	Mar 30, 2037	U-1854			
		12295927	Mar 30, 2037	U-1854			
		12295928	Mar 30, 2037	U-1854			
		12310935	Mar 30, 2037	U-1854			
ELAMIPRETIDE HYDROCHLORIDE - FORZINITY							
N 215244 001	>A>	11083771	Feb 28, 2034	U-4277		NCE	Sep 19, 2030
	>A>	11083772	Feb 28, 2034	U-4277			
	>A>	11771734	Feb 28, 2034	U-4277			
	>A>	12268724	Feb 28, 2034	U-4277			
	>A>	7576061	Jan 20, 2026	DS DP			
	>A>	9687519	Feb 28, 2034	U-4277			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)							
N 212273 001		10081621	Mar 25, 2031	DP U-3032		M-313	Dec 20, 2027
		10081621	Mar 25, 2031	DP U-3157		ODE-512	Dec 20, 2031
		10081621	Mar 25, 2031	DP U-4075			
		10239867	Apr 09, 2027	DS DP U-3033			
		10239867	Apr 09, 2027	DS DP U-3158			
		10239867	Apr 09, 2027	DS DP U-4056			
		10758534	Oct 06, 2035	DS DP U-3028			
		10758534	Oct 06, 2035	DS DP U-3144			
		10758534	Oct 06, 2035	DS DP U-4073			
		10793547	Dec 08, 2037	DS DP U-3028			
		10793547	Dec 08, 2037	DS DP U-3144			
		10793547	Dec 08, 2037	DS DP U-4073			
		11179367	Dec 08, 2037	DP U-3253			
		11179367	Dec 08, 2037	DP U-4071			
		11426407	Oct 06, 2035	DS DP U-3425			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	12350262	Jul 17, 2038	U-4221			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
	RE50453	May 01, 2027	DS DP			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 002	10081621	Mar 25, 2031	DP U-3157		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4075		ODE*	Oct 21, 2026
	10239867	Apr 09, 2027	DS DP U-3158		ODE*	Dec 21, 2027
	10239867	Apr 09, 2027	DS DP U-4056		ODE-512	Dec 20, 2031
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	12350262	Jul 17, 2038	U-4222			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3144			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 002	9974781	Apr 09, 2027	DP U-4073			
	RE50453	May 01, 2027	DS DP			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 001	10081621	Mar 25, 2031	DP U-3600		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4065		ODE-512	Dec 20, 2031
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
	RE50453	May 01, 2027	DS DP			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	10081621	Mar 25, 2031	DP U-3600		ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4065			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 217660 002	11578062	Mar 25, 2031	DP		U-3584	
	11578062	Mar 25, 2031	DP		U-4054	
	11639347	Apr 09, 2027	DS DP		U-3583	
	11639347	Apr 09, 2027	DS DP		U-4053	
	11752106	Feb 27, 2033	DP		U-3696	
	11752106	Feb 27, 2033	DP		U-4052	
	12214083	Feb 27, 2033	DP		U-4141	
	12350262	Jul 17, 2038			U-4220	
	8324242	Aug 05, 2027			U-3589	
	8324242	Aug 05, 2027			U-4066	
	8415387	Nov 12, 2027			U-3589	
	8415387	Nov 12, 2027			U-4066	
	8598181	May 01, 2027			U-3589	
	8598181	May 01, 2027			U-4066	
	8629162	Jun 24, 2025			U-3592	
	8629162	Jun 24, 2025			U-4072	
	9670163	Dec 28, 2026	DP		U-3591	
	9670163	Dec 28, 2026	DP		U-4068	
	9931334	Dec 28, 2026	DP		U-3591	
	9931334	Dec 28, 2026	DP		U-4068	
	9974781	Apr 09, 2027	DP		U-3589	
	9974781	Apr 09, 2027	DP		U-4066	
	RE50453	May 01, 2027	DS DP			
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 206788 001					PC	Nov 09, 2025
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 206788 002					PC	Nov 09, 2025
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 206788 003					PC	Nov 09, 2025
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 206788 004					PC	Nov 09, 2025
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 216620 001					PC	Nov 09, 2025
ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE						
A 216620 002					PC	Nov 09, 2025
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001	11813275	Apr 03, 2034			U-3759	
	11813275	Apr 03, 2034			U-3760	
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034			U-3776	
	11833166	Apr 03, 2034			U-3777	
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030			U-4023	
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034			U-4171	
>A>	12427162	Apr 03, 2034			U-4287	
>A>	12433906	Apr 03, 2034			U-4293	
>A>	12433906	Apr 03, 2034			U-4294	
>A>	12433906	Apr 03, 2034			U-4295	
>A>	12433906	Apr 03, 2034			U-4296	
>A>	12433906	Apr 03, 2034			U-4304	
>A>	12433906*PED	Oct 03, 2034				
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002	11833166	Apr 03, 2034			U-3776	
	11833166	Apr 03, 2034			U-3777	
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030			U-4023	

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN - JARDIANCE							
N 204629	002	12115179*PED	Aug 11, 2030				
		12263153	Apr 03, 2034	U-4171			
	>A>	12427162	Apr 03, 2034	U-4287			
	>A>	12433906	Apr 03, 2034	U-4293			
	>A>	12433906	Apr 03, 2034	U-4294			
	>A>	12433906	Apr 03, 2034	U-4295			
	>A>	12433906	Apr 03, 2034	U-4296			
	>A>	12433906	Apr 03, 2034	U-4304			
	>A>	12433906*PED	Oct 03, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073	001	11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12178819	May 04, 2027	DP			
		12364700	Jun 08, 2037	U-4224			
		12364700*PED	Dec 08, 2037				
	>A>	12433906	Apr 03, 2034	U-4293			
	>A>	12433906	Apr 03, 2034	U-4294			
	>A>	12433906	Apr 03, 2034	U-4295			
	>A>	12433906	Apr 03, 2034	U-4296			
	>A>	12433906	Apr 03, 2034	U-4304			
	>A>	12433906*PED	Oct 03, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI							
N 206073	002	11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12178819	May 04, 2027	DP			
		12364700	Jun 08, 2037	U-4224			
		12364700*PED	Dec 08, 2037				
	>A>	12433906	Apr 03, 2034	U-4293			
	>A>	12433906	Apr 03, 2034	U-4294			
	>A>	12433906	Apr 03, 2034	U-4295			
	>A>	12433906	Apr 03, 2034	U-4296			
	>A>	12433906	Apr 03, 2034	U-4304			
	>A>	12433906*PED	Oct 03, 2034				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	001	11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12364700	Jun 08, 2037	U-4224			
		12364700*PED	Dec 08, 2037				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	002	11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12364700	Jun 08, 2037	U-4224			
		12364700*PED	Dec 08, 2037				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614	003	11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12364700	Jun 08, 2037	U-4224			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614 003		12364700*PED	Dec 08, 2037				
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR							
N 212614 004		11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12364700	Jun 08, 2037	U-4224			
		12364700*PED	Dec 08, 2037				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 001		11666590	Apr 03, 2034	U-4154			
		11813275	Apr 03, 2034	U-3759			
		11813275*PED	Oct 03, 2034				
		11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12263153	Apr 03, 2034	U-4154			
	>A>	12427162	Apr 03, 2034	U-4287			
	>A>	12433906	Apr 03, 2034	U-4293			
	>A>	12433906	Apr 03, 2034	U-4294			
	>A>	12433906	Apr 03, 2034	U-4295			
	>A>	12433906	Apr 03, 2034	U-4296			
	>A>	12433906	Apr 03, 2034	U-4304			
	>A>	12433906*PED	Oct 03, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 002		11666590	Apr 03, 2034	U-4154			
		11813275	Apr 03, 2034	U-3759			
		11813275*PED	Oct 03, 2034				
		11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12263153	Apr 03, 2034	U-4154			
	>A>	12427162	Apr 03, 2034	U-4287			
	>A>	12433906	Apr 03, 2034	U-4293			
	>A>	12433906	Apr 03, 2034	U-4294			
	>A>	12433906	Apr 03, 2034	U-4295			
	>A>	12433906	Apr 03, 2034	U-4296			
	>A>	12433906	Apr 03, 2034	U-4304			
	>A>	12433906*PED	Oct 03, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 003		11666590	Apr 03, 2034	U-4154			
		11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12263153	Apr 03, 2034	U-4154			
	>A>	12427162	Apr 03, 2034	U-4287			
	>A>	12433906	Apr 03, 2034	U-4293			
	>A>	12433906	Apr 03, 2034	U-4294			
	>A>	12433906	Apr 03, 2034	U-4295			
	>A>	12433906	Apr 03, 2034	U-4296			
	>A>	12433906	Apr 03, 2034	U-4304			
	>A>	12433906*PED	Oct 03, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 004		11666590	Apr 03, 2034	U-4154			
		11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111 004		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12263153	Apr 03, 2034	U-4154			
	>A>	12427162	Apr 03, 2034	U-4287			
	>A>	12433906	Apr 03, 2034	U-4293			
	>A>	12433906	Apr 03, 2034	U-4294			
	>A>	12433906	Apr 03, 2034	U-4295			
	>A>	12433906	Apr 03, 2034	U-4296			
	>A>	12433906	Apr 03, 2034	U-4304			
	>A>	12433906*PED	Oct 03, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658 001		11666590	Apr 03, 2034	U-4154			
		11813275	Apr 03, 2034	U-3759			
		11813275*PED	Oct 03, 2034				
		11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12263153	Apr 03, 2034	U-4154			
	>A>	12427162	Apr 03, 2034	U-4287			
	>A>	12433906	Apr 03, 2034	U-4293			
	>A>	12433906	Apr 03, 2034	U-4294			
	>A>	12433906	Apr 03, 2034	U-4295			
	>A>	12433906	Apr 03, 2034	U-4296			
	>A>	12433906	Apr 03, 2034	U-4304			
	>A>	12433906*PED	Oct 03, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658 002		11666590	Apr 03, 2034	U-4154			
		11813275	Apr 03, 2034	U-3759			
		11813275*PED	Oct 03, 2034				
		11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12263153	Apr 03, 2034	U-4154			
	>A>	12427162	Apr 03, 2034	U-4287			
	>A>	12433906	Apr 03, 2034	U-4293			
	>A>	12433906	Apr 03, 2034	U-4294			
	>A>	12433906	Apr 03, 2034	U-4295			
	>A>	12433906	Apr 03, 2034	U-4296			
	>A>	12433906	Apr 03, 2034	U-4304			
	>A>	12433906*PED	Oct 03, 2034				
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658 003		11666590	Apr 03, 2034	U-4154			
		11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12263153	Apr 03, 2034	U-4154			
	>A>	12427162	Apr 03, 2034	U-4287			
	>A>	12433906	Apr 03, 2034	U-4293			
	>A>	12433906	Apr 03, 2034	U-4294			
	>A>	12433906	Apr 03, 2034	U-4295			
	>A>	12433906	Apr 03, 2034	U-4296			
	>A>	12433906	Apr 03, 2034	U-4304			
	>A>	12433906*PED	Oct 03, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR							
N 208658	004	11666590	Apr 03, 2034	U-4154			
		11833166	Apr 03, 2034	U-3776			
		11833166	Apr 03, 2034	U-3777			
		11833166*PED	Oct 03, 2034				
		12115179	Feb 11, 2030	U-4023			
		12115179*PED	Aug 11, 2030				
		12263153	Apr 03, 2034	U-4154			
	>A>	12427162	Apr 03, 2034	U-4287			
	>A>	12433906	Apr 03, 2034	U-4293			
	>A>	12433906	Apr 03, 2034	U-4294			
	>A>	12433906	Apr 03, 2034	U-4295			
	>A>	12433906	Apr 03, 2034	U-4296			
	>A>	12433906	Apr 03, 2034	U-4304			
	>A>	12433906*PED	Oct 03, 2034				
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY							
N 208351	001	7390791	Jan 07, 2025	DS DP			
		7390791*PED	Jul 07, 2025				
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE							
A 208452	001					PC	Nov 23, 2025
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY							
N 208215	001	7390791	Jan 07, 2025	DS DP	>A>	M-316	Jun 20, 2028
		7390791*PED	Jul 07, 2025				
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY							
N 208215	002	7390791	Jan 07, 2025	DS DP	>A>	M-316	Jun 20, 2028
		7390791*PED	Jul 07, 2025				
ENCORAFENIB - BRAFTOVI							
N 210496	001					I-957	Dec 20, 2027
ENCORAFENIB - BRAFTOVI							
N 210496	002	10005761	Aug 27, 2030	U-2335		I-957	Dec 20, 2027
		10005761	Aug 27, 2030	U-2802			
		10005761	Aug 27, 2030	U-2803			
		10005761	Aug 27, 2030	U-3738			
		10005761	Aug 27, 2030	U-4051			
		10258622	Nov 21, 2032	U-2802			
		10258622	Nov 21, 2032	U-4051			
		8541575	Feb 26, 2030	DS DP U-2335			
		8541575	Feb 26, 2030	DS DP U-2802			
		8541575	Feb 26, 2030	DS DP U-2803			
		8541575	Feb 26, 2030	DS DP U-3738			
		8541575	Feb 26, 2030	DS DP U-4051			
		9314464	Jul 04, 2031	U-2336			
		9314464	Jul 04, 2031	U-2802			
		9314464	Jul 04, 2031	U-2803			
		9314464	Jul 04, 2031	U-3738			
		9314464	Jul 04, 2031	U-4051			
		9474754	Aug 05, 2033	U-2802			
		9474754	Aug 05, 2033	U-4051			
		9850230	Aug 27, 2030	U-2334			
		9850230	Aug 27, 2030	U-2802			
		9850230	Aug 27, 2030	U-2803			
		9850230	Aug 27, 2030	U-3738			
		9850230	Aug 27, 2030	U-4051			
ENSARTINIB HYDROCHLORIDE - ENSACOVE							
N 218171	001	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
		8551995	Feb 09, 2029	DS			
		9126947	Nov 29, 2031	DS			
		9296724	Jun 18, 2029	DS U-4099			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENSARTINIB HYDROCHLORIDE - ENSACOVE						
N 218171 002	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS U-4099			
ENSIFENTRINE - OHTUVAYRE						
N 217389 001	12251384	Jun 25, 2044	DP			
	12409180	Feb 20, 2043	DP			
ENTRECTINIB - ROZLYTREK						
N 212725 001	8299057	Mar 10, 2032	DS DP			
ENTRECTINIB - ROZLYTREK						
N 212725 002	8299057	Mar 10, 2032	DS DP			
ENTRECTINIB - ROZLYTREK						
N 218550 001					ODE*	Aug 15, 2026
					ODE*	Aug 15, 2026
ENZALUTAMIDE - XTANDI						
N 203415 001	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
ENZALUTAMIDE - XTANDI						
N 213674 001	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
ENZALUTAMIDE - XTANDI						
N 213674 002	12161628	Feb 23, 2037	U-4101			
	12161628	Feb 23, 2037	U-4102			
	12161628	Feb 23, 2037	U-4103			
	12161628	Feb 23, 2037	U-4104			
EPHEDRINE SULFATE - EPHEDRINE SULFATE						
A 218271 001					PC	Feb 21, 2026
EPHEDRINE SULFATE - EPHEDRINE SULFATE						
A 218271 002					PC	Feb 21, 2026
EPINEPHRINE - EPINEPHRINE						
A 213708 001					PC	Jun 03, 2025
EPINEPHRINE - EPINEPHRINE						
A 219239 001					CGT	Sep 03, 2025
EPINEPHRINE - ADRENALIN						
N 204200 001	12280024	Mar 13, 2035	DP			
EPINEPHRINE - ADRENALIN						
N 204640 001	12280024	Mar 13, 2035	DP			
EPINEPHRINE - NEFFY						
N 214697 001	12324838	Feb 06, 2039	DP			
EPINEPHRINE - NEFFY						
N 214697 002	10576156	Feb 06, 2038	DP			
	10682414	Feb 06, 2039	U-3979			
	11173209	Feb 06, 2038	U-3979			
	11191838	Feb 06, 2039	DP U-3979			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - NEFFY						
N 214697 002	11717571	Feb 06, 2039	U-3979			
	11744895	Feb 06, 2039	U-3979			
	11918655	Feb 06, 2039	U-3979			
	12324838	Feb 06, 2039	DP			
EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)						
N 217388 001	8101743	Apr 01, 2026	DS DP			
ESKETAMINE HYDROCHLORIDE - SPRAVATO						
N 211243 001	10869844	Sep 10, 2035	U-3034		I-959	Jan 17, 2028
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
	10869844	Sep 10, 2035	U-4113			
	10869844	Sep 10, 2035	U-4114			
	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
	11173134	Sep 10, 2035	U-4115			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11311500	Sep 10, 2035	U-4116			
	11311500	Sep 10, 2035	U-4117			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	11446260	Mar 14, 2034	U-4118			
	11446260	Mar 14, 2034	U-4119			
	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
	11883526	Feb 18, 2040	U-4120			
	8785500	Mar 05, 2033	U-2502			
	8785500	Mar 05, 2033	U-4112			
	9592207	Mar 20, 2027	U-2502			
	9592207	Mar 20, 2027	U-4112			
ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE						
A 211199 001					PC	Nov 02, 2025
ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE						
A 211199 002					PC	Nov 02, 2025
ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE						
A 211199 003					PC	Nov 02, 2025
ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE						
A 211199 004					PC	Nov 02, 2025
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE						
N 214846 001	12325714	Sep 27, 2033	DS DP			
ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS						
A 214023 001					>A> CGT	Apr 15, 2026
ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS						
A 214023 002					>A> CGT	Apr 15, 2026
ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS						
A 214025 001					>A> CGT	Apr 15, 2026
ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS						
A 214025 002					>A> CGT	Apr 15, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS						
A 214025 003					>A> CGT	Apr 15, 2026
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV						
N 218718 001	12178824	Jun 24, 2041	DP			
ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA						
N 209627 001	12303518	Jun 21, 2039	DP			
ETRASIMOD ARGININE - VELSIPITY						
N 216956 001	12377071	Jan 06, 2036	U-4255			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 001	7612109	Feb 05, 2026	DS DP			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 002	7612109	Feb 05, 2026	DS DP			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 003	7612109	Feb 05, 2026	DS DP			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 004	7612109	Feb 05, 2026	DS DP			
FINERENONE - KERENDIA						
N 215341 001					I-970	Jul 11, 2028
FINERENONE - KERENDIA						
N 215341 002					I-970	Jul 11, 2028
FINERENONE - KERENDIA						
N 215341 003	8436180	Apr 12, 2029	DS DP		NCE	Jul 09, 2026
	RE49826	Jul 29, 2035	DS		NS	Jul 11, 2028
FISH OIL TRIGLYCERIDES - OMEGAVEN						
N 210589 001	9566260	Jul 30, 2026	DP U-2366			
FISH OIL TRIGLYCERIDES - OMEGAVEN						
N 210589 002	9566260	Jul 30, 2026	DP U-2366			
FITUSIRAN SODIUM - QFITLIA						
N 219019 001	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
FITUSIRAN SODIUM - QFITLIA						
N 219019 002	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
FLORBETABEN F-18 - NEURACEQ						
N 204677 001	9308284	Jul 14, 2032	DP			
FLORBETAPIR F-18 - AMYVID						
N 202008 001	8506929	Apr 30, 2027	DS DP U-4217			
FLORBETAPIR F-18 - AMYVID						
N 202008 002	8506929	Apr 30, 2027	DS DP U-4217			
FLORBETAPIR F-18 - AMYVID						
N 202008 003	8506929	Apr 30, 2027	DS DP U-4217			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLORBETAPIR F-18 - AMYVID							
N 202008 004		7687052	Apr 30, 2027	DS DP U-4217			
		8506929	Apr 30, 2027	DS DP U-4217			
FLOTUFOLASTAT F-18 GALLIUM - POSLUMA							
N 216023 001		12357711	Nov 22, 2038	DS			
		12377176	Nov 22, 2038	DS			
		12390540	Aug 23, 2038	DS			
	>A>	12427207	Nov 27, 2041	DP			
FLUOCINOLONE ACETONIDE - ILUVIEN							
N 201923 001		9849027	Nov 07, 2028	DP U-4157			
		9849027	Nov 07, 2028	DP U-708			
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA							
N 209482 001		12396986	Nov 29, 2030	DP			
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA							
N 209482 002		12396986	Nov 29, 2030	DP			
FOSCARBIDOPA; FOSLEVODOPA - VYALEV							
N 216962 001		12251365	Jun 10, 2040	U-4030		NP	Oct 16, 2027
FOSDENOPTERIN HYDROBROMIDE - NULIBRY							
N 214018 001		7504095	Apr 09, 2029	DP U-3092			
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 210493 001		12208109	Jun 02, 2037	DP			
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 210493 002		12208109	Jun 02, 2037	DP			
FUROSEMIDE - FUROSCIX							
N 209988 001		12370168	Apr 03, 2034	DP U-3462			
FUTIBATINIB - LYTGOBI							
N 214801 001		9108973	Feb 13, 2033	DS DP U-3456			
FUTIBATINIB - LYTGOBI							
N 214801 002		10434103	Mar 31, 2036	DS DP		NCE	Sep 30, 2027
		11833151	Nov 05, 2039	DP		ODE*	Sep 30, 2029
		9108973	Feb 13, 2033	DS DP U-3456			
GALLIUM GA-68 GOZETOTIDE - GOZELLIX							
N 219592 001		11027031	Jul 28, 2035	U-3317			
GANAXOLONE - ZTALMY							
N 215904 001	>A>	12115169	Sep 30, 2042	U-3374			
	>A>	12268696	Sep 30, 2042	U-3374			
GEMCITABINE HYDROCHLORIDE - INLEXZO							
N 219683 001		10729823	Aug 19, 2034	DP		NP	Sep 09, 2028
		12403086	Jun 28, 2030	DP			
		8679094	Apr 15, 2032	DP			
GEPIRONE HYDROCHLORIDE - EXXUA							
N 021164 001	>A>	7538116	Sep 02, 2030	U-3699			
GEPIRONE HYDROCHLORIDE - EXXUA							
N 021164 002	>A>	7538116	Sep 02, 2030	U-3699			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GEPIRONE HYDROCHLORIDE - EXXUA								
N 021164	003	>A>	7538116	Sep 02, 2030	U-3699			
GEPIRONE HYDROCHLORIDE - EXXUA								
N 021164	004	>A>	7538116	Sep 02, 2030	U-3699			
GEPOTIDACIN MESYLATE - BLUJEPA								
N 218230	001		8389524	Feb 12, 2029	DS DP U-4166		NCE	Mar 25, 2030
							GAIN	Mar 25, 2035
GLECAPREVIR; PIBRENTASVIR - MAVYRET								
N 209394	001		10028937	Jun 10, 2030	U-2141		I-967	Jun 10, 2028
			10028937	Jun 10, 2030	U-3237			
			10028937	Jun 10, 2030	U-4206			
			10028937*PED	Dec 10, 2030				
			10039754	Jun 10, 2030	U-2141			
			10039754	Jun 10, 2030	U-3237			
			10039754	Jun 10, 2030	U-4206			
			10039754*PED	Dec 10, 2030				
			10286029	Mar 14, 2034	U-3237			
			10286029	Mar 14, 2034	U-4206			
			10286029*PED	Sep 14, 2034				
			11484534	Mar 14, 2034	U-3237			
			11484534	Mar 14, 2034	U-4206			
			11484534*PED	Sep 14, 2034				
			8648037	Jan 19, 2032	DS DP U-2141			
			8648037	Jan 19, 2032	DS DP U-3237			
			8648037	Jan 19, 2032	DS DP U-4206			
			8648037*PED	Jul 19, 2032				
			9586978	Nov 06, 2030	U-2141			
			9586978	Nov 06, 2030	U-3237			
			9586978	Nov 06, 2030	U-4206			
			9586978*PED	May 06, 2031				
GLECAPREVIR; PIBRENTASVIR - MAVYRET								
N 215110	001		10028937	Jun 10, 2030	U-3238		I-967	Jun 10, 2028
			10028937	Jun 10, 2030	U-4206			
			10028937*PED	Dec 10, 2030				
			10039754	Jun 10, 2030	U-3238			
			10039754	Jun 10, 2030	U-4206			
			10039754*PED	Dec 10, 2030				
			10286029	Mar 14, 2034	U-3238			
			10286029	Mar 14, 2034	U-4206			
			10286029*PED	Sep 14, 2034				
			8648037	Jan 19, 2032	DS DP U-3238			
			8648037	Jan 19, 2032	DS DP U-4206			
			8648037*PED	Jul 19, 2032				
			9586978	Nov 06, 2030	U-3238			
			9586978	Nov 06, 2030	U-4206			
			9586978*PED	May 06, 2031				
GLUCAGON - GLUCAGON								
A 218813	001						>A> CGT	Apr 18, 2026
GLYCEROL PHENYLBUTYRATE - GLYCEROL PHENYLBUTYRATE								
A 205742	001						>A> PC	Apr 15, 2026
GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO								
N 216903	001		12383491	Oct 25, 2038	DP			
HEPARIN SODIUM; TAUROLIDINE - DEFENCATH								
N 214520	001		7696182	May 16, 2026	DS DP U-3774			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HEPARIN SODIUM; TAUROLIDINE - DEFENCATH							
N 214520	002	7696182	May 16, 2026	DS DP		U-3774	
HYDROCHLOROTHIAZIDE - INZIRQO							
N 219141	001	11878022	Jan 23, 2044	DP		U-4138	
		11878022	Jan 23, 2044	DP		U-4139	
HYDROCORTISONE - KHINDIVI							
N 218980	001	11904046	Feb 23, 2043	DP		U-4216	
		12133914	Feb 23, 2043			U-4215	
HYDROXYUREA - XROMI							
N 216593	001	12409156	Dec 23, 2041	DP			
IBRUTINIB - IMBRUVICA							
N 205552	001	8476284	Dec 28, 2026			U-1650	
		8476284	Dec 28, 2026			U-1946	
		8476284*PED	Jun 28, 2027				
		8497277	Dec 28, 2026			U-1491	
		8497277	Dec 28, 2026			U-1650	
		8497277	Dec 28, 2026			U-1946	
		8497277	Dec 28, 2026			U-2241	
		8497277	Dec 28, 2026			U-2242	
		8497277	Dec 28, 2026			U-3422	
		8497277*PED	Jun 28, 2027				
		9540382	Aug 18, 2033			U-1650	
		9540382	Aug 18, 2033			U-1684	
		9540382	Aug 18, 2033			U-1946	
		9540382*PED	Feb 18, 2034				
IBRUTINIB - IMBRUVICA							
N 205552	002	8476284	Dec 28, 2026			U-1650	
		8476284	Dec 28, 2026			U-1946	
		8476284*PED	Jun 28, 2027				
		8497277	Dec 28, 2026			U-1491	
		8497277	Dec 28, 2026			U-1650	
		8497277	Dec 28, 2026			U-1946	
		8497277	Dec 28, 2026			U-2241	
		8497277	Dec 28, 2026			U-2242	
		8497277	Dec 28, 2026			U-3422	
		8497277*PED	Jun 28, 2027				
		9540382	Aug 18, 2033			U-1491	
		9540382	Aug 18, 2033			U-1650	
		9540382	Aug 18, 2033			U-1946	
		9540382*PED	Feb 18, 2034				
IBRUTINIB - IMBRUVICA							
N 217003	001	12201690	Jun 14, 2039	DP			
		12364698	Apr 06, 2036	DP			
ICOSAPENT ETHYL - VASCEPA							
N 202057	001	12171738	Feb 09, 2030			U-4105	
ICOSAPENT ETHYL - VASCEPA							
N 202057	002	12171738	Feb 09, 2030			U-4105	
ILOPROST - AURLUMYN							
N 217933	001	12409183	Jul 18, 2044			U-4263	
		12409184	Aug 06, 2041	DP			
IMETELSTAT SODIUM - RYTELO							
N 217779	001	12171778	Jun 16, 2039			U-3956	
	>A>	12442000	Mar 15, 2033			U-3956	
		9388415	Sep 09, 2026			U-3956	
		9388416	Sep 09, 2026			U-3956	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IMETELSTAT SODIUM - RYTELO							
N 217779 001		12171778	Jun 16, 2039	U-3956			
	>A>	12442000	Mar 15, 2033	U-3956			
		9388415	Sep 09, 2026	U-3956			
		9388416	Sep 09, 2026	U-3956			
IMETELSTAT SODIUM - RYTELO							
N 217779 002		12171778	Jun 16, 2039	U-3956			
	>A>	12442000	Mar 15, 2033	U-3956			
		9388415	Sep 09, 2026	U-3956			
		9388416	Sep 09, 2026	U-3956			
IMLUNESTRANT TOSYLATE - INLURIYO							
N 218881 001	>A>	10654866	Jul 11, 2039	DS DP U-4278		>A> NCE	Sep 25, 2030
	>A>	11117902	Jul 11, 2039	DS DP U-4278			
INAVOLISIB - ITOVEBI							
N 219249 001	>A>	12410189	Jun 14, 2038	U-4024			
INAVOLISIB - ITOVEBI							
N 219249 002	>A>	12410189	Jun 14, 2038	U-4024			
INCLISIRAN SODIUM - LEQVIO							
N 214012 001		10125369	Aug 18, 2034	DS DP U-4249			
		10131907	Aug 24, 2028	DS DP U-4249			
		10851377	Aug 25, 2036	U-4249			
		8106022	Dec 12, 2029	DS DP U-4249			
		8222222	Dec 29, 2027	U-4249			
		8809292	May 10, 2027	DS DP U-4249			
		8828956	Dec 04, 2028	DS DP U-4249			
		9370582	Dec 04, 2028	DS DP U-4249			
IOMEPROL - IOMERVU							
N 216016 001						NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016 002						NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016 003						NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016 004						NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016 005						NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016 006						NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016 007						NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016 008						NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016 009						NCE	Nov 27, 2029
IOMEPROL - IOMERVU							
N 216016 010						NCE	Nov 27, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IOMEPROL - IOMERVU						
N 216016 011					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 012					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216016 013					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 001					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 002					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 003					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 004					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 005					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 006					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 007					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 008					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 009					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 010					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 011					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 012					NCE	Nov 27, 2029
IOMEPROL - IOMERVU						
N 216017 013					NCE	Nov 27, 2029
IOPAMIDOL - ISOVUE-300						
N 018735 002					>A> I-975	Oct 10, 2028
IOPAMIDOL - ISOVUE-370						
N 018735 003					>A> I-975	Oct 10, 2028
IOPAMIDOL - ISOVUE-200						
N 018735 006					>A> I-975	Oct 10, 2028
IOPAMIDOL - ISOVUE-250						
N 018735 007					>A> I-975	Oct 10, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IPRATROPIUM BROMIDE - ATROVENT HFA							
N 021527	001	8474447	Jan 17, 2030	DP	Y		
IPTACOPAN HYDROCHLORIDE - FABHALTA							
N 218276	001	10093663	Jul 14, 2034	U-3980		I-963	Mar 20, 2028
		10093663	Jul 14, 2034	U-4161			
		12285422	Aug 30, 2038	U-4181			
		12384758	May 17, 2041	U-3980			
		12384758	May 17, 2041	U-4161			
	>A>	12453726	Jul 15, 2041	U-4300			
IRINOTECAN HYDROCHLORIDE - ONIVYDE							
N 207793	001	12364691	Jun 12, 2033	U-1848			
IRON SUCROSE - IRON SUCROSE							
A 208977	001					CGT	Feb 08, 2026
IRON SUCROSE - IRON SUCROSE							
A 212559	002					CGT	Feb 07, 2026
IRON SUCROSE - IRON SUCROSE							
A 212559	003					CGT	Feb 07, 2026
IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE							
A 214051	001					PC	Jan 11, 2025
IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE							
A 214051	002					PC	Jan 11, 2025
IVACAFTOR - KALYDECO							
N 203188	001	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
		10646481*PED	Feb 13, 2030			PED	Jun 21, 2028
		11564916	Aug 13, 2029	U-3530			
		11564916*PED	Feb 13, 2030				
		8354427	Jul 06, 2026	U-1311			
		8354427	Jul 06, 2026	U-1905			
		8354427*PED	Jan 06, 2027				
		8410274	Dec 28, 2026	DP			
		8410274*PED	Jun 28, 2027				
		8754224	Dec 28, 2026	DS DP			
		8754224*PED	Jun 28, 2027				
		9670163	Dec 28, 2026	DP U-1311			
		9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO							
N 207925	001	10272046	Feb 27, 2033	DP U-2531		M-14	May 22, 2028
		10272046*PED	Aug 27, 2033			ODE-236	Apr 29, 2026
		10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
		10646481*PED	Feb 13, 2030			PED	Oct 29, 2026
		11147770	Feb 27, 2033	DP U-3339		PED	Jun 21, 2028
		11147770*PED	Aug 27, 2033			PED	Nov 22, 2028
		11564916	Aug 13, 2029	U-3528			
		11564916*PED	Feb 13, 2030				
		11752106	Feb 27, 2033	DP U-3697			
		11752106*PED	Aug 27, 2033				
		12214083	Feb 27, 2033	DP U-4126			
		12214083*PED	Aug 27, 2033				
		7495103	May 20, 2027	DS DP			
		7495103*PED	Nov 20, 2027				
		8324242	Aug 05, 2027	U-1311			
		8324242	Aug 05, 2027	U-1906			
		8324242	Aug 05, 2027	U-2527			
		8324242*PED	Feb 05, 2028				
		8354427	Jul 06, 2026	U-1311			
		8354427	Jul 06, 2026	U-1905			
		8354427	Jul 06, 2026	U-2528			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 001	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			ODE-236	Apr 29, 2026
	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Oct 29, 2026
	11147770	Feb 27, 2033	DP U-3339		PED	Jun 21, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 22, 2028
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4126			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 003	10272046	Feb 27, 2033	DP U-2967		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			ODE-236	Apr 29, 2026
	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Oct 29, 2026
	11147770	Feb 27, 2033	DP U-3339		PED	Jun 21, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 22, 2028
	11564916	Aug 13, 2029	U-3528			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4128			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2963			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2964			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 003	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2966			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 004	10272046	Feb 27, 2033	DP U-3605		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	10646481*PED	Feb 13, 2030			PED	Nov 03, 2026
	11147770	Feb 27, 2033	DP U-3604		PED	Nov 22, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 03, 2030
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4127			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-3608			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
IVACAFTOR - KALYDECO						
N 207925 005	10272046	Feb 27, 2033	DP U-3605		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	10646481*PED	Feb 13, 2030			PED	Nov 03, 2026
	11147770	Feb 27, 2033	DP U-3604		PED	Nov 22, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 03, 2030
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4127			
	12214083*PED	Aug 27, 2033				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-3608			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	001	RE50453	May 01, 2027	DS DP			
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	002	RE50453	May 01, 2027	DS DP			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	001	10076513	Dec 04, 2028	DP		U-2411	
		10076513*PED	Jun 04, 2029				
		10597384	Dec 04, 2028	DS DP		U-2777	
		10597384*PED	Jun 04, 2029				
		10646481	Aug 13, 2029	DP			
		10646481*PED	Feb 13, 2030				
		11052075	Dec 04, 2028	DP		U-3181	
		11052075*PED	Jun 04, 2029				
		11564916	Aug 13, 2029			U-3529	
		11564916*PED	Feb 13, 2030				
		12065432	Dec 04, 2028			U-3984	
		12065432*PED	Jun 04, 2029				
		7495103	May 20, 2027	DS DP			
		7495103*PED	Nov 20, 2027				
		7973038	Nov 08, 2026			U-1973	
		7973038*PED	May 08, 2027				
		8324242	Aug 05, 2027			U-1311	
		8324242	Aug 05, 2027			U-1911	
		8324242*PED	Feb 05, 2028				
		8410274	Dec 28, 2026	DP			
		8410274*PED	Jun 28, 2027				
		8507534	Sep 20, 2030	DS DP			
		8507534*PED	Mar 20, 2031				
		8653103	Dec 04, 2028	DP			
		8653103*PED	Jun 04, 2029				
		8716338	Sep 20, 2030	DP		U-1718	
		8716338	Sep 20, 2030	DP		U-1910	
		8716338*PED	Mar 20, 2031				
		8741933	Nov 08, 2026			U-1717	
		8741933	Nov 08, 2026			U-1909	
		8741933*PED	May 08, 2027				
		8754224	Dec 28, 2026	DS DP			
		8754224*PED	Jun 28, 2027				
		8846718	Jul 02, 2029			U-1717	
		8846718	Jul 02, 2029			U-1908	
		8846718*PED	Jan 02, 2030				
		8993600	Dec 11, 2030	DP			
		8993600*PED	Jun 11, 2031				
		9150552	Dec 04, 2028			U-1908	
		9150552*PED	Jun 04, 2029				
		9192606	Sep 29, 2029	DP		U-1912	
		9192606*PED	Mar 29, 2030				
		9216969	Nov 08, 2026	DS DP			
		9216969*PED	May 08, 2027				
		9670163	Dec 28, 2026	DP		U-1911	
		9670163*PED	Jun 28, 2027				
		9931334	Dec 28, 2026	DP		U-2276	
		9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	002	10597384	Dec 04, 2028	DS DP		U-2777	
		10597384*PED	Jun 04, 2029				
		10646481	Aug 13, 2029	DP			
		10646481*PED	Feb 13, 2030				
		11052075	Dec 04, 2028	DP		U-3181	
		11052075*PED	Jun 04, 2029				
		11564916	Aug 13, 2029			U-3529	
		11564916*PED	Feb 13, 2030				
		12065432	Dec 04, 2028			U-3984	
		12065432*PED	Jun 04, 2029				
		7495103	May 20, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 002	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 001	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-3424			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-3424			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 211358 003	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-3426			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-3424			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-3427			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-3427			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-3428			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-3429			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-3429			
	9931334*PED	Jun 28, 2027				
IVERMECTIN - IVERMECTIN						
A 215922 002					CGT	Oct 01, 2025
LACTULOSE - LACTULOSE						
A 217914 001					CGT	Sep 13, 2025
LACTULOSE - LACTULOSE						
A 217914 002					CGT	Sep 13, 2025
LAMOTRIGINE - LAMICTAL XR						
N 022115 001	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 002	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 003	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 004	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 005	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 006	8637512	Jan 07, 2029	DP			
LAMOTRIGINE - SUBVENITE						
N 218879 001	11596634	May 29, 2040	U-4271			
	11596634	May 29, 2040	U-4272			
	11596634	May 29, 2040	U-4273			
	11612566	May 29, 2040	U-4271			
	11612566	May 29, 2040	U-4272			
	11612566	May 29, 2040	U-4273			
LANDIOLOL HYDROCHLORIDE - RAPIBLYK						
N 217202 001	10722516	Apr 25, 2034	U-4235			
LAROTRECTINIB SULFATE - VITRAKVI						
N 210861 001	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAROTRECTINIB SULFATE - VITRAKVI							
N 210861 001		11337967	May 16, 2037	U-4123			
		11974998	May 16, 2037	U-4124			
LAROTRECTINIB SULFATE - VITRAKVI							
N 210861 002		11337967	May 16, 2037	U-4123			
		11974998	May 16, 2037	U-4124			
LAROTRECTINIB SULFATE - VITRAKVI							
N 211710 001		11337967	May 16, 2037	U-4123			
		11974998	May 16, 2037	U-4124			
LASMIDITAN SUCCINATE - REYVOW							
N 211280 001		12257246	Jul 07, 2030	U-2718			
LASMIDITAN SUCCINATE - REYVOW							
N 211280 002		12257246	Jul 07, 2030	U-2718			
LASMIDITAN SUCCINATE - REYVOW							
N 211280 003		12257246	Jul 07, 2030	U-2718			
LAZERTINIB MESYLATE - LAZCLUZE							
N 219008 001		12138351	Apr 13, 2041	DP			
	>A>	12318390	Apr 18, 2038	DP			
LAZERTINIB MESYLATE - LAZCLUZE							
N 219008 002		12138351	Apr 13, 2041	DP			
	>A>	12318390	Apr 18, 2038	DP			
LEFAMULIN ACETATE - XENLETA							
N 211672 001		8071643	Mar 25, 2033	DS DP			
LEFAMULIN ACETATE - XENLETA							
N 211673 001		12121582	Jun 14, 2036	DP			
		8071643	Mar 25, 2033	DS DP			
LENACAPAVIR SODIUM - YEZTUGO							
N 220018 001		10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
		11267799	Aug 16, 2038	DS		NP	Jun 18, 2028
		11807625	Nov 25, 2040	U-4190			
		9951043	Feb 28, 2034	DS DP U-4190			
LENACAPAVIR SODIUM - YEZTUGO							
N 220020 001		10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
		11267799	Aug 16, 2038	DS		NP	Jun 18, 2028
		9951043	Feb 28, 2034	DS DP U-4190			
LENVATINIB MESYLATE - LENVIMA							
N 206947 001		12083112	Mar 03, 2036	U-3996			
		12083112	Mar 03, 2036	U-3997			
		12083112*PED	Sep 03, 2036				
		12226409	May 15, 2038	U-4146			
		12226409*PED	Nov 15, 2038				
LENVATINIB MESYLATE - LENVIMA							
N 206947 002		12083112	Mar 03, 2036	U-3996			
		12083112	Mar 03, 2036	U-3997			
		12083112*PED	Sep 03, 2036				
		12226409	May 15, 2038	U-4146			
		12226409*PED	Nov 15, 2038				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)							
N 209935 001		12419894	Apr 14, 2036	DP			
LEUPROLIDE ACETATE - ELIGARD KIT							
N 021343 001		12397120	Dec 22, 2041	U-4001			
LEUPROLIDE ACETATE - ELIGARD KIT							
N 021379 001		12397120	Dec 22, 2041	U-4001			
LEUPROLIDE ACETATE - ELIGARD KIT							
N 021488 001		12397120	Dec 22, 2041	U-4001			
LEUPROLIDE ACETATE - ELIGARD KIT							
N 021731 001		12397120	Dec 22, 2041	U-4001			
LEUPROLIDE ACETATE - FENSOLVI KIT							
N 213150 001		12397120	Dec 22, 2041	U-3611			
LEUPROLIDE MESYLATE - CAMCEVI ETM							
N 219745 001						NS	Aug 25, 2028
LEVACETYLLEUCINE - AQNEURSA							
N 219132 001		11400067	Apr 19, 2037	U-4170			
	>A>	12433862	Apr 19, 2037	U-4284			
	>A>	12433863	Apr 19, 2037	U-4285			
LEVOKETOCONAZOLE - RECORLEV							
N 214133 001		12377096	Mar 02, 2040	U-4236		NCE*	Dec 30, 2026
		9918984	May 03, 2028	U-3283			
LIDOCAINE - BONDLIDO							
N 215029 001					>A>	NP	Sep 24, 2028
LINACLOTIDE - LINZESS							
N 202811 001	>A>	7304036	Aug 30, 2026	DS DP U-1278			
	>A>	7304036	Aug 30, 2026	DS DP U-1516			
	>A>	7304036*PED	Feb 28, 2027				
	>A>	8748573	Oct 30, 2031	U-1515			
	>A>	8748573	Oct 30, 2031	U-1516			
	>A>	8748573*PED	Apr 30, 2032				
	>A>	8802628	Oct 30, 2031	DP			
	>A>	8802628*PED	Apr 30, 2032				
	>A>	8933030	Feb 17, 2031	DP			
	>A>	8933030*PED	Aug 17, 2031				
	>A>	9708371	Aug 16, 2033	DP U-1515			
	>A>	9708371	Aug 16, 2033	DP U-1516			
	>A>	9708371*PED	Feb 16, 2034				
LINACLOTIDE - LINZESS							
N 202811 002	>A>	7304036	Aug 30, 2026	DS DP U-1278			
	>A>	7304036	Aug 30, 2026	DS DP U-1516			
	>A>	7304036*PED	Feb 28, 2027				
	>A>	8748573	Oct 30, 2031	U-1515			
	>A>	8748573	Oct 30, 2031	U-1516			
	>A>	8748573*PED	Apr 30, 2032				
	>A>	8802628	Oct 30, 2031	DP			
	>A>	8802628*PED	Apr 30, 2032				
	>A>	8933030	Feb 17, 2031	DP			
	>A>	8933030*PED	Aug 17, 2031				
	>A>	9708371	Aug 16, 2033	DP U-1515			
	>A>	9708371*PED	Feb 16, 2034				

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINACLOTIDE - LINZESS								
N 202811	003	>A>	10675325	Aug 11, 2031	DP			
		>A>	10675325*PED	Feb 11, 2032				
		>A>	10702576	Aug 11, 2031			U-1516	
		>A>	10702576	Aug 11, 2031			U-3644	
		>A>	10702576*PED	Feb 11, 2032				
		>A>	7304036	Aug 30, 2026	DS DP		U-1516	
		>A>	7304036	Aug 30, 2026	DS DP		U-3644	
		>A>	7304036*PED	Feb 28, 2027				
		>A>	8933030	Feb 17, 2031	DP		U-1516	
		>A>	8933030	Feb 17, 2031	DP		U-3644	
		>A>	8933030*PED	Aug 17, 2031				
		>A>	9708371	Aug 16, 2033	DP		U-1516	
		>A>	9708371	Aug 16, 2033	DP		U-3644	
		>A>	9708371*PED	Feb 16, 2034				
LINAGLIPTIN - TRADJENTA								
N 201280	001		12178819	May 04, 2027	DP			
			12364700	Jun 08, 2037			U-4224	
			12364700*PED	Dec 08, 2037				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO								
N 201281	001		12364700	Jun 08, 2037			U-4224	
			12364700*PED	Dec 08, 2037				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO								
N 201281	002		12364700	Jun 08, 2037			U-4224	
			12364700*PED	Dec 08, 2037				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO								
N 201281	003		12364700	Jun 08, 2037			U-4224	
			12364700*PED	Dec 08, 2037				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR								
N 208026	001		12364700	Jun 08, 2037			U-4224	
			12364700*PED	Dec 08, 2037				
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR								
N 208026	002		12364700	Jun 08, 2037			U-4224	
			12364700*PED	Dec 08, 2037				
LIRAGLUTIDE - LIRAGLUTIDE								
A 214568	001						PC	Feb 24, 2026
LISDEXAMFETAMINE DIMESYLATE - ARYNTA								
N 219847	001		11576878	Aug 30, 2040	DP			
			12433859	Apr 16, 2040	DP		U-842	
LISINOPRIL - QBRELIS								
N 208401	001		12186360	Nov 06, 2035	DP			
			12433931	Nov 06, 2035			U-1723	
			12433931	Nov 06, 2035			U-1864	
			12433931	Nov 06, 2035			U-3	
LONAFARNIB - ZOKINVY								
N 213969	001		7838531	Jul 26, 2029			U-3070	
LONAFARNIB - ZOKINVY								
N 213969	002		7838531	Jul 26, 2029			U-3070	
LOSARTAN POTASSIUM - ARBLI								
N 218772	001		11890273	Oct 07, 2041	DP			
			12156869	Oct 07, 2041	DP		U-4158	
			12156869	Oct 07, 2041	DP		U-4159	
			12156869	Oct 07, 2041	DP		U-4160	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOSARTAN POTASSIUM - ARBLI							
N 218772	001	11890273	Oct 07, 2041	DP			
		12156869	Oct 07, 2041	DP U-4158			
		12156869	Oct 07, 2041	DP U-4159			
		12156869	Oct 07, 2041	DP U-4160			
LOTILANER - XDEMVY							
N 217603	001	12171750	Dec 14, 2038	U-3674			
		12213964	Dec 14, 2038	DP			
		12364685	Dec 14, 2038	DP			
LUMATEPERONE TOSYLATE - CAPLYTA							
N 209500	001	11753419	Dec 10, 2040	DP	Y		
		12409176	Mar 15, 2039	U-4261			
		12410195	Dec 10, 2040	DP			
LUMATEPERONE TOSYLATE - CAPLYTA							
N 209500	002	11753419	Dec 10, 2040	DP	Y		
		12409176	Mar 15, 2039	U-4261			
		12410195	Dec 10, 2040	DP			
		RE48825	Mar 12, 2029	DS			
LUMATEPERONE TOSYLATE - CAPLYTA							
N 209500	003	11753419	Dec 10, 2040	DP	Y		
		12409176	Mar 15, 2039	U-4261			
		12410195	Dec 10, 2040	DP			
		RE48825	Mar 12, 2029	DS			
LURBINECTEDIN - ZEPZELCA							
N 213702	001	12324806	May 29, 2040	U-4212			
	>A>	12433890	May 29, 2040	U-4305			
	>A>	7763615	Dec 13, 2029	DS DP U-2836			
	>A>	7763615	Dec 13, 2029	DS DP U-4299			
LUTETIUM LU 177 DOTATATE - LUTATHERA							
N 208700	001	12415003	Jul 25, 2038	U-4036			
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN - PLUVICTO							
N 215833	001	10406240	Aug 15, 2028	DS DP U-4169		I-965	Mar 28, 2028
		11318121	Aug 15, 2028	DS DP U-4169			
		11951190	Nov 12, 2035	U-4169			
		12208102	Sep 18, 2041	U-4169			
MACITENTAN - OPSUMIT							
N 204410	001	10946015	Sep 11, 2026	DP U-1445		M-187	Feb 28, 2028
		10946015*PED	Mar 11, 2027			PED	Aug 28, 2028
		7094781	Dec 05, 2025	DS DP			
		7094781*PED	Jun 05, 2026				
		8268847	Apr 18, 2029	U-1446			
		8268847*PED	Oct 18, 2029				
		8367685	Oct 04, 2028	DP U-1445			
		8367685*PED	Apr 04, 2029				
		9265762	May 29, 2027	DP U-1820			
		9265762*PED	Nov 29, 2027				
MACITENTAN; TADALAFIL - OPSYNVI							
N 218490	001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
		10946015*PED	Mar 11, 2027			ODE-475	Mar 22, 2031
		7094781	Dec 05, 2025	DS DP		PED	Sep 22, 2027
		7094781*PED	Jun 05, 2026			PED	Sep 22, 2031
		8268847	Apr 18, 2029	DP U-3882			
		8268847*PED	Oct 18, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MACITENTAN; TADALAFIL - OPSYNVI							
N 218490	002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
		10946015*PED	Mar 11, 2027			ODE-475	Mar 22, 2031
		7094781	Dec 05, 2025	DS DP		PED	Sep 22, 2027
		7094781*PED	Jun 05, 2026			PED	Sep 22, 2031
		8268847	Apr 18, 2029	DP U-3882			
		8268847*PED	Oct 18, 2029				
MAGNESIUM SULFATE - MAGNESIUM SULFATE							
A 219777	001					CGT	Feb 01, 2026
MAGNESIUM SULFATE - MAGNESIUM SULFATE							
A 219777	004					CGT	Feb 01, 2026
MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE							
N 215344	001	12239659	Jun 14, 2044	U-4143			
		12290529	Aug 02, 2044	DP			
	>A>	12433914	Jun 14, 2044	U-4143			
MARALIXIBAT CHLORIDE - LIVMARLI							
N 214662	002	12350267	Oct 26, 2032	U-3973			
MARALIXIBAT CHLORIDE - LIVMARLI							
N 219485	001	10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
		11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
		11229661	Oct 26, 2032	U-4186			
		11260053	May 26, 2031	U-4187			
		11376251	Oct 26, 2032	U-4187			
		11497745	Feb 12, 2040	U-4187			
		12296050	Oct 05, 2043	DP U-4186			
		12296050	Oct 05, 2043	DP U-4187			
		12350267	Oct 26, 2032	U-3973			
MARALIXIBAT CHLORIDE - LIVMARLI							
N 219485	002	10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
		11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
		11229661	Oct 26, 2032	U-4186			
		11260053	May 26, 2031	U-4187			
		11376251	Oct 26, 2032	U-4187			
		11497745	Feb 12, 2040	U-4187			
		12296050	Oct 05, 2043	DP U-4186			
		12296050	Oct 05, 2043	DP U-4187			
		12350267	Oct 26, 2032	U-3973			
MARALIXIBAT CHLORIDE - LIVMARLI							
N 219485	003	10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
		11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
		11229661	Oct 26, 2032	U-4186			
		11260053	May 26, 2031	U-4187			
		11376251	Oct 26, 2032	U-4187			
		11497745	Feb 12, 2040	U-4187			
		12296050	Oct 05, 2043	DP U-4186			
		12296050	Oct 05, 2043	DP U-4187			
		12350267	Oct 26, 2032	U-3973			
MARALIXIBAT CHLORIDE - LIVMARLI							
N 219485	004	10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
		11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
		11229661	Oct 26, 2032	U-4186			
		11260053	May 26, 2031	U-4187			
		11376251	Oct 26, 2032	U-4187			
		11497745	Feb 12, 2040	U-4187			
		12296050	Oct 05, 2043	DP U-4186			
		12296050	Oct 05, 2043	DP U-4187			
		12350267	Oct 26, 2032	U-3973			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MARIBAVIR - LIVTENCITY							
N 215596	001	12213989	Nov 18, 2042	U-4137			
		12295940	Oct 11, 2043	DS DP			
	>A>	12433907	Nov 18, 2042	U-4289			
MELOXICAM - QAMZOVA							
N 217593	001	12059423	Jul 19, 2040	DS DP			
MELOXICAM - XIFYRM							
N 218395	001	12263176	Jul 31, 2041	DP			
MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO							
N 215431	001	10029010	Apr 11, 2036	U-4133		NP	Jan 30, 2028
		10058614	Apr 11, 2036	DP			
		10137131	Apr 11, 2036	DP U-1719			
		10195278	Apr 11, 2036	U-1719			
		10265324	Apr 11, 2036	U-1719			
		10363312	Apr 11, 2036	U-1719			
		10369224	Apr 11, 2036	U-4134			
		10426839	Apr 11, 2036	U-4135			
		10463736	Apr 11, 2036	DP			
		10471014	Apr 11, 2036	U-1719			
		10471069	Apr 11, 2036	U-1719			
		10512692	Apr 11, 2036	U-1719			
		10512693	Apr 11, 2036	U-1719			
		10517950	Apr 11, 2036	U-1719			
		10532101	Apr 11, 2036	U-1719			
		10537642	Apr 11, 2036	U-1719			
		10561664	Apr 11, 2036	U-1719			
		10583144	Apr 11, 2036	U-1719			
		10653777	Apr 11, 2036	U-1719			
		10688102	Apr 11, 2036	U-1719			
		10688185	Apr 11, 2036	U-1719			
		10695429	Apr 11, 2036	U-1719			
		10695430	Apr 11, 2036	U-1719			
		10702535	Apr 11, 2036	U-4136			
		10702602	Apr 11, 2036	U-1719			
		10722583	Apr 11, 2036	U-1719			
		10729696	Apr 11, 2036	U-1719			
		10729697	Apr 11, 2036	U-1719			
		10729773	Apr 11, 2036	U-1719			
		10758617	Apr 11, 2036	U-1719			
		10758618	Apr 11, 2036	U-1719			
		10780165	Apr 11, 2036	U-1719			
		10780166	Apr 11, 2036	U-1719			
		10799588	Apr 11, 2036	U-1719			
		10821181	Apr 11, 2036	U-1719			
		10821182	Apr 11, 2036	U-1719			
		10894053	Apr 11, 2036	U-1719			
		10905693	Apr 11, 2036	U-1719			
		10918722	Apr 11, 2036	U-1719			
		10933136	Apr 11, 2036	U-1719			
		10933137	Apr 11, 2036	U-1719			
		10940153	Apr 11, 2036	U-1719			
		10987358	Apr 11, 2036	U-1719			
		11013805	Apr 11, 2036	U-1719			
		11013806	Apr 11, 2036	U-1719			
		11020483	Apr 11, 2036	U-1719			
		11045549	Apr 11, 2036	U-1719			
		11135295	Apr 11, 2036	U-1719			
		11207328	Apr 11, 2036	U-1719			
		11219626	Apr 11, 2036	U-1719			
		11285213	Apr 11, 2036	U-1719			
		11331323	Apr 11, 2036	U-1719			
		11369684	Apr 11, 2036	U-1719			
		11426414	Apr 11, 2036	U-1719			
		11471464	Apr 11, 2036	U-1719			
		11471465	Apr 11, 2036	U-1719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO						
N 215431 001	11504429	Apr 11, 2036	U-1719			
	11510927	Apr 11, 2036	U-1719			
	11571428	Apr 11, 2036	U-1719			
	11602563	Apr 11, 2036	U-1719			
	11607456	Apr 11, 2036	U-1719			
	11617755	Apr 11, 2036	U-1719			
	11617756	Apr 11, 2036	U-1719			
	11617791	Apr 11, 2036	U-1719			
	11628173	Apr 11, 2036	U-1719			
	11712441	Apr 11, 2036	U-1719			
	11738085	Apr 11, 2036	U-1719			
	11759522	Apr 11, 2036	U-1719			
	11801250	Apr 11, 2036	U-1719			
	11806354	Apr 11, 2036	U-1719			
	11826370	Apr 11, 2036	U-1719			
	11865117	Apr 11, 2036	U-1719			
	12128052	May 28, 2040	U-1719			
	12370196	Dec 29, 2041	U-1719			
	9821075	Apr 11, 2036	DP U-1719			
MERCAPTOPURINE - MERCAPTOPURINE						
A 216418 001					CGT	Aug 25, 2025
MESNA - MESNA						
A 218871 001					CGT	Jul 13, 2025
METHOCARBAMOL - ATMEKSI						
N 219843 001	12390439	Oct 09, 2044	DP U-4253			
METHOTREXATE - OTREXUP						
N 204824 001	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 002	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 003	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 004	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 005	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 006	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 007	12357642	Mar 19, 2030	DP			
METHOTREXATE - OTREXUP						
N 204824 008	12357642	Mar 19, 2030	DP			
METHOTREXATE SODIUM - XATMEP						
N 208400 001	12396947	Jan 02, 2033	DP			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 001	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLNALTREXONE BROMIDE - RELISTOR							
N 021964	002	12303592	Aug 03, 2027	DP U-4197			
		12303592	Aug 03, 2027	DP U-4198			
METHYLNALTREXONE BROMIDE - RELISTOR							
N 021964	003	12303592	Aug 03, 2027	DP U-4197			
		12303592	Aug 03, 2027	DP U-4198			
METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI							
N 209388	001	12194008	Dec 22, 2029	U-2843			
		12194009	Dec 22, 2029	U-2843			
		12377064	Nov 17, 2038	U-2843			
METRONIDAZOLE - LIKMEZ							
N 216755	001	12257236	Jan 16, 2039	DP U-3169			
		12257236	Jan 16, 2039	DP U-4163			
		12257236	Jan 16, 2039	DP U-4164			
MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%							
N 216142	001	12403173	Dec 15, 2037	DP			
MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%							
N 216142	002	12403173	Dec 15, 2037	DP			
MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%							
N 216142	003	12403173	Dec 15, 2037	DP			
MIGALASTAT HYDROCHLORIDE - GALAFOLD							
N 208623	001	12280042	May 30, 2038	DS U-2371			
MIGLUSTAT - OPFOLDA							
N 215211	001	12246062	Sep 16, 2038	U-3726			
	>A>	12414985	Dec 29, 2036	U-3726			
	>A>	12419937	Mar 07, 2033	U-3726			
MIRABEGRON - MYRBETRIQ							
N 202611	001	12059409	Sep 28, 2029	DP			
		12059409*PED	Mar 28, 2030				
		12097189	Sep 28, 2029	U-2996			
		12097189	Sep 28, 2029	U-3670			
		12097189*PED	Mar 28, 2030				
MIRABEGRON - MYRBETRIQ							
N 202611	002	12059409	Sep 28, 2029	DP			
		12059409*PED	Mar 28, 2030				
		12097189	Sep 28, 2029	U-2996			
		12097189	Sep 28, 2029	U-3670			
		12097189*PED	Mar 28, 2030				
MIRDAMETINIB - GOMEKLI							
N 219379	001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
		11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
		11453641	Feb 17, 2041	U-4130			
		11571402	Feb 17, 2041	DP			
		11806321	Feb 17, 2041	U-4130			
		11806322	Apr 09, 2043	U-4130			
		11819487	Feb 17, 2041	U-4130			
		11839595	Mar 16, 2043	U-4130			
		11883375	Mar 16, 2043	U-4130			
		12011424	Feb 17, 2041	U-4130			
		12029711	Mar 15, 2044	DP U-4130			
		12037306	Feb 17, 2041	U-4130			
		12090128	Feb 17, 2041	DP U-4130			
		12220390	Mar 16, 2043	U-4130			
		12257215	Mar 16, 2043	U-4130			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIRDAMETINIB - GOMEKLI							
N 219379	001	12263146	Feb 17, 2041	U-4130			
		12295925	Feb 17, 2041	U-4130			
		12324791	Mar 16, 2043	U-4130			
		12357597	Feb 17, 2041	U-4130			
		12390430	Oct 10, 2044	U-4130			
MIRDAMETINIB - GOMEKLI							
N 219389	001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
		11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
		11453641	Feb 17, 2041	U-4130			
		11806321	Feb 17, 2041	U-4130			
		11806322	Apr 09, 2043	U-4130			
		11819487	Feb 17, 2041	U-4130			
		11839595	Mar 16, 2043	U-4130			
		11883375	Mar 16, 2043	U-4130			
		12011424	Feb 17, 2041	U-4130			
		12029711	Mar 15, 2044	DP U-4130			
		12037306	Feb 17, 2041	U-4130			
		12220390	Mar 16, 2043	U-4130			
		12257215	Mar 16, 2043	U-4130			
		12263146	Feb 17, 2041	U-4130			
		12275688	Feb 17, 2041	DP U-4130			
		12295925	Feb 17, 2041	U-4130			
		12324791	Mar 16, 2043	U-4130			
		12383517	Mar 15, 2044	DP U-4130			
		12390430	Oct 10, 2044	U-4130			
MIRDAMETINIB - GOMEKLI							
N 219389	002	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
		11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
		11453641	Feb 17, 2041	U-4130			
		11806321	Feb 17, 2041	U-4130			
		11806322	Apr 09, 2043	U-4130			
		11819487	Feb 17, 2041	U-4130			
		11839595	Mar 16, 2043	U-4130			
		11883375	Mar 16, 2043	U-4130			
		12029711	Mar 15, 2044	DP U-4130			
		12037306	Feb 17, 2041	U-4130			
		12220390	Mar 16, 2043	U-4130			
		12257215	Mar 16, 2043	U-4130			
		12263146	Feb 17, 2041	U-4130			
		12275688	Feb 17, 2041	DP U-4130			
		12295925	Feb 17, 2041	U-4130			
		12324791	Mar 16, 2043	U-4130			
		12383517	Mar 15, 2044	DP U-4130			
		12390430	Oct 10, 2044	U-4130			
MITOMYCIN - JELMYTO							
N 211728	001	12268745	Jan 20, 2031	U-4172			
MITOMYCIN - ZUSDURI							
N 215793	001	10039832	Jan 20, 2031	U-4256		NP	Jun 12, 2028
	>A>	12440568	Jan 20, 2031	U-4256			
		9040074	Jan 20, 2031	DP U-4256			
		9950069	Jan 20, 2031	DP U-4256			
MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS							
N 211746	001	12303635	Apr 08, 2039	DS DP			
MONOMETHYL FUMARATE - BAFIERTAM							
N 210296	001	10918615	Feb 27, 2035	DP U-1384			
		10918616	Feb 27, 2035	U-1384			
		10918617	Feb 27, 2035	DP			
		10945985	Feb 27, 2035	DP			
		11590095	Feb 27, 2035	U-1384			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MOTIXAFORTIDE ACETATE - APHEXDA							
N 217159	001	12257285	Dec 29, 2041	DP			
		12268725	Dec 29, 2041	DP			
MOXIDECTIN - MOXIDECTIN							
N 210867	001					NPP	Feb 07, 2028
MYCOPHENOLATE MOFETIL - MYHIBBIN							
N 216482	001	12194143	Aug 16, 2039	DP U-1752			
		12226526	Aug 16, 2039	DP U-1752			
NALDEMEDINE TOSYLATE - SYMPROIC							
N 208854	001	12350377	May 13, 2033	DP			
		RE46365	Feb 24, 2031	DS DP			
NALMEFENE HYDROCHLORIDE - OPVEE							
N 217470	001	12290596	Aug 04, 2042	U-4182			
NALOXONE HYDROCHLORIDE - KLOXXADO							
N 212045	001	12414915	Aug 26, 2034	DP			
NEDOSIRAN SODIUM - RIVFLOZA							
N 215842	001					NPP	Mar 27, 2028
NEDOSIRAN SODIUM - RIVFLOZA							
N 215842	002					NPP	Mar 27, 2028
NEDOSIRAN SODIUM - RIVFLOZA							
N 215842	003					NPP	Mar 27, 2028
NERANDOMILAST - JASCAYD							
N 218764	001	>A> 11406638	Oct 22, 2038	U-4297		>A> NCE	Oct 07, 2030
		>A> 11813266	Oct 22, 2038	U-4292			
		>A> 8609670	Aug 23, 2032	DS			
		>A> 8754073	Nov 26, 2029	DS DP U-4298			
		>A> 9802954	Feb 19, 2034	U-4298			
NERANDOMILAST - JASCAYD							
N 218764	002	>A> 11406638	Oct 22, 2038	U-4297		>A> NCE	Oct 07, 2030
		>A> 11813266	Oct 22, 2038	U-4292			
		>A> 8609670	Aug 23, 2032	DS			
		>A> 8754073	Nov 26, 2029	DS DP U-4298			
		>A> 9802954	Feb 19, 2034	U-4298			
NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE							
A 203640	001					PC	Nov 19, 2025
NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE							
A 203640	002					PC	Nov 19, 2025
NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE							
A 203640	003					PC	Nov 19, 2025
NILOTINIB TARTRATE - DANZITEN							
N 219293	001	12403140	Feb 18, 2040	DP			
NILOTINIB TARTRATE - DANZITEN							
N 219293	002	12403140	Feb 18, 2040	DP			
NIMODIPINE - NYMALIZE							
N 203340	002	12186308	Apr 16, 2038	DP U-2804			

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIRAPARIB TOSYLATE - ZEJULA							
N 214876	001	11730725	Jan 25, 2039	DP			
NIRAPARIB TOSYLATE - ZEJULA							
N 214876	002	11730725	Jan 25, 2039	DP			
NIRAPARIB TOSYLATE - ZEJULA							
N 214876	003	11730725	Jan 25, 2039	DP			
NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)							
N 217188	001					D-195	Jan 31, 2028
NIROGACESTAT HYDROBROMIDE - OGSIVEO							
N 217677	001	12234210	Jul 08, 2042	DP			
		12247012	Jul 08, 2042	DP			
		12297177	Aug 09, 2039	DP			
		7795447	Aug 18, 2030	DS			
		7951958	Mar 11, 2025	DS			
NIROGACESTAT HYDROBROMIDE - OGSIVEO							
N 217677	002	12234210	Jul 08, 2042	DP			
		12247012	Jul 08, 2042	DP			
		12297177	Aug 09, 2039	DP			
		7795447	Aug 18, 2030	DS			
		7951958	Mar 11, 2025	DS			
NIROGACESTAT HYDROBROMIDE - OGSIVEO							
N 217677	003	12234210	Jul 08, 2042	DP			
		12247012	Jul 08, 2042	DP			
		12297177	Aug 09, 2039	DP			
		7795447	Aug 18, 2030	DS			
		7951958	Mar 11, 2025	DS			
NITRIC OXIDE - INOMAX							
N 020845	003	11931377	Jun 30, 2029	DS DP		U-3903	
		11931377*PED	Dec 30, 2029				
		9279794	Feb 19, 2035	DP		U-1823	
		9279794*PED	Aug 19, 2035				
NITRIC OXIDE - INOMAX							
N 020845	004	11931377	Jun 30, 2029	DS DP		U-3903	
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE							
N 214313	001	12290494	Mar 08, 2041	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE							
N 214313	002	12290494	Mar 08, 2041	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 214628	001	12245996	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 214628	002	12245996	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 214628	003	12245996	Jan 30, 2038	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 215700	001	RE49422	Feb 26, 2035	DP			
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE							
N 215700	002	RE49422	Feb 26, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
N 215700 003	10251848	Feb 26, 2035	DP			
	RE49422	Feb 26, 2035	DP			
	RE49443	Feb 26, 2035	DP			
OCTREOTIDE ACETATE - MYCAPSSA						
N 208232 001	12246054	Feb 03, 2036			U-2857	
	12251418	Feb 03, 2036			U-2857	
OCTREOTIDE ACETATE - BYNFEZIA PEN						
N 213224 001	12350475	Dec 29, 2041			U-4007	
	12350475	Dec 29, 2041			U-4008	
	12350475	Dec 29, 2041			U-4009	
ODEVIXIBAT - BYLVAY						
N 215498 001	10011633	Nov 08, 2031			U-3186	
	10011633	Nov 08, 2031			U-3648	
	10093697	Nov 08, 2031			U-3186	
	10093697	Nov 08, 2031			U-3648	
	10487111	Nov 08, 2031			U-3186	
	10487111	Nov 08, 2031			U-3648	
	11365182	Jun 20, 2039			U-3186	
	11365182	Jun 20, 2039			U-3648	
	11732006	Nov 08, 2031			U-3186	
	11732006	Nov 08, 2031			U-3648	
	12187812	Nov 08, 2031			U-3186	
	12187812	Nov 08, 2031			U-3648	
	9694018	Nov 08, 2031			U-3186	
	9694018	Nov 08, 2031			U-3648	
ODEVIXIBAT - BYLVAY						
N 215498 002	10011633	Nov 08, 2031			U-3186	
	10011633	Nov 08, 2031			U-3648	
	10093697	Nov 08, 2031			U-3186	
	10093697	Nov 08, 2031			U-3648	
	10487111	Nov 08, 2031			U-3186	
	10487111	Nov 08, 2031			U-3648	
	11365182	Jun 20, 2039			U-3186	
	11365182	Jun 20, 2039			U-3648	
	11732006	Nov 08, 2031			U-3186	
	11732006	Nov 08, 2031			U-3648	
	12187812	Nov 08, 2031			U-3186	
	12187812	Nov 08, 2031			U-3648	
	9694018	Nov 08, 2031			U-3186	
	9694018	Nov 08, 2031			U-3648	
ODEVIXIBAT - BYLVAY						
N 215498 003	10011633	Nov 08, 2031			U-3186	
	10011633	Nov 08, 2031			U-3648	
	10093697	Nov 08, 2031			U-3186	
	10093697	Nov 08, 2031			U-3648	
	10487111	Nov 08, 2031			U-3186	
	10487111	Nov 08, 2031			U-3648	
	11365182	Jun 20, 2039			U-3186	
	11365182	Jun 20, 2039			U-3648	
	11732006	Nov 08, 2031			U-3186	
	11732006	Nov 08, 2031			U-3648	
	12187812	Nov 08, 2031			U-3186	
	12187812	Nov 08, 2031			U-3648	
	9694018	Nov 08, 2031			U-3186	
	9694018	Nov 08, 2031			U-3648	
ODEVIXIBAT - BYLVAY						
N 215498 004	10011633	Nov 08, 2031			U-3186	
	10011633	Nov 08, 2031			U-3648	
	10093697	Nov 08, 2031			U-3186	
	10093697	Nov 08, 2031			U-3648	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ODEVIXIBAT - BYLVAY						
N 215498 004	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 001	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 002	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 003	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 004	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
OLAPARIB - LYNPARZA						
N 208558 001	12178816	Oct 07, 2029	DP			
OLAPARIB - LYNPARZA						
N 208558 002	12178816	Oct 07, 2029	DP			
OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)						
N 218614 001	9127276	May 01, 2034	DS		ODE-515	Dec 19, 2031
	9157082	Apr 27, 2032	U-4050			
	9163239	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
	9593333	Feb 14, 2034	U-4050			
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT						
N 206756 001	7396341	Oct 10, 2026	DP	Y		
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP	Y		
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP	Y		
	9027967	Mar 31, 2027	DP	Y		
OLUTASIDENIB - REZLIDHIA						
N 215814 001	12275715	Sep 18, 2035	DS DP U-3684			
OMADACYCLINE TOSYLATE - NUZYRA						
N 209816 001	9265740	Oct 24, 2030	DP U-1569			
OMADACYCLINE TOSYLATE - NUZYRA						
N 209817 001	9265740	Mar 05, 2029	DP			
OMAVELOXOLONE - SKYCLARYS						
N 216718 001					M-270	Dec 20, 2027
OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEP						
N 213593 001	12329752	Jul 16, 2039	DP			
>A>	12440566	Jul 16, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEP							
N 213593 001		12329752	Jul 16, 2039	DP			
	>A>	12440566	Jul 16, 2039	DP			
OMIDENEPAG ISOPROPYL - OMLONTI							
N 215092 001		12290511	Dec 27, 2038			U-3454	
		12295946	Jan 08, 2035	DP		U-3454	
OSILODROSTAT PHOSPHATE - ISTURISA							
N 212801 001		10709691	Oct 12, 2035			U-2770	
		10709691	Oct 12, 2035			U-4177	
		8609862	Jan 13, 2031			U-2770	
		8609862	Jan 13, 2031			U-4177	
OSILODROSTAT PHOSPHATE - ISTURISA							
N 212801 002		10709691	Oct 12, 2035			U-2770	
		10709691	Oct 12, 2035			U-4177	
		8609862	Jan 13, 2031			U-2770	
		8609862	Jan 13, 2031			U-4177	
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 001		12246094	Aug 24, 2027	DP			
		12280152	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 002		12246094	Aug 24, 2027	DP			
		12280152	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 003		12246094	Aug 24, 2027	DP			
		12280152	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 004		12246094	Aug 24, 2027	DP			
		12280152	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 005		12246094	Aug 24, 2027	DP			
		12280152	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 006		12246094	Aug 24, 2027	DP			
		12280152	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272 007		12246094	Aug 24, 2027	DP			
		12280152	Aug 24, 2027	DP			
OXYMETAZOLINE HYDROCHLORIDE - RHOFADE							
N 208552 001		12350255	Jun 11, 2035			U-3494	
OZANIMOD HYDROCHLORIDE - ZEPOSIA							
N 209899 001		8481573	Mar 24, 2033	DS DP		U-2774	
OZANIMOD HYDROCHLORIDE - ZEPOSIA							
N 209899 002		8481573	Mar 24, 2033	DS DP		U-2774	
OZANIMOD HYDROCHLORIDE - ZEPOSIA							
N 209899 003		8481573	Mar 24, 2033	DS DP		U-2774	
PALBOCICLIB - IBRANCE							
N 207103 001		10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
		10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
		RE47739	Mar 05, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALBOCICLIB - IBRANCE							
N 207103 001		RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE							
N 207103 002		10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
		10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
		RE47739	Mar 05, 2027	DS DP			
		RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE							
N 207103 003		10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
		10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
		RE47739	Mar 05, 2027	DS DP			
		RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE							
N 212436 001		10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
		10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
		11065250	Aug 19, 2036	DP			
		11065250*PED	Feb 19, 2037				
		RE47739	Mar 05, 2027	DS DP			
		RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE							
N 212436 002		10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
		10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
		11065250	Aug 19, 2036	DP			
		11065250*PED	Feb 19, 2037				
		RE47739	Mar 05, 2027	DS DP			
		RE47739*PED	Sep 05, 2027				
PALBOCICLIB - IBRANCE							
N 212436 003		10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
		10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
		11065250	Aug 19, 2036	DP			
		11065250*PED	Feb 19, 2037				
		RE47739	Mar 05, 2027	DS DP			
		RE47739*PED	Sep 05, 2027				
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264 001	>A>	9439906	Jan 26, 2031	U-2757			
	>A>	9439906	Jan 26, 2031	U-2758			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264 002	>A>	9439906	Jan 26, 2031	U-2757			
	>A>	9439906	Jan 26, 2031	U-2758			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264 003	>A>	9439906	Jan 26, 2031	U-2757			
	>A>	9439906	Jan 26, 2031	U-2758			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264 004	>A>	9439906	Jan 26, 2031	U-2757			
	>A>	9439906	Jan 26, 2031	U-2758			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264 005	>A>	9439906	Jan 26, 2031	U-2757			
	>A>	9439906	Jan 26, 2031	U-2758			
PALIPERIDONE PALMITATE - INVEGA HAFYERA							
N 207946 005		12208100	May 07, 2041	U-3359			
		12208100	May 07, 2041	U-4110			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALIPERIDONE PALMITATE - INVEGA HAFYERA							
N 207946 006		12208100	May 07, 2041	U-3359			
		12208100	May 07, 2041	U-4110			
PALOPEGTERIPARATIDE - YORVIPATH							
N 216490 001		12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
		12403182	Nov 12, 2042	DP U-3982			
	>A>	12453778	Sep 28, 2037	U-3982			
PALOPEGTERIPARATIDE - YORVIPATH							
N 216490 002		12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
		12403182	Nov 12, 2042	DP U-3982			
	>A>	12453778	Sep 28, 2037	U-3982			
PALOPEGTERIPARATIDE - YORVIPATH							
N 216490 003		12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
		12403182	Nov 12, 2042	DP U-3982			
	>A>	12453778	Sep 28, 2037	U-3982			
PALOVAROTENE - SOHONOS							
N 215559 001		12201614	Jun 08, 2037	U-4031			
PALOVAROTENE - SOHONOS							
N 215559 002		12201614	Jun 08, 2037	U-4031			
PALOVAROTENE - SOHONOS							
N 215559 003		12201614	Jun 08, 2037	U-4031			
PALOVAROTENE - SOHONOS							
N 215559 004		12201614	Jun 08, 2037	U-4031			
PALOVAROTENE - SOHONOS							
N 215559 005		12201614	Jun 08, 2037	U-4031			
PALTUSOTINE HYDROCHLORIDE - PALSONIFY							
N 219070 001	>A>	10351547	Jul 12, 2037	DS DP U-4283		>A> NCE	Sep 25, 2030
	>A>	10464918	Jan 16, 2039	DS			
	>A>	10597377	Jul 12, 2037	DS DP U-4283			
	>A>	10875839	Jul 12, 2037	U-4283			
	>A>	11266641	Sep 07, 2041	DP U-4283			
	>A>	11414397	Jul 12, 2037	DS DP U-4283			
	>A>	11957674	Sep 07, 2041	U-4283			
	>A>	12208092	Mar 25, 2044	U-4282			
	>A>	9896432	Jul 12, 2037	DS DP U-4283			
PALTUSOTINE HYDROCHLORIDE - PALSONIFY							
N 219070 002	>A>	10351547	Jul 12, 2037	DS DP U-4283		>A> NCE	Sep 25, 2030
	>A>	10464918	Jan 16, 2039	DS			
	>A>	10597377	Jul 12, 2037	DS DP U-4283			
	>A>	10875839	Jul 12, 2037	U-4283			
	>A>	11266641	Sep 07, 2041	DP U-4283			
	>A>	11414397	Jul 12, 2037	DS DP U-4283			
	>A>	11957674	Sep 07, 2041	U-4283			
	>A>	12208092	Mar 25, 2044	U-4282			
	>A>	9896432	Jul 12, 2037	DS DP U-4283			
PATISIRAN SODIUM - ONPATTRO							
N 210922 001		8168775	Aug 10, 2032	DS DP U-2378			
PEGCETACOPLAN - EMPAVELI							
N 215014 001		10875893	Nov 15, 2033	DS U-3124		I-972	Jul 28, 2028
		10875893	Nov 15, 2033	DS U-4242			
		11040107	Apr 09, 2038	DP U-3172			
		11040107	Apr 09, 2038	DP U-3173			
		11040107	Apr 09, 2038	DP U-3174			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT DELIST REQUESTED	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGCETACOPLAN - EMPAVELI								
N 215014	001		11040107	Apr 09, 2038		DP U-4241		
			11292815	Nov 15, 2033	DS	DP U-3124		
			11292815	Nov 15, 2033	DS	DP U-3354		
			11292815	Nov 15, 2033	DS	DP U-4242		
			11292815	Nov 15, 2033	DS	DP U-4243		
			11661441	Jan 13, 2033	DS	U-3124		
			11661441	Jan 13, 2033	DS	U-4242		
			11844841	Dec 09, 2038		DP U-3172		
			11844841	Dec 09, 2038		DP U-3173		
			11844841	Dec 09, 2038		DP U-3174		
			11844841	Dec 09, 2038		DP U-4241		
			12290566	Dec 14, 2038		DP U-4174		
			12290566	Dec 14, 2038		DP U-4175		
			12290566	Dec 14, 2038		DP U-4238		
			12290566	Dec 14, 2038		DP U-4239		
			12290566	Dec 14, 2038		DP U-4240		
			9169307	Nov 18, 2027	DS	U-3123		
			9169307	Nov 18, 2027	DS	U-4244		
PEGCETACOPLAN - SYFOVRE								
N 217171	001	>A>	12458695	Dec 14, 2038		DP		
PEGULICIANINE ACETATE - LUMISIGHT								
N 214511	001		11592396	Sep 01, 2030	DS			
PEMETREXED - PEMFEXY								
N 209472	001		12115164	Feb 19, 2036		U-4246		
			12115164	Feb 19, 2036		U-4247		
			12115164	Feb 19, 2036		U-4248		
PERAMPANEL - PERAMPANEL								
A 209801	001						PC	Nov 25, 2025
PERAMPANEL - PERAMPANEL								
A 209801	002						PC	Nov 25, 2025
PERAMPANEL - PERAMPANEL								
A 209801	003						PC	Nov 25, 2025
PERAMPANEL - PERAMPANEL								
A 209801	004						PC	Nov 25, 2025
PERAMPANEL - PERAMPANEL								
A 209801	005						PC	Nov 25, 2025
PERAMPANEL - PERAMPANEL								
A 209801	006						PC	Nov 25, 2025
PHENTOLAMINE MESYLATE - RYZUMVI								
N 217064	001		12201615	Dec 25, 2039		U-3804		
			12201616	Oct 25, 2039		U-3804		
			12350366	Jan 31, 2034		DP		
PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV								
N 203826	004		12257342	Sep 26, 2036		DP		
PHENYLEPHRINE HYDROCHLORIDE - IMMPHENTIV								
N 203826	005		12257342	Sep 26, 2036		DP		
PHYTONADIONE - PHYTONADIONE								
A 214966	001						CGT	Sep 06, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRTOBRUTINIB - JAYPIRCA						
N 216059 001	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	12268666	Jul 29, 2039	DP			
PIRTOBRUTINIB - JAYPIRCA						
N 216059 002	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
	12268666	Jul 29, 2039	DP			
PONESIMOD - PONVORY						
N 213498 001	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 002	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 003	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 004	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 005	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 006	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 007	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 008	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 009	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
PONESIMOD - PONVORY						
N 213498 010	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE						
N 212832 004	11813291	Oct 12, 2041	DP U-4185			
	11925661	Oct 12, 2041	DP U-4185			
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE						
N 212832 005	11813291	Oct 12, 2041	DP U-4185			
	11925661	Oct 12, 2041	DP U-4185			
PROGESTERONE - PROGESTERONE						
A 218391 001					CGT	Mar 22, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PRUCALOPRIDE SUCCINATE - MOTEGRITY								
N 210166 001							M-14	Jul 10, 2028
PRUCALOPRIDE SUCCINATE - MOTEGRITY								
N 210166 002							M-14	Jul 10, 2028
PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE								
N 217604 001		12233166	Jun 18, 2038	DP				
RAMIPRIL - VOSTALLY								
N 219757 001		12343338	Aug 16, 2039	DP U-4233				
RELUGOLIX - ORGOVYX								
N 214621 001		12325714	Sep 27, 2033	DS DP				
		12336990	Sep 29, 2037	U-3020				
REMIBRUTINIB - RHAPSIDO								
N 218436 001	>A>	10457647	Nov 13, 2034	U-4280		>A>	NCE	Sep 30, 2030
	>A>	12419889	Jan 20, 2043	U-4281				
	>A>	9512084	Nov 13, 2034	DS DP				
REPOTRECTINIB - AUGTYRO								
N 218213 001		12187739	Jul 05, 2036	DP			ODE-483	Jun 13, 2031
		12310968	Jul 20, 2036	U-3755				
	>A>	RE50634	Jan 23, 2035	DS DP				
REPOTRECTINIB - AUGTYRO								
N 218213 002		12187739	Jul 05, 2036	DP			ODE-483	Jun 13, 2031
		12310968	Jul 20, 2036	U-3755				
	>A>	RE50634	Jan 23, 2035	DS DP				
RESMETIROM - REZDIFFRA								
N 217785 001		12377104	Feb 04, 2045	U-3861				
RESMETIROM - REZDIFFRA								
N 217785 002		12377104	Feb 04, 2045	U-3861				
RESMETIROM - REZDIFFRA								
N 217785 003		12377104	Feb 04, 2045	U-3861				
REVEFENACIN - YUPELRI								
N 210598 001		12285417	Aug 29, 2039	U-2440				
REVUMENIB CITRATE - REVUFORJ								
N 218944 001							ODE-504	Nov 15, 2031
							ODE-505	Nov 15, 2031
REVUMENIB CITRATE - REVUFORJ								
N 218944 002							ODE-504	Nov 15, 2031
							ODE-505	Nov 15, 2031
REVUMENIB CITRATE - REVUFORJ								
N 218944 003							ODE-504	Nov 15, 2031
							ODE-505	Nov 15, 2031
RIBOCICLIB SUCCINATE - KISQALI								
N 209092 001		12419894	Apr 14, 2036	DP				
RIBOFLAVIN 5'-PHOSPHATE - EPIOXA HD/EPIOXA KIT								
N 219910 001						>A>	NP	Oct 17, 2028

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIFAXIMIN - XIFAXAN							
N 021361	001	>A> 10703763	Feb 27, 2026	U-2848			
		>A> 8741904	Feb 27, 2026	DS DP U-2848			
RIFAXIMIN - XIFAXAN							
N 021361	002	>A> 10703763	Feb 27, 2026	U-1708			
		>A> 10703763	Feb 27, 2026	U-2847			
		8309569	Jul 18, 2029	U-1707	Y		
		8309569	Jul 18, 2029	U-1708	Y		
		>A> 8741904	Feb 27, 2026	DS DP U-1707			
		>A> 8741904	Feb 27, 2026	DS DP U-1708			
		>A> 8741904	Feb 27, 2026	DS DP U-2847			
RILPIVIRINE HYDROCHLORIDE - EDURANT							
N 202022	001					NPP	Mar 15, 2027
						PED	Sep 15, 2027
RILPIVIRINE HYDROCHLORIDE - EDURANT PED							
N 219016	001					NP	Mar 15, 2027
						PED	Sep 15, 2027
RILZABRUTINIB - WAYRILZ							
N 219685	001	11708370	Feb 20, 2041	DS		NCE	Aug 29, 2030
		12178818	Oct 13, 2040	U-4267			
		8940744	Sep 06, 2033	DS DP U-4270			
		9266895	Sep 06, 2033	DS DP U-4268			
		9580427	Mar 01, 2033	DS DP			
		9994576	Sep 06, 2033	DS DP U-4268			
		9994576	Sep 06, 2033	DS DP U-4269			
RIPRETINIB - QINLOCK							
N 213973	001	12213967	Dec 30, 2040	DP			
		12213968	Dec 30, 2040	DP			
		12226406	Dec 30, 2040	DP			
		12295944	Aug 12, 2040	U-4183			
		12318373	Aug 12, 2040	U-4191			
		12318374	Dec 30, 2040	DP			
RISDIPLAM - EVRYSDI							
N 213535	001	12350273	Oct 01, 2038	U-1943			
RISDIPLAM - EVRYSDI							
N 219285	001	11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
		11827646	Jan 25, 2036	U-1943		NCE	Aug 07, 2025
		12122789	Apr 15, 2041	DS DP			
		12350273	Oct 01, 2038	U-1943			
		9586955	Feb 08, 2033	DS DP			
		9969754	May 11, 2035	DS DP U-1943			
RISPERIDONE - UZEDY							
N 213586	001	>A> 12128132	Sep 11, 2040	DP U-543			
		>A> 12128132	Sep 11, 2040	DP U-601			
		12329851	Mar 17, 2042	U-4214			
		>A> 12383493	Sep 11, 2040	DP U-543			
		>A> 12383493	Sep 11, 2040	DP U-601			
		>A> 8221778	Nov 12, 2027	DP U-543			
		>A> 8221778	Nov 12, 2027	DP U-601			
RISPERIDONE - UZEDY							
N 213586	002	>A> 12128132	Sep 11, 2040	DP U-543			
		>A> 12128132	Sep 11, 2040	DP U-601			
		12329851	Mar 17, 2042	U-4214			
		>A> 12383493	Sep 11, 2040	DP U-543			
		>A> 12383493	Sep 11, 2040	DP U-601			
		>A> 8221778	Nov 12, 2027	DP U-543			
		>A> 8221778	Nov 12, 2027	DP U-601			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - UZEDY							
N 213586 002	>A>	12128132	Sep 11, 2040	DP U-543			
	>A>	12128132	Sep 11, 2040	DP U-601			
		12329851	Mar 17, 2042	U-4214			
	>A>	12383493	Sep 11, 2040	DP U-543			
	>A>	12383493	Sep 11, 2040	DP U-601			
	>A>	8221778	Nov 12, 2027	DP U-543			
	>A>	8221778	Nov 12, 2027	DP U-601			
RISPERIDONE - UZEDY							
N 213586 003	>A>	12128132	Sep 11, 2040	DP U-543			
	>A>	12128132	Sep 11, 2040	DP U-601			
		12329851	Mar 17, 2042	U-4214			
	>A>	12383493	Sep 11, 2040	DP U-543			
	>A>	12383493	Sep 11, 2040	DP U-601			
	>A>	8221778	Nov 12, 2027	DP U-543			
	>A>	8221778	Nov 12, 2027	DP U-601			
RISPERIDONE - UZEDY							
N 213586 004		12329851	Mar 17, 2042	U-4214			
		12383493	Sep 11, 2040	DP U-543			
RISPERIDONE - UZEDY							
N 213586 005		12329851	Mar 17, 2042	U-4214			
		12383493	Sep 11, 2040	DP U-543			
RISPERIDONE - UZEDY							
N 213586 006		12329851	Mar 17, 2042	U-4214			
		12383493	Sep 11, 2040	DP U-543			
RISPERIDONE - UZEDY							
N 213586 007		12329851	Mar 17, 2042	U-4214			
		12383493	Sep 11, 2040	DP U-543			
ROCURONIUM BROMIDE - ROCURONIUM BROMIDE							
N 219108 001	>A>	11998605	Jul 22, 2039	DP			
ROFLUMILAST - ZORYVE							
N 215985 001		12220409	Jun 07, 2037	DP			
		12257242	Jun 07, 2037	DP			
		12310956	Jun 07, 2037	U-3748			
		12336983	Jun 07, 2037	DP			
ROFLUMILAST - ZORYVE							
N 215985 002		12220409	Jun 07, 2037	DP			
		12257242	Jun 07, 2037	DP			
		12310956	Jun 07, 2037	U-3970			
		12336983	Jun 07, 2037	DP			
ROFLUMILAST - ZORYVE							
N 215985 003	>A>	10940142	Jun 07, 2037	DP		>A> NS	Oct 04, 2028
	>A>	11129818	Aug 25, 2037	U-4301			
	>A>	11793796	Jun 07, 2037	DP			
	>A>	11819496	Jun 07, 2037	U-4301			
	>A>	11992480	Jun 07, 2037	U-4301			
	>A>	12005051	Jun 07, 2037	U-4301			
	>A>	12005052	Jun 07, 2037	DP			
	>A>	12011437	Jun 07, 2037	DP			
	>A>	12016848	Jun 07, 2037	DP			
	>A>	12042487	Jun 07, 2037	DP			
	>A>	12220409	Jun 07, 2037	DP			
	>A>	12257242	Jun 07, 2037	DP			
	>A>	12310956	Jun 07, 2037	U-4301			
	>A>	12336983	Jun 07, 2037	DP			
	>A>	9884050	Jun 07, 2037	DP			
	>A>	9907788	Jun 07, 2037	U-4301			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROFLUMILAST - ZORYVE							
N 215985	003	>A> 10940142	Jun 07, 2037	DP		>A> NS	Oct 04, 2028
		>A> 11129818	Aug 25, 2037	U-4301			
		>A> 11793796	Jun 07, 2037	DP			
		>A> 11819496	Jun 07, 2037	U-4301			
		>A> 11992480	Jun 07, 2037	U-4301			
		>A> 12005051	Jun 07, 2037	U-4301			
		>A> 12005052	Jun 07, 2037	DP			
		>A> 12011437	Jun 07, 2037	DP			
		>A> 12016848	Jun 07, 2037	DP			
		>A> 12042487	Jun 07, 2037	DP			
		>A> 12220409	Jun 07, 2037	DP			
		>A> 12257242	Jun 07, 2037	DP			
		>A> 12310956	Jun 07, 2037	U-4301			
		>A> 12336983	Jun 07, 2037	DP			
		>A> 9884050	Jun 07, 2037	DP			
		>A> 9907788	Jun 07, 2037	U-4301			
ROFLUMILAST - ZORYVE							
N 217242	001	11129818	Aug 25, 2037	U-3773		I-969	May 22, 2028
		11129818	Aug 25, 2037	U-4203			
		11819496	Jun 07, 2037	U-3773			
		11819496	Jun 07, 2037	U-4203			
		11992480	Jun 07, 2037	U-3773			
		11992480	Jun 07, 2037	U-4203			
		12005051	Jun 07, 2037	U-3773			
		12005051	Jun 07, 2037	U-4203			
		12220409	Jun 07, 2037	DP			
		12257242	Jun 07, 2037	DP			
		12310956	Jun 07, 2037	U-3773			
		12310956	Jun 07, 2037	U-4203			
		12329751	Dec 03, 2041	U-3773			
		12336983	Jun 07, 2037	DP			
		12390453	Jun 07, 2037	DP			
		9907788	Jun 07, 2037	U-3773			
		9907788	Jun 07, 2037	U-4203			
RUXOLITINIB PHOSPHATE - OPZELURA							
N 215309	001	12226419	May 20, 2031	DP		>A> NPP	Sep 18, 2028
		12233067	Jul 28, 2040	U-4151			
SEBETRALSTAT - EKTERLY							
N 219301	001	10364238	Nov 26, 2035	DS DP		NCE	Jul 03, 2030
		10611758	Nov 26, 2035	U-4223			
		11001578	Nov 26, 2035	DS DP			
		11084809	Nov 26, 2035	DS DP U-4223			
		11198691	Nov 26, 2035	U-4223			
		11230537	Dec 25, 2037	DS DP			
		11234939	Jan 26, 2039	DP U-4223			
		11739068	Jun 23, 2037	U-4223			
SECNIDAZOLE - SOLOSEC							
N 209363	001	12280037	Dec 11, 2041	U-3302			
SELADELPAR LYSINE - LIVDELZI							
N 217899	001	7301050	Aug 02, 2026	DS DP			
SELINEXOR - XPOVIO							
N 212306	001	12291508	Jul 26, 2032	U-2584			
		12291508	Jul 26, 2032	U-2855			
		12291508	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO							
N 212306	002	12291508	Jul 26, 2032	U-2584			
		12291508	Jul 26, 2032	U-2855			
		12291508	Jul 26, 2032	U-3018			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELINEXOR - XPOVIO						
N 212306 002	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO						
N 212306 003	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO						
N 212306 004	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
SELINEXOR - XPOVIO						
N 212306 005	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	11746102	Aug 14, 2035	U-2584			
	11746102	Aug 14, 2035	U-2855			
	11746102	Aug 14, 2035	U-3018			
	11753401	Aug 14, 2035	DP U-2584			
	11753401	Aug 14, 2035	DP U-2855			
	11753401	Aug 14, 2035	DP U-3018			
	11787771	Jul 26, 2032	U-2584			
	11787771	Jul 26, 2032	U-2855			
	11787771	Jul 26, 2032	U-3018			
	11807629	Aug 14, 2035	DS			
	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			
	8999996	Jul 03, 2033	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELPERCATINIB - RETEVMO						
N 213246 001					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
SELPERCATINIB - RETEVMO						
N 213246 002					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
SELPERCATINIB - RETEVMO						
N 218160 001					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	Sep 21, 2029
					ODE*	Sep 21, 2029
					ODE*	May 29, 2031
					ODE*	May 29, 2031
					ODE*	May 29, 2031
SELPERCATINIB - RETEVMO						
N 218160 002					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELPERCATINIB - RETEVMO						
N 218160 002					ODE*	May 08, 2027
					ODE*	Sep 21, 2029
					ODE*	Sep 21, 2029
					ODE*	May 29, 2031
					ODE*	May 29, 2031
					ODE*	May 29, 2031
SELPERCATINIB - RETEVMO						
N 218160 003					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	Sep 21, 2029
					ODE*	Sep 21, 2029
					ODE*	May 29, 2031
					ODE*	May 29, 2031
					ODE*	May 29, 2031
SELPERCATINIB - RETEVMO						
N 218160 004					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	May 08, 2027
					ODE*	Sep 21, 2029
					ODE*	Sep 21, 2029
					ODE*	May 29, 2031
					ODE*	May 29, 2031
					ODE*	May 29, 2031
SELUMETINIB SULFATE - KOSELUGO						
N 213756 001	12220403	Mar 26, 2029	DP		>A> NPP	Sep 10, 2028
	12318367	Mar 26, 2029	DP			
	12364684	Mar 26, 2029	U-4274			
	7425637	Mar 13, 2026	DS			
	8178693	Mar 13, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-4274			
SELUMETINIB SULFATE - KOSELUGO						
N 213756 002	12220403	Mar 26, 2029	DP		>A> NPP	Sep 10, 2028
	12318367	Mar 26, 2029	DP			
	12364684	Mar 26, 2029	U-4274			
	7425637	Mar 13, 2026	DS			
	8178693	Mar 13, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-4274			
SELUMETINIB SULFATE - KOSELUGO						
N 219943 001	7425637	Mar 13, 2026	DS		>A> NP	Sep 10, 2028
	8178693	Mar 13, 2026	DS DP		>A> ODE*	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-4274			
SELUMETINIB SULFATE - KOSELUGO						
N 219943 002	7425637	Mar 13, 2026	DS		>A> NP	Sep 10, 2028
	8178693	Mar 13, 2026	DS DP		>A> ODE*	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-4274			
SEMAGLUTIDE - OZEMPIC						
N 209637 001	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - OZEMPIC						
N 209637 001	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 27, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 002	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 003	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	12295988	Oct 10, 2038	U-2628			
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - OZEMPIC						
N 209637 004	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
SEMAGLUTIDE - RYBELSUS						
N 213051 001	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - RYBELSUS						
N 213051 002	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 003	10278923	May 02, 2034	U-2628			
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 004	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 005	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 006	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DS DP U-2628			
SEMAGLUTIDE - WEGOVY						
N 215256 001	11478533	May 13, 2040	U-3861		I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 002	11478533	May 13, 2040	U-3861		I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 003	11478533	May 13, 2040	U-3861		I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 004	11478533	May 13, 2040	U-3861		I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
SEMAGLUTIDE - WEGOVY						
N 215256 005	11478533	May 13, 2040	U-3861		I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
SEPIAPTERIN - SEPHIENCE						
N 219666 001	11072614	Apr 16, 2038	DS U-4251		NCE	Jul 28, 2030
	11752154	Sep 04, 2038	DP U-4251			
	12213982	Sep 04, 2038	U-4251			
	12257252	Mar 06, 2042	U-4250			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEPIAPTERIN - SEPHIENCE							
N 219666	002	11072614	Apr 16, 2038	DS U-4251		NCE	Jul 28, 2030
		11752154	Sep 04, 2038	DP U-4251			
		12213982	Sep 04, 2038	U-4251			
		12257252	Mar 06, 2042	U-4250			
SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE							
A 218853	001					CGT	Jan 18, 2026
SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE							
A 218853	002					CGT	Jan 18, 2026
SETMELANOTIDE ACETATE - IMCIVREE							
N 213793	001	8039435	Aug 21, 2032	DS DP		NPP	Dec 20, 2027
						ODE-508	Dec 20, 2031
						ODE-509	Dec 20, 2031
SILDENAFIL CITRATE - LIQREV							
N 214952	001	12186321	Dec 24, 2038	DP U-3582			
SIPONIMOD - MAYZENT							
N 209884	001	11944602	Apr 23, 2036	U-3889			
SIPONIMOD - MAYZENT							
N 209884	002	11944602	Apr 23, 2036	U-3889			
SIPONIMOD - MAYZENT							
N 209884	003	11944602	Apr 23, 2036	U-3889			
SITAGLIPTIN HYDROCHLORIDE - BRYNOVIN							
N 219122	001	11944621	Oct 23, 2040	DP			
		12295953	Oct 23, 2040	DP			
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE							
N 201444	001	12304813	Feb 10, 2030	DP			
SODIUM OXYBATE - LUMRYZ							
N 214755	001	12226377	Jul 21, 2037	DP			
		12303478	Jul 21, 2037	U-4189			
SODIUM OXYBATE - LUMRYZ							
N 214755	002	12226377	Jul 21, 2037	DP			
		12303478	Jul 21, 2037	U-4189			
SODIUM OXYBATE - LUMRYZ							
N 214755	003	12226377	Jul 21, 2037	DP			
		12303478	Jul 21, 2037	U-4189			
SODIUM OXYBATE - LUMRYZ							
N 214755	004	12226377	Jul 21, 2037	DP			
		12303478	Jul 21, 2037	U-4189			
SODIUM PHENYLBUTYRATE - OLPRUVA							
N 214860	007	>A> 11154521	Oct 17, 2036	DP			
		>A> 11433041	Oct 17, 2036	DP			
SODIUM PHENYLBUTYRATE - OLPRUVA							
N 214860	008	>A> 11154521	Oct 17, 2036	DP			
		>A> 11433041	Oct 17, 2036	DP			
SODIUM THIOSULFATE - SODIUM THIOSULFATE							
N 203923	001	12304813	Feb 10, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 002					ODE*	Mar 19, 2027
SOFPIRONIUM BROMIDE - SOFDRA						
N 217347 001	12156865	May 22, 2034	DP U-2398			
	12357609	May 22, 2034	DP U-2398			
	12398102	May 22, 2034	DP U-2398			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 001	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
	12263145	Dec 30, 2042	U-3693			
	12318362	Mar 19, 2040	U-3765			
	12384743	Nov 01, 2038	DS DP U-2548			
	12390419	Sep 05, 2037	DP U-2548			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 002	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
	12384743	Nov 01, 2038	DS DP U-2548			
	12390419	Sep 05, 2037	DP U-2548			
SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE						
N 022306 001	12390431	Aug 14, 2038	U-2769			
	12403109	Aug 14, 2028	U-2769			
SOTALOL HYDROCHLORIDE - SOTYLIZE						
N 205108 001	12290495	Apr 01, 2034	U-2096			
	12290495	Apr 01, 2034	U-2494			
SOTORASIB - LUMAKRAS						
N 214665 001	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
	12398133	May 20, 2040	DS DP U-3306			
	12398133	May 20, 2040	DS DP U-4107			
SOTORASIB - LUMAKRAS						
N 214665 002	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
	12398133	May 20, 2040	DS DP U-3306			
	12398133	May 20, 2040	DS DP U-4107			
SOTORASIB - LUMAKRAS						
N 214665 003	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
	12280056	Nov 18, 2039	U-4107			
	12398133	May 20, 2040	DS DP U-3306			
	12398133	May 20, 2040	DS DP U-4107			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUCCINYLCHOLINE CHLORIDE - SUCCINYLCHOLINE CHLORIDE						
N 215143 001	12295932	Nov 02, 2041	DP			
SUGAMMADEX SODIUM - BRIDION						
N 022225 001					NPP	Dec 12, 2027
					PED	Jun 12, 2028
SUGAMMADEX SODIUM - BRIDION						
N 022225 002					NPP	Dec 12, 2027
					PED	Jun 12, 2028
SUNVOZERTINIB - ZEGFROVY						
N 219839 001	11007198	Jan 28, 2039	DS DP		NCE	Jul 02, 2030
	11504375	Jan 28, 2039	DS DP U-3220			
	11896597	Jan 28, 2039	DS DP U-3220			
SUNVOZERTINIB - ZEGFROVY						
N 219839 002	11007198	Jan 28, 2039	DS DP		NCE	Jul 02, 2030
	11504375	Jan 28, 2039	DS DP U-3220			
	11896597	Jan 28, 2039	DS DP U-3220			
SUZETRIGINE - JOURNAVX						
N 219209 001	11834441	Dec 04, 2040	DS DP U-4125		NCE	Jan 30, 2030
TACROLIMUS - ENVARSUS XR						
N 206406 001	12403095	May 30, 2028	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 002	12403095	May 30, 2028	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 003	12403095	May 30, 2028	DP			
TADALAFIL - TADLIQ						
N 214522 001	12186322	Dec 24, 2038	DP U-3397			
TAFAMIDIS - VYNDAMAX						
N 212161 001	7214695	Dec 19, 2026	DS DP			
	7214696	Dec 19, 2026	U-2524			
TAFAMIDIS MEGLUMINE - VYNDAQEL						
N 211996 001	7214695	Dec 19, 2026	DS DP			
	7214696	Dec 19, 2026	U-2524			
TALETRECTINIB ADIPATE - IBTROZI						
N 219713 001	9187489	Jun 03, 2033	DS DP U-4207		NCE	Jun 11, 2030
	9751887	Jun 03, 2033	DS DP U-4207			
TAPINAROF - VTAMA						
N 215272 001	10426743	May 19, 2036	U-2625		I-956	Dec 12, 2027
	10426743	May 19, 2036	U-4048			
	11497718	Nov 13, 2039	U-4048			
	11612573	May 19, 2036	U-2625			
	11612573	May 19, 2036	U-4048			
	11938099	Nov 13, 2039	U-4048			
TASIMELTEON - HETLIOZ						
N 205677 001	12201604	Jan 25, 2033	U-3003			
	12201604	Jan 25, 2033	U-3865			
TASIMELTEON - HETLIOZ LQ						
N 214517 001	12201604	Jan 25, 2033	U-3003			
>A>	12447141	Dec 11, 2040	U-3003			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TASIMELTEON - HETLIOZ LQ							
N 214517 001		12201604	Jan 25, 2033	U-3003			
	>A>	12447141	Dec 11, 2040	U-3003			
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK							
N 211723 001		12161645	Sep 12, 2031	U-2853			
		12162865	May 21, 2034	U-2736			
		12168014	May 03, 2038	U-2736			
		12168014	May 03, 2038	U-2852			
		12168014	May 03, 2038	U-2853			
		12168015	Sep 12, 2031	DS DP			
		12168016	Sep 12, 2031	U-2736			
		12168016	Sep 12, 2031	U-2853			
TECOVIRIMAT - TPOXX							
N 208627 001	>A>	12433868	Mar 23, 2031	DP			
TEDIZOLID PHOSPHATE - SIVEXTRO							
N 205435 001						NPP	Apr 04, 2028
TEDIZOLID PHOSPHATE - SIVEXTRO							
N 205436 001						NPP	Apr 04, 2028
TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY							
N 208464 001		7390791	Jan 07, 2025	DS DP			
		7390791*PED	Jul 07, 2025				
TERAZOSIN HYDROCHLORIDE - TEZRULY							
N 218139 001		11224572	Feb 01, 2041	DP U-3990			
		11224572	Feb 01, 2041	DP U-3991			
		12427108	Feb 01, 2041	DP U-3990			
		12427108	Feb 01, 2041	DP U-3991			
TESTOSTERONE UNDECANOATE - TLANDO							
N 208088 001		12310978	Feb 21, 2039	U-4194			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953 001		12357643	Mar 15, 2033	DP U-2506			
		12403146	Mar 29, 2041	DP U-2506			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953 002		12357643	Mar 15, 2033	DP U-2506			
		12403146	Mar 29, 2041	DP U-2506			
TESTOSTERONE UNDECANOATE - KYZATREX							
N 213953 003		12357643	Mar 15, 2033	DP U-2506			
		12403146	Mar 29, 2041	DP U-2506			
TETRACAINE HYDROCHLORIDE - TETRACAINE HYDROCHLORIDE							
A 217227 001						CGT	Jun 25, 2025
THIOTEPA - TEPADINA AND SODIUM CHLORIDE							
N 208264 003		9931458	May 31, 2037	DP			
THIOTEPA - TEPYLUTE							
N 216984 002		11975013	Aug 16, 2041	DP			
TICAGRELOR - TICAGRELOR							
A 208390 001						PC	Oct 28, 2025
TICAGRELOR - TICAGRELOR							
A 208531 001						PC	Oct 28, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT						
N 021936 001	7396341	Oct 10, 2026	DP	Y		
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP	Y		
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP	Y		
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP	Y		
	9027967*PED	Sep 30, 2027				
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 001	12295987	Dec 30, 2041			U-4192	
	12295987	Dec 30, 2041			U-4193	
	12343382	Jul 22, 2039			U-4229	
	12343382	Jul 22, 2039			U-4230	
	12343382	Jul 22, 2039			U-4231	
	12343382	Jul 22, 2039			U-4232	
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 002	12295987	Dec 30, 2041			U-4192	
	12295987	Dec 30, 2041			U-4193	
	12343382	Jul 22, 2039			U-4229	
	12343382	Jul 22, 2039			U-4230	
	12343382	Jul 22, 2039			U-4231	
	12343382	Jul 22, 2039			U-4232	
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 003	12295987	Dec 30, 2041			U-4192	
	12295987	Dec 30, 2041			U-4193	
	12343382	Jul 22, 2039			U-4229	
	12343382	Jul 22, 2039			U-4230	
	12343382	Jul 22, 2039			U-4231	
	12343382	Jul 22, 2039			U-4232	
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 004	12295987	Dec 30, 2041			U-4192	
	12295987	Dec 30, 2041			U-4193	
	12343382	Jul 22, 2039			U-4229	
	12343382	Jul 22, 2039			U-4230	
	12343382	Jul 22, 2039			U-4231	
	12343382	Jul 22, 2039			U-4232	
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 005	12295987	Dec 30, 2041			U-4192	
	12295987	Dec 30, 2041			U-4193	
	12343382	Jul 22, 2039			U-4229	
	12343382	Jul 22, 2039			U-4230	
	12343382	Jul 22, 2039			U-4231	
	12343382	Jul 22, 2039			U-4232	
TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)						
N 215866 006	12295987	Dec 30, 2041			U-4192	
	12295987	Dec 30, 2041			U-4193	
	12343382	Jul 22, 2039			U-4229	
	12343382	Jul 22, 2039			U-4230	
	12343382	Jul 22, 2039			U-4231	
	12343382	Jul 22, 2039			U-4232	
TIRZEPATIDE - MOUNJARO						
N 215866 007	12295987	Dec 30, 2041			U-4192	
	12295987	Dec 30, 2041			U-4193	
	12343382	Jul 22, 2039			U-4229	
	12343382	Jul 22, 2039			U-4230	
	12343382	Jul 22, 2039			U-4231	
	12343382	Jul 22, 2039			U-4232	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - MOUNJARO						
N 215866 008	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO						
N 215866 009	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO						
N 215866 010	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO						
N 215866 011	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - MOUNJARO						
N 215866 012	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 001	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 002	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 003	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 004	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 005	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)						
N 217806 006	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIRZEPATIDE - ZEPBOUND						
N 217806 007	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND						
N 217806 008	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND						
N 217806 009	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND						
N 217806 010	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND						
N 217806 011	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIRZEPATIDE - ZEPBOUND						
N 217806 012	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 001	7166722	Nov 16, 2028	DS DP			
TIVOZANIB HYDROCHLORIDE - FOTIVDA						
N 212904 002	7166722	Nov 16, 2028	DS DP			
TIZANIDINE HYDROCHLORIDE - ONTRALFY						
N 216190 001	12263158	May 07, 2042	DP U-2779			
TOFACITINIB CITRATE - XELJANZ						
N 203214 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
TOFACITINIB CITRATE - XELJANZ						
N 203214 002	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 001	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	11253523*PED	Sep 14, 2034				
	9937181	Mar 14, 2034	DP			
	9937181*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
TOFACITINIB CITRATE - XELJANZ XR						
N 208246 002	10639309	Mar 14, 2034	DP			
	10639309*PED	Sep 14, 2034				
	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	11253523*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOFACITINIB CITRATE - XELJANZ						
N 213082 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
TOLVAPTAN - TOLVAPTAN						
A 216063 001					PC	Nov 08, 2025
TOLVAPTAN - TOLVAPTAN						
A 216063 002					PC	Nov 08, 2025
TOLVAPTAN - TOLVAPTAN						
A 216063 003					PC	Nov 08, 2025
TOLVAPTAN - TOLVAPTAN						
A 216063 004					PC	Nov 08, 2025
TOLVAPTAN - TOLVAPTAN						
A 216063 005					PC	Nov 08, 2025
TOPIRAMATE - TOPIRAMATE						
A 216683 003					CGT	Feb 01, 2026
TOPIRAMATE - TOPIRAMATE						
A 217795 001					PC	Jan 05, 2026
TOPIRAMATE - EPRONTIA						
N 214679 001	12290503	Aug 21, 2040	DP U-3413			
	12290503	Aug 21, 2040	DP U-3414			
	12290503	Aug 21, 2040	DP U-3415			
TRAVOPROST - IDOSE TR						
N 218010 001	12201555	Feb 14, 2031	DS DP			
	12201557	Jun 18, 2030	DS DP U-4129			
TREOSULFAN - GRAFAPEX						
N 214759 001	7199162	Mar 21, 2026	U-4142		NCE	Jan 21, 2030
					ODE-513	Jan 21, 2032
					ODE-514	Jan 21, 2032
TREOSULFAN - GRAFAPEX						
N 214759 002	7199162	Mar 21, 2026	U-4142		NCE	Jan 21, 2030
					ODE-513	Jan 21, 2032
					ODE-514	Jan 21, 2032
TREPROSTINIL - TYVASO DPI						
N 214324 001	11357782	May 14, 2027	U-1849			
TREPROSTINIL - TYVASO DPI						
N 214324 002	11357782	May 14, 2027	U-1849			
TREPROSTINIL - TYVASO DPI						
N 214324 003	11357782	May 14, 2027	U-1849			
TREPROSTINIL - TYVASO DPI						
N 214324 004	11357782	May 14, 2027	U-1849			
TREPROSTINIL - TYVASO DPI						
N 214324 005	11357782	May 14, 2027	U-1849			
TREPROSTINIL SODIUM - YUTREPIA						
N 213005 001	10898494	May 05, 2037	U-4200		NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	11712442	May 05, 2037	U-4200			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL SODIUM - YUTREPIA							
N 213005 001		11744835	May 05, 2037	DP			
		11744836	May 05, 2037	DP			
		12390475	May 05, 2037	DP			
TREPROSTINIL SODIUM - YUTREPIA							
N 213005 002		10898494	May 05, 2037	U-4200		NP	May 23, 2028
		11660304	May 05, 2037	U-4200			
		11712442	May 05, 2037	U-4200			
		11744835	May 05, 2037	DP			
		11744836	May 05, 2037	DP			
		12390475	May 05, 2037	DP			
TREPROSTINIL SODIUM - YUTREPIA							
N 213005 003		10898494	May 05, 2037	U-4200		NP	May 23, 2028
		11660304	May 05, 2037	U-4200			
		11712442	May 05, 2037	U-4200			
		11744835	May 05, 2037	DP			
		11744836	May 05, 2037	DP			
		12390475	May 05, 2037	DP			
TREPROSTINIL SODIUM - YUTREPIA							
N 213005 004		10898494	May 05, 2037	U-4200		NP	May 23, 2028
		11660304	May 05, 2037	U-4200			
		11712442	May 05, 2037	U-4200			
		11744835	May 05, 2037	DP			
		11744836	May 05, 2037	DP			
		12390475	May 05, 2037	DP			
TRIAMCINOLONE ACETONIDE - XIPERE							
N 211950 001	>A>	12419833	Apr 16, 2040	DP U-3234			
TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR							
N 215760 001		12358861	May 03, 2039	DS DP U-4262			
		12358862	May 03, 2039	DS DP U-4262			
TRILACICLIB DIHYDROCHLORIDE - COSELA							
N 214200 001		12168666	Nov 13, 2040	DS DP			
TUCATINIB - TUKYSA							
N 213411 001		7452895	Nov 16, 2025	DS DP U-2788			
		7452895	Nov 16, 2025	DS DP U-4153			
TUCATINIB - TUKYSA							
N 213411 002		7452895	Nov 16, 2025	DS DP U-2788			
		7452895	Nov 16, 2025	DS DP U-4153			
UBROGEPANT - UBRELVY							
N 211765 001		12168004	Jan 30, 2035	DP			
		12194030	Dec 22, 2041	U-4121			
		12194030	Dec 22, 2041	U-4122			
		12220408	Jan 30, 2035	DP			
		12310953	Jan 30, 2035	DP			
		12329750	Dec 22, 2041	U-4213			
	>A>	12458632	Jan 30, 2035	DP			
	>A>	12458633	Jan 30, 2035	DP			
UBROGEPANT - UBRELVY							
N 211765 002		12168004	Jan 30, 2035	DP			
		12220408	Jan 30, 2035	DP			
		12310953	Jan 30, 2035	DP			
	>A>	12458632	Jan 30, 2035	DP			
	>A>	12458633	Jan 30, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA							
N 203975 001		12396986	Nov 29, 2030	DP			
UPADACITINIB - RINVOQ							
N 211675 001	>A>	11564922	Mar 09, 2038	U-3624		I-966	Apr 28, 2028
	>A>	11564922	Mar 09, 2038	U-4303			
	>A>	11607411	Mar 09, 2038	U-3341			
	>A>	11607411	Mar 09, 2038	U-4302			
		12365689	Oct 17, 2036	U-3945			
UPADACITINIB - RINVOQ							
N 211675 002	>A>	11564922	Mar 09, 2038	U-3624			
	>A>	11564922	Mar 09, 2038	U-4303			
	>A>	11607411	Mar 09, 2038	U-3341			
	>A>	11607411	Mar 09, 2038	U-4302			
UPADACITINIB - RINVOQ							
N 211675 003	>A>	11564922	Mar 09, 2038	U-3624			
	>A>	11564922	Mar 09, 2038	U-4303			
	>A>	11607411	Mar 09, 2038	U-3341			
	>A>	11607411	Mar 09, 2038	U-4302			
UPADACITINIB - RINVOQ LQ							
N 218347 001		12365689	Oct 17, 2036	U-3945			
VAMOROLONE - AGAMREE							
N 215239 001		12201639	Mar 17, 2040	DS DP U-3747			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN							
N 211962 001		12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN							
N 211962 002		12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN							
N 211962 003		12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN							
N 211962 004		12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN							
N 211962 005		12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN							
N 211962 006		12161690	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - TYZAVAN							
N 211962 007		12161690	Nov 06, 2035	DP			
VASOPRESSIN - VASOSTRICT							
N 204485 003		12186362	Jan 30, 2035	DP			
VASOPRESSIN - VASOSTRICT							
N 204485 004		12186362	Jan 30, 2035	DP			
VASOPRESSIN - VASOSTRICT							
N 204485 005		12186362	Jan 30, 2035	DP			
VASOPRESSIN - VASOSTRICT							
N 204485 006		12186362	Jan 30, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VASOPRESSIN - VASOPRESSIN IN SODIUM CHLORIDE 0.9%							
N 217569 001	>A>	12447190	Sep 27, 2044	DP			
VASOPRESSIN - VASOPRESSIN IN SODIUM CHLORIDE 0.9%							
N 217569 002	>A>	12447190	Sep 27, 2044	DP			
VIBEGRON - GEMTESA							
N 213006 001		12180219	Mar 12, 2034	DS DP		I-955	Dec 18, 2027
		12357636	May 04, 2042	U-4219			
VIGABATRIN - VIGAFYDE							
N 217684 001		12290499	Oct 17, 2042	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE							
N 211964 001		9662338	Apr 02, 2035	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE							
N 211964 002		9662338	Apr 02, 2035	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE							
N 211964 003		9662338	Apr 02, 2035	DP			
VIMSELTINIB - ROMVIMZA							
N 219304 001		11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
		11679110	Feb 03, 2040	U-4145			
		12285430	Dec 23, 2039	U-4145			
	>A>	12447149	Dec 06, 2044	DP			
		9181223	Mar 14, 2034	DS DP			
VIMSELTINIB - ROMVIMZA							
N 219304 002		11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
		11679110	Feb 03, 2040	U-4145			
		12285430	Dec 23, 2039	U-4145			
	>A>	12447149	Dec 06, 2044	DP			
		9181223	Mar 14, 2034	DS DP			
VIMSELTINIB - ROMVIMZA							
N 219304 003		11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
		11679110	Feb 03, 2040	U-4145			
		12285430	Dec 23, 2039	U-4145			
	>A>	12447149	Dec 06, 2044	DP			
		9181223	Mar 14, 2034	DS DP			
VONOPRAZAN FUMARATE - VOQUEZNA							
N 215151 001						NCE	May 03, 2027
						GAIN	May 03, 2032
VONOPRAZAN FUMARATE - VOQUEZNA							
N 215151 002						NCE	May 03, 2027
						GAIN	May 03, 2032
VORASIDENIB - VORANIGO							
N 218784 001	>A>	12433895	Jul 11, 2034	U-4286			
VORASIDENIB - VORANIGO							
N 218784 002	>A>	12433895	Jul 11, 2034	U-4286			
VOSORITIDE - VOXZOGO							
N 214938 001		12233106	Jul 11, 2042	U-3927			
VOSORITIDE - VOXZOGO							
N 214938 002		12233106	Jul 11, 2042	U-3927			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VOSORITIDE - VOXZOGO						
N 214938 003	12233106	Jul 11, 2042	U-3927			
VUTRISIRAN SODIUM - AMVUTTRA						
N 215515 001					I-964	Mar 20, 2028
ZANUBRUTINIB - BRUKINSA						
N 218785 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2537		ODE*	Nov 14, 2026
	10570139	Apr 22, 2034	U-2666		ODE*	Aug 31, 2028
	10570139	Apr 22, 2034	U-3063		ODE*	Sep 14, 2028
	10570139	Apr 22, 2034	U-3486		ODE*	Jan 19, 2030
	10570139	Apr 22, 2034	U-3860		ODE*	Mar 07, 2031
	10927117	Aug 15, 2037	DS DP			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	11591340	Aug 15, 2037	U-3727			
	11591340	Aug 15, 2037	U-3728			
	11591340	Aug 15, 2037	U-3729			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	12233069	Jun 10, 2040	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZANUBRUTINIB - BRUKINSA						
N 218785 001	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
ZONGERTINIB - HERNEXEOS						
N 219042 001	11608343	Jul 21, 2041	DS DP U-4245		NCE	Aug 08, 2030
	12171739	Nov 15, 2026	DS DP			
ZURANOLONE - ZURZUVAE						
N 217369 001	11884696	Aug 23, 2037	U-2552			
ZURANOLONE - ZURZUVAE						
N 217369 002	11884696	Aug 23, 2037	U-2552			
ZURANOLONE - ZURZUVAE						
N 217369 003	11884696	Aug 23, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 45TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm